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ABSTRACT 
Mutations in FKRP (fukutin related protein) are associated with the dystroglycanopathies, a 
group of neuromuscular conditions with a spectrum of clinical phenotypes.  However, as 
there is currently no method for detecting Fkrp expression, or measuring its activity, the 
function has not been fully elucidated.  Here, the implications of Fkrp deficiency have been 
evaluated to provide further insight into the role of this protein.   
 
In the muscle, brain and eye (three tissues severely affected in dystroglycanopathy 
patients), it was shown using the FKRPKD mouse, with its global reduction in Fkrp expression 
of 80%, that basement membrane deposition was perturbed in the muscle fibres of the 
tongue, the pial basement membrane of the cortex and both ocular basement membranes 
(Bruch’s and the inner limiting membrane).  It was also demonstrated that these basement 
membrane defects were associated with altered, reduced glyosylation of α-dystroglycan, 
and that these changes had marked consequences for cortical and retinal lamination.  
Interestingly, this investigation highlighted an important, previously undescribed, role for 
glycosylated α-dystroglycan in early brain and retinal development.   
 
To investigate the effects of reduced Fkrp expression on muscle, a novel mouse (FKRPMD) 
was generated, with had restored f Fkrp expression in the central nervous system.  This 
mouse developed a mild dystrophic pathology, associated with defects in basement 
membrane deposition and altered, reduced glycosylation of α-dystroglycan.  
LARGE upregulation has been published as a successful short-term therapeutic strategy in 
other preclinical dystroglycanopathy models, but none with impaired Fkrp expression.  Here, 
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it was demonstrated that long-term LARGE upregulation exacerbated dystrophic pathology 
in the FKRPMD mouse, despite increased α-dystroglycan glycosylation. 
 
In combination, this work highlights the critical role of Fkrp for basement membrane 
deposition in muscle, brain and eye, identifies the downstream consequences for these 
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IdoA      Iduronic acid 
ILM      Inner Limiting Membrane 
ISPD      Isoprenoid synthase domain containing 
LG domain     Laminin globular domain 
LN domain     Laminin N-terminus domain 
LARGE      Like-acetylglucosaminyltransferase 
LARGE2     Like-acetylglucosaminyltransferase 2 
LGMD      Limb girdle muscular dystrophy 
LV5 mouse     FKRP-NeoTyr307Asn-/-Sox1Cre-/-LARGE+/- 
Man      Mannose 
MAPK/ERK     Mitogen-activated protein kinase 
MEB      Muscle Eye Brain Disease 
MyHC      Myosin Heavy Chain 
Mrf4      Myogenic regulatory factor 4 
Myf5      Myogenic Factor 5 
MyoD      Myoblast determining protein 1 
nNOS      neuronal Nitrogen Oxide Synthase  
NH2      N-terminal 
NMD      Neuromuscular Disease 
Pax3    Paired box 3 
Pax7    Paired box 7  
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PBS    Phosphate Buffered Saline 
Pial BM   Pial basement membrane 
PCR    Polymerase chain reaction 
POMGnT1    Protein O-mannose β-1, 2-N-acetylglucosaminyltransferase 
POMT1    Protein O-mannosyl transferase 1 
POMT2    Protein O-mannosyl transferase 2 
RPE    Retinal Pigmented Epithelium 
SA    Sialic Acid 
SEA    sperm protein, enterokinase, agrin 
Sox1    Sex determining region Y-box 1 
Sox1Cre mouse  FKRP-NeoTyr307Asn-/-Sox1Cre+/- 
Sox1CreLV5 mouse  FKRP-NeoTyr307Asn-/-Sox1Cre+/-LARGE+/- 
Src    Sarcoma 
SV40     Simian Virus 40 
TA    Tibialis Anterior 
TAg    large tumour antigen 
TBE    Tris-Boric Acid EDTA 
TBR1    T box brain 1 
TBR2    T box brain 2 
TMEM5   Transmembrane protein 5 
T-Tubules   Transverse Tubules 
TsA58    Temperature sensitive A58 
Tyr    Tyrosine 
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Vldlr    Very low density lipoprotein receptor 
WWS    Walker-Warburg Syndrome 
Xyl    Xylose 
 




Muations in Fkrp have been associated clinically in human patients with both congenital 
muscular dystrophies and limb girdle muscular dystrophies, so a brief description of these 
conditions will be provided first.  The dystroglycanopathies are a subgroup of 
neuromuscular disorders associated with altered, reduced glycosylation of α-dystroglycan 
and to date mutations in 11 genes, including Fkrp, have been implicated with this group of 
conditions.  Therefore, the dystroglycanopathies will then be described, which will include a 
more detailed description of the clinical phenotypes.  As the muscle, brain and eye are the 
most severely affected tissues, this will be followed by an overiview of the structure, 
function and development of these tissues.  The commonality linking the muscle, brain and 
eye defects identified in the dystroglycanopathies are basement membrane abnormalities, 
so an overview of the basement membrane structure, including a description of selected 
basement membrane proteins, a summary of basement membrane composition in the 
muscle, brain and eye and an outline on the process of basement membrane deposition will 
then be provided.  Basement membranes contact cells by binding to cellular adhesion 
receptors in the sarcolemma, such as the dystrophin associated glycoprotein complex.  This 
receptor complex will be briefly summarised before focusing on dystroglycan, a component 
of this complex.  Firstly, the structure of dystroglycan will be described, followed by a 
description of its glycosylation pattern and the known involvement of the genes associated 
with the dystroglycanopathies in this process, with Fkrp, the main focus of this thesis 
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detailed in a subsequent, separate section.  Finally, this will be followed by a summary of 
this thesis, finishing with an overall thesis hypothesis. 
 
1.1 CONGENITAL MUSCULAR DYSTROPHY 
The Congenital Muscular Dystrophies (CMDs) are a heterogeneous group of degenerative 
neuromuscular conditions (including but not limited to the dystroglycanopathies) with an 
autosomal recessive inheritance (Muntoni and Voit, 2004).  Their incidence is estimated at 
4.65 x 10-5, with a prevalence of 8 x 10-6. (Mostacciuolo et al., 1996).  Classically patients 
present with symptoms within the first year of life (Godfrey et al., 2007, Collins and 
Bonnemann, 2010), affecting skeletal muscle, and in some cases, the central nervous system 
and/or the eye, as described in more detail in Section 1.4.  Additionally, after the first 
decade of life, cardiomyopathy has been identified in some conditions (Muntoni, 2003). 
 
1.2 LIMB GIRDLE MUSCULAR DYSTROPHY 
Limb girdle muscular dystrophies (LGMDs) are a group of genetic conditions with 
progressive symmetrical weakness and wasting of muscles, primarily the proximal muscles 
of the pelvic and shoulder girdles (Poppe et al., 2003, Nigro et al., 2011).  Generally LGMDs 
have a later onset of weakness when compared to CMDs, presenting after patients acquire 
ambulation (Godfrey et al., 2007, Collins and Bonnemann, 2010).  LGMDs can have 
autosomal dominant inheritance (LGMD1) or autosomal recessive inheritance (LGMD2), 
with a subsequent alphabetical letter indicating the affected gene (Nigro et al., 2011), for 
example LGMD2I is an disease with an autosomal recessive inheritance caused by mutations 
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in FKRP (FUKUTIN RELATED PROTEIN).  Additionally, LGMDs are usually associated with 
cardiomyopathy and can present with or without central nervous system involvement 
(Godfrey et al., 2007).  Several LGMDs belong to the group now referred to as the 
dystroglycanopathies – LGMD2I, LGMD2K, LGMD2M and LGMD2N, and the clinical 
symptoms associated with these will be discussed in more detail in section 1.4 
 
1.3  DYSTROGLYCANOPATHIES 
The dystroglycanopathies are a heterogeneous sub-group of the congenital and limb-girdle 
muscular dystrophies characterised by a variable reduction in α-dystroglycan glycosylation 
on patient muscle biopsy (Brown et al., 2004, van Reeuwijk et al., 2007, Jimenez-Mallebrera 
et al., 2009, Godfrey et al., 2011).  This hypoglycosylation of α-dystroglycan is associated 
with altered distribution of basement membrane ligands, with the localisation of laminin α2 
to the muscle fibre basement membrane particularly affected (Jimenez-Mallebrera et al., 
2009).   
 
The dystroglycanopathies can be subdivided into primary dystroglycanopathies, where 2 
patients have been identified with mutations in the DAG1, encoding for DYSTROGLYCAN 
(Frost et al., 2010, Hara et al., 2011a), or secondary dystroglycanopathies, where mutations 
have been identified in genes associated with downstream processing of α-dystroglycan.  To 
date, mutations in a number of genes have been associated with the secondary 
dystroglycanopathies, including POMT1 (Protein O-mannosyl transferase 1) (Beltran-Valero 
de Bernabe et al., 2002, Currier et al., 2005), POMT2 (Protein O-mannosyl transferase 2) 
(van Reeuwijk et al., 2005, Yanagisawa et al., 2009), POMGnT1 (Protein O-mannose β-1, 2-N-
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acetylglucosaminyltransferase), (Yoshida et al., 2001, Manya et al., 2003, Diesen et al., 2004, 
Biancheri et al., 2006, Hehr et al., 2007, Clement et al., 2008b, Vuillaumier-Barrot et al., 
2011) Fukutin (Toda, 1999, Toda and Kobayashi, 1999, de Bernabe et al., 2003, Vuillaumier-
Barrot et al., 2009, Yis et al., 2011), FKRP (Brockington et al., 2001a, Brockington et al., 
2001b, Driss et al., 2003, Topaloglu et al., 2003, Beltran-Valero de Bernabe et al., 2004, 
Louhichi et al., 2004, Walter et al., 2004, MacLeod et al., 2007), LARGE (Like-
acetylglucosaminyltransferase) (Longman et al., 2003, van Reeuwijk et al., 2007, Clarke et 
al., 2011), TMEM5 (Transmembrane protein 5) (Vuillaumier-Barrot et al., 2012), ISPD 
(Isoprenoid synthase domain containing) (Roscioli et al., 2012, Vuillaumier-Barrot et al., 
2012, Willer et al., 2012, Cirak et al., 2013, Tasca et al., 2013), DPM3 (Dolichyl-phosphate 
mannosyltransferase polypeptide 3) (Lefeber et al., 2009) and DPM2 (Dolichyl-phosphate 
mannosyltransferase polypeptide 2) (Barone et al., 2012).   
 
1.4 CLINICAL PHENOTYPE OF THE SECONDARY DYSTROGLYCANOPATHIES 
Mutations in POMT1, POMT2, POMGnT1, FKRP, FUKUTIN and LARGE are associated with a 
broad spectrum of clinical phenotypes, which are classified along a scale of decreasing 
clinical severity (Godfrey et al., 2007).  At the most severe end of the spectrum is 1) WWS 
(Walker Warburg Syndrome)  and WWS-like, which present at birth with severe structural 
brain abnormalities, eye defects and absent motor development, with death occurring in 
the first year of life (Godfrey et al., 2007).  2) MEB (Muscle Eye Brain disease) and FCMD-like 
(Fukuyama Congenital Muscular Dystrophy) present with less severe brain abnormalities, 
eye abnormalities and congenital muscular dystrophy, with ambulation, if it occurs, delayed 
(Godfrey et al., 2007).  The next three divisions on the scale are CMDs with varying degrees 
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of central nervous system involvement - 3) CMD with cerebellar involvement 4) CMD with 
mental retardation and 5) CMD with no mental retardation (Godfrey et al., 2007).  The last 
two divisions on the clinical phenotype scale are 6) LGMD with mental retardation and 7) 
LGMD without mental retardation (Godfrey et al., 2007).  As summarised in Table 1-1, 
mutations in individual genes have been associated with several different clinical 
phenotypes, suggesting that the severity of the clinical condition depends upon the specific 
mutation in individual genes, not the gene carrying the mutation (Godfrey et al., 2007, 
Godfrey et al., 2011).   
 
The cortical abnormalities identified in dystroglycanopathy patients include, but are not 
limited to type II (cobblestone) lissencephaly, pachygyria (thickened gyria), polymicrogyria 
(multiple smooth gyri), rudimentary cortical folding, cortical hypoplasia, agenesis of the 
corpus callosum, preferential fronto-parietal abnormalities, hydrocephalus, dilated 
ventricles, occipital encephalocele, developmental delay with or without mental 
retardation, seizures, Dandy-Walker malformation and hypomyelination or aberrant 
myelination of the white matter (Manya et al., 2003, Topaloglu et al., 2003, Beltran-Valero 
de Bernabe et al., 2004, Martin, 2006, Godfrey et al., 2007, Doe et al., 2011).  Additionally a 
number of subcortical abnormalities have been identified including cerebellar cysts, 
pontocerebellar hypoplasia, cerebellar hyoplasia (both vermal and general) and a flattened 
brain stem with small pyramidal regions (Manya et al., 2003, Topaloglu et al., 2003, Vajsar 
and Schachter, 2006, Martin, 2007, Collins and Bonnemann, 2010). 
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A number of unilateral or bilateral eye defects, affecting both the anterior and the posterior 
eye, have also been identified in dystroglycanopathy patients. These include severe 
congenital myopia, pallor of the optic discs, cataracts, anterior chamber malformation, 
microcornea, persistent hyaloid artery, microopthalmia, persistent hyperplastic primary 
vitreous, lens defects, coloboma, rarefaction of the retinal pigment epithelium, Peter’s 
Anomaly, congenital glaucoma, nystagmus, strabismus, buphthalmos, an absence of 
macular demarcation and atrophy of the optic nerve and macula (Cormand et al., 2001, 
Beltran-Valero de Bernabe et al., 2004, Muntoni and Voit, 2004, Vajsar et al., 2006).  The 
retina is not spared in these conditions, with some patients reportedly suffering from 
chorioretinal atrophy or retinal detachment, dysplasia and hypoplasia (Cormand et al., 2001, 
Beltran-Valero de Bernabe et al., 2004, Muntoni and Voit, 2004, Martin, 2006, Vajsar and 
Schachter, 2006).  Physiologically, these defects manifest as visual impairment, including in 
some cases total blindness and when an electroretinogram is used, an attenuated or 
isoelectric b-wave is apparent (Pihko et al., 1995, Fahnehjelm et al., 2001, Muntoni et al., 
2004, Satz et al., 2008). 
 
Various clinical signs have been identified in the skeletal muscle phenotype of patients with 
the congenital muscular dystrophies including hypotonia (decreased muscle tone), the 
variable appearance of contractures (permanent shortening of a muscle or joint), motor 
developmental delay, muscle fibre weakness and elevated serum creatinine kinase (CK) 
levels (Godfrey et al., 2007).  The degree of physical disability depends on the severity of the 
condition, with patients at the severe end of the spectrum (for example WWS) born floppy, 
with motor and facial weakness evident from birth, while patients at the milder end of the 
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spectrum (for example with Congenital Muscular Dystrophy type 1C) may achieve 
ambulation, but those that do will have delayed motor milestones (Manya et al., 2003, 
Godfrey et al., 2007).  Additionally, calf hypertrophy has been reported as component of the 
clinical phenotype in several LGMDs, which includes some of those associated with the 
dystroglycanopathy subgroup (Bushby et al., 2009). 
 
Skeletal muscle biopsies from these patients with CMD typically show dystrophic changes 
such as degenerating fibres, muscle fibre regeneration (indicated by fibres with centralised 
nuclei), fibrosis and infiltration, by either inflammatory cells or adipocytes (Collins and 
Bonnemann, 2010).  Examples of these histopathological features in mouse muscle are 
shown in Figure 1-1, along with a picture of wildtype mouse muscle. 
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Gene WWS MEB/FCMD CMD LGMD 
POMT1 Yes 
(Beltran-Valero 
de Bernabe et 
al., 2002, Currier 
et al., 2005) 
 
Not reported at 
time of thesis 
submission 
(Pane et al., 
2012) 
Yes 
(Balci et al., 
2005) 
POMT2 Yes 
(van Reeuwijk et 
al., 2005) 
Not reported at 





al., 2009, Pane 
et al., 2012) 
Yes 
(Biancheri et al., 
2007) 
POMGNT1 Yes 
(Taniguchi et al., 
2003) 
Yes 
(Yoshida et al., 
2001, Manya et 
al., 2003, 
Taniguchi et al., 
2003, 
Vuillaumier-




(Biancheri et al., 
2006, Hehr et 
al., 2007, Pane 
et al., 2012) 
Yes 
(Clement et al., 
2008b) 
Fukutin Yes 
(de Bernabe et 
al., 2003, 
Godfrey et al., 
2006, Cotarelo 
et al., 2008, Yis 















Barrot et al., 













Topaloglu et al., 
2003, Louhichi 
et al., 2004, 
MacLeod et al., 




al., 2001b, Driss 
et al., 2003, 
Walter et al., 
2004) 
LARGE Yes 
(van Reeuwijk et 
al., 2007, 
Vuillaumier-
Barrot et al., 
2011) 
Not reported at 
time of thesis 
submission 
Yes 
(Longman et al., 
2003) 
Not reported at 
time of thesis 
submission 
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TABLE 1-1 PUBLISHED ASSOCIATION OF DYSTROGLYCANOPATHY GENES 
This table lists 4 main subdivisions of the dystroglycanopathy clinical phenotype – Walker 
Warburg Syndrome (WWS), Muscle Eye Brain (MEB) Disease or Fukyama Congenital 
Muscular Dystrophy (FCMD), Congenital Muscular Dystrophy (CMD) and Limb Girdle 
Muscular Dystrophy (LGMD) and details whether they have been associated with mutations 
in POMT1, POMT2, POMGnT1, FUKUTIN, FKRP or LARGE.  Where mutations in these genes 
have been identified in the patients, the publications are listed in the text.   
 
This table shows that mutations in these 6 genes are associated with phenotypes across the 
dystroglycanopathy spectrum, suggesting it is the nature of the mutation in each individual 
gene that determines clinical phenotype. 
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1.5 SKELETAL MUSCLE 
SKELETAL MUSCLE IS A HIGHLY ORGANISED, STABLE, POSTMITOTIC, COMPOSITE 
NERVES, BLOOD VESSELS, FAT AND CONNECTIVE TISSUE ALONGSIDE MUSCLE 
BULK OF THE TISSUE (KARPATI, 2010, GILLES AND LIEBER, 2011).  EVERY SKELETAL 
SURROUNDED BY A LAYER OF CONNECTIVE TISSUE, THE EPIMYSIUM AND WITHIN 
FIBRES ARE BUNDLED INTO FASCICLES, WHICH ARE SURROUNDED AN ADDITIONAL 
TISSUE, THE PERIMYSIUM (GILLES AND LIEBER, 2011) ( 
FIGURE 1-1 HISTOLOGICAL MUSCLE STRUCTURE ).  ADDITIONALLY, EACH 
INDIVIDUAL MUSCLE FIBRE IS SURROUNDED BY ANOTHER LAYER OF CONNECTIVE 
TISSUE THE ENDOMYSIUM (GILLES AND LIEBER, 2011) ( 
Figure 1-1 Histological Muscle Structure ).  The specific composition of the connective 
tissue varies between these different layers (Gilles and Lieber, 2011). 
 
MUSCLE FIBRES, THE BASIC UNIT OF SKELETAL MUSCLE ARE CYLINDRICAL, 
WITH A HIGHLY ORGANISED STRUCTURE - POSTMITOTIC NUCLEI ARE ALIGNED 
BENEATH THE SARCOLEMMA ( 
Figure 1-1 Histological Muscle Structure ), while the centre is packed with myofibrils 
(the contractile apparatus) and scaffolding proteins (Davies and Nowak, 2006).  Myofibrils 
are encircled by the sarcoplasmic reticulum, a network of endoplasmic reticulum which is 
specialised for calcium release and reuptake (Davies and Nowak, 2006).  Transverse tubules 
(T-tubules) are sarcolemmal infoldings, enriched in membrane proteins including calcium 
release channels and transporters that penetrate into the muscle and are closely opposed to 
the sarcoplasmic reticulum at specialised junctions, called triads (Davies and Nowak, 2006).  
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These triads are the sites where action potential depolarisation is coupled to calcium release 
and skeletal muscle contraction (Davies and Nowak, 2006, Karpati, 2010). 
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FIGURE 1-1 HISTOLOGICAL MUSCLE STRUCTURE  
This digital image of wildtype mouse muscle in the transverse plane (A) has been included to 
show the basic structure of muscle. The following structures have been labelled- individual 
muscle fibres with their peripheral nuclei, grouped into fascicles (outlined in black) and the 
three connective tissue layers – epimysium, perimysium and endomysium.   
 
Images B-G are exerts from digital images of dystrophic mouse muscle generated in the 
course of this thesis and have been included to show different histopathological features of 
dystrophic musle.  The arrows in images B and C indicate degenerating and regenerating 
musle fibres respectively, whilst inflammatory infiltrates are denoted in image D.  Image E 
shows muscle fibres with centralised nuclei, which indicates muscle fibres that have 
successfully regenerated.  Eventually the cycles of degeneration and regeneration fail in the 
muscular dystrophies, leading to replacement of muscle fibres with connective tissues or 
adipocytes, denoted by the black arrown in image E.  Finally, muscle fibres splitting (E) and 
hyperchromatic fibres (F) are also features which can be identified in dystrophic muscle. 
 
These images were digitally captured with a DC500 colour camera (Leica Microsystems) 
using the Leica Application Suite software (Leica Microsystems) of transverse 10µm 
cryosections from wildtype mouse mouse stained with haematoxylin and eosin, viewed 
under light microscopy using a DM4000B upright microscope (Leica Microsystems).  This 
image was generated using Adobe Photoshop CS4 and Microsoft Powerpoint (Office 2010).   
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Myofibrils are the contractile units of skeletal muscle, which are organised into a series of 
repeated units, called sarcomeres (Figure 1-2) (Davies and Nowak, 2006, Karpati, 2010).  
Each sarcomere is a few microns long and consists of highly ordered arrays of myosin (thick) 
filaments and actin (thin) filaments (Karpati, 2010, Gautel, 2011b) (Figure 1-2).  Thin 
filaments - filamentous actin, entwined by troponin C and tropomyosin are arranged into 
overlapping, anti-parallel arrays, which cross-link at the Z-disk (Figure 1-2) (Karpati, 2010).  
Thick filaments are composed of heavy and light myosin chains; each myosin heavy chain 
(MyHC) is arranged with its globular head (containing the actin binding site and ATPase 
activity) pointing outwards and the tail region pointing inwards, to form a central assembly 
of tails, curled round each other  (Figure 1-2) (Karpati, 2010).  Z-disks are an ensemble of 
several proteins, including α-actinin, that act as a border between sarcomeres and anchor 
the tails of myosin filaments in a stable antiparallel array (Karpati, 2010, Gautel, 2011b).  
Titin is a large, modular elastic protein, running from the Z-disk to the M-band, which acts to 
(i) regulate sarcomere length during muscle development and contraction, (ii) provide 
passive elasticity in the sarcomere and additionally (iii) provide a hub for signal transduction 
(Karpati, 2010, Gautel, 2011a, Gautel, 2011b) (Figure 1-2).  The second large filamentous 
protein of the sarcomere, nebulin, spans the thin actin filament and anchors them to the Z-
disc, where it is thought to be involved in structurally supporting myofibrils during 
contraction (Ottenheijm et al., 2012) (Figure 1-2). 
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FIGURE 1-2 SARCOMERE SCHEMATIC 
Labelled schematic of a sarcomere at rest, with the myosin filaments are shown as blue 
rectangles and the actin filaments are shown as green lines.  The molecule α-actinin, linking 
the actin filaments is shown in light green.  Titin filaments are shown as pink bands and 
nebulin filaments are shown as purple bands.  Myomesin at the M band is represented by a 
black line.  The sarcomere is also labelled to show the M-band, A-band, I-band and Z-disc.  
This illustration was based on information taken from (Davies and Nowak, 2006, Karpati, 
2010, Gautel, 2011b) 
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1.5.1  CONTRACTION 
Each muscle fibre is innervated by a single motor neuron at the neuromuscular junction, a 
large synapse localised approximately halfway along the muscle fibre, specialised for 
transduction of nervous impulses into mechanical contraction (Karpati, 2010).  All muscle 
fibres innervated by a given motor neuron comprise a single motor unit, and the number of 
fibres in each unit depends on muscle function i.e. those associated with fine dextrous 
movements will be smaller than those involved in locomotion (Karpati, 2010). 
 
An action potential is propagated along the nerve fibre to the presynaptic terminal, where it 
triggers the release of acetylcholine.  Acetylcholine diffuses across the synaptic cleft and 
binds to nicotinic receptors on the postsynaptic muscle membrane, triggering an action 
potential.  As the action potential propagates through the muscle T tubule-system it triggers 
calcium release from the sarcoplasmic reticulum (Karpati, 2010).  Calcium then binds to 
troponin C, uncovering the myosin binding site on the actin filaments and enabling the 
actin-myosin cross-bridges to form (Karpati, 2010)  Cross-bridge formation alters the 
enzymatic activity of the myosin ATPase, which hydrolyses ATP and breaks the cross-bridge, 
allowing the myosin head to swivel to the next actin binding site (Karpati, 2010).  Thus, 
muscle contraction is attributed to the sliding of the thick and thin filaments over each 
other, under the influence of ATP, shortening the sarcomere and causing contraction 
(Karpati, 2010).  Therefore, sarcomere length is important for muscle function, as the force 
generated by a muscle is proportional to the amount of overlap between the actin and 
myosin filaments (Ottenheijm et al., 2012).  This is in part determined by titin and neublin, 
which are thought to be involved in controlling sarcomere size by regulating the length of 
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the thick filaments and the thin filaments respectively (Gautel, 2011a, Gautel, 2011b, 
Ottenheijm et al., 2012)  
 
1.5.2 ARRANGEMENT 
The structural and functional properties of a muscle fibre are referred to as the muscle fibre 
type and in adult mammalian muscle, 4 main fibre types have been identified – Type I, Type 
IIA, Type IIB and Type IIX, related to both the muscle fibre’s myosin heavy chain (MyHC) 
isoform and oxidative capacity (Schiaffino and Reggiani, 2011).   
 
Type I fibres, expressing MyHC class 1, are slow twitch fibres, resistant to fatigue and as they 
generate ATP by oxidative metabolism, they have abundant mitochondria (Karpati, 2010, 
Schiaffino and Reggiani, 2011).  Type IIA fibres, expressing MyHC IIA, are fast twitch fibres 
that are resistant to fatigue, capable of producing ATP by either oxidative or glycolytic 
mechanisms, as they have relatively abundant mitochondria and glycogen stores (Karpati, 
2010, Schiaffino and Reggiani, 2011).  Type IIX fibres, which express MyHC IIX are also fast 
twitch glycolytic fibres, capable of producing ATP by either oxidative or glycolytic 
mechanisms, but they are less resistant to fatigue than Type IIA fibres (Schiaffino and 
Reggiani, 2011).  Finally, Type IIB fibres are also fast twitch fibres, expressing a different 
myosin heavy chain- MyHC IIB, but they are easily fatigued, as they have relatively few 
mitochondria, instead relying on ATP production from their extensive glycogen stores 
(Schiaffino and Reggiani, 2011).  Each individual muscle is highly adapted to its function, and 
this is reflected in its fibre type composition, with each muscle composed of a unique 
spectrum of fibre types (Schiaffino and Reggiani, 20011).  However, it must be noted that 
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the fibre type composition of any given muscle fibre is plastic, and can be shifted by external 
influences, such as exercise and neuronal activity, allowing muscles to respond and adapt to 
changing demands (Schiaffino and Reggiani, 20011). 
 
Although all the muscle fibres within an individual motor unit are homogeneous, each 
muscle is composed of a heterogeneous pool of motor units, with a mixture of contraction 
speeds and force outputs, enabling muscles to respond to a wide variety of functional 
demands (Karpati, 2010, Schiaffino and Reggiani, 2011).  For example in the mouse, the TA 
(tibialis anterior) and the EDL (extensor digitorum longus) are fast-twitch muscles, 
specialised for fast and powerful actions, so consequently have a high proportion of 
glycolytic fibres (50% of the total fibre number), relative to oxidative fibres, while 
contrastingly the soleus, a postural muscle specialised for long-lasting repetitive activities, 
has a large percentage of slow-twitch fibres (again over 50% total fibre number) (Warren et 
al., 1994, Gumerson et al., 2010). 
 
Additionally, the fibre type distribution varies between different mammalian species, for 
example between human and mice (Patton, 2003).  Most murine muscles are predominantly 
Type IIB and IIX, with a minor component of Type IIA, whilst type I fibres are rare and mostly 
identified only in certain muscles, such as the soleus (Patton, 2003).  Contrastingly, human 
muscles are most Type I or Type IIA, with a minor component of Type IIX – Type IIB muscle 
fibres have not been identified in human muscle (Patton, 2003).   
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1.5.3 DEVELOPMENT 
The skeletal muscle fibres of the limb and trunk derive from progenitor cells in the somites, 
pairs of transient epithelial segments that arise early in vertebrate development (Karpati, 
2010).  The somites give rise to the progenitor cells of the hypaxial muscles (the voluntary 
skeletal muscles, the diaphragm, the abdominal muscles and isolated vertebral muscles) and 
the epaxial muscles (muscles of the vertebral column and base of the skull), whilst the 
paraxial and prechordal mesoderm give rise to the craniofacial muscles – the extraocular, 
brachial, laryngoglossal and oesophageal muscles of the head (Karpati, 2010). 
 
Once progenitor cells in the somites have committed towards a muscle cell fate, they 
translocate and form the myotome, a transient structure formed during development, 
where these cells further differentiate into myoblasts (Buckingham et al., 2003, Bismuth and 
Relaix, 2010, Thorsteinsdottir et al., 2011).  As progenitor cells differentiate and commit to a 
muscle fate lineage, they upregulate Pax3 (Paired box 3) and Pax7 (Paired box 7), which 
activates the expression of myogenic regulatory genes – Myf5 (Myogenic factor 5), Mrf4 
(Myogenic regulatory factor 4) and MyoD (Myoblast determining protein 1) (Lagha et al., 
2008).  Depending on the ultimate target of the myoblasts, there are two different 
migration pathways involved in hypaxial myogenesis – 1) ventral translocation for the 
intercostal and abdominal muscle precursors or alternatively 2) delamination and migration 
for progenitors of the limb, tongue and diaphragm (Thorsteinsdottir et al., 2011).   
 
In the second pathway, once the myoblasts have delaminated, they migrate to the 
contralateral limb field and are guided into position by the mesencyhmal limb cells, where 
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proliferation and further differentiation is induced by MyoD and Myf5 (Buckingham et al., 
2003, Mayer, 2003, Bismuth and Relaix, 2010). 
 
Primary myogenesis, the first wave of myoblast fusion, occurs in the mouse limb between 
developmental stages E10.5 and E12.5, when embryonic, terminally differentiated 
myoblasts align and fuse with each other or myotomal myocytes to form primary myotubes 
(Buckingham et al., 2003, Thorsteinsdottir et al., 2011).  Primary myotubes are important for 
the orientation of the muscle fibres, and act as a scaffold for secondary myogenesis 
(Thorsteinsdottir et al., 2011).  Additionally, during primary myogenesis, there is a switch 
from a fibronectin rich extracellular matrix to a laminin-containing basement membrane, 
with laminin 211 deposition first seen at the muscle fibre basement membrane at 
approximately E11.5 in the mouse, in a patchy, discontinuous pattern (Kuhl et al., 1986, 
Thorsteinsdottir et al., 2011).   
 
The second wave of myoblast fusion (secondary myogenesis), coinciding with the 
innervation of muscle fibres by motor neurons, is mediated by foetal myoblasts between 
E14.5 and E20.5 in the mouse (Buckingham et al., 2003).  Here, secondary myoblasts enter 
the myogenic program and either form secondary myotubes, using the existing primary 
myotubes as a scaffold or alternatively fuse to the end of primary myotubes, resulting in 
muscle growth (Thorsteinsdottir et al., 2011).  Thus, each muscle mass in the developing 
mouse limb contains a heterogeneous population at various stages of differentiation (Lagha 
et al., 2008).  Interestingly in humans there is a third wave of myoblast fusion, referred to as 
the tertiary wave, which evident at 16-17 weeks of gestation (Draeger et al., 1987). 
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Once secondary myogenesis is complete, the developing mouse muscle contains large, 
multinucleated muscle fibres (secondary muscle fibres) and a pool of resident muscle stem 
cells that either differentiate into myoblasts, contributing to the subsequent foetal and 
postnatal growth of skeletal, or remain as skeletal muscle progenitors which eventually 
become quiescent satellite cells (Buckingham et al., 2003, Lagha et al., 2008, Scharner and 
Zammit, 2011, Thorsteinsdottir et al., 2011).  The number of muscle fibres is largely 
determined around the time of birth and further increases in muscle size occur by fibre 
hypertrophy (an increase in size) rather than hyperplasia; the former being driven by the 
addition of muscle fibre nuclei (Scharner and Zammit, 2011, Relaix and Zammit, 2012). 
 
1.5.4 DEGENERATION AND REGENERATION 
In muscular dystrophies, such as the dystroglycanopathies, it is currently thought 
perturbation of the linkage between the intracellular actin cytoskeleton and the 
extracellular basement membrane results in repeated cycles of muscle fibre degeneration 
and necrosis (as described below) (Emery, 2002, Karpati, 2010).  Skeletal muscle fibres 
damaged either by acute injury or as consequence of disease are capable of regeneration 
(as described below), however, over time, regeneration fails in the muscular dystrophies, 
leading to a loss of muscle fibres and their replacement with fibrotic tissue or adipocytes, 
resulting in muscle weakness (Emery, 2002).  These features can be seen histologically in 
muscle, as shown in Figure 1-1. 
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Due to the postmitotic nature of the myonuclei, muscle fibre repair and regeneration 
parallels muscle fibre development,; thus newly generated myoblasts either fuse together, 
leading to formation of new myotubes, or they fuse to damaged muscle fibres (Scharner and 
Zammit, 2011, Relaix and Zammit, 2012).   
 
Satellite cells, first identified in 1961, are considered to be the resident muscle fibre stem 
cell, initially providing myoblasts for muscle growth and then becoming quiescent, activating 
only for muscle fibre growth or repair (Relaix and Zammit, 2012) .  Satellite cells exist in a 
niche on the muscle fibre surface between the sarcolemma and the basement membrane 
and are commonly identified by expression of Pax7, (Gnocchi et al., 2009, Tedesco et al., 
2010, Relaix and Zammit, 2012).  In uninjured adult mouse muscle, it is estimated 4.8-5.8% 
of the myonuclei are satellite cells (Scharner and Zammit, 2011).  Once activated by a 
stimulus, satellite cells leave their niche, activate expression of myogenic regulatory factors 
(Myf5 and MyoD) and divide asymmetrically, to generate both myoblasts and satellite cells, 
so the satellite cell pool is replenished after regeneration (Tedesco et al., 2010, Scharner 
and Zammit, 2011).  These myoblasts then divide symmetrically and mediate muscle fibre 
repair (Tedesco et al., 2010).  Although satellite cells are considered to be the primary 
source of postnatal myoblasts, recently a number of non-satellite cell myogenic precursors 
(i.e. progenitors identified outside the muscle basal lamina) have been identified (Relaix and 
Zammit, 2012) and shown to have regenerative potential in vitro or after transplantation 
(Tedesco et al., 2010).  However, despite this, recent ablation studies have shown that 
satellite cells are crucial for muscle regeneration, as regeneration does not occur in the 
absence of satellite cells (Murphy et al., 2011). 
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1.6 CENTRAL NERVOUS SYSTEM 
As outlined above in Section 1.3, where the phenotype of secondary dystroglycanopathy 
patients was described, the central nervous system (along with muscle) is one of the organs 
affected, particularly in those patients at the severe end of the clinical spectrum.  Therefore, 
here a brief description of the mature central nervous will be provided.  Finally, as basement 
membrane deposition and cortical lamination in the developing mouse cortex will be 
evaluated in one experimental chapter of this thesis (Chapter 3), a brief description of 
neural developmental will also be provided. 
 
The mature human central nervous system is considered to have 7 major parts –1) the 
spinal cord, 2) the medulla oblongata, 3) the pons and 4) the cerebellum (also collectively 
referred to as the hindbrain), 5) the midbrain, 6) the diencephalon and 7) the cerebral 
hemispheres (collectively referred to as the forebrain), which can be further subdivided into 
the basal ganglia, the hippocampus, the amygdala and the cerebral cortex, which will be 
focused on here (Kandel et al., 2000).  A simple schematic of these 7 components is shown 
in Figure 1-3, although the cortex is shown as a whole, rather than subdivided into its 
component structures.  The mammalian cortex is surrounded by the meninges, specialised 
membranes surrounding the adult brain to protect it from injury (Siegenthaler and Pleasure, 
2011).  There are 3 layers to the meninges – the dura mater, arachnoid mater and pia 
mater.  Underneath the meninges, the cerebral cortex is divided into 2 hemispheres, 
connected by the corpus callosum, a tract of commissural nerve fibres that connect similar 
regions on the left and right sides of the brain.  The cerebral cortex is concerned with 
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perception, motor and cognitive functions , which can be mapped to specific areas, or 
regions of the cortex (Kandel et al., 2000). 
  





FIGURE 1-3 HUMAN CENTRAL NERVOUS SYSTEM 
 
This representative schematic shows the main structures of the human central nervous 
system including the spinal cord, cerebellum, medulla oblongata, pons, midbrain, 
diencephalon and the cortex.  Additionally the lateral ventricle underneath the cortex has 
been labelled.   
 
This schematic was prepared using Powerpoint (Microsoft Office 2010) and is not drawn to 
scale.  
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The mammalian cerebral cortex is composed of multiple different cell types including 
neurons, astrocytes, microglia and Cajal-Retzius cells.  Histologically, these cells are 
organised into 6 distinctive cell layers, although the precise arrangement varies throughout 
the cortex depending on the function of that area.  These layers are numbered 1-6 from the 
pia mater and are primarily composed of the following neuronal subtypes, although each 
layer will contain additional elements, such as dendrites from neurons in other layers.  Layer 
I, the molecular layer, is an acellular layer occupied by dendrites; Layers II and IV are 
composed of small spherical granule cells and are referred to as the internal and external 
granule cell layer respectively.  Layers III and V contain pyramidal cells and are referred to as 
the external and internal pyramidal layers respectively.  Finally, layer VI, referred to as the 
multiform layer is a heterogeneous layer of neurons that blends with the underlying white 
matter (Kandel et al., 2000). 
 
1.6.1 CORTICAL DEVELOPMENT 
Cortical development is postulated to have 3 phases - progenitor expansion, followed by 
neurogenesis and then finally gliogenesis (Miyata et al., 2010).  During neurogenesis, 
cortical neurons are generated in the ventricular zone, by repeated divisions of progenitor 
cells and migrate until they reach the marginal zone where they are arranged into distinct 
cell layers (Valiente and Marin, 2010).  Neurons migrate in an inside-out fashion and the 
birthdate of a neuron is thought to define its final position (Figure 1-5). 
 
Neuroepithelial cells, the principal cells of the developing neural tube are the precursor cells 
for radial glia, and consequently both neurons and glial cells (Schroder et al., 2007).  These 
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cells divide symmetrically (to generate two daughter neuroepithelial cells) during the 
expansion phase, which lasts until approximately E11 in the mouse (Temple, 2001, Lathia et 
al., 2007, Farkas and Huttner, 2008, Miyata et al., 2010).  At the beginning of neurogenesis 
(approximately E12 in the mouse), the neuroepithelial cells begin to divide asymmetrically 
and differentiate into radial glia  (Kriegstein and Gotz, 2003, Haubensak et al., 2004, Gotz 
and Huttner, 2005, Kriegstein et al., 2006, Farkas and Huttner, 2008, Miyata et al., 2010).  
Radial glia cells, although capable of symmetrical cell division, most commonly divide by 
self-renewing asymmetric division, to produce a differentiated neural cell, whilst self-
renewing the progenitor cell (Lathia et al., 2007, Lesage et al., 2010). 
 
A schematic of neuroepithelial and radial glia cells is shown in Figure 1-4, and due to 
similarities in structures, including their apical-basal polarity, these cells are often referred 
to as the apical progenitor cells (Farkas and Huttner, 2008).  As Figure 1-4 shows, these cells 
have a palisade-like morphology, and span the entire cortical wall, with one end-foot at the 
ventricular zone (basal surface) and the other terminating on the pial basement membrane 
(Blank et al., 2002, Kriegstein and Gotz, 2003, Lathia et al., 2007, Schroder et al., 2007).  
During the cell cycle their nucleus undergoes interkinetic migration, migrating apically 
during the first growth phase (G1), maintaining this basal localisation during S phase when 
DNA is synthesised and then migrating towards the basal surface during the second growth 
phase (G2), with mitosis occurring in the ventricular zone (Figure 1-4) (Gotz and Huttner, 
2005, Farkas and Huttner, 2008). 
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Additionally, the rodent neocortex has basal progenitors, which are present only after the 
onset of neurogenesis (Farkas and Huttner, 2008).  These cells undergo mitosis in, or within 
close proximity to the subventricular zone and do not display interkinetic nuclear migration 
(Farkas and Huttner, 2008).  Basal progenitors can be generated in two ways – by 
neuroepithelial or radial glia cells undergoing a self-renewing asymmetric division to 
produce a basal progenitor, or self-amplification, with the basal progenitors dividing 
symmetrically (approximately 10% are estimated to be capable of self-renewal) (Farkas and 
Huttner, 2008).  The vast majority of basal progenitors then divide symmetrically to 
generate two differentiated neurons. 
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FIGURE 1-4 SCHEMATIC OF NEUROEPITHELIAL AND RADIAL GLIAL CELLS 
Schematic showing polarised organisation of neuroepithelial cells (green) and radial glia 
(pink), with end-feet at both the apical surface (ventricular zone – VZ) and basal surfaces 
(pial basement membrane – pial BM).  Neuroepithelial and radial glial cells undergo 
interkinetic nuclear migration (nuclei in blue) during the cell cycle as shown here.  During G1 
(labelled 1), the nucleus migrates apically – reaching the pial basement membrane in the 
neuroepithelial cells and the subventricular zone in radial glial cells, where it remains 
localised during S phase (labelled 2).  During G2 (labelled 3), the nucleus migrates basally 
back to the ventricular zone where mitosis occurs.  The differentiated neurons generated by 
the radial glia are shown in yellow. 
 
This figure was based on information from (Gotz and Huttner, 2005).  
Page 54 of 551 
 
There are two main types of neuronal migration in the developing cortex – tangential 
migration and radial migration.  Tangential migration is the process by which cortical 
interneurons, which originate in the ganglionic eminence, reach their destination in the 
cortex.  Alternatively, the vast majority of cortical projection neurons (which originate in the 
ventricular zone) migrate radially.  These cells migrate from the ventricular zone migrate 
towards the marginal zone, using the processes of the radial glial scaffold as a guide 
(Valiente and Marin, 2010).  Once the cells have reached the marginal zone, they halt their 
migration, detach from the glial process, position themselves within the cortical plate and 
begin to differentiate (Valiente and Marin, 2010).  The cortex patterns in an inside-out 
fashion with later-born neurons migrating past earlier born neurons which are already 
differentiating within the cortical plate.  This pattern of cortical histogenesis and lamination 
is shown as a schematic in Figure 1-5. 
 
It is considered the Cajal-Retzius cells localised to the marginal zone are involved in 
patterning the cortical layers and establishing lamination, through the synthesis of Reelin, 
an extracellular matrix glycoprotein (D'Arcangelo et al., 1997).  Since significant defects in 
neuronal positioning are observed in the Reeler mutant mouse, which has defective Reelin 
expression (D'Arcangelo et al., 1995), this protein is considered to be crucial for cortical 
lamination.  Reelin has two receptors - ApoER2 (Apolipoprotein E Receptor 2) and Vldlr (very 
low density lipoprotein receptor) and recently it has been shown with knockout mice that 
the actions of these two Reelin receptors are molecularly distinguishable, with actions 
downstream of ApoER2 involved in establishing cortical layering and those through Vldlr 
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preventing invasion of the migrating neurons into the marginal zone (Hack et al., 2007, 
Valiente and Marin, 2010).   
Page 56 of 551 
 
 
FIGURE 1-5 CORTICAL LAMINATION SCHEMATIC 
Schematic showing mammalian cortical lamination during early neurogenesis (A) and later 
cortical development (B).  The black lines show the basal basement membrane (underneath 
the ventricular zone - VZ) and pial basement membrane (above the marginal zone).  The 
marginal zone (MZ) is shown with grey clouds representing the Cajal-Retzius cells.  The tear 
drops represent postnatal neurons, coloured yellow, purple and blue to denote neurons 
generated at different developmental times.   
 
Neurons generated in the ventricular zone migrate towards the marginal zone, where 
migration is halted.  In early developmental stages (A) this region is referred to as the pre-
plate.  At later stages of neuronal migration (B), neurons continue the same pattern of 
migration through the cortex accumulating in the cortical plate.  Thus, neurons generated 
later in development migrate past earlier born neurons that are already differentiating and 
it is said the cortex patterns in an inside-out fashion.  
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1.7 EYE 
As outlined above in Section 1.3, where the phenotype of secondary dystroglycanopathy 
patients was described, along with the muscle and brain defects, eye abnormalities have 
also been identified, particularly in those patients at the severe end of the clinical spectrum.  
Therefore, here a brief summary of eye anatomy will be given.  As basement membrane 
deposition in the extraocular muscles will be evaluated in one of the experimental chapters 
(Chapter 3), this will be followed by an introduction to the extraocular muscles.  Finally, as 
retinal lamination will be investigated in the second experimental chapter (Chapter 4), a 
brief description of eye development will be also be given. 
 
The mammalian eye (shown as a schematic in  
Figure 1-6) is made up of three basic layers, - the outer corneo-scleral layer is a tough, 
fibroelastic capsule which supports the eye, provides attachment for the extraocular 
muscles, and in the anterior portion (the cornea) focuses light on the retina.  The second 
uveal layer contains the ciliary body and the iris, which are involved in focussing and 
regulating the amount of light entering the eye respectively along with the choroid, which 
provides nutrient support for the retina and absorbs excess light to sharpen the visual image 
(Young and Heath, 2000).   
 
The lens, suspensory ligament and ciliary body anatomically partition the eye into two 
compartments - the anterior (just described) and posterior compartment, with the vitreous 
body (transparent gelatinous mass of extracellular matrix which supports the eye while 
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providing a non-refractive medium) and the retina (Young and Heath, 2000, Halfter et al., 
2005a).    




FIGURE 1-6 SCHEMATIC OF EYE STRUCTURE 
Labelled schematic showing the major components of the eye, both the anterior portion 
(containing the lens, iris, ciliary muscle, suspensory ligament, iris and pupil and the posterior 
portion (the vitreous body, retina, retinal pigmented epithelium, choroid, macula, optic disc 
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The vertebrate retina is a thin sheet of neural tissue located on the inner surface of the 
posterior eye (Bassett and Wallace, 2012) that converts light into nervous impulses, which 
are then transmitted to visual processing centres, where this incoming sensory information 
is interpreted into a visual signal (Pang and Clark, 2010).  This tissue is classified 
histologically into 10 layers, working from the outside in – 1) the RPE (Retinal Pigmented 
Epithelium), 2) photoreceptors (rods and cones), 3) outer limiting membrane, 4) outer 
nuclear layer, 5) outer plexiform layer, 6) inner nuclear layer, 7) inner plexiform layer, 8) 
ganglion cell layer, 9) nerve fibres and 10) the inner limiting membrane (ILM), although 
there is some slight variation in detail between different species (Grigorian, 2001, Pang and 
Clark, 2010).  The RPE, the non-neuronal portion of the retina is a simple cuboidal 
epithelium which has a wide range of biological functions  including phagocytosis of outer 
segment discs, creation of the outer aspect of blood-retinal barrier, maintenance of 
choroidal vasculature, recycling vitamin A and quenching photons not absorbed during the 
first pass through the retina (Grigorian, 2001, Pang and Clark, 2010). 
 
The major macroglial cells of the retina, Mϋller glia, have extensive processes and span the 
length of the retina, with their end-feet forming pyramidal tight junctions at the ILM (Pang 
and Clark, 2010).  As well as having a structural space filling role, and ensheathing individual 
synapses to maintain a high signal: noise ratio, the Müller glia support the 
microenvironment of the retina, for example by contributing to the inner aspect of the 
blood retinal barrier, trafficking Vitamin A derivatives and removal of waste products (Pang 
and Clark, 2010).  However, the retina can also contain other glial cells types including 
microglia and astrocytes (Grigorian, 2001).   
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1.7.1 EXTRAOCULAR MUSCLES 
There are 6 extraocular muscles which are arranged in 3 antagonist pairs – 1) the medial 
rectus (adduction) and lateral rectus (abduction) which rotate the eye horizontally, 2) the 
superior rectus (supraductor) and the inferior rectus (infraductor) which rotate the eye 
vertically and 3) the superior oblique (intort) and inferior oblique (extort) which implement 
tortion around the line of sight ( traube and B ttner, 200 ) ( 
Figure 1-7).   
 
Instead of having a heterogeneous distribution of the muscle fibre types I, IIA, IIB and IIX 
described above across their cross-sectional area (Schiaffino and Reggiani, 2011), 
extraocular muscles have 6 fibre types - 1) orbital singly innervated, 2) orbital multiple 
innervated, 3) global red single innervated, 4) global white single innervated, 5) global 
intermediate single innervated and 6) global multiple innervated ( traube and B ttner, 
2007).  These fibre types in part arise through the compartmentalisation of the extraocular 
muscles into two layers - an inner, or deep “global” layer and an outer, or superficial C-
shaped “orbital” layer (Porter, 2002, Noden and Francis-West, 2006,  traube and B ttner, 
2007, Zeiger et al., 2010).  The orbital layer is composed of small diameter muscle fibres 
with a high mitochondrial content, well-developed microvascular system and oxidative 
enzymes, which correlates with high levels of continuous activity, while the inner global 
layer contains muscle fibres of a larger diameter ( traube and B ttner, 2007, Zeiger et al., 
2010)    




FIGURE 1-7 SCHEMATIC DIAGRAM OF HUMAN EXTRAOCULAR MUSCLES 
Schematics indicating the 6 extraocular muscles (superior oblique, superior rectus, lateral 
rectus, medial rectus, inferior rectus and inferior oblique) of the left eye (from a coronal 
plane) (A) and the right eye from a sagittal plane (B).  In B, the medial rectus is not visible or 
labelled because it is obscured by the lateral rectus. 
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All fibres in muscles such as the gastrocnemius and tongue are singly innervated – they have 
one neuromuscular junction where the nerve synapses with the muscle fibre to initiate 
contraction in an “all-or-nothing” response, similarly to approximately 80-85% of 
extraocular muscle fibres (Straube and B ttner, 200 ).  However, the remaining extraocular 
muscle fibres (15-20%) have a different pattern of innervation – they are multiply 
innervated non-twitch skeletal muscle fibres, a type which is otherwise absent from 
mammalian muscles ( traube and B ttner, 200 ).  Here, specialised nerve endings (palisade 
endings) form cuffs around the muscle fibre and instead of propagating action potentials, 
these fibres generate slow graded contractions to gradually increase muscle force (Porter, 
2002,  traube and B ttner, 200 ) and consequently are able to maintain tension for longer 
periods at a lower metabolic “cost” ( traube and B ttner, 200 ).  Thus it is thought these 
multiply innervated fibres are responsible for maintaining eye positioning, while the single 
innervated muscle fibres drive eye movement ( traube and B ttner, 200 ).   
 
1.7.2 VERTEBRATE EYE DEVELOPMENT 
The vertebrate eye develops from the anterior neural plate through a series of 
morphogenetic movements after approximately E9 in the mouse (Wittbrodt and Rosa, 1994, 
Martinez-Morales et al., 2005, Gilbert, 2006).  The first step in eye development is in the 
lateral evagination of retinal precursors into the two specialised epithelial sheets (optic 
vesicles), which extend from the forebrain towards the surface ectoderm (Wittbrodt and 
Rosa, 1994, Martinez-Morales et al., 2005, Gilbert, 2006).  This is followed, at E11 by the 
simultaneous formation of the lens vesicle and the folding of the optic vesicles into the optic 
cup (Wittbrodt and Rosa, 1994, Martinez-Morales et al., 2005, Gilbert, 2006).  The lens 
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vesicle then further differentiates while inducing the formation of anterior eye structures, 
such as the lens and the cornea, while the inner and outer layers of the optic cup contain 
the precursors for the neural retina and RPE respectively (Grigorian, 2001, Gilbert, 2006).  
 
As in the cortex, the stem cells are the neuroepithelial cells, which then become the retinal 
progenitors and eventually the Müller glial cells (Blank et al., 2002, Bassett and Wallace, 
2012).  These retinal progenitors span the width of the retina, with their cell bodies forming 
the outer neuroblastic layer at the basal surface and their extending processes to the vitreo-
retinal interface, where the ILM forms (Montanaro et al., 1995, Bassett and Wallace, 2012).  
Similarly to the cortex, retinal progenitor cells divide at the basal surface to generate 
differentiated neuronal types, and these cells migrate through the retina to the vitreal 
surface of the developing eye (Bassett and Wallace, 2012). 
 
Retinal progenitor cells are multi-potent and generate all the different cell types of the 
retina in overlapping chronological intervals (Grigorian, 2001, Bassett and Wallace, 2012), 
with retinal ganglion cells, cone photoreceptors, amacrine cells and horizontal cells 
generated prior to birth, rod photoreceptors differentiating at around P0 and the remaining 
cell types (bipolar neurons and Müller glia) generated after birth (Blackshaw et al., 2004).   
 
Cell fate specification in the retina is based on a competence model – retinal progenitor cells 
proceed irreversibly through defined competence states throughout development, and at 
any given developmental time point, progenitor cells have heterogeneity in their 
competence (Blackshaw et al., 2004, Bassett and Wallace, 2012).  A vast number of 
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transcription factors and programs are involved  (Bassett and Wallace, 2012), although cell 
fates can also be affected by extrinsic factors, such as the migration and positioning of the 
progenitor cells in the neuroblastic layer and the microenvironment of the retina (Grigorian, 
2001, Blackshaw et al., 2004, Bassett and Wallace, 2012).  Retinal progenitor cells are also 
heterogenic across the retina and at each developmental age, neuronal progenitors in the 
central retina  are more mature and further differentiated in comparison to those in the 
peripheral retina (Harman and Beazley, 1989, Anezary et al., 2001, Fischer and Reh, 2003, 
Fischer et al., 2004, Ghai et al., 2008, Bassett and Wallace, 2012).  
 
1.8 BASEMENT MEMBRANES  
A wide range of human disorders are caused by, or associated with basement membrane 
defects (Yurchenco and Patton, 2009), including the dystroglycanopathies, and 
consequently basement membranes are considered to be important for tissue 
morphogenesis, development and function (Miner and Yurchenco, 2004).  Therefore, the 
basic structure of the basement membrane will now be described, and a brief description of 
important basement membrane ligands laminin, collagen type IV, nidogen, perlecan, agrin 
and collagen XVIII will be provided.  However, the specific ligand composition of each 
basement membrane is tissue specific, so this overview will be followed by a summary of 
basement membrane distribution in the three tissues predominantly affected in the 
dystroglycanopathies – the muscle, brain and eye.  Finally, an account of basement 
membranes deposition will also be provided. 
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There are two types of extracellular matrixes – interstitial and pericellular matrices - the 
interstitial matrix is a loose network of fibres found in the interstitial space, while 
pericellular matrices are in close contact with cells (Thorsteinsdottir et al., 2011).  An 
example of a pericellular matrix is the basement membrane, formed adjacent to epithelial, 
endothelial, neural, muscle and adipose cells (Henry et al., 2001, Thorsteinsdottir et al., 
2011).  Basement membranes are organised, sheet-like structures, usually between 50-
100nm that stabilise cells by physically linking the intracellular cytoskeleton to the loose 
interstitial matrix outside the cell (Patton, 2000, Anderson et al., 2007, Munoz et al., 2010, 
Hohenester and Yurchenco, 2013).  Basement membranes have a characteristic appearance 
on electron micrograph following conventional fixation, with the outer layer, lamina densa 
separated from the plasma membrane by a translucent layer, the lamina lucida (Miosge, 
2001, Yurchenco and Patton, 2009).  As well as physically stabilising cells, basement 
membranes have been shown to influence biological functions, such as cell proliferation and 
differentiation (Patton, 2000, Yurchenco and Patton, 2009).   
 
The basic framework of the basement membrane is created by indepdendent laminin and 
collagen networks, bridged or stablised by other proteins including, heparan sulfate 
glycosaminoglycans (agrin and perlecan), tenascin, fibronectin, nidogen and anchored to the 
cell plasma membrane through binding to cellular adhesion receptors, such as dystroglycan 
and integrins (LeBleu et al., 2007, Singhal and Martin, 2011, Hohenester and Yurchenco, 
2013) ( 
Figure 1-8).   
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Basement membranes have important biological functions in the body for tissue 
development, support, growth and maintenance (Hohenester and Yurchenco, 2013).  
Consequently loss of basement membrane proteins in mice results in embryonic lethality at 
various developmental ages – E5.5 for laminin γ1-/- (Smyth et al., 1999) and laminin β1-/- 
(Miner et al., 2004), E  for laminin α1-/- (Miner et al., 2004), E10.5-E11.5 for collagen type IV 
(Poschl et al., 2004), E10.5 or perinatally for perlecan deficient mice (Arikawa-Hirasawa et 
al., 1999, Costell et al., 1999), E13-E1  for laminin α5 knockout mice (Miner et al., 1998) and 
the early perinatal period for nidogen-1 and nidogen-2 double knockout mutants (Bader et 
al., 2005) and agrin-deficient mice (Gautam et al., 1996).  
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FIGURE 1-8 SCHEMATIC OF BASEMENT MEMBRANE STRUCTURE 
Schematic denoting the structure of a basement membrane.  The laminin network is 
anchored to integrins, α-dystroglycan or sulphated glycolipids/sulfatides and additionally, 
makes collateral interactions with the heparan sulphate proteoglycans agrin and perlecan.  
An independent network is made by collagen type IV, with the laminin and collagen 
networks linked by agrin, nidogen and perlecan. 
 
This image was taken from (Hohenester and Yurchenco, 2013).  This article is Open Access 
under a Creative Commons license http://creativecommons.org/licenses/by-nc/3.0/ 
and although the journal was contacted no permission was needed for reproduction. 
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1.8.1 LAMININ 
Laminins are large (over 800kDa), heterotrimeric multidomain glycoproteins, composed of 
one α, one β and one γ chain (Figure 1-9).  To date, in human and mouse 5α, 3β and 3γ 
chains have been identified, which, when splice variants are included, assemble into 16 
different heterotrimers (Colognato and Yurchenco, 2000, Patton, 2000, Miner and 
Yurchenco, 2004, Aumailley et al., 2005, Hamill et al., 2009).  These heterotrimers listed in 
Table 1-2, along with their laminin chain composition and nomenclature, both old (Burgeson 
et al., 1994) and new (Aumailley et al., 2005).  Previously, laminin heterotrimers were given 
a number, from 1-16, but since 2005, these have been re-named with respect to their 
individual chain composition, for example laminin 211 contains laminin α2, β1 and γ1 
(Aumailley et al., 2005).  For clarity, only the new nomenclature will be used in this thesis 
and in the case of any citations published before the new nomenclature was adopted, the 
older nomenclature will have been converted into new nomenclature. 
 
Laminins are cross-shaped as shown in Figure 1-9, with three short arms, one from each of 
the individual component chains and one long arm, which is an α-helical coiled-coil 
structure formed from all three chains (Hohenester and Yurchenco, 2013).  The N-terminus, 
or LN domain which found on all laminin chains, with the exception of laminin α4, β2, γ2 
and a splice variant of laminin α3 (α3A), mediates polymerisation of laminin monomers into 
the basement membrane network as described in Section 1.9 below (Patton, 2000, 
Yurchenco and Patton, 2009, Hohenester and Yurchenco, 2013).  The C-terminus at the end 
of the long arm contains 5 LG (laminin G-like) domains, which are divided into 2 regions, 
LG1-3 and LG4-5 with a hinge-like region separating the two (Yurchenco and Patton, 2009).  
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Integrins bind via LG domains 1-3 (Ido et al., 2004, Ido et al., 2007) whilst dystroglycan, 
heparan sulfates and sulfatides bind  LG domains 4-5 in a calcium dependent manner (Gee 
et al., 1993, Talts et al., 1999, Smirnov et al., 2002, Ido et al., 2004). 
 
  




FIGURE 1-9 STRUCTURE OF LAMININ TRIMERS 
Schematic structure showing examples of two different structures of mouse or human 
laminin heterotrimers.  The numbers underneath suggest laminin trimers which might have 
that structure.  The Greek letters next to the chain indicate the individual chains – α in 
orange, β in blue and γ in green.  The LG domains at the C-terminus that mediate adhesion 
receptor binding are labelled LG1-3 and LG4-5.  This schematic is based on information from 
(Aumailley et al., 2005, Domogatskaya et al., 2012).  
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1.8.2 COLLAGEN TYPE IV  
Collagen type IV, a non-fibrillar collagen, is common to all mammalian basement 
membranes during development and adulthood (Erickson and Couchman, 2000, Hutter et 
al., 2000, Hohenester and Yurchenco, 2013).  It is first expressed in the mouse at E4.5 and is 
considered to account for approximately 50% of all basement membrane proteins (LeBleu et 
al., 2007).  In mammals there are 6 genes encoding for 6 distinct chains of collagen type IV 
(α1-α6) which are highly conserved amongst vertebrates (MacDonald et al., 2006, LeBleu et 
al., 2007).  Each individual collagen chain is approximately 400nm long and contains a N-
terminal 7S domain, a triple helical collagenous domain with a repetitive Gly-X-Y amino acid 
sequence and a C-terminal non-collagenous globular domain (LeBleu et al., 2007).  Collagen 
molecules are secreted as heterotrimers of three α-chains and these protomers are the 
building blocks of the type IV collagen network (LeBleu et al., 2007), with collagen the only 
other basement membrane component apart from laminin to form a polymeric network 
(Timpl et al., 1981, Yurchenco and Furthmayr, 1984, Yurchenco and Ruben, 1987, 
Hohenester and Yurchenco, 2013).   
 
1.8.3 NIDOGEN 
Nidogen, first expressed at E10.5 in the mouse, becomes ubiquitously expressed in adult 
mammalian basement membranes and is estimated to be between 2-3% of total basement 
membrane protein (Hutter et al., 2000, Leimeister et al., 2004, LeBleu et al., 2007).  
Nidogens bind with high affinity to the other basement membrane proteins laminin γ1, 
perlecan and collagen type IV (Fox et al., 1991, Chung et al., 1993, Mayer et al., 1993, Hopf 
et al., 2001, Erickson and Couchman, 2000).  The core nidogen protein contains 3 G 
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domains, separated by two rod-like segments, with approximately 10% of the total protein 
occupied by carbohydrates, an equal proportion of N-linked and O-linked oligosaccharide 
chains (LeBleu et al., 2007).  There are two different nidogen proteins – nidogen-1 (30nm 
long) and nidogen-2 (40nm) encoded for by two different genes, with the two proteins 
having low sequence homology but a similar structural organisation (Kimura et al., 1998, 
LeBleu et al., 2007).  Moreover, there is thought to be some functional redundancy between 
the two proteins (Miosge et al., 2002) as mouse models deficient in nidogen-1 (Murshed et 
al., 2000), or nidogen-2 (Schymeinsky et al., 2002) have histologically normal basement 
membranes, while mice deficient in both nidogen-1 and nidogen-2 expression display 
significant basement membrane abnormalities and die in the early perinatal period (Bader 
et al., 2005).  
 
1.8.4 PERLECAN 
Perlecan is a heparan sulphate proteoglycan with a molecular weight of 400-500kDa 
ubiquitously expressed in basement membranes (LeBleu et al., 2007), with expression first 
detected in mice at E10.5 (Handler et al., 1997, French et al., 1999).  Structurally, perlecan 
has 5 distinct domains, with its overall structure likened to resemble “pearls on a string” 
(LeBleu et al., 2007).  The core protein contains various binding sites for collagen type IV, 
nidogen and integrins (LeBleu et al., 2007).  Domain I of the perlecan N-terminus is 
covalently linked to 3 glycosaminoglycan side chains (LeBleu et al., 2007).  Similarly to 
nidogen, perlecan molecules do not self-assemble into a network - they are secreted as 
single molecules and incorporated into the basement membrane through binding to laminin 
and collagen type IV in the extracellular space (LeBleu et al., 2007, Yurchenco and O'Rear, 
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1994, Paulsson, 1992).  Perlecan deficient mice are estimated to have 40% lethality at E10.5, 
with the remainder of mutant mice dying in the early neonatal period (Arikawa-Hirasawa et 
al., 1999, Costell et al., 1999), suggesting perlecan has an important role in basement 
membrane stability.    
 
1.8.5 AGRIN 
Agrin is a heparan sulphate proteoglycan (Kirn-Safran et al., 2009).  The agrin precursor 
protein is 2045 amino acids in size, with a 29 amino acid signal peptide cleaved just before 
secretion to generate the core agrin protein (Kirn-Safran et al., 2009).  This core protein has 
a unique N-terminus domain (amino acids 30-157) where agrin binds to laminin 
(Mascarenhas et al., 2005), followed by 8 Kasal-like domains (Kirn-Safran et al., 2009).  The 
central portion of the agrin protein contains a SEA (sperm protein, enterokinase, agrin) 
domain, flanked by two serine/threonine residues where glycosaminoglycan side chains, or 
chondroitin sulphate is attached (Kirn-Safran et al., 2009).  Between the SEA domain and the 
C-terminal region, agrin contains alternating EGF (epidermal growth factor)-like and LG 
domains, the latter mediating its interaction with the dystroglycan and integrin receptor 
complexes (Kirn-Safran et al., 2009).  Agrin null mice also die in the early perinatal period 
(Gautam et al., 1996). 
 
1.8.6 COLLAGEN XVIII 
Collage XVIII, a nonfibrillar member of the multiplexin protein family, the first collagen 
identified with heparan sulphate proteoglycan side chains is expressed at some (but not all) 
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mammalian basement membrane (Halfter et al., 1998, Erickson and Couchman, 2000).  
Structurally, collagen XVIII has a repeated Gly-X-Y motif, which allows the 3 polypeptide 
chains to fold into its 10 triple helical collagenous domains, making them rigid and inflexible 
(Oh et al., 1994, Erickson and Couchman, 2000).  These collagenous domains are separated 
by 11 non-collagenous domains (Oh et al., 1994, Erickson and Couchman, 2000).  There are 
3 variants of collagen type XVIII in the mouse and 2 in the human, which have a variable 
tissue distribution and expression levels (Muragaki et al., 1995, Rehn and Pihlajaniemi, 1995, 
Rehn et al., 1996).  Collagen XVIII is localised to chromosome 10 in the mouse and 21.q22.3 
in the human (Erickson and Couchman, 2000), with the human sequence for collagen XVIII 
having an 81.6% sequence identity with the mouse (Rehn and Pihlajaniemi, 1994).   
 
1.8.7 TISSUE SPECIFIC VARIATIONS IN BASEMENT MEMBRANE COMPOSITION 
As already mentioned, although all basement membranes have the same basic framework 
(described above in Section 1.8), the specific ligand composition of this structure varies 
between tissues (LeBleu et al., 2007), particularly with regards to the composition of the 
laminin chains.  Therefore, the basement membrane ligand composition of the tissues 
affected in the dystroglycanopathies - muscle fibre basement membrane, pial basement 
membrane and the two basement membranes of the eye (ILM and Bruch’s membrane) will 
now be introduced, with the laminin distribution summarised in Table 1-2.  
  









Published expression in the brain, eye 
and/or muscle 
α1 β1 γ1 111 1 Myotendinous Junction 
α2 β 1γ1 211 2 Muscle fibre basement membrane 
α1 β2 γ1 121 3 Myotendinous Junction 
α2 β2 γ1 221 4 Neuromuscular Junction 
α3A β3 γ2 332, or 3A32 5, or 5A Not documented 
α3B β3 γ2 3B32 5B Not documented 
α3A β1 γ1 311, or 3A11 6, or 6A Not documented 
α3A β2 γ1 321, or 3A21 7, or 7A Not documented 
α4 β1 γ1 411 8 Not documented 
α4 β2 γ1 421 9 Neuromuscular Junction (mouse) and 
muscle fibre basement membrane 
(human) 
α5 β1 γ1 511 10 Not documented 
α5 β2 γ1 521 11 Neuromuscular Junction 
α2 β1 γ3 213 12 Not documented 
α3 β2 γ3    323 13 Central nervous system and retina 
α4β2γ3 423 14 Central nervous system and retina 
α5β2γ3 523 15 Central nervous system and retina 
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TABLE 1-2 LAMININ TRIMER COMPOSITION AND THEIR EXPRESSION IN MUSCLE, 
EYE AND BRAIN 
 
This table shows the composition of each of the laminin trimers along with the new 
nomenclature, which is an abbreviated list of their laminin chain composition (Aumailley et 
al., 2005) .  It also includes the old nomenclature, where laminin trimers were designated 1-
15 in order of discovery (Burgeson et al., 1994).  Additionally, for each laminin chain, 
information is provided on its expression pattern in the muscle, brain and eye, the three 
major organs affected in patients with the dystroglycanopathies (Wewer et al., 1997, 
Hallmann et al., 2005, Singhal and Martin, 2011). 
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1.8.7.1 MUSCLE FIBRE BASEMENT MEMBRANE 
All individual muscle fibres are surrounded by a basement membrane, which has been 
shown to have roles in myogenesis, muscle maintenance and regeneration and additionally 
dissipating the mechanical forces of contraction (Sanes, 2003).  The components of this 
basement membrane are individually secreted by the muscle fibre itself (Karpati, 2010), 
with the basement membrane assembled on the extracellular surface of the fibre.  The 
basement membrane of the developing muscle fibre contains the laminin trimers 111, 211, 
411 and 511, with, as the muscle fibre matures, expressions of laminin 411 and 511 lost and 
laminin 111 restricted to the myotendinous junction (Patton et al., 1997, Singhal and 
Martin, 2011).  Thus, the mature muscle fibre basement membrane has been shown to 
contain collagen type IV (Sanes, 2003), collagen XVIII (Halfter et al., 1998), fibronectin, 
nidogen-1, perlecan and the laminin trimer 211 (Sanes et al., 1990, Singhal and Martin, 
2011).   
 
The neuromuscular junction of each muscle fibre has a specialised region of basement 
membrane which becomes established during development and has been shown to contain 
the ligands agrin, collagen XIII, neurexin, neuregulin and nidogen 2, along with the laminin 
trimers 221, 421 and 521 (Singhal and Martin, 2011). 
 
1.8.7.2  PIAL BASEMENT MEMBRANE COMPOSITION 
The pial basement membrane (one of the meningeal layers of the central nervous system), 
which acts as both the anchoring site for the end-feet of the radial cells and a physical 
barrier for the migrating neurons, is secreted and organised by the meningeal cells 
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(Siegenthaler and Pleasure, 2011).  Interestingly the meningeal cells surround the forebrain 
originate from the neural crest, whereas those surrounding the remainder of the cortex and 
the spinal cord are mesenchymal in origin (Siegenthaler and Pleasure, 2011).  The 
developing and mature pial basement membrane has been shown to contain the laminin 
chains α1 (Falk et al., 1999), γ1 and γ3 (Li et al., 2012), along with other basement 
membrane ligands, collagen XVIII (Halfter et al., 1998), collagen type IV, nidogen-1, agrin, 
fibronectin and perlecan (Lathia et al., 2007).  
 
1.8.7.3  ILM COMPOSITION 
The ILM, approximately 70-80nm thick is a sheet of basement membrane proteins, which 
defines the border between the retina and vitreous body, maintains the adherence of the 
retina and the vitreous body, aligns the Müller glial cells in their correct origination and is 
necessary for normal retinal development in both chick and mouse (Halfter et al., 2005a, 
Halfter et al., 2008, Franze et al., 2007, Balasubramani et al., 2010). A number of different 
basement membrane ligands have been detected at the ILM, including collagen XVIII 
(Halfter et al., 1998), perlecan, nidogen-1, collagen IV (Halfter et al., 2008) and additionally 
laminin – both the trimer 111 (Falk et al., 1999, Halfter et al., 2008) and chain γ3 (Li et al., 
2012). 
 
Interestingly, the ILM is assembled in a different way to other basement membranes –
ligands present in the vitreous body bind to cellular adhesion receptors in the retina 
(expressed at the end-feet of the glial cells) and the ILM is assembled on the retinal surface 
(Halfter et al., 2008).  Thus, during embryonic development, the vitreous body with its high 
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abundance of basement membrane ligand monomers, acts as a reservoir and allows for 
rapid deposition of the ILM during  eye development (Halfter et al., 2008).  Interestingly, 
although expression of some ligands (laminin 111, perlecan and collagen IV) can still be 
detected in the adult vitreous body, their concentration is much reduced because the 
turnover of the adult ILM is low (Halfter et al., 2008).  These ILM components are 
synthesised by various parts of the developing eye including the lens (perlecan), ciliary body 
and optic disc (collagen XVIII, laminin 111, nidogen-1 and collagen IV) and the retinal 
ganglion cells (agrin) (Halfter et al., 2005a, Halfter et al., 2008).  
 
1.8.7.4  BRUCH’  MEMBRANE 
Although it was initially though that Bruch’s membrane was a simple sheet of extracellular 
matrix occupying the space between the RPE and the choroid layers, it is now known that 
Bruch’s membrane is a pentalaminar structure, with the 5 layers considered to be 1) the 
basement membrane of the retinal pigmented epithelium, 2) an inner collagen layer, 3) an 
elastin layer, 4) an outer collagen layer and 5) the basement membrane of the choroidal 
capillaries (Booij et al., 2010).  The basement membrane of the RPE is a continuous 
basement membrane layer containing many ligands commonly found in other basement 
membranes including collagen type IV, laminin (γ3) and fibronectin (Booij et al., 2010, Li et 
al., 2012).  Both the inner and outer collagen layers are composed of collagen fibres which 
are arranged into a multi-layered grid (Booij et al., 2010).  The elastin layer is composed of 
stacked layers of elastin fibres, of various shapes and sizes (Booij et al., 2010).  The 
basement membrane of the choriocapillaries is a non-continuous, interrupted basement 
membrane layer (Booij et al., 2010).   
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Bruch’s membrane forms a single functional unit with the RPE and the choroidal capillaries 
and it has a passive transport function, as it is involved in the exchange of biomolecules, 
nutrients, oxygen, fluid and metabolic waste products between the retina and the choroidal 
capillaries (Booij et al., 2010).  Bruch’s membrane is acellular, so the basement membrane 
components are synthesised by the RPE and the cells of the choroidal capillaries (Booij et al., 
2010, Aisenbrey et al., 2006).  The structure of Bruch’s membrane is different in the central 
retina than the peripheral – it is 3-6x thinner and 2-5x more porous in the central retina, 
relative to the peripheral (Chong et al., 2005, Booij et al., 2010).  Additionally, Bruch’s 
membrane has a supporting role, since it acts as an adhesion site for the RPE and is thought 
to be involved in RPE differentiation (Gong et al., 2008, Booij et al., 2010).    
 
1.9 BASEMENT MEMBRANE DEPOSITION 
Basement membranes deposit by self-assembly on the cellular surface and the first step in 
this process is considered to be the polymerisation of laminin monomers (McKee et al., 
2007, Thorsteinsdottir et al., 2011).  Laminin polymerisation has two steps – 1) nucleation, 
the calcium-independent formation of individual laminin trimers at the cell surface and 2) 
propagation/polymerisation, the calcium-dependent formation of the laminin network 
(Yurchenco and Patton, 2009).   
 
Laminin polymerisation/propagation is reversible, entropy driven, cooperative and requires 
a crucial concentration of laminin monomers (Yurchenco and Patton, 2009).  It is a process 
driven by the formation of interlocking LN domains from the α, β, and γ short arms of 
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neighbouring laminin chains which bind to each other (Yurchenco and Patton, 2009).  The 
current model of laminin polymerisation is the “three-arm interaction model” of laminin 
self-assembly – laminins self-assemble and form ternary nodes with their N-terminals, with 
each ternary node containing one α, one β and one γ chain (Hohenester and Yurchenco, 
2013), as shown in Figure 1-10.  
 
In vivo laminin polymerisation occurs at the cell surface, when laminin monomers are 
anchored to cellular adhesion receptors such as dystroglycan (Hohenester and Yurchenco, 
2013), i.e. receptor-mediated self-assembly into the polygonal laminin network (Karpati, 
2010).  It is thought that binding to cellular adhesion receptors, such as integrin receptor 
complexes or dystroglycan, reduces the critical concentration of laminin monomers required 
for polymerisation in the laminin network (Maniotis et al., 1997) and once bound to the 
laminin network, the distribution of dystroglycan and integrin receptors is altered to 
complement the basement membrane network (Karpati, 2010).   
  
Page 83 of 551 
 
FIGURE 1-10 LAMININ SELF-POLYMERISATION SCHEMATIC 
This is a schematic drawing of the three arm interaction model of laminin self-assembly.  
The ternary nodes in the network are formed by the N-terminal regions of one α, one β and 
one γ chain.  The long terminal regions of the laminin chains are bound to cellular adhesion 
receptors on the cell surface – they are not involved in network formation. 
 
This image was taken from (Hohenester and Yurchenco, 2013).  This article is Open Access 
under a Creative Commons license http://creativecommons.org/licenses/by-nc/3.0/ 
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The integrins are a large family of 24 heterodimeric cellular adhesion receptors (Hynes, 
2004, Barczyk et al., 2010), that form transmembrane connections between the intracellular 
cytoskeleton and the extracellular matrix (Barczyk et al., 2010).  Each integrin receptor is 
composed of one α and one β subunit non-covalently associated (Hynes, 2002)., with 18 α 
and 8β subunits identified across the 24 different integrin heterodimers (Hynes, 2002, Hu 
and Luo, 2013), arranged by ligand specificity, which itself is dependent on the combination 
of α- and β- subunits – for example integrin α3β1, α6β1, α6β4 and α β1 are the laminin 
binding integrins (Hynes, 2002, Hu and Luo, 2013). 
 
A functional role for integrin receptors has been implicated in many biological functions 
including cell proliferation, shape, polarity, motility, differentiation and survival, tissue 
development and homeostasis, immune responses, and cancer (Hynes et al., 2002, Ginsberg 
et al., 2005, Hu and Luo, 2013).  Integrin receptor complexes mediate bidirectional 
signalling, i.e. both inside-out and outside-in (Hu and Luo, 2013).  The binding of 
extracellular ligands to the receptors transmits signals inwards through activation of 
cytoplasmic interactors and downstream effectors (Meighan and Schwarzbauer, 2008, Hu 
and Luo, 2013).  However, integrins are not constitutively active, when not signalling or 
bound to their ligand they are in an “OFF” state (Hynes, 2002, Hu and Luo, 2013), but when 
activated through inside-out signalling, the receptor undergoes  a conformation, the two 
subunits separate and the integrin receptor is activated, with a high ligand affinity, ready for 
binding (Barczyk et al., 2010, Schurpf and Springer, 2011, Hu and Luo, 2013).   
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1.10 DYSTROPHIN ASSOCIATED PROTEIN COMPLEX 
As shown in Figure 1-11, dystroglycan is part of the dystrophin-associated protein complex 
(DAPC), a multimeric complex linking the intracellular actin cytoskeleton, through 
dystrophin or utrophin, to the various ligands of the extracellular basement membrane 
(Ervasti and Campbell, 1993, Gee et al., 1993, Bowe et al., 1994, Campanelli et al., 1994, 
Michele and Campbell, 2003).  The DAPC has been implicated in multiple cellular processes 
including adhesion, spreading, migration, differentiation, proliferation and survival (Winder, 
2001, Noël et al., 2005, Thompson et al., 2010), by providing mechanical support to cells and 
acting as a focus for signalling pathways, binding to Src (sarcoma) kinases (James et al., 
2000, Ilsley et al., 2001, Sotgia et al., 2001), MAPK (mitogen activated protein kinases) 
(Spence et al., 2004) and Akt (Rando, 2001, Langenbach and Rando, 2002). 
 
The DAPC can be subdivided into 3 groups, (i) the sarcoglycan-sarcospan complex, (ii) the 
dystrobrevins and syntrophins and (iii) dystroglycan, which, due to association with the 
dystroglycanopathies will be discussed in more detail in Section 1.11.  The composition of 
the sarcoglycan complex varies between tissues, and of the 6 different sarcoglycans 
identified, it has been shown in skeletal muscle this complex contains α-, β-, γ- and δ- 
sarcoglycan (Karpati, 2010).  The sarcoglycan complex is thought to stabilise other parts of 
the DAPC, facilitate nNOS (neuronal Nitrogen Oxide Synthase) localisation and integrate 
mechanical information between the DAPC and the integrin receptor complexes (Dalkilic 
and Kunkel, 2003, Karpati, 2010).  Additionally, α- and β- sarcoglycan have been shown to 
bind indirectly to α-dystroglycan, through interaction with biglycan (Bowe et al., 2000, 
Dalkilic and Kunkel, 2003).  Dystrophin binds to α-dystrobrevin (which is highly expressed in 
Page 86 of 551 
 
skeletal muscle) ,β-dystrobrevin and the 3 isoforms of syntrophin at the muscle fibre 
sarcolemma (Dalkilic and Kunkel, 2003).  Again, this complex is thought to be involved in the 
localisation of nNOS to the DAPC (Dalkilic and Kunkel, 2003). 
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FIGURE 1-11 DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX 
Schematic showing the muscle dystrophin associated glycoprotein complex (DAPC) which is 
composed of dystroglycan (both α- and β- subunits are shown), sarcospan, sarcoglycan 
complex, dystrophin or utrophin, α-dystrobrevin, the syntrophins, actin (which binds to 
dystrophin) and nNOS (neuronal nitrogen oxide synthase) which binds to α-dystrobrevin and 
the syntrophins.  These different components are labelled in the diagram and are shown in 
different colours.  This schematic was created based on information taken from (Michele 
and Campbell, 2003)  
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1.11 DYSTROGLYCAN 
Dystroglycan, first cloned and sequenced in 1992 (Ibraghimov-Beskrovnaya et al., 1992), is a 
ubiquitously expressed cellular adhesion receptor (Winder, 2001) localised to the plasma 
membrane (Winder, 2001, Moore and Winder, 2010).  Functionally, dystroglycan acts as a 
membrane anchor, performing two basic functions - it acts as a physical connection 
between the basement membrane and the cytoskeleton and a signal transducer, both 
directly and indirectly, by providing a scaffold for signalling proteins (Moore and Winder, 
2010).  Dystroglycan is coded for by DAG-1, which is localised to chromosome 3p21 in man 
(Ibraghimov-Beskrovnaya et al., 1993) and chromosome 9 in the mouse (Gorecki et al., 
1994), with over 96% sequence identity between the human and the mouse (Brancaccio et 
al., 1995).  The gene has 2 exons, separated by 1 large intron, with a transcript of 5.8kb 
(Winder, 2001, Barresi and Campbell, 2006) and disruption of the gene in mice leads to 
embryonic lethality at E5.5, caused by disruptions and perturbations of Reichert’s 
membrane (Williamson et al., 1997).  The transcript produced from the Dag1 gene is an 895 
amino acid propeptide, which undergoes autoproteolysis at a SEA domain around amino 
acid serine654 to produce the two protein subunits, α- and β-dystroglycan (Ibraghimov-
Beskrovnaya et al., 1993, Esapa et al., 2003, Akhavan et al., 2008).  This dystroglycan 
propeptide has not been detected in native tissues, only cells overexpressing dystroglycan, 
suggesting the cleavage occurs shortly after translation (Holt et al., 2000).  The two 
dystroglycan subunits (α- and β-) then undergo post-translation processing, before being 
trafficked separately to the cell membrane, with β-dystroglycan incorporated into the cell 
membrane and α-dystroglycan  secreted into the extracellular space.  These two subunits 
then associate non covalently to form the mature protein   (Holt et al., 2000).  
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β-dystroglycan, with a molecular weight of 45kDa is a type 1 transmembrane glycoprotein, 
binding intracellularly to dystrophin, utrophin, the actin cytoskeleton and/or other 
intracellular signalling partners (Barresi and Campbell, 2006, Moore and Winder, 2010) and 
extracellularly to the carboxy terminal domain of α-dystroglycan (Ibraghimov-Beskrovnaya 
et al., 1992, Ibraghimov-Beskrovnaya et al., 1993, Moore and Winder, 2010).  Structurally, 
the β-dystroglycan subunit has a single transmembrane domain, 1 potential N-linked 
glycosylation site and  a 121 reside C-terminal cytoplasmic tail (Barresi and Campbell, 2006).   
 
α-dystroglycan, is the extracellular, ligand binding component and structurally is composed 
of two globular domains, the C-terminal and N-terminal domains, connected by a central, 
mucin-rich domain, which is characterised by extensive O-linked glycosylation (Smalheiser 
and Kim, 1995, Barresi and Campbell, 2006, Mokkapati et al., 2011).  Most commonly, 
dystroglycan is localised to the plasma membrane, as part of the DAPC (Henry and 
Campbell, 1999, Michele and Campbell, 2003), although, the N-terminal domain of α-
dystroglycan has a convertase like activity (Kanagawa et al., 2004), and consequently, α-
dystroglycan can be shed from the surface as a result to the actions of matrix 
metalloproteases and furin, a protease convertase (Matsumura et al., 1997, Shimizu et al., 
1999, Singh et al., 2004). 
 
1.11.1 DYSTROGLYCAN GLYCOSYLATION  
The primary sequence of α-dystroglycan predicts a molecular mass of 72 k-Da, however in 
reality the molecular weight of α-dystroglycan is much higher and varies between tissues, 
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for example 156 kDa in muscle, 140kDa in cardiac muscle and 120kDa in brain, due to 
differences in its glycosylation profile (Ibraghimov-Beskrovnaya et al., 1993).  Commonly, 10 
different monosaccharides have been identified which could potentially be incorporated 
into mammalian glycans – fucose, galactose (Gal), glucose (Glc) N-acetylgalactosamine 
(GalNAc), mannose (Man), glucuronic acid (GlcA), xylose (Xyl), N-acetylglucosamine 
(GlcNAc), iduronic acid (IdoA) and sialic acid (SA) (Moremen et al., 2012).   
 
Mammalian glycans are synthesised in biosynthetic pathways and the products depend 
upon competition between enzymes for the same glycans (Moremen et al., 2012).  
Competition and inefficiency of the enzyme reactions results in a diverse ensemble of 
branched glycan structures, with different glycans even seen at the same glycosylation sites 
on some proteins (Moremen et al., 2012).  Glycosyltransferases are enzymes that transfer 
sugars (most commonly hexoses in either D- or L- orientation) from activated donor 
molecules (nucleotide or lipid-linked sugars) and although glycosyltransferases are a diverse 
group of enzymes only 2 structural superfamilies have been identified (Hu and Walker, 
2002, Moremen et al., 2012).   
 
A loss of the glycosylation on α-dystroglycan leads to a loss of ligand binding activity (Ervasti 
and Campbell, 1993) and so a number of glycomic analyses of α-dystroglycan have been 
undertaken, to try and decipher this glycosylation arrangement, with discrepancies between 
the different studies attributed to different methods of isolation and purification (Gomez 
Toledo et al., 2012).  This “mapping” of α-dystroglycan glycosylation is hindered by the 
considerable heterogeneity in the (i) number of glycosyl structures identified (ii) the core 
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glycan structures, (iii) the extended glycan structures and (iii) the terminal decorations (one 
of Fuc, hexose, Neu5Ac or Neu5Gc) on isolated α-dystroglycan (Gomez Toledo et al., 2012, 
Stalnaker et al., 2010).  However, three different types of glycans have been identified on α-
dystroglycan, N-linked glycans, and restricted to the central mucin region, O-GalNac glycans 
and O-mannosyl glycans have been identified (Barresi and Campbell, 2006).  This heavily 
glycosylated mucin region of α-dystroglycan, contains the binding sites for various basement 
membrane ligands and the arrangement of glycans in this region is crucial for these 
interactions, and consequently basement membrane composition and integrity (Barresi and 
Campbell, 2006).   
 
Interestingly recent work shows there is some restriction across the mucin domain, with O-
mannose linked structures identified at the N-terminus part of the mucin domain (amino 
acids 313-425) and O-GalNAc exclusively found at the C-terminal part of the mucin domain 
(429-509), with this restriction conserved between mouse, human and rabbit (Gomez 
Toledo et al., 2012).  O-mannosylation is a rare glycan modification and prior to its 
identification on mammalian α-dystroglycan, was thought to be restricted to yeast proteins 
(Willer et al., 2003).  To date, a number of O-mannose glycan structures on α-dystroglycan 
have been identified, the most prevalent of which (Stalnaker et al., 2010) is the sialylated 
tetrasaccharide, -Neu5Acα2-3,Galβ1-4,GlcNacβ1-2,Man- (Chiba et al., 1997, Sasaki et al., 
1998, Smalheiser et al., 1998, Willer et al., 2003), although this is not thought to be the 
laminin binding moiety (Yoshida-Moriguchi et al., 2010).  Additionally, it has been shown 
recently that α-dystroglycan contains a phosphorylated O-mannosyl glycan –GalNACβ1-
3,GlcNAcβ1-4,Man-ol (Yoshida-Moriguchi et al., 2010) and a repeating polysaccharide unit, 
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[-3Xylα1-3,GlcAβ1-] (Inamori et al., 2012).  These three O-mannosylation structures are 
shown below in Figure 1-12. 
 
Due to the association of the dystroglycanopathies with hypoglycosylated forms of α-
dystroglycan and defects in ligand binding, it was proposed that the genes associated with 
the secondary dystroglycanopathies (POMT1, POMT2, POMGnT1, FKRP, FUKUTIN and 
LARGE) were involved in O-mannosylation of α-dystroglycan.  So far, only the roles of 
POMT1, POMT2, POMGnT1 and LARGE as glycosyltransferases have been characterised and 
their actions, shown in the schematic of O-mannosylation (Figure 1-12) will now be 
discussed in more detail below.  
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FIGURE 1-12 SCHEMATIC OF α-DYSTROGLYCAN O-MANNOSYLATION 
Schematic of selected O-mannosylation glycans identified on α-dystroglycan.  Black lines 
represent attachments between sugar residues which are coded as shown in the key, with 
the abbreviations – xylose (Xyl), N-acetylglucosamine (GlcNAc), sialicylated sugar (NeuAc), 
mannose (Man), galactose (Gal) and N-acetylgalactosamine (GalNAc).  Although the glycans 
are shown on the same mannose residue, the diagram is representative and does not 
denote their exact localisation.  The reactions catalysed by the POMT1/POMT2, POMGnT1 
and LARGE are shown, with red brackets surround the glycan LARGE is thought to add 
because this has been identified on dystroglycan isolated from in vitro sources.  This 
schematic was created using information from the following references (Chiba et al., 1997, 
Sasaki et al., 1998, Yoshida et al., 2001, Willer et al., 2003, Manya et al., 2004, Yoshida-
Moriguchi et al., 2010, Blockus and Chedotal, 2012, Inamori et al., 2012).   
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1.11.2 DYSTROGLYCAN GLYCOSYLATION AND THE DYSTROGLYCANOPATHIES 
POMT1 and POMT2 catalyse the first step in O-mannosylation, combining to form a 
heterocomplex which attaches mannose to a serine or threonine residue on α-dystroglycan 
(Manya et al., 2004).  POMGnT1 catalyses a subsequent step in O-mannosylation, linking the 
GlcNac glycan to the mannose (Yoshida et al., 2001) and this forms the backbone of the 
Neu5Acα2-3,Galβ1-4,GlcNacβ1-2,Man tetrasaccharide (Chiba et al., 1997, Sasaki et al., 
1998, Willer et al., 2003, Smalheiser et al., 1998).  
 
LARGE, over 664 kb in size, is a ubiquitously expressed glycosyltransferase localised to 
chromosome 22 in the human (Peyrard et al., 1999), which is involved in adding a sugar 
modification to two threonine residues (Thr317 and Thr-319) on the mucin domain near the 
N-terminus of α-dystroglycan (Hara et al., 2011b).  Recently, it was shown that LARGE has 
both xylosyltransferase and glucuronyltransferase activity, resulting in the addition of the 
repeating Xyl-GlcA polysaccharide unit describe above in Section 1.11.1 to α-dystroglycan 
(Inamori et al., 2012).  Additionally, it has also been shown that LARGE is associated with the 
synthesis of the phosphorylated O-mannosyl glycan described above in Section 1.11.1, 
although its specific role with respect to this the synthesis of this glycan has not been fully 
elucidated (Yoshida-Moriguchi et al., 2010).   
 
In 2005, a paralog gene for LARGE (LARGE2 - Like-acetylglucosaminyltransferase 2) was 
identified, localised to human chromosome 11p11.2, with 64.2% sequence identified to 
LARGE (Fujimura et al., 2005).  Recently it has been shown that LARGE2, similarly to LARGE 
is a bifunctional glycosyltransferase, with xylosyltransferase and glucuronyltransferase, 
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along with polymerising activity (Inamori et al., 2013, Ashikov et al., 2013).  However, these 
two proteins are thought to have distinct mechanisms of action in α-dystroglycan 
glycosylation (Inamori et al., 2013), since overexpression LARGE2 in vitro results in a higher 
molecular weight of α-dystroglycan when compared to LARGE1 (Fujimura et al., 2005, 
Grewal et al., 2005) and expression of LARGE1 and LARGE2 varies between different tissues, 
with high levels of LARGE1 and low levels of LARGE2 reported in the brain and skeletal 
muscle (Fujimura et al., 2005, Grewal et al., 2005).  
 
The DPM synthase complex, a heterotrimeric protein composed of DPM1, DPM2 and DPM3, 
catalyses the formation of Dol-P-Man (Dolicol-phosphate-mannose), which acts a donor of 
mannose during O-mannosylation (Maeda et al., 1998, Ashida et al., 2006).  ISPD encodes 
for an isoprenoid synthase domain containing protein, which belongs to a family of 
nucleotide diP sugar transferases (Vuillaumier-Barrot et al., 2012), but despite being 
characterised in bacteria and plants, the function of this protein in vertebrates and 
consequently glycosylation of α-dystroglycan is currently unknown (Roscioli et al., 2012, 
Vuillaumier-Barrot et al., 2012).  However, it is currently thought that ISPD is involvement in 
synthesising a nucleotide sugar, perhaps for the initial POMT1/POMT2 mediated step of O-
mannosylation, as this modification does not occur in the absence of ISPD (Roscioli et al., 
2012, Vuillaumier-Barrot et al., 2012, Willer et al., 2012).   
 
Glycosyltransferases are enzymes that transfer sugars (most commonly hexoses in either D- 
or L- orientation) from activated donor molecules (nucleotide or lipid-linked sugars) and 
although they are a diverse group of enzymes only 2 structural superfamilies have been 
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identified, GT-A and GT-B (Hu and Walker, 2002, Moremen et al., 2012).  The GT-A 
superfamily of glycosyltransferases localise either to either Golgi apparatus or the ER 
(endoplasmic reticulum), and contain a DxD motif, which binds to divalent cations (most 
commonly magnesium) and is involved in anchoring the phosphoryl group of the uridine 
diphosphate donor in the active site (Hu and Walker, 2002).  Sequence analysis suggests 
TMEM5 is 443 amino acid type II transmembrane protein which carries a DxD motif, and 
given its associated with the dystroglycanopathies, is thus thought to be as a 
glycosyltransferase, although its function is currently unknown (Vuillaumier-Barrot et al., 
2012).   
 
FKRP and Fukutin localise to the Golgi apparatus, with hydrophobicity plots and structural 
analysis also predicting these to be type II membrane proteins (Esapa et al., 2002), and 
sequence analysis suggesting a similar structure to phosphoryl ligand transferases (Aravind 
and Koonin, 1999, Harnett et al., 2010).  Additionally, both FKRP and FUKUTIN contain a DxD 
motif, suggestive of a glycosyltransferase, (Brockington et al., 2001a), although no catalytic 
activity has been demonstrated for either protein.  As FKRP is the main focus of my work, 
this will now be described in more detail below. 
 
1.12 FKRP 
FKRP, approximately 12kb in size, has 4 exons in the human, mapping to chromosome 
19q13.3 (Brockington et al., 2001a) and 3 exons in the mouse, where it maps to 
chromosome 7 (http://genome.ucsc.edu/cgi-bin/hgGateway?hgsid=321685715 – University 
of California, Santa Cruz Genome Browser).  The entire coding region is localised to one 
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exon (human exon 4 (approximately 3.8kb) and mouse exon 3 (Esapa et al., 2002), which 
contains the 5’ untranslated region, the entire open reading frame and the 3’ untranslated 
region (Brockington et al., 2001a).  There is a 94% sequence identity between mouse Fkrp 
and human FKRP (Esapa et al., 2002).  Fkrp is widely expressed in mammals, but the levels 
are highest in the brain, lungs, kidney heart, placenta and liver (Brockington et al., 2001a, 
Esapa et al., 2002, Ackroyd et al., 2009).  Over 150 mutations in FKRP have been identified in 
patients from across the dystroglycanopathy spectrum (Brown and Winder, 2012). 
 
FKRP contains 495 amino acids (Brockington et al., 2001a) and has a molecular weight of 
approximately 58kDa (Matsumoto et al., 2004, Alhamidi et al., 2011). Structurally, the 
protein is thought to have 3 distinct domains, (i) a hydrophobic N-terminal transmembrane 
domain which contains the sequence anchor targeting the protein to the Golgi apparatus, 
(ii) a stem region and (iii) the C-terminal domain which contains the putative catalytic or 
active site (Brockington et al., 2001a, Esapa et al., 2002) ( 
Figure 1-13).  Additionally, FKRP has two putative N-glycosylation sites which are occupied 
with either a high molecular weight mannose or hybrid oligosaccharide (Alhamidi et al., 
2011) ( 
Figure 1-13).  Recently, it has also been shown that Fkrp may perform its function by 
interacting with itself, to form homodimers and large multimeric complexes (Alhamidi et al., 
2011).     
 
There is some debate about the intracellular localisation of wildtype Fkrp in the cell - 
although most studies suggest Fkrp is localised to the Golgi apparatus (Esapa et al., 2002, 
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Dolatshad et al., 2005, Esapa et al., 2005, Torelli et al., 2005, Keramaris-Vrantsis et al., 
2007), it has also been identified at the ER (Matsumoto et al., 2004) and the muscle fibre 
sarcolemma (Beedle et al., 2007).  Additionally, one recent in vitro study demonstrated that 
Fkrp can be secreted into the culture medium (Lu et al., 2010). 
 
However, as currently, as there is no reliable, commercially available antibody for Fkrp, 
(Brown and Winder, 2012) investigators either generate their own (Matsumoto et al., 2004, 
Esapa et al., 2005, Beedle et al., 2007, Keramaris-Vrantsis et al., 2007), making it difficult to 
compare results between different groups, or, they express a tagged recombinant protein 
(Esapa et al., 2002, Dolatshad et al., 2005, Keramaris-Vrantsis et al., 2007), which could 
affect the structure, function and localisation.  Associated with this, whilst it is relatively 
easy to make an antibody that recognises recombinant protein, it is less easy to generate 
one that recognises the endogenous protein, although a possible explanation with respect 
to Fkrp could be that its expression in endogenous tissues is very low. 
 
Additionally, due to the unknown function of Fkrp, there is currently no biological assay for 
analysing its activity, so the specific effect of disease causing mutations has not been 
documented (Brown and Winder, 2012) although it is thought most mutations result in 
protein misfolding (Alhamidi et al., 2011), affecting the trafficking of Fkrp between the ER 
and the Golgi apparatus (Esapa et al., 2002, Esapa et al., 2005, Brown and Winder, 2012).   
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FIGURE 1-13 STRUCTURE OF FKRP 
Schematic shows a potential model for FKRP structure based on a type II transmembrane 
glycosyltransferase, with a globular catalytic domain at the carboxy terminal (COOH), a stem 
region, a single pass transmembrane domain and a cytoplasmic N-terminal (NH2), with a 
disulfide bond between two cysteine residues (Cys) potentially mediating homodimer 
interaction shown (S-S).  Additionally, two putative N-glycosylation sites (Y) are shown on 
the catalytic domain. 
 
This schematic was taken from Alhamidi et al., 2011.  This article is Open Access under a 
Creative Commons license http://creativecommons.org/licenses/by-nc/3.0/ so no 
permission was needed for reproduction.  
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1.13 THESIS AIMS 
A reduction in α-dystroglycan glycosylation is now considered to be central to the disease 
process in the dystroglycanopathies. Our laboratory previously generated a mouse model 
with a global reduction in Fkrp expression of approximately 80%, referred to as the FKRPKD 
mouse.  This mouse dies in the early perinatal period, but is a good model for the severe 
end of the dystroglycanopathy spectrum and has provided valuable insight into the disease 
process in the brain and eye (Ackroyd et al., 2009, Ackroyd et al., 2011).   
 
This thesis had two main objectives.  The first was to evaluate basement membrane 
deposition in vivo in the muscle (using the extraocular muscle and tongues), eye (ILM and 
Bruch’s membrane) and the brain (pial basement membrane). However, as this work only 
provides a gross assessment of basement membrane ligand distribution, an in vitro 
myogenic cell line with a reduction in Fkrp expression was generated and used to assess 
dynamic basement membrane deposition.  Central to these studies was the hypothesis that 
a reduction in Fkrp expression resulted in aberrant laminin incorporation into the basement 
membrane, through a reduction in α-dystroglycan glycosylation. 
 
The second main objective was to test the hypothesis that one therapeutic approach in 
diseases associated with Fkrp mutations could be to increase α- dystroglycan glycosylation 
by up-regulation of LARGE. This approach has been shown to be promising in in vitro studies 
and work in other dystroglycanopathy mouse models (Barresi et al., 2004, Kanagawa et al., 
2009, Hu et al., 2011b).  However, this required the generation of a novel mouse model with 
restored Fkrp expression in the brain but not muscle (referred to as the FKRPMD mouse), 
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which was achieved by crossing the FKRPKD with a line expressing Cre recombinase under 
the Sox1 Cre promoter (active in the developing neural tube). As was hypothesised this 
successfully bypassed the perinatal lethality of the FKRPKD providing a novel model for the 
milder end of the clinical spectrum in which it was possible to determine the effect of LARGE 
overexpression.  
 
1.14 THESIS HHYPOTHESIS 
 
A reduction in Fkrp expression will result in aberrant laminin incorporation into the 
basement membrane.  These basement membrane defects will induce lamination defects in 
the cortex and retina and a dystrophic phenotype in the muscle.  Upregulation of LARGE in a 
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2 MATERIALS AND METHODS 
 
2.1 SOLUTIONS AND MEDIA 
 
2.1.1 PHOSPHATE BUFFERED SALINE (PBS) (OXOID, THERMOFISCHER, U.K) 
Distilled water with 8g/L w/v sodium chloride, 0.2g/L w/v potassium chloride, 1.15g/L w/v 
disodium hydrogen phosphate, 0.2g/L w/v potassium dihydrogen phosphate. 
 
2.1.2 ENZYME SOLUTION FOR MUSCLE DISSOCIATION 
PBS (Section 2.1.1) with 0.5mg/mL w/v collagenase (Sigma-Aldrich, U.S.A.), 1mg/mL w/v 
bovine serum albumin (BSA, Sigma-Aldrich) and 6% v/v Trypsin-EDTA 
(Ethylenediaminetetraacetic acid, Invitrogen, U.S.A.). 
 
2.1.3 PROLIFERATION MEDIA FOR MUSCLE CULTURES 
Dulbecco’s Modified Eagle Medium (DMEM - 4.5g/L glucose, Gluta-MAX and L-glutamine 
(Invitrogen)), 20% v/v heat-inactivated foetal bovine Serum (PAA, France), 2% v/v filter 
sterilised (VWR, U.K.) chick embryo extract (Sera Laboratories, U.K.), 4mM v/v L-glutamine 
(Sigma-Aldrich), 100U/mL Penicillin/100µg/mL Streptomycin v/v (Invitrogen) and 2µL/mL 
v/v γ –interferon (Millipore, U.S.A) 
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2.1.4 DIFFERENTIATION MEDIA FOR MUSCLE CULTURES 
DMEM (4.5g/L glucose, Gluta-MAX and L-glutamine (Invitrogen), 5% v/v heat inactivated 
horse serum (Invitrogen), 4mM v/v L-glutamine (Sigma-Aldrich)) 
 
2.1.5 0.5X TRIS-BORIC ACID-EDTA (TBE) 
Distilled water with 5.3g/L w/v Trizma base (Sigma-Aldrich), 2.75g/L w/v boric acid (Sigma-
Aldrich) and 2ml/L v/v 0.5M EDTA (Invitrogen). 
 
2.2 IN VIVO MOUSE STUDIES  
Mice were housed in a 12h light-dark cycle with food and water freely available.  All in vivo 
work was conducted under the regulations of the United Kingdom Animals (Scientific 
Procedures) Act (1986), by holders of a Home Office Personal Licence.  This includes all 
procedures routinely carried out in the maintenance of a transgenic mouse colony – such as 
setting up breeding pairs or ear biopsying of animals for identification and genotyping.  The 
vast majority of animals generated in the course of this work were culled by myself using a 
Schedule 1 method.  Where digital photographs of mice have been included, they were 
captured with the permission of the Certificate Holder at the Royal Veterinary College using 
an Fe-300 digital camera (Olympus, Japan) and compiled into figures using Photoshop CS4 
or CS5 (Adobe, U.S.A.).  If necessary, the background of the photograph was manipulated 
using Photoshop CS4 or CS5. 
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2.2.1 MAINTAINANCE OF THE FKRPKD MOUSE COLONY 
As FKRPKD mice die at or around birth (Ackroyd et al., 2009), the colony is maintained as 
heterozygote breeding pairs, with the frequency of FKRPKD mice generated from these pairs 
approximately 1:4 (Ackroyd et al., 2009).  Here, heterozygote mice from this colony 
(referred to as FKRPKD heterozygote) were used to generate (i) FKRPKD mutant mice and (ii) 
novel transgenic mouse colonies as outlined below. 
 
2.2.2 GENERATION OF H2K-FKRPKD MOUSE COLONY 
The H2K-FKRPKD mutant mouse was generated by two breeding crosses involving mice from 
the Immortomouse (a kind gift from Dr Jennifer Morgan, University College London) and 
FKRPKD mouse colonies (shown as a schematic in Figure 2-1.  These breeding crosses 
generated mice of 9 different genotypes, listed in Table 2-1 
 
In the initial breeding cross, female FKRPKD heterozygote mice were crossed with male 
Immortomice (H2K+/+FKRP-NeoTyr307Asn-/-) to introduce the H-2Kb-tsA58 transgene into the 
background of the FKRPKD colony, which generated F1 (First Generation) animals of two 
different genotypes – hemizygous H2K-FKRPKD heterozygote (H2K+/-FKRP-NeoTyr307Asn+/-) and 
hemizygous Immortomice (H2K+/-FKRP-NeoTyr307Asn-/-) (Figure 2-1).  This cross was performed 
with male Immortomice because they have a longer viability period than female 
Immortomice (Jat et al., 1991).   
 
In the F2 (Second Generation) breeding cross (shown as breeding cross B in Figure 2-1)), two 
hemizygous H2K-FKRPKD mice were mated with each other in breeding crosses that were not 
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brother-sister to generate animals of 9 different genotypes, including the 2 genotypes 
generated in the F1 breeding cross.  These additional genotypes generated in the second 
breeding cross (B) were wildtype (H2K-/-FKRP-NeoTyr307Asn-/-), homozygous Immortomice, 
FKRPKD heterozygote (H2K-/-FKRP-NeoTyr307Asn+/-), homozygous H2K-FKRPKD heterozygote 
(H2K+/+FKRP-NeoTyr307Asn+/-), FKRPKD (H2K-/-FKRP-NeoTyr307Asn+/+) hemizygous H2K-FKRPKD 
(H2K+/-FKRP-NeoTyr307Asn+/+) and homozygous H2K-FKRPKD (H2K+/+FKRP-NeoTyr307Asn+/+) mice.  
Although only one copy of the H-2Kb-tsA58 transgene is necessary for the conditional 
immortalisation of cells (Morgan et al., 1994), the breeding cross was set up with both 
parents carrying the H2K transgene to increase the frequency of H2K-FKRPKD offspring.  
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Abbreviation FKRP H2K transgene Genotype 
Wildtype Wildtype - H2K-/-FKRP-NeoTyr307Asn-/- 
Hemizyogus 
Immortomouse 
Wildtype + H2K+/-FKRP-NeoTyr307Asn-/- 
Homozygous 
Immortomouse 
Wildtype + H2K+/+FKRP-NeoTyr307Asn-/- 
FKRPKD 
heterozygote 








Heterozygote + H2K+/+FKRP-NeoTyr307Asn+/- 
FKRPKD Mutant - H2K-/-FKRP-NeoTyr307Asn+/+ 
Hemizygous 
H2K-FKRPKD 
Mutant + H2K+/-FKRP-NeoTyr307Asn+/+ 
Homozygous 
H2K-FKRPKD 
Mutant + H2K+/+FKRP-NeoTyr307Asn+/+ 
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TABLE 2-1 GENOTYPES PRESENT IN THE H2K-FKRPKD MOUSE COLONY 
 
This table lists the 9 different genotypes produced by the breeding crosses used in the 
generation and maintenance of the H2K-FKRPKD mouse colony.  It also lists the shorthand 
abbreviated terms that will be used throughout the text when referring to these mice.   
 
The genotypes of the mice that were used for tissue culture were (i) hemizygous 
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FIGURE 2-1 THE GENERATION OF H2K-FKRPKD MICE  
Schematic diagram of the breeding programs performed to generate H2K-FKRPKD mice.  The 
mouse chromosomes are represented by the black lines, while the genes are denoted by 
square boxes – wildtype Fkrp in green, mutant Fkrp in blue and the Immortomouse 
transgene in purple. 
 
The F1 breeding cross (A) between FKRPKD heterozygote and a homozygous Immortomouse 
produced animals of 2 different genotypes – hemizygous Immortomouse and a H2K-FKRPKD 
heterozygote mouse.  The F2 breeding cross (B) between two H2K-FKRPKD mice, produced 
animals of 9 different genotypes, from left to right – wildtype, hemizygous Immortomouse, 
homozygous Immortomouse, FKRPKD heterozygote, hemizygous H2KF-KRPKD heterozygote 
mouse, homozygous H2K-FKRPKD heterozygote mouse, FKRPKD mouse, hemizygous H2K-
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2.2.3 GENERATION OF FKRPMD MICE 
The breeding program used to generate FKRPMD mice is outlined in more detail in Section 
5.2.1, but briefly in the F1 breeding cross, female heterozygote FKRPKD mice were bred with 
male mice expressing Cre recombinase under the control of the Sox1 promoter (a kind gift 
from Professor Liz Robertson, Sir William Dunn School of Pathology, Oxford U.K.).  In the F2 
breeding cross, FKRPKD heterozygote mice carrying Cre recombinase (henceforth referred to 
as FKRPMD heterozygote mice) were crossed with FKRPKD heterozygote mice to generate 
FKRPMD mice.  Once the colony was established, it was maintained by three different 
breeding strategies – 1) FKRPKD heterozygote x FKRPMD heterozygote, 2) FKRPMD x FKRP
KD 
heterozygote and 3) FKRPMD x FKRPMD.  When setting up these breeding pairs, to try and 
ensure all animals generated in the colony (and subsequently used in this thesis) only had a 
single copy of the transgene, only one animal in each breeding pair contained the Cre 
recombinase as genotyped by PCR (Polymerase Chain Reaction).  
 
Each pregnant female in the colony was checked daily for new litters and the number of live 
and dead births per cage was noted.  This data was then compiled using Excel 2010 
(Microsoft Office, U.S.A.) and statistically analysed using GraphPad Prism version 5.0 or 6.0 
for Windows (GraphPad Software, United States of America). 
 
2.2.4 GENERATION OF FKRPMDLARGE MICE 
The breeding program used to generated FKRPMDLARGE mice is outlined in more detail in 
Section 6.2.1, but briefly in the F1 generation, LV5 mice overexpressing human LARGE (a 
kind gift from Professor Dominic Wells, Royal Veterinary College, United Kingdom) were 
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crossed with FKRPMD heterozygote mice.  In the subsequent F2 generation, FKRP
MD 
heterozygotes carrying LV5 were crossed with FKRPKD heterozygote mice to generate 
FKRPMDLARGE mice.  Once the colony was established, an alternative breeding strategy of 
FKRPMD x FKRPKDLARGE heterozygote mice was also adopted. 
 
2.2.5 EVALUATION OF MOUSE BODY WEIGHT 
Male and female mice of 3 different genotypes (wildtype, FKRPMD and FKRPMDLARGE) at the 
ages of 6 weeks (male WT n=6,FKRPMD n=29 and FKRPMDLARGE n=4; female WT n=14, 
FKRPMD n=12 and FKRPMDLARGE n=3), 12 weeks (male WT n=7, FKRPMD n=12 and 
FKRPMDLARGE n=8; female WT n=14, FKRPMD n=24, FKRPMDLARGE n=5) and 20 weeks of age 
(male WT n=6, FKRPMD n=14; female WT n=7, female FKRPMD n=12 and FKRPMDLARGE n=4) 
were weighed between 10:00-10:30am using a weighing balance (OHAUS Scout Pro Balance, 
U.S.A.).  The results were compiled using Excel 2010 (Microsoft Office, U.S.A.), graphs were 
prepared using GraphPad Prism version 5.0 for Windows (GraphPad Software, U.S.A.) and 
the data was analysed using a Mixed Linear Effects Model performed using SPSS Statistics 
version 20 (IBM Corporation, U.S.A.) 
 
2.2.6 EVALUATION OF MOUSE HINDLIMB EXTENSION REFLEX 
The hindlimb extension reflex of wildtype, FKRPMD and FKRPMDLARGE was evaluated in both 
male (WT n=6, FKRPMD n=16, FKRPMDLARGE n=7) and female (WT n=11, FKRPMD n=16, 
FKRPMDLARGE n=5) mice at 12 weeks of age.  The mouse was lifted by the tail and the 
positioning of the hindlimbs observed and classified into either normal (hindlimbs and feet 
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extended away from the body) or abnormal (partial or full collapse of the reflex with 
potential hindlimb clasping) - examples of this are shown in Figure 2-2.  The data was 
compiled using Excel 2010 (Microsoft Office) and tables were prepared using SPSS Statistics 
version 20 (IBM Corporation, U.S.A.). 
 
2.2.7 EVALUATION OF FORELIMB GRIP STRENGTH 
The forelimb grip strength of 11-13 week old male and female wildtype (male n=5; female 
n=6), FKRPMD (male n=14; female n=14) and FKRPMDLARGE (male n=3; female n=3) mice was 
evaluated using a grip strength meter (Chantillon, U.S.A.).  Mice were held by the tail and 
moved towards the grip strength meter.  Once the mouse had clasped onto the bar with 
both paws, the mouse was gently pulled back by the tail and the peak tension (kg) 
generated by the mouse was recorded.  Values were discarded if the mouse twisted its grip 
or did not hold onto the vertical bar correctly.  An average grip strength measurement was 
calculated from a maximum of 4 different trials, but each mouse successfully performed 3 
trials.  Mice were given at least a 10 minute rest between trials.  Mice were weighed so the 
mean forelimb grip strength could be normalised to the weight of the mouse.  This 
methodology was based upon the standard operating protocols from the Treat NMD 
(Neuromuscular disease) website (www.treat-nmd.eu) for work in the mdx mouse (de Luca, 
2010).  Data was compiled using Excel 2010 and analysed statistically with either an 
unpaired two-tailed t-test or a Kruskal-Wallis test with a post-hoc Dunn’s comparison test 
using GraphPad Prism version 5.0 for Windows. 
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FIGURE 2-2 MOUSE HINDLIMB EXTENSION REFLEX 
Examples of a normal (A) and an abnormal hindlimb extension reflex (B).  These digital 
photographs were captured with an Olympus Fe-3000 digital camera and compiled into this 
figure using Adobe Photoshop CS4 or CS5.  The background of the figure was manipulated 
using Adobe Photoshop CS4 or CS5. 
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2.2.9 ELECTROPHYSIOLOGICAL EVALUATION 
This procedure was performed by either Dr Rebecca Terry or Dr Kim Wells (Royal Veterinary 
College, U.K.)  Briefly, female mice were surgically prepared as described in these 
publications (Sharp et al., 2008, Sharp et al., 2011).  Isometric force measurements were 
made from the TA muscle and maximum isometric tetanic force (Po) was determined from 
the plateau of the force – frequency curve (Sharp et al., 2008).  After completing the ﬁnal 
isometric contraction, the muscle was allowed to rest for 5 min before the eccentric 
contraction protocol was started.  A tetanic contraction was induced using a stimulus of 120 
Hz for 700ms, with the muscle was stretched by 15% of LO at a velocity of 0.5 Los
-1 and 
relaxed at 0.5 Los
-1 during the last 200 ms of this contraction..  The isometric tension 
recorded prior to the ﬁrst stretch was used as a baseline. The muscle was then subjected to 
10 eccentric contractions separated by a 2 min rest period to avoid the confounding effect 
of muscle fatigue. The isometric tension prior to each stretch was recorded and expressed 
as a percentage of the baseline tension (Sharp et al., 2008).  The mouse was then 
euthanised and the muscle was carefully removed and weighed. 
 
2.3 GENOTYPING OF ANIMAL MODELS 
All animals used in this project were genotyped by PCR (polymerase chain reaction) analysis 
using gDNA (genomic DNA) isolated from either ear biopsies or a sample of tail taken post-
mortem.  Tissue was digested overnight at 55°c with 0.2mg/mL Proteinase K (Roche 
Diagnostics, U.K.) diluted in either DirectPCR Ear buffer (Viagen, U.S.A.) or DirectPCR Tail 
buffer (Viagen) depending on the origin of the tissue sample. The following morning, the 
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sample was heat inactivated at 85°c for 45 minutes (to inactivate the Proteinase K).  A PCR 
was then performed with 0.5µL or 600ng of gDNA using the BioMix Red PCR reagent 
(Bioline, U.K.) or MyTaq Red PCR Reagent (Bioline), according to the manufacturer’s 
instructions, with the appropriate primers (Invitrogen) for the colony as listed in Table 2-2.  
The specification for each PCR program is listed in (Table 2-3).  The products were then run 
on a 2% agarose (Bioline, U.K.) gel, dissolved in 0.5x TBE.  Mice were genotyped for the 
three transgenes - Cre recombinase, LV5 and H-2Kb-tsA58 by the presence or absence of a 
band (Figure 2-3).  Mice were genotyped for Fkrp in 2 different PCR reactions using the same 
reverse primer – one with a forward primer designed to amplify over the Neomycin 
selection cassette, which identified the mutant allele and the second with a forward primer 
designed to target the wildtype allele at the insertion site of the Neomycin selection 
cassette (Figure 2-3).  Therefore, wildtype mice only had one band in the PCR for the 
wildtype allele, H2K-FKRPKD FKRPMD or FKRP
KD mutant mice had a band only in the PCR for 
the mutant allele and heterozygote mice, which have one copy of each allele had a band in 
both PCR reactions (Figure 2-3). 
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PCR Forward Primer Reverse Primer Mouse 
Strains 
















CCCAGGCTAAGTGCCTTCTC CCAGGTTCGTTCACTCATGG FKRPMD and 
FKRPMDLARGE 








TABLE 2-2 PCR PRIMERS 
This table lists the primers (both forward and reverse) which were used in the PCR reactions 








TABLE 2-3 PCR PROGRAM CONDITIONS 
This table lists the conditions used for the PCR programs designed to amplify products from 
the Fkrp gene and Cre recombinase, T antigen and LV5 transgenes.  Each PCR program has 
an initial denaturation step at 94°c for 5 minutes, followed by a number of cycles (listed in 
the table above) with 30 seconds of denaturation, annealing and elongation at the 
temperatures listed in the table.  The final step in each PCR is a 5 minute elongation phase 
at the temperature listed in the table above, with the exception of LV5 which has a 10 
















FKRP 94 30 94 57 72 72 
Cre 
recombinase 
94 50 94 54.6 72 72 
T Antigen 94 30 94 55 72 72 
LV5 94 35 94 55 72 72 
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FIGURE 2-3 REPRESENTATIVE GELS SHOWING PRODUCTS FOLLOWING FKRP AND 
LV5 PCR 
Mice from all colonies (FKRPKD, H2K-FKRPKD, FKRPMD and FKRPMDLARGE) were genotyped to 
identify their Fkrp status as wildtype, heterozygote or mutant.  This involved 2 PCR reactions 
designed to generate products from either the wildtype (A), or the mutant (B) allele.  
Products from the mutant allele (B) were generated by a forward primer designed against 
the Neomycin selection cassette, while products from the wildtype allele (A) were 
generated by a forward primer designed against the wildtype Fkrp sequence, at the 
insertion site of the Neomycin selection cassette.  Both reactions use the same reverse 
primer, which generates products of different sizes in the two PCR reactions - 513bp in the 
wildtype (A) and 615bp in the mutant (B).   
 
As an example, PCR products from 6 mice (labelled 1-5) are shown in A-B.  Mouse 2 was a 
wildtype, mouse 4 was a mutant and mice 1, 3, 5 and 6 were heterozygote mice.  4 controls 
were ran with each PCR – 3 mice of known genotypes (mutant, heterozygote and wildtype), 
along with a water only negative control. 
 
Additionally mice from the H2K-FKRPKD, FKRPMD and FKRPMDLARGE colonies were genotyped 
for the presence of absence of a transgene (Cre recombinase, LV5 or H2K).  An example of 
such a PCR, in this case for the LV5 transgene is shown in C.  Mice 1 and 2 carry the 
transgene, while mice 3 and 4 do not carry the transgene.  With each PCR 3 controls were 
run – two mutant mice carrying the LV5 transgene and a water only negative control.   
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2.4 SAMPLE PREPARATION FOR HISTOLOGY 
Wildtype, FKRPMD and FKRPMDLARGE at 6, 12, or 30 weeks of age.and P0 mice from the 
FKRPKD colony were culled by a Schedule 1 method.  To obtain embryonic samples from the 
FKRPKD mouse colony, breeding females were checked daily for plugs with the day of the 
plug noted as 0.5 days post conception, with the mother and embryos culled by Schedule 1 
method on the appropriate day post conception. 
 
Dissected tissue samples from these mice were coated in Optimal Cutting Temperature 
medium (Bright, U.K.), mounted on corks (ThermoFischer Scientific and frozen in isopentane 
(VWR International or ThermoFischer Scientific) cooled in liquid nitrogen.  10µm sections 
were cut with a cryostat (Bright – OFT500) at a temperature of approximately -20°c for 
muscle and -15°c for embryonic and newborn heads.  Sections were mounted on SuperFrost 
Plus Slides (VWR International) and stored at -40°c or -80°c until processed for either 
histological analysis as described below in Section 2.5, or immunohistochemistry as 
described in Section 2.6.   
 
2.5 HISTOLOGICAL ANALYSIS 
All cryosections stained histologically with haematoxylin and eosin or Alizarin Red (as 
described below) were visualised under light microscopy using a DM4000B upright 
microscope (Leica Microsystems, Germany).  Images were digitally captured with a DC500 
colour camera (Leica Microsystems) using the Leica Application Suite (Leica Microsystems) 
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software provided and compiled into figures using Photoshop CS4 or CS5 (Adobe, U.S.A.).  
Where necessary, colour corrections were applied using Photoshop CS4 or CS5. 
 
2.5.1 HAEMATOXYLIN AND EOSIN  
Cryosections were incubated in Harris’ Haematoxylin (Lamb, ThermoFischer Scientific) for 5 
minutes, washed in running tap water for 2 minutes and then left in 1% (w/v) eosin (Gurr’s, 
U.K.) for 2 minutes.  After a brief rinse in tap water, sections were dehydrated in a series of 
graded alcohols (Industrial Methylated Spirits; VWR International diluted v/v in water) for 
approximately 1 minute each – 50%, 70%, 95%, 100%, 100% and 100%.  Sections were then 
incubated in Xylene (ThermoFischer Scientific or Leica Microsystems), changed 3 times, for 
10 minutes each before coverslips (Menzel-Gläser, ThermoFischer Scientific) were mounted 
using DPX (Distyrene Plasticizer Xylene) mountant (VWR International).   
 
2.5.2 ALIZARIN RED  
Sections were fixed in -20°c acetone (VWR International) for 10 minutes and then washed in 
distilled water.  Alizarin red solution (20g/L w/v Alizarin Red S (BDH, now part of VWR 
International) dissolved in water and adjusted to pH 4.2 with hydrochloric acid 
(ThermoFischer Scientific) was then dropped onto the slides and incubated for 
approximately 1 minute.  The slides were then blotted dry and rinsed in acetone for 30 
seconds and then 1:1 v/v xylene-acetone for 15 seconds.  Slides were then incubated in 3 
changes of xylene (ThermoFischer Scientific) for 30 minutes each and coverslips were 
mounted on the slides using DPX mountant. 
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2.5.3 CORTICAL NEURON COUNTS 
Digital images of P0 wildtype (n=3) and FKRPKD (n=3) cortex immunolabelled with antibodies 
against the transcription factors Tbr1 (T box brain 1) and Tbr2 (T box brain 2) and Hoechst 
33342 to visualise the nuclei (kindly provided by Dr Mark Ackroyd, Royal Veterinary College) 
were processed and counted using Adobe Photoshop CS4 or CS5.  A 0.5cm wide region of 
cortex adjacent to the interhemispheric fissure was randomly selected, isolated and then 
arbitrarily divided into 6 equal regions, with zone 1 closest to the ventricular zone and zone 
6 adjacent to the pial basement membrane (shown in Figure 3-11)..  Both the total number 
of nuclei in each layer and the total number of Tbr1 and Tbr2 positive neurons was counted 
for each layer.  Where a nucleus was lying on the border between two layers, it was 
assigned to the layer where the majority of it resided.  This information was collated in Excel 
2010 and analysed using GraphPad Prism version 5.0 for Windows. 
 
2.5.4 MEASUREMENTS OF HEAD AND EYE SIZE 
Images were captured as described above in Section 2.5 of haematoxylin and eosin stained 
6µm Bouin’s fixed, paraffin embedded sections kindly provided by Ms. Helen Booler (Royal 
Veterinary College London).  Sections were only used if a complete representation of the 
eye was visible.  Using ImageJ (National Institute of Health, U.S.A) measurements were 
obtained from P0 wildtype (n=3) and FKRPKD (n=3) mice of the surface area of the entire 
head and also the eyes.  Measurements were taken from at least 5 images per mouse to 
account for variations in plane of section across the eye, and a mean value was calculated.  
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Data was collated using Excel (Microsoft Office 2007 or 2010, U.S.A.) and analysed using 
GraphPad Prism version 5.0 for Windows (GraphPad Software Inc.). 
 
2.5.5 MEASUREMENTS OF RETINAL WIDTH 
Images of mouse eyes stained with haematoxylin and eosin from wildtype and FKRPKD mice 
were captured as described above in Section 2.5.  Using ImageJ measurements were 
obtained in the region of the central retina (wildtype n=7, FKRPKD n=7) and peripheral retina 
(wildtype n=6, FKRPKD n=5).  Images were discarded if not a complete representation of the 
eye was shown and at least 3 different eye sections were measured for each mouse (to 
account for variations in plane of section across the eye) and a mean value per mouse was 
generated.  Total retinal depth and inner retinal depth were measured, with the value for 
outer retinal depth obtained by subtracting the depth of the inner retina from the total 
retinal depth.  Where percentage values are shown, the percentage was calculated for each 
individual section and again a mean value was obtained per mouse.  Data was compiled 
using Excel 2007 or 2010 and analysed using GraphPad Prism version 5.0 for Windows. 
 
2.5.6 CENTRAL NUCLEATION COUNTS 
Images were captured as described above in Section 2.5 of the soleus, gastrocnemius and 
diaphragm from 12 and 30 week old wildtype (n=3 of each muscle at each age), FKRPMD (n=3 
of each muscle at each age) and FKRPMD (n=3 of each muscle at each age).  For the Random 
Areas counts, 3 images were taken at 10x magnification of each muscle, with the area 
captured randomly chosen.  For the Photomerged images, one section was chosen per 
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mouse; overlapping images were taken across the whole muscle and merged into one 
composite image using Adobe Photoshop CS4 or CS5.  The fraction of centrally nucleated 
muscle fibres and peripherally nucleated muscle fibres was then counted using Adobe 
Photoshop CS4 or CS5 and the percentage of centrally nucleated muscle fibres was 
calculated.  This data was compiled using Microsoft Office Excel 2007 or 2010 and analysed 
using GraphPad Prism version 5.0 for Windows or IBM SPSS Statistics (IBM Corporation, 
U.S.A.).  A Generalised Estimating Equations Statistical test was performed to assess 
whether age, muscle and genotype were significant interacting factors affecting the 
percentage of centrally nucleated muscle fibres. 
 
2.5.7 QUANTIFICATION OF SPLIT FIBRE NUMBER 
Images were captured as described above in Section 2.5 of the gastrocnemius from 12 week 
old wildtype (n=3 of each muscle at each age), FKRPMD (n=3 of each muscle at each age) and 
FKRPMD (n=3 of each muscle at each age).  One section was chosen per mouse and 
overlapping images across the whole muscle were merged into one composite image using 
Adobe Photoshop CS4 or CS5.  The number of split fibres across each muscle section was 
counted using Adobe Photoshop CS4 and compiled using Microsoft Office Excel 2010.  This 
data was then analysed using GraphPad Prism version 5.0 for Windows. 
 
2.6 IMMUNOHISTOCHEMISTRY 
All antibodies were used on unfixed cryosections with the exception of Brn3 and RC2, where 
sections were fixed in PBS with 4% (w/v) paraformaldehyde for 10 minutes and laminin α4 
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where sections were fixed in -20°c acetone (VWR International) for 10 minutes.  
Additionally, for the RC2 antibody, sections were then incubated for two minutes in 65°c 
0.03M (w/v) sodium citrate buffer (Sigma-Aldrich) for antigen retrieval prior to 
immunolabelling.  To perform double immunolabelling for Brn3 and perlecan, the 
antibodies were incubated sequentially.   
 
All primary antibodies are listed in Table 2-4 with the dilution used, the supplier and the 
species of secondary antibody.  All antibodies were diluted v/v in PBS with the exception of 
laminin β2 (PBS, 1% w/v BSA) and β-dystroglycan (PBS, 5% v/v horse serum (a kind gift from 
Mr Jacob Ross, (University College London)). 
 
Between incubations three, five minute washes in PBS were carried out.  All primary 
antibodies were incubated for 60 minutes at room temperature or overnight at 4°c.  The 
appropriate secondary antibody (Table 2-4) coupled to an Alexa fluorophore (Invitrogen) 
diluted 1:1000 v/v in PBS was then incubated for 30 minutes at room temperature.  For IIH6 
and RC2 immunolabelling only, a biotinylated anti-mouse IgM (diluted 1:200 v/v in PBS) 
secondary antibody was incubated for 30 minutes at room temperature (Table 2-4).  
Sections were then incubated with streptavidin, diluted 1:1000 v/v in PBS.  Nuclei were 
labelled with Hoechst 33342 trichloride (Sigma-Aldrich) diluted 1:2000 v/v in PBS.  Controls 
were prepared by the same method, but PBS was applied instead of the primary antibody.  
Coverslips were then mounted onto the slides using Hydromount (Diagnostic Laboratories).  
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The vast majority of immunolabelled sections were visualised using a DM4000B upright 
microscope (Leica Microsystems) under epifluorescence microscopy and images were 
digitally captured with a mRM monochrome camera (Zeiss, U.K.) using the Axiovision 
software (Zeiss) provided.  A small number of cryosections were visualised using a Nikon 
E1000M Microscope and images were digitally captured with CoolSnap HQ (Photometrics) 
CCD monochrome camera using an Image Pro Plus Imaging system. All images were 
compiled into figures and manipulated using Photoshop CS4 or CS5.  Where comparisons of 
immunolabelling intensity are made, images were captured at the same exposure and 
identical manipulations using Photoshop CS4 or CS5 were applied.  












1:3000 Abeam, U.K. Rat IgG Immunoprecipitation 
with laminin 211, ELISA 
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1:20  Southern 
Biotech 
Goat IgG ELISA using human 
collagen type IV 
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Laminin α4 1:400  R&D Systems, 
U.S.A. 
Goat IgG ELISA and Western Blot 






IIH6 1:200 Millipore Mouse IgM Western Blot for α-
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1:100  Leica 
Microsystems 
(Germany) 
Mouse IgG Immunolabelling and 
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Rabbit IgG ELISA and radio-
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Brn3 1:400 Santa-Cruz, 
U.S.A. 
Goat IgG Epitope mapping (Santa 
Cruz Biotechnology) 
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Professor 
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Research Genetics and 
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the peptide sequence.  
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used to confirm specific 







residues 50 - 
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TBR1. 
Tbr1 1:1000 Abcam Rabbit IgG Immunohistochemistry(B
ayatti et al., 2008) and 










Mouse TBR2 . 
Tbr2 1:1000 Abcam Rabbit IgG Western Blotting and 
immunohistochemistry 
(Abcam) 
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TABLE 2-4 PRIMARY ANTIBODIES FOR IMMUNOHISTOCHEMISTRY 
This table lists all the primary antibodies used for immunolabelling of cryosections with their 
suppliers, dilution factor and species of secondary antibody.  
 
The information regarding the primary immunogen and the specificity testing was obtained 
from the antibody datasheets (if commercially available) and/or the following published 
literature:  
laminin α2 - http://www.abcam.com/Laminin-2-alpha-antibody-4H8-2-ab11576-
references.html (Abcam) (Schuler and Sorokin, 1995); perlecan - 
http://www.millipore.com/coa.nsf/a73664f9f981af8c852569b9005b4eee/23d148372f471c
0e85257a59005d9833/$FILE/MAB1948P_2049814.pdf (Millipore), (Couchman and 
Ljubimov, 1989); collagen type IV - http://www.southernbiotech.com/techbul/1340.pdf 
(Biotech), laminin α4 - http://www.rndsystems.com/Products/AF3837 (Systems); IIH6 -  
http://www.millipore.com/catalogue/item/05-593 (Millipore), (Ervasti and Campbell, 1991); 
integrin β1 - http://www.rndsystems.com/pdf/MAB2405.pdf (Systems); β-dystroglycan -  
http://www.leicabiosystems.com/fileadmin/img_uploads/novocastra_reagents/Novocastra
_datasheets/b-dg.pdf (Biosystems), (Bewick et al., 1993, Cullen et al., 1994); laminin β2 - 
(Sasaki et al., 2002), pan-laminin - http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Datasheet/4/l9393dat.pdf (Sigma-Aldrich); Brn3 - 
http://datasheets.scbt.com/sc-6026.pdf (Santa Cruz Biotechnology); RC2 - 
http://dshb.biology.uiowa.edu/radial-glial (Bank); laminin α1 - (Sorokin et al., 1992); 
Collagen XVIII (Erickson and Couchman, 2001); Tbr1 - http://www.abcam.com/tbr1-
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2.7 RT-PCR ANALYSIS 
Real-time PCR analysis was performed by Dr Mark Ackroyd (Royal Veterinary College).  Brain 
and muscle samples extracted from 12 week (±1 week) wildtype (n=4) and FKRPMD (n=4) 
mice were placed in RNAlater® (Qiagen, U.K.) and, following storage at -40°c until use, were 
homogenised with liquid nitrogen using a mortar and pestle and the lysate passed through 
a QiaShredder®(Qiagen).  The RNA was isolated from the homogenised tissue using an 
RNeasy®kit (Qiagen) and for muscle RNeasy® Fibrous Tissue Kit (Qiagen) eluted with 30 µl 
RNase free H2O.  1 µg of RNA was reverse transcribed with Superscript
®III Platinum for qRT-
PCR kit (Invitrogen).  qRT-PCR was performed on a 7500 FAST Real-Time PCR system 
(Applied Biosystems, U.S.A) using a FAM(tm) reporter dye system.  For each reaction 0.8 µl of 
complementary DNA was used as template in a PCR mix consisting of 1 µl of primer mix, 10 
ul TaqMan Universal PCR Mastermix (Applied Biosystems) and 8.2 µl H2O.  The primers for 
the gene expression assays were sourced commercially from Applied Biosystems (FKRP 
Mm00557870_mL, GAPDH Mm99999915_gL).  Each experiment represents a minimum of 
n=4 (of either sex) and all reactions were performed in triplicate.  Data was compiled and 
analysed using GraphPad Prism version 5.0 for Windows. 
 
2.8 SERUM CREATININE KINASE ANALYSIS 
A small blood sample (50-100µL) was collected from the tail vein of 3 wildtype, 3 FKRPMD 
and 3 FKRPMDLARGE male mice aged between 12 and 14 weeks and left to clot on ice for 
between 30 and 60 minutes.  Blood samples were then spun at 4°c for 10 minutes at 1800g, 
the plasma sample was removed and stored until use. 
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Reagents from a CK assay kit from Randox, Laboratories, U.K (prepared according to 
manufacturer’s instructions) was used to analyse the serum samples at 37°c with an ELISA 
plate reader (Anthos HTIII, Austria).  Each sample was run in triplicate, with controls run in 
duplicate – the positive control was a serum sample from a 6 week old mdx mouse (kindly 
provided by Dr Sofia Muses, Royal Veterinary College) whilst the negative control was the 
reagent alone.  After 1 minute incubation, readings were taken every minute for 5 minutes, 
with the plate shaken for 5 seconds prior to reading.  The maximum change in absorbance 
over time was then blank corrected and calculated and converted into CK U/litre.  
 
2.9 GENERATION FKRPKD AND WILDTYPE CLONAL CELL LINES 
Newborn mice from the H2K-FKRPKD mouse colony were killed by a Schedule 1 method.  The 
legs were removed, sterilised in 70% ethanol (ThermoFischer diluted v/v with water), 
skinned and washed twice in sterile Dulbecco’s PB  (calcium and magnesium free) 
(Invitrogen).   
 
The legs were triturated to physically dissociate them and then incubated in enzyme 
solution (Section 2.1.2) at 37°c for 15 minutes.  Again, each leg was triturated to physically 
dissociate it before proliferation media (Section 2.1.3- without γ-interferon) was added and 
mixed with the tissue to inactivate the enzyme solution.  The supernatant was then 
collected.  This process was repeated another three times to fully digest the leg.  The 
supernatants were then filtered using a 100µm cell strainer (BD Biosciences, U.S.A.) and 
centrifuged (Eppendorf Centrifuge 5804R) for 3 minutes at room temperature at 200g.  The 
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pellets were resuspended in proliferation media (Section 2.1.3), plated onto tissue culture 
plastic previously coated in 0.1mg/mL Matrigel (BD Biosciences, prepared as described in 
section 2.10) and incubated under proliferative conditions - 33°c, 5% CO2. 
 
Once the cells had reached 70-80% confluency the spent media was removed and the cells 
were washed in sterile PBS.  0.05x Trypsin-EDTA was then added to the cells for 5 minutes, 
before proliferation media was added to inactivate the trypsin.  Cells were then centrifuged 
at 200g (Eppendorf Centrifuge 5804R) for 5 minutes.  The supernatant was removed and the 
cells were resuspended in proliferation Media.  A small volume of these resuspended cells 
were diluted 2:1 in Trypan Blue (Sigma-Aldrich) and a cell count was performed using a 
haemocytometer (Marenfeld Superior, Germany) to calculate the cell density.  Cells were 
then plated in 96 well plastic tissue culture plates (pre-coated in Matrigel as described in 
section 2.10) at a concentration of 10 cells/mL so that the average cell concentration was 1 
cell per well.  Within 24 hours, the wells where all cells had been generated from a single 
clone were identified and these were left to proliferate, with the media changed twice a 
week. 
 
Each individual clone was then expanded until approximately 1 x106 cells had been 
generated.  The spent media was then removed, cells were washed once in Dulbecco’s PB  
(Invitrogen) and incubated with 0.05x Trypsin-EDTA (Invitrogen) for 5 minutes at 37°c to 
detach the cells.  Proliferation media was added to inactivate the trypsin and the cells were 
collected and pelleted at 200g for 5 minutes at room temperature.  The cells were then 
resuspended in proliferation media, with approximately 80% of the cell suspension 
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prepared for long-term storage in liquid nitrogen as described in Section 2.10.1, whilst the 
remaining 20% was plated for terminal differentiation as described in Section 2.11.  All 
clones were classified as myogenic if they terminally differentiated into multinucleated 
myotubes. 
 
2.10 PROLIFERATION  
In addition to the clonal cell lines described above, an additional clonal cell was obtained, 
H2Kb-2B4 (a kind gift from Dr Sofia Muses, Royal Veterinary College, U.K.) for use as a 
control.  This is a clonal myoblast cell line previously derived from adult muscle fibres 
isolated from the Immortomouse (Muses et al., 2011).  All clonal lines were proliferated on 
plastic tissue culture flasks (Nunc, ThermoFischer Scientific, U.S.A.) pre-coated with 
0.1mg/mL Matrigel (BD Biosciences, U.K., diluted in DMEM (Invitrogen)) under proliferative 
conditions - 33°c, 5%CO2.  Matrigel is a soluble, sterile preparation of proteins derived from 
the EHS (Engelbreth-Holm-Swarm) tumour (Kleinman and Martin, 2005).  For proliferation, 
the diluted Matrigel was added to the growth surface, incubated at 33°c for at least 30 
minutes and removed just before the cells were plated. 
 
Cells were harvested once they reached a confluency of 70-80%.  The spent media was 
removed and cells were washed once in Dulbecco’s PB  (calcium and magnesium free) 
(Invitrogen).  Cells were then incubated with 0.05x Trypsin-EDTA (Invitrogen) for 5 minutes 
at 37°c to detach the cells.  Proliferation media was added to inactivate the trypsin and the 
cells were collected and pelleted at 200g for 5 minutes at room temperature.  The 
supernatant was removed and the cells were re-suspended in fresh growth media and 
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plated into fresh tissue culture flasks.  Cells were passaged in this way 2-3 times a week to 
maintain their proliferative capability (Morgan et al., 1994). 
 
2.10.1 LIQUID NITROGEN CELL STORAGE 
Cells were harvested and counted as described above in Section 2.9.  The volume of cells to 
be frozen for long-term storage in liquid nitrogen was removed, pelleted by centrifugation 
at 200g at room temperature for 5 minutes and re-suspended in freezing solution 
(Proliferation media (Section 2.1.3), 10% v/v DMSO (Dimethyl sulfoxide) (Sigma-Aldrich)).  
Cell solutions were aliquoted into labelled cryovials (ThermoFischer) and placed into 
cryofreezing containers (Mr Frosty, Nalgene) containing isopropanol (ThermoFischer 
Scientific or VWR International) overnight at -80°c, which cooled the cell suspensions at a 
rate of 1°c/min, allowing for optimum cryopreservation.  Cells were then transferred into 
liquid nitrogen for long-term storage. 
 
Cells stored in liquid nitrogen were thawed at 37°c, diluted in fresh proliferation media and 
pelleted at 200g for 5 minutes at room temperature.  The supernatant was removed; cells 
were re-suspended in fresh proliferation media and grown as described above in Section 
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2.11 TERMINAL DIFFERENTIATION 
Clonal cell lines were differentiated on either Boroscillicate glass coverslips (VWR 
International, U.S.A.) or 8 well tissue culture chamber slides (Nunc, U.K.), both pre-coated 
with 0.1mg/mL (v/v) Matrigel at 37°c for 30minutes to an hour.  After this time period, the 
Matrigel was removed and the growth surface was covered with DMEM, which was 
removed just before the cells were plated. 
 
Cells were harvested and counted as described above in Sections 2.9 and 2.10.  Cells were 
removed, pelleted at 200g for 5 minutes at room temperature, resuspended in 
differentiation media and incubated under non-permissive (differentiating) conditions - 
37°c, 5% CO2 for 5 days. 
 
2.12 ANALYSIS BASEMENT MEMBRANE DEPOSITION IN VITRO 
After differentiation, cells were fixed in PBS with 4% w/v paraformaldehyde (VWR 




For all antibodies, apart from IIH6, cells were incubated in blocking solution (PBS, 1% v/v fish 
skin gelatin (Sigma-Aldrich, U.K.)) prior to immunolabelling.  All subsequent antibody 
dilutions (v/v) were made in this block, with the exception of IIH6 immunolabelling, where 
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all dilutions (v/v) were made in PBS.  All primary antibodies were incubated for 60 minutes 
at room temperature or overnight at 4°c at the dilutions specified in   
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Table 2-5.  The appropriate secondary antibody was then applied and left for 30 minutes at 
room temperature (  
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Table 2-5).  For IIH6 staining only, streptavidin 594 (v/v 1:1000) was subsequently incubated 
for 30 minutes.  Nuclei were labelled with Hoechst 33342 (Sigma-Aldrich), diluted 1:2000 v/v 
in PBS.  Secondary antibody controls were prepared by the same method, but PBS was 
applied instead of the primary antibody.  After staining, the coverslips were mounted on 
SuperFrost Plus Slides (ThermoFischer Scientific) using Hydromount (Diagnostic 
Laboratories, U.K.).   
 
Once stained, the cells were visualised using a DM4000B upright microscope (Leica, 
Germany) under epifluorescence microscopy.  Images were digitally captured with an 
Axiovision monochrome camera (Zeiss International, U.S.A), manipulated and compiled 
using Photoshop CS4 or CS5.  Where comparisons of immunolabelling intensity are made, 
images were captured at the same exposure and identical manipulations were applied in 
Photoshop CS4 or CS5 
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TABLE 2-5 IMMUNOCYTOCHEMISTRY ANTIBODIES 
This table lists all primary antibodies used for immunolabelling of terminally differentiated 
cells, with their suppliers, dilution factor and species of secondary antibody.  
 
The information regarding the primary immunogen and the specificity testing was obtained 
from the antibody datasheets (if commercially available) and/or the following published 
literature:  
IIH6 -  http://www.millipore.com/catalogue/item/05-593 (Millipore), (Ervasti and Campbell, 
1991); laminin α2 - http://www.abcam.com/Laminin-2-alpha-antibody-4H8-2-ab11576-
references.html (Abcam) (Schuler and Sorokin, 1995); laminin α1 - (Sorokin et al., 1992), 
laminin γ1 http://www.millipore.com/catalogue/item/mab1914p# (Millipore); laminin α4 - 
http://www.rndsystems.com/Products/AF3837 (Systems); pan-laminin - 
http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Datasheet/4/l9393dat.pdf (Sigma-Aldrich); perlecan - 
http://www.millipore.com/coa.nsf/a73664f9f981af8c852569b9005b4eee/23d148372f471c
0e85257a59005d9833/$FILE/MAB1948P_2049814.pdf (Millipore), (Couchman and 
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2.12.2 IMMUNOCYTOCHEMICAL ANALYSIS OF BASEMENT MEMBRANE DEPOSITION 
Terminally differentiated cells immunolabelled with antibodies against basement 
membrane proteins were analysed to evaluate basement membrane deposition.  First, the 
degree of laminin immunolabelling across the extracellular surface was qualitatively graded, 
by comparison to pan-laminin immunolabelling, which allowed an assessment of the 
distribution of each individual laminin chain to be made. 
 
Secondly, the structure of the basement membrane deposits were investigated and 
classified into one of three structures – punctate clusters, linear arrays and plaques, 
similarly to those identified by (Henry et al., 2001) on the extracellular surface of embryoid 
bodies.  Punctate deposits were defined as small, rounded, dispersed points of basement 
membrane deposition.  Linear arrays were defined as parallel lines of basement membrane 
deposit, while plaques, the most mature form of cluster identified were identified as 
elongated, wide complex structures.  The presence or absence of each cluster structure 
following immunolabelling for basement membrane proteins was noted. 
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The FKRP-NeoTyr307Asn+/+ (FKRPKD) mouse was initially reported by Ackroyd, Skordis and 
colleagues in 2009. This mouse contains a Neomycin resistance cassette in intron 2 of Fkrp 
and a point mutation – A>T at position 919 of the open reading frame, which induces an 
asparagine to tyrosine (Tyr307Asn) substitution (Ackroyd et al., 2009).  A schematic of these 
genetic modifications is shown in Figure 3-1.  Mice homozygous for these changes have a 
reduction in Fkrp expression of approximately 80%, which induces a severe MEB phenotype 
and mutants die soon after birth due to central nervous system involvement (Ackroyd et al., 
2009).  The Neomycin cassette is floxed and global removal with Cre recombinase prevents 
the reduction in Fkrp expression and the mutant phenotype does not develop (mice 
homozygous for the Tyr307Asn mutation alone are phenotypically normal) (Ackroyd et al., 
2009).  Data from a masters project (not presented here), confirmed that homozygous 
expression of the missense mutation in combination with heterozygous expression of the 
Neomycin cassette failed to induce a phenotype (Whitmore, unpublished data). This work is 
reported in full in Ackroyd et al., 2009 and showed the reduction in Fkrp expression 
(achieved through insertion of the Neomycin cassette), rather than the missense point 
mutation causes the muscle, eye brain phenotype in the mouse.  Interestingly this contrasts 
markedly with human patients, where the Tyr307Asn mutation has been associated with a 
severe MEB phenotype (Beltran-Valero de Bernabe et al., 2004, Mercuri et al., 2006).  




FIGURE 3-1 SCHEMATIC OF FKRPKD MUTANT ALLELE 
Schematic showing the wildtype Fkrp gene (top), and the mutant Fkrp (bottom).  The gene is 
represented by a black line and the 3 Fkrp exons are shown in purple.  The Tyr 307 Asn 
substitution is indicated by the red triangle in exon 3 and the Neomycin selection cassette 
(NeoR) is shown in intron 2, flanked by loxP sites (green triangles).  HindIII digestion sites are 
indicated by “H”.  Mice homozygous for these changes are designated FKRPKD (FKRP-
NeoTyr307Asn+/+).   
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A brief characterisation of the FKRPKD phenotype in the muscle, eye and brain has already 
been published (Ackroyd et al., 2009, Ackroyd et al., 2011), with part of the data presented 
in this chapter included in this publication (Ackroyd et al., 2011), on which I am second 
author.  However, to fully elucidate the functional implications of Fkrp deficiency, a more 
detailed study on basement membrane deposition in selected tissues of these mice has 
been undertaken here.  To test the hypothesis that a reduction in Fkrp expression affects 
the distribution of basement membrane proteins in the muscle, cerebral cortex and eye - 
firstly basement membrane deposition was evaluated by immunofluorescence and secondly 
these tissues were evaluated histologically, to evaluate the functional consequences of 
abnormal basement membrane deposition.  These tissues were selected due to their 
relevance in the clinical phenotype of dystroglycanopathy patients.  The results from the 
muscle and cortex will be reported and discussed in this chapter, while the results from the 
eye will be presented in the next chapter, Chapter 4.  
 
At the severe end of the dystroglycanopathy clinical spectrum (WWS and MEB disease), 
cortical neuron migration and/or positioning is altered, a feature that has been associated 
with defects in the pial basement membrane (Muntoni and Voit, 2004, Muntoni et al., 
2011).  Additionally, macroglossia (hypertrophy of the tongue) has been identified in 
patients with dystroglycanopathies, including those carrying mutations in FKRP (Quijano-Roy 
et al., 2002, Mercuri et al., 2003, Louhichi et al., 2004), FUKUTIN (Vuillaumier-Barrot et al., 
2009) and POMT2 (Yanagisawa et al., 2009) and involvement of the tongue has been 
reported in the Largemyd dystroglycanopathy mouse model (Lane et al., 1976, Holzfeind et 
al., 2002).  Tongue hypertrophy has also been reported in a small number of Duchenne 
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Muscular Dystrophy (DMD) patients carrying a duplication mutation in dystrophin (Weiss et 
al., 2007), further implicating the role of the DAPC in this phenotype.  Contrastingly, the 
extraocular muscles have been reported to be “spared” in various muscular dystrophies 
including DMD (Kaminski et al., 1992, Khurana et al., 1995,  traube and B ttner, 200 ) 
laminin α2 deficient muscular dystrophy (Porter and Karathanasis, 1998), sarcoglycan 
deficiency (Porter et al., 2001) and CMD (Mendell et al., 1995). 
 
Studies conducted in the FKRPKD mouse have, to date, only provided global information on 
the distribution of basement membrane proteins and how this is affected by a reduction in 
Fkrp expression.  A loss of Fkrp expression could affect basement membrane deposition in 
two ways, it could either deposit incorrectly, or a correctly deposited basement membrane 
could destabilise and become disrupted.  As detailed previously in the Introduction Section 
1.8, basement membranes are important for tissue development and function, so this will 
be affected when basement membrane deposition is perturbed.  Dystroglycan is a 
ubiquitously expressed receptor (Winder, 2001),  which is thought to have a central role in 
basement membrane deposition (Williamson et al., 1997, Henry et al., 2001).  Reduced 
activity or expression of Fkrp alters, or reduces dystroglycan glycosylation in human patients 
(Brockington et al., 2001b, Brockington et al., 2001a) and the FKRPKD mouse (Ackroyd et al., 
2009), impairing its ability to bind to basement membrane ligands.  Thus, to test a second 
hypothesis of this chapter that a reduction in Fkrp expression affects how the basement 
membrane deposits on the extracellular surface, the glycosylation of α-dystroglycan and 
deposition of basement membrane ligands was evaluated immunocytochemically using 
terminally differentiated muscle cell lines generated from the FKRPKD mouse. 




The first aim of this chapter is to provide a detailed description of basement membrane 
deposition at the pial basement membrane in the cortex and the basement membrane 
surrounding muscle fibres in the tongue and the extraocular muscles to test the hypothesis 
that a reduction in Fkrp expression will alter the distribution of basement membrane ligands 
at the pial basement membrane and the tongue, but not the extraocular muscles.  The 
resulting disorganisation of the pial basement membrane will result in aberrant cortical 
neuron positioning.   
 
The second aim of this chapter is to generate a conditionally immortalised myogenic cell line 
with a reduction in Fkrp expression to test the hypothesis that the altered distribution of 
basement membrane ligands in vivo is a direct consequence of their altered arrangement, 








3.3.1 ALTERED DISTRIBUTION OF α- BUT NOT β-DYSTROGLYCAN IN THE FKRPKD MOUSE 
The glycosylation status of α-dystroglycan in the cortex, tongue and extraocular muscles 
was investigated by IIH6 immunolabelling.  The IIH6 antibody is considered to recognise the 
laminin binding glycosylated epitope of α-dystroglycan (Ervasti and Campbell, 1993, Brown 
et al., 1999) and a reduction in IIH6 immunolabelling is commonly seen in both 
dystroglycanopathy patients and animal models (Brown et al., 2004, Muntoni et al., 2008), 
suggesting a reduction in α-dystroglycan glycosylation and reduced ligand binding capability. 
 
In wildtype mice, IIH6 immunolabelling has already been reported at the pial basement 
membrane (Ackroyd et al., 2009) and here IIH6 immunolabelling was additionally observed 
at the sarcolemma of muscle fibres in the tongue and extraocular muscles (  
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Figure 3-2).  Although the level of IIH6 immunolabelling was similar in all muscle fibres of 
the tongue, in the extraocular muscles, a variable intensity of IIH6 immunolabelling between 
muscle fibres was observed - some muscle fibres stained very brightly for IIH6, whilst others 
stained at a lower intensity, more comparable to those in the tongue (  
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Figure 3-2).  This difference in immunolabelling with the IIH6 epitope suggests a variation in 
either (i) the overall level of dystroglycan, or (ii) the pattern of α-dystroglycan glycosylation.  
 
In the FKRPKD mouse, IIH6 immunolabelling was reduced at the pial basement membrane 
(Ackroyd et al., 2009).  Consistent with these observations, IIH6 immunolabelling here was 
reduced at the sarcolemma of muscle fibres in the tongue and extraocular muscles (  
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Figure 3-2).  This suggests a reduction in Fkrp expression altered the glycosylation pattern of 
α-dystroglycan, resulting in reduced IIH6 immunolabelling in comparison to wildtype mice.  
However, in the FKRPKD extraocular muscles, a small population of fibres with increased IIH6 
immunolabelling was identified, although this was not at a comparable intensity to 
wildtype.  Again, this suggests there is variation in either the overall level of dystroglycan, or 
the pattern of α-dystroglycan glycosylation between the tongue and extraocular muscle 
fibres. 
 
Immunolabelling with an antibody against β-dystroglycan was equivalent in both wildtype 
and FKRPKD mice at the pial basement membrane and the sarcolemma of muscle fibres in 
the tongue and extraocular muscles (Figure 3-3), suggesting the glycosylation pattern of α-
dystroglycan was altered between these tissues, rather than the level of dystroglycan itself.  
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FIGURE 3-2 IIH6 IMMUNOLABELLING OF WILDTYPE AND FKRPKD MICE 
IIH6 immunolabelling (red) was identified at the sarcolemma of muscle fibres in the 
wildtype tongue (A), which was lost in the FKRPKD (B) suggesting altered reduced 
glycosylation of α-dystroglycan.  IIH6 immunolabelling (red) was identified at the 
sarcolemma of muscle fibres in wildtype extraocular muscles (C) and as shown in a 
monochrome image of increased magnification, some muscle fibres display increased IIH6 
immunolabelling.  IIH6 Immunolabelling was markedly reduced at the sarcolemma of 
extraocular muscle fibres in the FKRPKD mouse (D), suggesting altered, reduced α-
dystroglycan glycosylation.  A small population of muscle fibres with increased IIH6 
immunolabelling persisted, identified by a white arrow are magnified in the corner of panel 
D, although the level of immunolabelling is not equivalent to wildtype. 
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C) and FKRPKD (n=3) (B, D) mice 
were immunolabelled with the IIH6 antibody against glycosylated α-dystroglycan (red) and 
Hoechst 33342 to visualise the nuclei (blue).  At least 2 sections from each mouse (each 
separated by a distance of approximately 120µm) were viewed under epifluorescence using 
a DM4000B upright microscope (Leica Microsystems), with the pattern of immunolabelling 
described above observed in all sections.  Images were captured with an mRM monochrome 
camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures 
using Photoshop CS4 or CS5 (Adobe).  All images were captured at the same exposure, with 
representative images shown.  Scale bar denotes 50µm.  The following structures are 
indicated – the rectus extraocular muscle (EOM) and the retina (Retina). 
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FIGURE 3-3 β-DYSTROGLYCAN LOCALISATION IN THE FKRPKD MOUSE 
Immunolabelling for β-dystroglycan was identified in wildtype and FKRPKD mice at the pial 
basement membrane (A-B) and the sarcolemma of muscle fibres in the tongue (C-D) and 
extraocular muscles (E-F), with no difference in immunolabelling intensity.  
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C, E) and FKRPKD (n=3) (B, D, F) 
mice were immunolabelled with an antibody against β-dystroglycan (green) and Hoechst 
33342 (blue) to visualise the nuclei.  At least 2 sections (each separated by a distance of 
approximately 120µm) were evaluated from each mouse were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems), with the 
pattern of immunolabelling documented apparent in all sections.  Images were captured 
with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) 
provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were 
captured at the same exposure, with representative images shown.  Scale bar denotes 
50µm.  The following structures are indicated – the pial basement membrane (Pial BM), the 
rectus extraocular muscle (EOM) and the retina (Retina). 
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3.3.2 BASEMENT MEMBRANE COMPOSITION WAS ALTERED BY A REDUCTION IN FKRP 
EXPRESSION 
One of the main ligands in the basement membrane which binds to -dystroglycan is 
laminin (Ibraghimov-Beskrovnaya et al., 1992).  Immunolabelling with a pan-laminin 
antibody visualised laminin localisation at the pial basement membrane of both wildtype 
and FKRPKD mice at comparable immunolabelling intensities, although the pial basement 
membrane was disrupted in the FKRPKD mouse (Figure 3-4).  At least two sections from five 
FKRPKD mice were evaluated and this disruption was identified in all sections evaluated, 
although the degree of disruption and the region of the pial basement membrane where it 
was observed varied between individual mice.  Additionally, pan-laminin immunolabelling 
was identified at the basement membrane surrounding muscle fibres in the tongue and 
extraocular muscles in at least two sections from three  individual wildtype and three 
FKRPKD mice, with no difference in immunolabelling intensity (Figure 3-4). 
 
This perturbation of laminin deposition at the pial basement membrane has already been 
described by Dr Mark Ackroyd in Ackroyd et al., 2011.  It has been included here to allow a 
comparison between the pial basement membrane and the basement membranes of the 
tongue and extraocular muscles.  Additionally, this work has been expanded on here by 
looking at the distribution of other laminin chains (β2) and other basement membrane 
components (collagen types IV and XVIII). 
 
However, the pan-laminin antibody used in this section has been raised against laminin 111 
isolated from the Engelbreth Holm-Swarm mouse sarcoma (Orkin et al., 1977) and whilst a 
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good marker for laminin localisation, it fails to provide any insight into the deposition 
pattern of specific laminin chains, as it will react with multiple distinct laminin isoforms 
(Domogatskaya et al., 2012).  Therefore, cryosections were immunolabelled with antibodies 
raised against individual laminin chains – α1 and β2, to further characterise the composition 
of the laminin trimer in these three basement membranes and evaluate how this is affected 
by a reduction in Fkrp expression.  
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FIGURE 3-4 PAN-LAMININ LOCALISATION IN THE FKRPKD MOUSE 
Laminin was localised to the pial basement membrane (indicated by a white arrow) of 
wildtype (A) and FKRPKD (B) mice, with no difference in immunolabelling intensity, although 
the pial basement membrane was disrupted in FKRPKD mice.  Laminin was localised to the 
basement membrane of muscle fibres in the tongue (red) (C-D) and extraocular muscles (E-
F) of both wildtype and FKRPKD mice with no difference in immunolabelling intensity.  This 
deposition of pan-laminin at the pial basement membrane was initially documented by Dr. 
Mark Ackroyd in Ackroyd et al., 2011 and has been repeated here by myself to facilitate the 
comparison with the tongue and extraocular muscles. 
 
Transverse 10µm cryosections from P0 wildtype (n=4) (A, C, E) and FKRPKD (n=5) (B, D, F) 
mice were immunolabelled with a pan-laminin antibody and Hoechst 3342 to visualise the 
nuclei.  At least 2 sections from each mouse (separated by a distance of approximately 
120µm) were viewed under epifluorescence using a DM4000B upright microscope (Leica 
Microsystems).  The pattern of immunolabelling described was apparent in all sections, 
although the pial basement membrane disruption, whilst always evident, varied between 
individual FKRPKD mice, with respect to the degree of disruption and the specific region of 
the pial basement membrane.  Images were captured with an mRM monochrome camera 
(Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures using 
Photoshop CS4 or CS5 (Adobe).  Images A-B, C-D and E-F were captured at the same 
exposure, with representative images shown.  Scale bar denotes 50µm.  The following 
structures are indicated in these images - pial basement membrane (pial BM), extraocular 
muscles (EOM) and the retina (Retina)..  
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Laminin β2, has been identified at the basement membrane of mature muscle fibres in 
human (Wewer et al., 1997) and interestingly this localisation of laminin β2 was reduced in 
patients with congenital muscular dystrophies (Cohn et al., 1997).   
 
Here, laminin β2 was identified at the pial basement membrane of three wildtype and three 
FKRPKD mice, with no difference in immunolabelling intensity, although laminin β2 
immunolabelling in the FKRPKD mouse was disrupted, due to the fragmented pial basement 
membrane in these mice (Figure 3-5).  This disorganisation was identified in the three 
FKRPKD mice evaluated here, although the degree of disruption and the specific region of the 
pial basement membrane affected varied between individual mice.  Laminin β2 
immunolabelling was also identified at the basement membrane of muscle fibres in the 
tongue and extraocular muscles of wildtype and FKRPKD mice, with no difference in 
immunolabelling intensity observed (Figure 3-5).   
 
Laminin α1 was identified at the pial basement membrane of three wildtype and three 
FKRPKD mice, although in the FKRPKD there was a reduction in immunolabelling intensity, and 
additionally the localisation was markedly disrupted, due to the fragmented pial basement 
membrane (Figure 3-6).  This disorganisation was identified in the three FKRPKD mice 
evaluated here, although the degree of disruption and the specific region of the pial 
basement membrane affected varied between individual mice.  Laminin α1 was also 
identified at the basement membrane near the end of muscle fibres in the wildtype tongue, 
where the fibres insert into neighbouring connective tissue and whilst laminin α1 was 
observed at this region in the FKRPKD tongue, immunolabelling intensity was reduced in 
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comparison to wildtype (Figure 3-6).  Laminin α1 immunolabelling was not identified at the 
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FIGURE 3-5 LAMININ β2 LOCALISATION IN THE FKRPKD MOUSE 
Laminin β2 was localised to the pial basement membrane (indicated by a white arrow) of 
both wildtype (A) and FKRPKD (B) mice, with no difference in immunolabelling intensity.  
Laminin β2 localisation at the pial basement membrane of FKRPKD mice was markedly 
disrupted, due to the fragmented pial basement membrane in these mice.  Laminin β2 was 
localised to the basement membrane of muscle fibres in the tongue (C-D) and extraocular 
muscles (indicated by a white arrow) (E-F) of both wildtype and FKRPKD mice with no 
difference in immunolabelling intensity. 
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C, E) and FKRPKD (n=3) (B, D, F) 
mice were immunolabelled with an antibody raised against laminin β2.  At least 2 sections 
from each mouse (separated by a distance of approximately 120µm) were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems), with the 
pattern of immunolabelling documented above apparent in all sections, although the 
degree of pial basement membrane disruption, whilst always present, varied between 
FKRPKD mice, both with respect to the degree of disruption and the specific region of the pial 
basement membrane affected.  Images were captured with an mRM monochrome camera 
(Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures using 
Photoshop CS4 or CS5 (Adobe).  Images A-B, C-D and E-F were captured at the same 
exposure, with representative images shown.  Scale bar denotes 50µm.  The following 
structures are indicated in these images - pial basement membrane (pial BM), extraocular 
muscles (EOM), cortical blood vessels (BV) and the retina (Retina). 
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FIGURE 3-6 LAMININ α1 LOCALISATION IN THE FKRPKD MOUSE  
Laminin α1 was localised to the pial basement membrane in wildtype mice (A) and this 
localisation was markedly perturbed and reduced in FKRPKD mice (B).  Laminin α1 was 
localised to the ends of muscle fibres in the tongue, at the region where they insert into the 
surrounding connective tissue in both wildtype (C) and FKRPKD (D) mice, with reduced 
immunolabelling intensity in the FKRPKD mice.  Laminin α1 was not identified at the 
basement membrane of muscle fibres in the extraocular muscles of wildtype (E) or FKRPKD 
(F) mice.  This deposition of laminin α1 at the pial basement membrane was initially 
documented by Dr. Mark Ackroyd and is published in Ackroyd et al., 2011.  It has been 
repeated and shown here to facilitate the comparison with the tongue and extraocular 
muscles. 
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C, E) and FKRPKD (n=3)_ (B, D, F) 
mice were immunolabelled with an antibody against laminin α1.  At least 2 sections from 
each mouse (separated by a distance of approximately 120µm) were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems), with the 
pattern of immunolabelling documented above observed in all sections, although the pial 
basement membrane disruption, whilst always present, varied between FKRPKD mice.Images 
were captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision 
software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  
Images A-B and C-F were captured at the same exposure, with representative images 
shown..  Scale bar denotes 50µm.  The following structures are indicated in these images - 
pial basement membrane (pial BM), extraocular muscles (EOM) and the retina (Retina). 
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To evaluate whether the deposition of other LG domain containing proteins is perturbed, 
the localisation of perlecan (Peng et al., 1998) was evaluated in the FKRPKD mouse.  In both 
wildtype and FKRPKD mice, perlecan immunolabelling was identified at the pial basement 
membrane and the basement membrane of muscle fibres in the tongue and extraocular 
muscles, although the disrupted pial basement membrane described above was also 
identified in the FKRPKD mouse (Figure 3-7).  This disorganisation was identified in the five 
FKRPKD mice evaluated, although the degree of disruption and the specific region of the pial 
basement membrane affected varied between individual mice.  Despite this, no difference 
in overall immunolabelling intensity was observed between wildtype and FKRPKD mice along 
the length of the pial basement membrane or between different muscle fibres across the 
tongue (Figure 3-7).  However, some variation in immunolabelling intensity was identified 
between the different muscle fibres of the extraocular muscles in wildtype and FKRPKD mice 
(Figure 3-7). 
 
Immunolabelling was also performed to visualise collagen type IV, a basement membrane 
ligand which binds to integrins and other basement membrane proteins (laminin, nidogen 
and heparin sulphate proteoglycans), but not dystroglycan (Aumailley et al., 1989, Paulsson, 
1992, Eble et al., 1993, Hopf et al., 1999, Carmignac and Durbeej, 2012).  Collagen type IV 
was localised to the pial basement membrane and the muscle fibre basement membrane in 
the extraocular muscles and the tongue (  
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Figure 3-8).  Interestingly there seemed to be a slight increase in immunolabelling in the 
FKRPKD tongue (relative to wildtype), which was not seen in the FKRPKD extraocular muscles (  
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Figure 3-8).  Immunolabelling intensity at the FKRPKD pial basement membrane was 
consistent with that of wildtype mice, although again the marked disruption of the pial 
basement membrane in the FKRPKD mice was observed (  
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Figure 3-8).  
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FIGURE 3-7 PERLECAN LOCALISATION IN THE FKRPKD MOUSE  
Perlecan was localised to the pial basement membrane in wildtype (A) and FKRPKD mice (B), 
with comparable immunolabelling intensity, although localisation was markedly disrupted in 
the FKRPKD mouse, with frequent breaks observed.  Perlecan was localised to the basement 
membrane of muscle fibres in the wildtype (C) and FKRPKD (D) tongue with no difference in 
localisation or immunolabelling intensity between the two genotypes.  Perlecan was 
identified at the basement membrane of muscle fibres in the wildtype (E) and FKRPKD (F) 
extraocular muscles, although immunolabelling intensity varies between the muscle fibres.  
This deposition of perlecan at the pial basement membrane was initially documented by Dr. 
Mark Ackroyd and published in Ackroyd et al., 2011.  It has been repeated and shown here 
to facilitate the comparison with the tongue and extraocular muscles. 
 
Transverse 10µm cryosections from P0 wildtype (n=4) (A, C, E) and FKRPKD (n=5) (B, D, F) 
mice were immunolabelled with an antibody against perlecan (green) and Hoechst 33342 to 
visualise the nuclei (blue).  At least 2 sections per mouse (separated by a distance of 
approximately 120µm) were viewed under epifluorescence using a DM4000B upright 
microscope (Leica Microsystems), with the pattern of immunolabelling documented above 
observed in all sections, although the pial basement membrane disruption, whilst always 
present, varied between FKRPKD mice, both with respect to the degree of disruption and the 
region of pial basement membrane affected.  Images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were captured at the 
same exposure, with representative images shown.  Scale bar denotes 50µm.  The following 
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structures are indicated in these images - pial basement membrane (pial BM), extraocular 
muscles (EOM), cortical blood vessels (CBV) and the retina (Retina). 
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FIGURE 3-8 COLLAGEN TYPE IV LOCALISATION IN THE FKRPKD MOUSE 
Collagen type IV immunolabelling was identified at the pial basement of wildtype (A) and 
FKRPKD (B) mice, with similar immunolabelling intensities, although the pial basement 
membrane was markedly disrupted in the FKRPKD mouse.  Images C-F are colour composites 
with collagen type IV (red) and Hoechst 3342 to visualise the nuclei (blue).  Collagen type IV 
was localised to the basement membrane of muscle fibres in the tongue and extraocular 
muscles of wildtype and FKRPKD mice, with no difference in immunolabelling intensity. 
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C, E) and FKRPKD (n=3) (B, D, F) 
mice were immunolabelled with an antibody against collagen type IV and Hoechst 33342 to 
visualise the nuclei.  At least 2 sections from each individual mouse (separated by a distance 
of approximately 120µm) were viewed under epifluorescence using a DM4000B upright 
microscope (Leica Microsystems) with the pattern of immunolabelling documented above 
observed in all sections, although the pial basement membrane disruption, whilst always 
present, varied between FKRPKD mice. Images were captured with an mRM monochrome 
camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures 
using Photoshop CS4 or CS5 (Adobe).  All images were captured at the same exposure, with 
representative images shown.  Scale bar denotes 50µm.  The following structures are 
indicated in these images - pial basement membrane (pial BM), extraocular muscles (EOM), 
cortical blood vessels (CBV) and the retina (Retina). 
 
  
Page 179 of 551 
 
Collagen XVIII has been identified at the pial basement membrane and the basement 
membrane of striated muscle fibres in the chick (Halfter et al., 1998).  In both wildtype and 
FKRPKD mice at P0, collagen XVIII was identified at the pial basement membrane, with 
localisation markedly disrupted in the FKRPKD mouse, displaying the frequent breaks in 
immunolabelling observed in the pial basement membrane described above (Figure 3-9).  
This disruption was identified in all FKRPKD mouse sections evaluated, although there was 
some variation between the individual mice with respect to the degree of disruption and the 
region of the pial basement membrane affected.  However, where collagen XVIII was 
identified at the pial basement membrane of FKRPKD mice, immunolabelling intensity was 
similar to wildtype mice (Figure 3-9).  Collagen type XVIII was not identified at the basement 
membrane of muscle fibres in the tongue of wildtype or FKRPKD mice (Figure 3-9).  
Contrastingly, collagen XVIII immunolabelling was identified at the muscle fibre basement 
membrane of extraocular muscles in both wildtype and FKRPKD mice, with no difference in 
immunolabelling intensity observed between the two genotypes (Figure 3-9). 
  
These observations and conclusions on basement membrane deposition are summarised in 
Table 3-1. 
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FIGURE 3-9 COLLAGEN XVIII IN THE FKRPKD MOUSE 
Collagen type XVIII was identified at the pial basement membrane (illustrated with a white 
arrow) of wildtype mice (A) and FKRPKD mice (B) at comparable immunolabelling intensity, 
although localisation was markedly disrupted in the FKRPKD mouse, with frequent breaks.  
Collagen type XVIII was localised to the muscle fibre basement membrane in the extraocular 
muscles of wildtype (C) and FKRPKD mice (D), at comparable immunolabelling intensity.  
Collagen type XVIII was not identified at the basement membrane of muscle fibres in the 
wildtype (E) or FKRPKD (F) tongue. 
 
Transverse 10µm cryosections from P0 wildtype (n=3) (A, C, E) and FKRPKD (n=3) (B, D, F) 
mice were immunolabelled with an antibody against Collagen XVIII (green) and Hoechst 
33342 to visualise the nuclei (blue).   At least 2 sections from each individual mouse 
(separated by a distance of approximately 120µm) were viewed under epifluorescence using 
a DM4000B upright microscope (Leica Microsystems) with the pattern of immunolabelling 
documented above observed in all sections, although the pial basement membrane 
disruption, whilst always present, varied between FKRPKD mice both with respect to the 
degree of disruption and the region of the pial basement membrane affected.  Images were 
captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision software 
(Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images 
were captured at the same exposure and representative images are shown.  Scale bar 
denotes 50µm.  The following structures are indicated in these images - pial basement 
membrane (pial BM), extraocular muscles (EOM) and the retina (Retina). 
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TABLE 3-1 SUMMARY OF THE BASEMENT MEMBRANE PROTEIN DISTRIBUTION 
This table summarises the data regarding the localisation of pan-laminin, laminin β2, 
collagen type IV, perlecan, collagen type VXIII and laminin α1 at the following basement 
membranes – pial basement membrane, or the basement membranes of muscle fibres in 
the  tongue and extraocular muscles.  Immunolabelling for these basement membrane 
proteins was assessed in at least three wildtype and three FKRPKD mice, with at least two 
sections (separated by a distance of approximately 120µm) evaluated from each individual 
mouse. 
 
First the table lists whether immunolabelling for each of these basement membranes 
proteins was identified in either the wildtype or FKRPKD basement membrane for each of the 
three tissues.  Secondly, the distribution of basement membrane proteins was evaluated in 
the FKRPKD mouse, to assess whether a reduction in Fkrp expression resulted in (i) a 
disturbed arrangement of basement membrane ligands, or (ii) reduced localisation of 
proteins to the basement membranes, in comparison to wildtype mice.  To assess the 
localisation of proteins, the immunolabelling intensity in the FKRPKD sections was 
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3.3.3 HISTOLOGICAL OBSERVATIONS IN THE FKRPKD MOUSE AT P0 
As summarised in Table 3-1, a reduction in Fkrp expression was associated with altered 
basement membrane deposition in the cortex, tongue and extraocular muscles.  Therefore, 
these three tissues were evaluated histologically at P0, to assess the functional implications 
of these basement membrane defects. 
 
The FKRPKD extraocular muscles and tongue were evaluated histologically for the indicators 
of dystrophic histopathology described in the introduction and illustrated in Figure 1-2, such 
as loss of muscle fibres, the presence of inflammatory infiltrates or a variation in muscle 
fibre size.  At least three sections (separated by a distance of 120µm) from three individual 
wildtype and FKRPKD mice were evaluated, - representative images of these sections are 
shown in Figure 3-10.  As these images suggest, these indicators of muscular dystrophy were 
not identified in the tongue or extraocular muscles from the wildtype or FKRPKD mice 
evaluated here (Figure 3-10). 
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FIGURE 3-10  TONGUE AND EXTRAOCULAR MUSCLES 
At least two cryosections (separated by a distance of 120µm) of the extraocular muscles and 
the tongue from three individual wildtype and FKRPKD mice (stained with haematoxylin and 
eosin) were evaluated histologically for evidence of dystrophic muscle pathology such as the 
loss of muscle fibres, the presence of inflammatory infiltrates or a variation in muscle fibre 
size.  Representative images of the wildtype (A,C ) and FKRPKD (B, D) extraocular muscles (A-
B) and tongue are shown.  No evidence of dystrophic histopathology was observed in any of 
the sections of the FKRPKD extraocular muscles or tongue evaluated in this thesis. 
 
Transverse 10µm cryosections from P0 wildtype (A, C) and FKRPKD (B, D) mice  of the 
extraocular muscles (A-B) and tongue (C-D) stained with haematoxylin and eosin were 
viewed under light microscopy using a DM4000B upright microscope (Leica Microsystems).  
Images were digitally captured with a DC500 colour camera (Leica Microsystems) using the 
Leica Application Suite software (Leica Microsystems) and compiled using Photoshop CS4 or 
CS5 (Adobe).  Scale bar represents 50µm.   
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In the initial characterisation of the FKRPKD published in 2009 (Ackroyd et al., 2009), 
significant histological defects were observed in the FKRPKD cortex, including a marked 
disruption of cortical lamination.   To further characterise this aspect of the phenotype, the 
cortex of wildtype and FKRPKD mice was arbitrarily divided into 6 equal regions, with zone 1 
closest to the ventricular zone and zone 6 adjacent to the pial basement membrane (since 
the cortical plate has not developed fully at P0) and the number of Tbr1 and Tbr2 positive 
neurons counted across the cortex (Figure 3-11).   These counts were performed by myself, 
on images kindly provided by Dr Mark Ackroyd, and this data was included in the Ackroyd et 
al., 2011 publication. 
 
Tbr1, used as marker of postmitotic neurons, is expressed in glutamatergic projection 
neurons localised to layer VI in the adult human cortex (Englund et al., 2005, Bedogni et al., 
2010).  In the wildtype mouse cortex at P0 Tbr1 was expressed in a restricted pattern, with 
the highest number of Tbr1 positive neurons identified in Zone 2 next to the ventricular 
zone (Figure 3-11).  Contrastingly, the distribution of Tbr1 neurons was disorganised in the 
FKRPKD mouse - identified in all the zones across the cortex (Figure 3-11), implying neuronal 
positioning was affected in the FKRPKD.  Consequently there was a singicant reduction in the 
number of Tbr1 positive neurons localised to zone 2 in the FKRPKD mice, when compared to 
wildtype (Figure 3-11). 
 
Tbr2 is expressed in basal progenitors in the cortex (Englund et al., 2005) and its expression 
was identified at the ventricular zone of both wildtype and FKRPKD mice, with no significant 
difference in localisation or cell number, suggesting a reduction in the number of basal 
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progenitors was not associated with the reduction in the number of postmitotic projection 
neurons observed above (Figure 3-11).    
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FIGURE 3-11 CORTICAL LAMINATION IS PERTURBED IN THE FKRPKD MOUSE 
Digital images of control and FKRPKD cortex immunolabelled with antibodies against Tbr1 or 
Tbr2 and Hoechst 33342 to visualise the nuclei were provided by Dr Mark Ackroyd (Royal 
Veterinary College).  Example images of wildtype (A) and FKRPKD (B) cortex at P0 labelled 
with Tbr1 (red) and Hoechst 33342 (blue) are shown (A-B).  These images show a 
disorganisation in the distribution of Tbr1 positive nuclei in the FKRPKD cortex (n=3) when 
compared to wildtype mice (n=3).   
 
To analyse this disorganisation further, a 1cm slice, angled to run vertically from the 
ventricular zone to the marginal zone was isolated from an area randomly chosen near the 
midline and extracted from the images stained with an antibody against Tbr1 and Hoescht 
to visaluse the nuclei.  C shows an example of a cortical slice from a control mouse – a 
monochrome image of Hoechst 33342 immunolabelling and is divided up into the 6 layers of 
the cortex.  Where a nucleus was overlying the boundary of a zone, it was counted as being 
part of the zone where the majority of the nucleus was located.  
 
Tbr1 cell counts were performed using Adobe Photoshop CS4 or CS5 and the data was 
compiled using Microsoft Excel.  The number of cells in each zone was expressed as a 
proportion of total cells across the slice, as shown in panel D, which was prepared using 
GraphPad Prism version 5.0 for Windows.  To test the hypothesis that a reduction in Fkrp 
expression reduced the percentage of Tbr1 positive neurons localised to zone 2 of the 
cortex, a one-tailed Mann-Whitney test was performed using GraphPad Prism version 5.0 
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for Windows, with significance shown as follows - *0.01≤p<0.05, suggesting the hypothesis 
should be accepted.   
 
To evaluate whether this reduced percentage of correctly localised Tbr1 positive neurons is 
associated with an altered number of basal progenitors, the distribution of Tbr2 positive 
basal progenitors was evaluated across the cortex in a similar manner.  This graph, prepared 
using GraphPad Prism version 5.0 for Windows, is shown in panel E.  This showed that Tbr2 
postive neurons were localised to the ventricular zone in both wildtype and FKRPKD mice.  A 
Mann-Whitney test was performed using GraphPad Prism version 5.0 for Windows to test 
the null hypothesis that there was no difference in the number of Tbr2 positive cells 
between wildtype and FKRPKD mice.  This returned a p value of 0.2612, suggesting the null 
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3.3.4 DEVELOPMENTAL BASEMENT MEMBRANE DEPOSITION IN THE FKRPKD MOUSE 
As described in Section 1.6.1, the radial glia scaffold is exceedingly important for neuronal 
migration and guides the cells to their correct location within the cortex (Valiente and 
Marin, 2010).  Defects in this scaffold are evident in the FKRPKD mouse at P0 and have been 
attributed to disorganisation of the pial basement membrane (Ackroyd et al., 2011).  These 
observations raise the question as to how early such defects are manifested. To evaluate 
this, the arrangement of the glial scaffold and basement membrane deposition was 
assessed by immunofluorescence in wildtype and FKRPKD mice at two developmental ages, 
E12.5 and E15.5. 
 
In wild type mice the glial scaffold was visualised by immunolabelling with the RC2 antibody 
which recognises an intermediate filament protein present in the apical progenitor cells, 
both neuroepithelial cells and radial glia  (Park et al., 2009).  Using this RC2 antibody, apical 
progenitor cells were seen to span the cortex, with processes running from the ventricular 
zone to the cortical surface, where the end-feet contacted the pial basement membrane 
(Figure 3-12).  This arrangement was disrupted in the two FKRPKD mice evaluated at both 
E12.5 and E15.5– the processes of the neuroepithelial cells and radial glia respectively 
appeared to be orientated at a slightly different angle and additionally, the glial end-feet did 
not always terminate on the pial basement membrane (Figure 3-12).  However, evaluation 
of more mice, with further quantification of endfeet angle would be required to confirm 
this.  
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FIGURE 3-12 GLIAL SCAFFOLD AT E12.5 AND E15.5 
RC2 (red) was expressed in the neuroepithelial cells at E12.5 (A-B) and radial glial cells at 
E15.5 (C-D) of wildtype and FKRPKD mice.  In wildtype mice, both scaffolds run from the 
ventricular zone of the cortex to the pial surface, where the end-feet contact the basal 
lamina (green).  This arrangement appeared disrupted in the two FKRPKD mice evaluated at 
each age (shown in images B and D) - the glial processes were orientated at a slightly 
different angle and the end-feet did not always terminate on the pial basement membrane.   
 
Transverse 10µm cryosections from wildtype (n=2) (A, C) and FKRPKD (n=2) (B, D) mice at the 
ages of E12.5 (A-B) and E15.5 (C-D) were immunolabelled with antibodies against pan-
laminin (green) and RC2 (red) and Hoechst 33342 to visualise the nuclei (blue).  At least 2 
sections from each mouse (separated by a distance of approximately 120µm) were viewed 
under epifluorescence using a DM4000B upright microscope (Leica Microsystems).  The 
pattern of immunolabelling described was apparent in all sections, although the degree of 
radial glial disruption varied between individual FKRPKD mice.  Images were captured with an 
mRM monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  Images A-B and C-D were 
captured at the same exposure.  Scale bar denotes 25µm in A-B and 50µm in images C-F.  All 
images are labelled to show the pial basement membrane. 
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At E15.5, the pial basement membrane was visualised following immunolabelling with 
antibodies against perlecan, laminin β2 and laminin α1 (Figure 3-13).  Whilst in the three 
wildtype mice evaluated the pial basement membrane was continuously observed at the 
cortical surface, this basement membrane was markedly disrupted in the three FKRPKD mice 
evaluated, with significant fragmentation observed, although immunolabelling was at a 
comparable intensity between wildtype and FKRPKD mice (Figure 3-13).   
 
Immunolabelling with the pan-laminin antibody at E12.5 showed the pial basement 
membrane was largely continuous in the FKRPKD mouse, although the staining pattern 
appeared more diffuse in the two mice evaluated and additionally some isolated areas of 
fragmentation were observed (Figure 3-14).  This suggests defects in the pial basement 
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FIGURE 3-13 BASEMENT MEMBRANE DEPOSITION IN THE FKRPKD MOUSE AT E15.5 
Perlecan (A), laminin β2 (C) and laminin α1 (E) were localised to the pial basement 
membrane of wildtype mice.  This immunolabelling was markedly disrupted at the pial 
basement membrane of the FKRPKD, with frequent breaks in localisation observed.  Where 
immunolabelling for perlecan (B), laminin β2 (D) and laminin α1 were identified at FKRPKD 
pial basement membrane, it was at an intensity comparable to wildtype.   
 
Transverse 10µm cryosections from E15.5 wildtype (n=3) (A, C, E) and FKRPKD (n=3) (B, D, F) 
mice were immunolabelled with antibodies against perlecan (A-B), laminin β2 (C-D), (both in 
green) and laminin α1 (red) and Hoechst 33342 to visualise the nuclei (blue).  At least 2 
sections from each mouse (separated by a distance of approximately 120µm) were viewed 
under epifluorescence using a DM4000B upright microscope (Leica Microsystems).  The 
pattern of immunolabelling described was apparent in all sections, although the pial 
basement membrane disruption, whilst always evident, varied between individual FKRPKD 
mice, with respect to the degree of disruption and the specific region of the pial basement 
membrane.  Images were captured with an mRM monochrome camera (Zeiss, U.K.) using 
the Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or 
CS5 (Adobe).  Images A-B, C-D and E-F were captured at the same exposure.  Scale bar 
denotes 25µm in A-B and 50µm in images C-F.  All images are labelled to show the pial 
basement membrane. 
   




FIGURE 3-14 BASEMENT MEMBRANE DEPOSITION IN THE FKRPKD CORTEX AT E12.5 
Both wildtype (A) and FKRPKD (B) mice have pan-laminin immunolabelling at the pial 
basement membrane, at a similar intensity, with some small isolated regions of disruption 
identified in the FKRPKD pial basement membrane.. 
 
Transverse 10µm cryosections from E12.5 wildtype (n=2) (A) and FKRPKD (n=2) (B) mice were 
immunolabelled with the pan-laminin antibody (green) and Hoechst 33342 to visualise the 
nuclei (blue).  At least 2 sections from each mouse (separated by a distance of 
approximately 120µm) were viewed under epifluorescence using a DM4000B upright 
microscope (Leica Microsystems).  The pattern of immunolabelling described was apparent 
in all sections.  Images were captured with an mRM monochrome camera (Zeiss, U.K.) using 
the Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or 
CS5 (Adobe).  The two images were captured at the same exposure.  The scale bar denotes 
25µm.  All images are labelled to show the pial basement membrane. 
  
Page 201 of 551 
 
3.3.5 GLYCOSYLATION OF α-DYSTROGLYCAN WAS DEVELOPMENTALLY REGULATED IN THE 
MOUSE CORTEX 
In the FKRPKD mouse, disruption of the pial basement membrane and the neuroepithelial 
scaffold was identified at E12.5.  Thus, the developing mouse cortex was examined to 
evaluate whether these time points coincide with changes in the glycosylation pattern of α-
dystroglycan, visualised with IIH6 immunolabelling. 
 
It has already been shown at P0 that IIH6 immunolabelling can be identified at the pial 
basement membrane (suggestive of glycosylated α-dystroglycan) of wildtype mice and this 
glycosylation is lost in FKRPKD mice (Ackroyd et al., 2009).  Interestingly, in the three 
wildtype mouse cortices evaluated at E12.5, strong IIH6 immunolabelling was identified at 
the pial basement membrane, which was comparatively reduced in the three mice 
evaluated at each of the two later developmental ages (E15.5 and P0) (Figure 3-15).  
Additionally, weak IIH6 immunolabelling was identified in the processes of the 
neuroepithelial scaffold at E12.5 and this immunolabelling was absent at later 
developmental ages (E15.5 and P0) (Figure 3-15).   This highlights a role for α-dystroglycan 
glycosylation in both deposition of the pial basement membrane and in the maintenance of 
the neuroepithelial scaffold early during cortical development. 
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FIGURE 3-15   IIH6 IMMUNOLABELLING OF DEVELOPING WILDTYPE CORTEX 
At E12.5 (A-C) strong IIH6 (red) immunolabelling can be seen at the ventricular zone and the 
pial basement membrane and additionally faint immunolabelling can be seen throughout 
the processes of the neuroepithelial cells.  IIH6 immunolabelling can be seen at the pial 
basement membrane at E15.5 (D-F) and P0 (G-I), although it is significantly reduced in 
intensity, relative to E12.5.  At E15.5 and P0, IIH6 immunolabelling is not observed in the 
processes of the radial glial scaffold. 
 
Transverse 10µm cryosections from wildtype mice at E12.5 (n=3) (A-C), E15.5 (n=3) (D-F) 
and P0 (n=3) (G-I) were immunolabelled with the pan-laminin (green) and IIH6 antibodies 
(red).  The nuclei were labelled with Hoechst 3342 (blue).  At least 2 sections from each 
mouse (separated by a distance of approximately 120µm) were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems).  The pattern of 
immunolabelling described was apparent in all sections.  Images were captured with an 
mRM monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were captured at the 
same exposure.  Scale bar denotes 50µm.  The following structures are indicated in these 
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3.3.6 ASSAY PARAMETERS FOR EVALUATING BASEMENT MEMBRANE DEPOSITION IN 
VITRO 
Whilst the above evaluations showed a reduction in Fkrp expression affected basement 
membrane composition in various tissues (which had downstream effects on tissue 
architecture), these observations only reflect gross changes or abnormalities in the 
basement membrane.  Thus, to evaluate the early stages of basement membrane 
deposition, and how this might be affected by a reduction in Fkrp expression, it was 
necessary to conduct the next phase of this work in vitro. 
 
The H-2Kb-tsA58 (Immortomouse) is a transgenic mouse strain expressing the tsA58 mutant 
of the SV40 (simian virus 40) large tumour (T) antigen (TAg) (Jat et al., 1991).  This gene is 
under the mouse major histocompatibility complex H-2Kb class I promoter, whose 
expression is induced by γ-interferon (Jat et al., 1991).  The practical implications of this are 
that cell lines derived from the Immortomouse are conditionally immortalised, proliferating 
when grown under permissive conditions (33°c in the presence of γ-interferon) and 
terminally differentiating when grown under non-permissive conditions (37°c in the absence 
of γ-interferon) (Jat et al., 1991).   Myogenic cells lines derived from the Immortomouse 
were first published in 1994 (Morgan et al., 1994) and since then have been commonly used 
in vitro to investigate aspects of muscle development.  In 2011, a wildtype clonal myogenic 
cell line (H2K 2B4) was derived from the Immortomouse, which reproducibly terminally 
differentiated into uniform myotubes which expressed the myogenic regulatory factors 
MyoD and Myogenin along with the muscle specific proteins desmin and Myf5 (Muses et al., 
2011).  
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Crossing the FKRPKD mouse colony with this colony allowed the generation of H2K-FKRPKD 
mutant mice, with a reduction in Fkrp expression carrying the Immortomouse transgene.  
From these mice, conditionally immortalised myogenic cell lines with a reduction in Fkrp 
expression were generated, to test the hypothesis that a reduction in Fkrp expression 
affects the early deposition of the basement membrane.  
 
As basement membrane deposition will be evaluated in terminally differentiated myotubes, 
several parameters affecting myotube formation (cell seeding concentration and media 
volume) were evaluated using H2K 2B4 cells (Muses et al., 2011).  The optimum conditions 
for evaluation of basement membrane deposition (greatest density of viable myotubes that 
could be easily assessed for surface deposition of extracellular matrix) were identified as a 
seeding density of 9 x 104 cells in 1mL of media (Figure 3-16).  Additionally, Matrigel-coated 
glass coverslips, rather than Matrigel-coated tissue culture plastic were used as the glass 
provided greater optical clarity of the basement membrane deposits (Figure 3-17).  
  




FIGURE 3-16  OPTIMISATION OF TERMINAL DIFFERENTIATION –CONDITIONS 
- SEEDING DENSITY AND DIFFERENTIATION VOLUME 
A and B show H2K 2B4 cells terminally differentiated for 5 days.  These cells were seeded at 
the same density, 9x104 in two different media volumes, 500µL and 1mL.  The density of the 
myotubes was increased in image B, the larger differentiation volume, so it was decided to 
seed cells for terminal differentiation at a concentration of 9 x 104, in a differentiation 
volume of 1mL. 
 
H2K 2B4 cells,were differentiated under non-permissive conditions in different volumes of 
differentiation media (500µL or 1mL) for 5 days. Cells were then fixed in 4% PFA for 10 
minutes and immunolabelled with the IIH6 antibody against glycosylated α-dystroglycan.  
Cells were viewed under epifluorescence using a DM4000B upright microscope (Leica 
Microsystems) and the density of myotubes across the coverslip was visually assessed.  
Images of a randomly chosen area of the coverslip were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
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compiled into figures using Photoshop CS4 or CS5 (Adobe).  Images were captured at the 
same exposure.  Scale bar denotes 100µm. 
 
  




FIGURE 3-17  ASSESSMENT OF MATRIGEL COATED GROWTH SURFACE 
Pan-laminin deposits are apparent on the extracellular surface of H2K 2B4 myotubes 
terminally differentiated on both Matrigel coated tissue culture plastic (A) and glass 
coverslips (B).  However, the optical clarity of the laminin deposits is increased and the 
background staining of the Matrigel is reduced when the cells are terminally differentiated 
on glass coverslips.  Consequently, all analyses of basement membrane deposition were 
conducted on cells terminally differentiated on Matrigel coated glass. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 3 days on Matrigel coated tissue culture plastic (A) or 5 days on Matrigel 
coated glass coverslips (B).  Cells were then  fixed in 4% PFA for 10 minutes and 
immunolabelled with the pan-laminin antibody.  Cells were viewed under epifluorescence 
using a DM4000B upright microscope (Leica Microsystems) and the optical clarity of pan-
laminin deposits was evaluated on approximately 15 myotubes differentiated on each 
surface.  Representative images were captured with an mRM monochrome camera (Zeiss, 
U.K.) using the Axiovision software (Zeiss) provided and compiled into figures using 
Photoshop CS4 or CS5 (Adobe).  All images were captured at the same exposure.  Scale bar 
denotes 50µm in A and 25µm in B.  
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Since, the aim is to generate an in vitro model for basement membrane deposition in the 
dystroglycanopathies, and it had already been noted that both α-dystroglycan glycosylation 
(as identified by IIH6) and laminin α2 were reduced in FKRPKD mice (Ackroyd et al., 2009), it 
was decided to initially focus on the spatial distribution of IIH6 immunolabelling and laminin 
α2 at specific stages of terminal differentiation. 
 
IIH6 immunolabelling was identified at the plasma membrane of terminally differentiated 
H2K 2B4 myotubes 24 hours post-fusion (Whitmore, unpublished data from an MRes 
Dissertation project).  An immunocytochemical analysis of laminin α2 deposition on 
myotubes terminally differentiated for 3 days showed isolated basement membrane 
deposits on the extracellular surface (  
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Figure 3-18), which increased after 5 days of terminal differentiation.  Therefore, it was 
decided to focus the evaluation of basement membrane deposition on myotubes that had 
been terminally differentiating for 5 days. 
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FIGURE 3-18 TIMESCALE OF LAMININ α2 DEPOSITION IN H2K 2B4 MYOTUBES 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 3 days (A-B) and 5 days (C-D).   mall amounts of laminin α2 immunolabelling 
were identified on myotubes after 3 days of terminal differentiation.  After 5 days terminal 
differentiation, laminin α2 immunolabelling was dramatically increased across the 
extracellular surface of H2K 2B4 myotubes.  Therefore, it was decided to evaluate basement 
membrane deposition on myotubes that had been terminally differentiating for 5 days. 
 
Terminally differentiated H2K 2B4 cells were fixed in 4% PFA for 10 minutes and 
immunolabelled with an antibody against laminin α2.  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems) and the 
distribution of laminin α2 deposits across the extracellular surface of at least 10 myotubes 
at each developmental age was evaluated.  Representative images of these myotubes were 
captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision software 
(Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  Both A and 
C and B and D were captured at the same exposures.  Scale bar denotes 100µm in A and C 
and 20µm in B and D.   
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3.3.7 BASEMENT MEMBRANE DEPOSITION ON THE EXTRACELLULAR SURFACE OF 
MYOTUBES 
Previous in vitro studies reported laminin deposits in discrete clusters on the extracellular 
surface of embryoid cells (Henry and Campbell, 1998) and mouse embryonic stem cells 
(Henry et al., 2001).  These clusters can be categorised into one of three different 
morphologies (listed in order of immaturity) – puncta, linear arrays and plaques (Henry et 
al., 2001).  The formation of these different structures is dynamic, with puncta identified 
first, which are then consolidated into the larger, more complex structures – linear arrays 
and finally plaques (Henry et al., 2001).  The purpose of this part of the work was to 
establish the pattern of laminin deposition on the surface of terminally differentiated H2K 
2B4 myotubes, so it can then be evaluated how this might be perturbed by a reduction in 
Fkrp expression.  Laminin deposition was evaluated in two ways – by grading the degree of 
expression across the surface of the terminally differentiated myotubes and identifying 
which cluster structures were observed on the extracellular surface. 
 
Immunolabelling with the generic pan-laminin antibody visualised laminin deposits across 
the extracellular surface of terminally differentiated myotubes, which could be classified 
into the three cluster structures – puncta, linear arrays and plaques (Figure 3-19).  Each 
myotube had multiple laminin clusters distributed across the extracellular surface and these 
could be classified into the same cluster structure, or a cluster structure of different 
maturity (Figure 3-19).  However, since pan-laminin is a generic antibody which recognises 
multiple laminin chains (Domogatskaya et al., 2012), to further evaluate laminin deposition 
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on the extracellular surface, terminally differentiated myotubes were also immunolabelled 
with antibodies against individual laminin chains.  
 
Antibodies against laminin γ1 (Figure 3-20) and α2 (Figure 3-21) revealed widespread 
immunolabelling across the extracellular surface of the myotubes, with all three cluster 
structures (puncta, linear arrays and plaques) apparent.  Each myotube in the culture had 
multiple clusters of laminin γ1 (Figure 3-20) and laminin α2 (Figure 3-21), and these clusters 
were of the same, or different maturities (Figures 3-20 and3-21).  Interestingly, the patterns 
of laminin α1 and α4 immunolabelling are slightly different.  Although all myotubes had 
clusters of laminin α1 and α4, only two cluster structures were visualised (puncta and linear 
array) – no plaque structures were observed (Figure 3-22 and 3-23).   
 
Additionally, a qualitative evaluation of at least 20 myotubes immunolabelled with laminin 
α1 (Figure 3-22) and α4 (Figure 3-23) suggested a reduced distribution of these proteins 
across the extracellular surface in comparison to pan-laminin, laminin γ1 and laminin α2 
(Figures 3-19, 3-20 and 3-21).   
 
Immunolabelling with an antibody against perlecan revealed deposits on the extracellular 
surface of H2K 2B4 myotubes, arranged into puncta and linear arrays, with plaque 
structures rarely observed (Figure 3-27).  The level of perlecan immunolabelling across the 
extracellular surface of the H2K 2B4 myotubes appeared much reduced (Figure 3-27) in 
comparison to pan-laminin, laminin α2 and laminin γ1 (Figures 3-19, 3-20 and 3-21). 
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FIGURE 3-19  PAN-LAMININ IMMUNOLABELLING OF H2K 2B4 MYOTUBES 
Images A, C and E show monochrome images of pan-laminin immunolabelling alone, while 
images B, D and F show colour composites with pan-laminin immunolabelling in red and 
Hoechst 33342 in blue.  Following immunolabelling with the pan-laminin antibody, three 
different cluster structures of laminin deposits – punctate clusters (arrow in A-B), linear 
arrays (* in C-F) and plaques (** in C-D) were identified on the extracellular surface of 
terminally differentiated H2K 2B4 myotubes.  As shown in images A-F, myotubes contain 
more than one cluster of pan-laminin, and these clusters can be of different maturities. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 5 days on Matrigel coated glass coverslips.  Cells were fixed in 4% PFA for 10 
minutes and immunolabelled with the pan-laminin antibody and Hoechst 33342 to visualise 
the nuclei.  Cells were viewed under epifluorescence using a DM4000B upright microscope 
(Leica Microsystems) and the distribution of pan-laminin deposits across the extracellular 
surface of approximately 30 myotubes randomly chosen across three coverslips was 
evaluated.  Representative images of these myotubes were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were captured at the 
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FIGURE 3-20 LAMININ γ1 IMMUNOLABELLING OF H2K 2B4 MYOTUBES 
Images A, C and E show monochrome images of laminin γ1 immunolabelling alone, while 
images B, D and F show colour composites with laminin γ1 immunolabelling in red and 
Hoechst 33342 in blue.  Following immunolabelling with the laminin γ1 antibody, three 
different structures of laminin deposits - punctate clusters (A-B), linear arrays (C-D) and 
plaques (E-F) were identified on the extracellular surface of terminally differentiated H2K 
2B4 myotubes.  As shown in images A and B, myotubes contain more than one cluster of 
laminin γ1, and these clusters can be of different maturities. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 5 days on Matrigel coated glass coverslips.  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems) and the 
distribution of laminin γ1 deposits across the extracellular surface of approximately 30 
myotubes randomly chosen across three coverslips was evaluated.  Representative images 
of these myotubes were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  All images were captured at the same exposure.  Scale bar denotes 50µm.   
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FIGURE 3-21 LAMININ α2 DEPOSITION ON H2K 2B4 MYOTUBES 
Images A, C and E show monochrome images of laminin α2 immunolabelling alone, while 
images B, D and F show colour composites with laminin α2 immunolabelling (red) and 
Hoechst 33342 in blue.  Following immunolabelling with the laminin α2 antibody, three 
different structures of laminin deposits - punctate clusters (A-B), linear arrays (C-D) and 
plaques (E-F) were identified on the extracellular surface of terminally differentiated H2K 
2B4 myotubes.  As shown in images A and B, myotubes contain more than one cluster of 
laminin γ1, and these clusters can be of different maturities. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 5 days on Matrigel coated glass coverslips.  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems) and the 
distribution of laminin α2 deposits across the extracellular surface of approximately 30 
myotubes randomly chosen across three coverslips was evaluated.  Representative images 
of these myotubes were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  All images were captured at the same exposure.  Scale bar denotes 50µm.   
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FIGURE 3-22  LAMININ α1 IMMUNOLABELLING IN H2K 2B4 MYOTUBES 
Images A and C show monochrome images of laminin α1 immunolabelling alone, while B 
and D show colour composites with laminin α1 (red) and Hoechst 33342 in blue.  Following 
immunolabelling with the laminin α1 antibody, two different structures of laminin deposits - 
punctate clusters (A-B denoted by **) and linear arrays (C-D denoted by *) were identified 
on the extracellular surface of H2K 2B4 myotubes.  As shown in images A and B, myotubes 
contain more than one cluster of laminin γ1, and these clusters can be of different 
maturities. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 5 days on Matrigel coated glass coverslips.  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems) and the 
distribution of laminin α1 deposits across the extracellular surface of approximately 20 
myotubes randomly chosen across three coverslips was evaluated.  Representative images 
of these myotubes were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
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FIGURE 3-23 LAMININ α4 IMMUNOLABELLING OF H2K 2B4 MYOTUBES 
Images A and C show monochrome images of laminin α4 immunolabelling alone, while B 
and D show colour composites with laminin α4 (red) and Hoechst 33342 in blue.  Following 
immunolabelling with the laminin α4 antibody, two different structures of laminin deposits - 
punctate clusters (A-B denoted by *) and linear arrays (C-D denoted by *) were identified on 
the extracellular surface of H2K 2B4 myotubes.  As shown in images A and B, myotubes 
contain more than one cluster of laminin γ1, and these clusters can be of different 
maturities. 
 
H2K 2B4 cells seeded at a density of 9x104 were differentiated under non-permissive 
conditions for 5 days on Matrigel coated glass coverslips.  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems) and the 
distribution of laminin α4 deposits across the extracellular surface of approximately 20 
myotubes randomly chosen across three coverslips was evaluated.  Representative images 
of these myotubes were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  All images were captured at the same exposure.  Scale bar denotes 50µm.   
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This deposition of basement membrane proteins pan-laminin, laminin γ1, α2, α4 and 
perlecan described above was summarised below in Table 3-2.  This table lists whether the 
basement membrane structures puncta, linear arrays and plaques were identified following 
immunolabelling for these proteins.  Additionally, this table contains an assessment of 
laminin γ1, α2, α4 and perlecan localisation across the extracellular surface of the 
myotubes, in comparison to pan-laminin, allowing the distribution of different basement 
membrane proteins to be compared.   
 
However, in the future this should be further evaluated for each basement membrane 
protein by quantifying both the number of total clusters and the number of clusters of 
different maturities.  In combination with this, the surface area of plaque structures present 
on myotubes should also be evaluated. 
 
  





Puncta Linear Array Plaques Overall 
deposition 
Pan-Laminin Identified Identified Identified ++++    (4) 
Laminin γ1 Identified Identified Identified +++      (3) 
Laminin α2 Identified Identified Identified +++      (3) 
Laminin α1 Identified Identified Not identified ++        (2) 
Laminin α4 Identified Identified Not identified ++        (2) 
Perlecan Identified Identified Not identified +          (1) 
 
TABLE 3-2 SUMMARY OF BASEMENT MEMBRANE IMMUNOLABELLING IN H2K 
2B4 MYOTUBES 
This table summarises the distribution of basement membrane proteins across the 
extracellular surface of H2K 2B4 myotubes terminally differentiated for 5 days.   
 
Here, it was identified that the basement proteins cluster into one of three organisations 
(listed in order of increasing maturity) – puncata, linear arrays and plaques.   
 
First this table summarises whether these structures were identified on the extracellular 
surface of at least 20 H2K 2B4 myotubes across 3 independent coverslips, which were 
evaluated following immunolabelling for pan-laminin, laminin γ1, α2, α1, α4 and perlecan.   
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Additionally, this table includes a qualitative assessment of the distribution of laminin γ1, 
α1, α2, α4 and perlecan across the extracellular surface of these myotubes, in comparison 
to pan-laminin.  The distribution of pan-laminin across the extracellular surface of H2K 2B4 
myotubes was assigned a numerical value of 4, and the other proteins were given a 
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3.3.8 MYOGENIC CLONE H2K-FKRPKD 1.C10 HAD ALTERED α-DYSTROGLYCAN 
GLYCOSYLATION  
During the course of this thesis at least 74 H2K-FKRPKD clonal cell lines were generated, with 
observation of their terminal differentiation behaviour suggesting that 3 of these clones 
were myogenic.  The first clone to be generated was H2K-FKRPKD 1.C10 and (i) confirmation 
of myogenicity, (ii) an analysis of α-dystroglycan glycosylation and (ii) the evaluation of 
basement membrane deposition for this clone has been performed as shown here.  
Therefore, this analysis should be repeated in the future for the other two myogenic clones 
to confirm these findings are representative.  
 
Terminallly differentiated H2K-FKRPKD 1.C10 cells were shown to express desmin (an 
intermediate filament protein expressed in skeletal muscle), with comparable 
immunolabelling intensity to terminally differentiated H2K 2B4 cells (Figure 3-24).  Gross 
observation of at least 12H2K-FKRPKD 1.C10 cultures seeded for terminal differentiation in 
three different experiments did not suggest a difference in myotube formation, although 
calculation of the fusion index would be required in the future to confirm this.Additionally, 
in comparison to H2K 2B4 myotubes, IIH6 immunolabelling at the plasma membrane was 
dramatically reduced in H2K-FKRPKD 1C10 myotubes terminally differentiated for 5 days 
(Figure 3-25) suggesting altered, reduced glycosylation of α-dystroglycan in H2K-FKRPKD 
1C10 cells (Figure 3-25).  
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FIGURE 3-24 DESMIN IMMUNOLABELLING OF H2K-FKRPKD 1.C10 
A and C show greyscale images of desmin immunolabelling alone, while B and D show a 
colour composite with desmin immunolabelling in green and Hoechst 33342, in blue.  
Desmin, a myogenic marker, was identified in terminally differentiated H2K 2B4 myotubes 
and terminally differentiated H2KFKRPKD 1.C10 cells 
 
H2K 2B4 and H2K-FKRPKD 1.C10 cells seeded at a density of 9x104 were differentiated under 
non-permissive conditions for 5 days on Matrigel coated glass coverslips, fixed in 4% PFA for 
10 minutes and immunolabelled with an antibody against desmin (green) and Hoechst 
33342 (blue) to visualise the nuclei.  Cells were viewed under epifluorescence using a 
DM4000B upright microscope (Leica Microsystems) and myotubes across three coverslips 
for each genotype were evaluated for the presence of desmin immunolabelling.  
Representative images were captured with an mRM monochrome camera (Zeiss, U.K.) using 
the Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or 
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FIGURE 3-25 IIH6 IMMUNOLABELLING OF H2KFKRPKD 1.C10  
A and C show images of IIH6 immunolabelling alone, while B and D shows a colour 
composite with IIH6 immunolabelling in red and Hoechst 33342 in blue.  Images show IIH6 
immunolabelling was reduced at the plasma membrane of H2K-FKRPKD 1.C10 myotubes in 
comparison to H2K 2B4 myotubes, suggesting altered, reduced glycosylation of α-
dystroglycan.  These images were manipulated so the myotubes in panel C and D can be 
visualised. 
 
H2K 2B4 (A-B) and H2K-FKRPKD 1.C10 (C-D) cells seeded at a density of 9x104  were 
terminally differentiated under non-permissive conditions for 5 days, fixed in 4% PFA for 10 
minutes and immunolabelled with the IIH6 antibody and Hoechst 33342 to visualise the 
nuclei.  Cells were viewed under epifluorescence using a DM4000B upright microscope 
(Leica Microsystems) and and myotubes across three coverslips for each genotype were 
evaluated for the presence of IIH6 immunolabelling.  Representative images were captured 
with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) 
provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were 
captured at the same exposure.  Scale bar denotes 50µm.  White arrows are used to identify 
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3.3.9 BASEMENT MEMBRANE DEPOSITION WAS PERTURBED IN H2K-FKRPKD 1.C10 
As described above in Section 3.3.7, laminin deposits on the extracellular surface of H2K 2B4 
can be visualised with several antibodies, including pan-laminin and laminin α1.  Previous 
work in other cell types suggested that cell receptors including dystroglycan (Williamson et 
al., 1997, Henry et al., 2001) play a key role in this laminin clustering.  The main aim of this 
part of the work was to identify how these processes might be altered by a reduction in -
dystroglycan glycosylation.  Two antibodies were chosen for this initial evaluation, pan-
laminin, to establish the effect on overall laminin distribution and laminin α1, because it is 
one of the first laminin α chains present in the muscle fibre basement membrane.  If these 
processes were altered, then in the future, this analysis should be expanded to include the 
other laminin chains investigated above in Section 3.2 – γ1, α2 and α4. 
 
There was a reduction in both pan-laminin and laminin α1 deposits on the extracellular 
surface of terminally differentiated H2K-FKRPKD 1.C10 myotubes when compared to H2K 
2B4 myotubes, with respect to both immunolabelling intensity and the distribution of 
laminin across the extracellular surface (Figure 3-26), suggesting that a reduction in Fkrp 
expression perturbed laminin deposition.  Additionally, the only laminin cluster structure 
evident on the extracellular surface of H2K-FKRPKD 1.C10 myotubes was puncta, while in 
comparison puncta, linear arrays and plaques were identified on the extracellular surface of 
H2K 2B4 myotubes (Figure 3-26), which suggests laminin clusters on the extracellular 
surface of H2K-FKRPKD myotubes were less mature. 
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Additionally, to determine whether the distribution of other basement membrane proteins 
that bind to dystroglycan was altered, the distribution of perlecan on the extracellular 
surface of H2K 2B4 myotubes was explored.  Immunolabelling for perlecan also showed a 
reduced distribution across the extracellular surface of terminally differentiated H2K-FKRPKD 
1.C10 myotubes, when compared to H2K 2B4, although no difference in immunolabelling 
intensity or cluster structure was identified between terminally differentiated H2K 2B4 and 
FKRPKD 1.C10 myotubes (Figure 3-27). 
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FIGURE 3-26 LAMININ DEPOSITION IN H2K 2B4 AND H2KFKRPKD 1.C10 MYOTUBES 
Laminin α1 (A) and pan-laminin (C) deposits were localised to the extracellular surface of 
H2K 2B4 myotubes.  These deposits appeared reduced on the extracellular surface of H2K-
FKRPKD 1.C10 myotubes (B and D respectively)– both in intensity and number. 
 
H2K 2B4 (A,C) and H2KFKRPKD 1.C10 (B,D) cells, differentiated under non-permissive 
conditions for 5 days and fixed in 4% PFA for 10 minutes, were immunolabelled with 
antibodies against laminin α1 (A-B) and pan-laminin (C-D).  Cells were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems), with the 
distribution of immunolabelling evaluated on the extracellular surface of at least 15 
myotubes across 2-3 coverslips for each genotype.  Images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were captured at the 
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FIGURE 3-27 PERLECAN IMMUNOLABELLING ON H2K 2B4 AND FKRPKD 1.C10 
MYOTUBES 
Perlecan deposits were localised to the extracellular surface of H2K 2B4 myotubes (A and C) 
and H2K-FKRPKD 1.C10 myotubes (B and D), although the distribution of perlecan appeared 
reduced on H2K-FKRPKD 1.C.10 myotubes.  Perlecan deposits were identified in puncta and 
linear array structures on the extracellular surface of both H2K 2B4 and H2K-FKRPKD 1.C10 
myotubes. 
 
H2K 2B4 (A,C) and H2KFKRPKD 1.C10 (B,D) cells, differentiated under non-permissive 
conditions for 5 days and fixed in 4% PFA for 10 minutes, were immunolabelled with an 
antibody against perlecan (A-B).  Cells were viewed under epifluorescence using a DM4000B 
upright microscope (Leica Microsystems),with the distribution of perlecan evaluated on the 
extracellular surface of at least 15 myotubes across 2-3 coverslips for each genotype.  
Images were captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision 
software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  
All images were captured at the same exposure.  Scale bar denotes 50µm.  White arrows 
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3.4 DISCUSSION 
In this chapter, differences in the composition of three basement membranes – the pial 
basement membrane and the basement membranes surrounding the muscle fibres of the 
tongue and extraocular muscles were identified.  Additionally, differences in IIH6 
immunolabelling were identified between different tissues, at different stages of 
development, suggestive of changes in α-dystroglycan glycosylation.  A reduction in Fkrp 
expression was associated with a reduction in IIH6 immunolabelling at these basement 
membranes suggestive of altered α-dystroglycan glycosylation.  This affected the 
composition of these three basement membranes and additionally caused marked 
disruptions in the pial basement membrane.  These disturbances in the pial basement 
membrane were associated with defects in cortical lamination.  Finally, it has also been 
demonstrated here in vitro that a reduction in Fkrp expression directly affects the 
deposition of the basement membrane, particularly laminin. 
 
3.4.1 A REDUCTION IN FKRP EXPRESSION AFFECTS THE TONGUE AND EXTRAOCULAR 
MUSCLES DIFFERENTLY 
Histologically no evidence of dystrophic pathology was identified in the tongue or 
extraocular muscles of the FKRPKD mouse at P0, suggesting the FKRPKD mouse is limited with 
respect to evaluating the development of dystrophic pathology.  This absence of pathology 
in the FKRPKD tongue at P0 is consistent with reported observations in the Largemyd mouse 
(another dystroglycanopathy mouse model), where severe dystrophic lesions and fibrotic 
tissue in the tongue does not develop until 4-6months of age (Lane et al., 1976, Holzfeind et 
al., 2002).   
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In several muscle dystrophies, the extraocular muscles are reported to be “spared”, in 
comparison to other skeletal muscles (Kaminski et al., 1992, Khurana et al., 1995, Mendell et 
al., 1995, Porter and Karathanasis, 1998, Porter et al., 2001,  traube and B ttner, 200 ).  A 
variety of intrinsic differences between the extraocular muscles and the tongue have been 
implicated in this, including improved calcium buffering of the extraocular muscles (Zeiger 
et al., 2010) and different patterns of myosin gene and protein expression (Porter, 2002).  
Here, differences in the composition of the basement membrane between muscle fibres in 
the tongue and extraocular muscles have been identified and these variances could also 
contribute to the sparing of extraocular muscles. 
 
A small population of muscle fibres with increased IIH6 immunolabelling was identified in 
the extraocular muscles of both wildtype and FKRPKD mice, suggesting that the glycosylation 
pattern of α-dystroglycan may vary within the muscles.  Interestingly this pattern was still 
apparent in the extraocular muscles of the FKRPKD mouse, despite an overall reduction in 
IIH6 immunolabelling compared to wild type controls.  A small population of muscle fibres 
with increased perlecan immunolabelling suggested this may reflect a real difference 
between the fibres, although double labelling experiments would be required to confirm 
this.  Approximately 15% of muscle fibres in the extraocular muscles are multiply innervated 
and instead of one neuromuscular junction inducing an all-or-nothing contraction response, 
the nerve terminals form “cuffs” around the muscle fibres, which subsequently contract 
with a slow, graded tonic contraction (Porter, 2002,  traube and B ttner, 200 ).  The DAPC 
is enriched at the neuromuscular junction (Pilgram et al., 2010) and therefore IIH6 
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immunolabelling at the neuromuscular junction of skeletal muscle fibres is enhanced.  
Therefore, the increased IIH6 immunolabelling identified in the extraocular muscles here 
could be the synapses of these multiply innervated muscle fibres, although double 
immunolabelling with α-bungarotoxin would be required to confirm this. 
 
Another factor to be considered is a potential difference in maturity of the muscle fibres at 
(P0), which might also account for some of the variation seen in the extraocular muscles 
which was not apparent for example in the tongue.  In the early postnatal period, the mouse 
pup suckles on its mother for milk to eat, and the tongue will presumably be required for 
this, so as a muscle, the tongue needs to be relatively mature at birth.  However, it would be 
expected that mice do not use their extraocular muscles until approximately postnatal day 
14, when they open their eyes (http://www.informatics.jax.org/silver/chapters/4-4.shtml) 
(Silver, 1995), so perhaps they would not be as well developed as the tongue in the 
perinatal period.   
 
3.4.2 A REDUCTION IN FKRP EXPRESSION AFFECTS PIAL BASEMENT MEMBRANE 
DEPOSITION AND CORTICAL LAMINATION 
A preliminary analysis of the cortical pathology associated with pial basement membrane 
defects in the FKRPKD mouse was published in 2009, showing the fusion of the 
interhemispheric fissure and a disruption of cortical layering (Ackroyd et al., 2009).  This 
work was expanded on here, with quantification of immunohistochemically labelled 
neurons demonstrating significant disorganisation of differentiated neurons in the FKRPKD 
cortex.  The distribution and number of basal progenitors seemed consistent between the 
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wildtype and FKRPKD cortex, suggesting that a reduction in the number of basal progenitors 
was not associated with the phenotype.  In the FKRPKD cortex, Tbr1 positive neurons are not 
localised correctly, they are distributed through the cortex.  These neurons are involved in 
the development of the corticospinal tract (Han et al., 2011) and defects in the corticospinal 
tract have been identified in patients with muscle eye brain disease (Clement et al., 2008a).  
This suggests that the corticospinal tract could be abnormal in the FKRPKD mouse, which 
could be confirmed by evaluating sections of the spinal cord. 
 
Associated with defects in cortical neuronal positioning, the radial glial scaffold is disrupted 
in the FKRPKD mouse, both during development as shown here and at P0 as previously 
published (Ackroyd et al., 2011).  Here, it has also been shown, that glycosylation of α-
dystroglycan (detected with IIH6 immunolabelling) is enriched at the pial basement 
membrane, ventricular zone and the neuroepithelial scaffold at E12.5, with IIH6 
immunolabelling becoming markedly reduced as development progresses (E15.5 and P0).  
Interestingly, this developmental time point coincides with the onset of neurogenesis in the 
mouse telencephalon (approximately E13), when the neuroepithelial cells transition into 
radial glia (Kriegstein and Gotz, 2003, Gotz and Huttner, 2005, Farkas and Huttner, 2008, 
Miyata et al., 2010).  This suggests glycosylated α-dystroglycan might be important for 
anchoring the neuroepithelial end-feet to the pial basement membrane, but that once the 
end-feet have anchored and neurogenesis has started, the requirement for glycosylated α-
dystroglycan diminishes, so either overall levels of dystroglycan are reduced or the 
glycosylation pattern is altered, both of which would result in a reduction of IIH6 
immunolabelling. 
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A reduction in Fkrp expression is associated with reduced IIH6 immunolabelling at the pial 
basement membrane (Ackroyd et al., 2009).  This alters the distribution of ligands at the pial 
basement membrane and additionally markedly disrupts its localisation, with frequent 
breaks in immunolabelling observed.  Although associated with a reduction in Fkrp 
expression here, these disruptions in the pial basement membrane are not unique to 
models of Fkrp deficiency, as they as they are seen in mutant mice with perturbed 
expression of integrin adhesion receptors (Georges-Labouesse et al., 1998, Haubst et al., 
2006), dystroglycan (Moore et al., 2002) or basement membrane proteins such as perlecan 
(Costell et al., 1999), laminin γ1II4-/- mice (mice with a deletion of the nidogen binding site 
on laminin γ1) (Haubst et al., 2006) and collagen type IV (Poschl et al., 2004), suggesting 
these disruptions are a consequence of impaired interaction between basement membrane 
proteins and the end-feet of the glial scaffold. 
 
So, in the FKRPKD mouse, a reduction in Fkrp expression results in an altered pattern of α-
dystroglycan glycosylation, which would perturb the anchoring of the neuroepithelial end-
feet to the pial basement membrane.  Combined with the defects in the FKRPKD pial 
basement membrane, this would lead to a retraction of the glial end-feet from the pial 
basement membrane (Ackroyd et al., 2011), thereby disrupting the scaffold and altering 
neuronal positioning.  A similar phenomenon has been seen in other mutant mice models 
where this interaction between the glial end-feet and the pial basement membrane has 
been disrupted – integrin α6 (Georges-Labouesse et al., 1998), integrin β1 (Graus-Porta et 
al., 2001), laminin γII4-/- (Haubst et al., 2006) and perlecan-/- (Haubst et al., 2006) mice.   
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However, it must be noted that although these histological observations suggest neuronal 
migration has been altered, and dystroglycan has been shown to have a role in adhesion 
complexes and migration of other cell types such as myoblasts (Moore and Winder, 2010), 
neuronal motility itself was not evaluated in this study.  This could be demonstrated in the 
future by evaluating the movement of neurons from both wildtype and FKRPKD mouse 
cortex across different substrates in vitro. 
 
3.4.3 PATTERNING OF BASEMENT MEMBRANE DEPOSITION IN VITRO 
Whilst this in vivo mouse work provides global information on the distribution of basement 
membrane proteins, it does not help to elucidate the pattern of basement membrane 
deposition or how this might be affected by a reduction in Fkrp expression.  
 
Here it has been shown for the first time that laminin deposits on the surface of terminally 
differentiated myotubes derived from the Immortomouse, in one of three cluster structures 
(puncta, linear arrays or plaques), similarly to those structures identified on embryoid 
bodies by Henry et al., 2001.  There are variances in the pattern of laminin deposition 
between different cell types in vitro, for example, laminin 511 was identified in puncta and 
linear arrays on choriocarcinoma cells (Church and Aplin, 1998), laminin 311 is initially 
identified in punctate clusters, which consolidate into fibrillar structures on the surface of 
alveolar epithelial cells (Jones et al., 2005, DeBiase et al., 2006), laminin 111 was identified 
in puncta on mammary epithelial cells (Weir et al., 2006), exogenous laminin organises into 
a reticular, mesh-like structure on the surface of Schwann cells (Tsiper and Yurchenco, 2002, 
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Hamill et al., 2009) and laminin 332 is organised into rosette structures on non-migrating 
keratinocytes and then fibrillar arrays on migrating keratinocytes (Sehgal et al., 2006).  
Additionally, work with terminally differentiated C2C12 cells showed punctate laminin 
clusters on the extracellular surface with some larger aggregates (Montanaro et al., 1999), 
although no assessment of cluster structure was published.  This suggests the pattern of 
laminin deposition varies depending on both the cell type and the laminin trimer.  However, 
as different tissues express different laminin trimers (Hallmann et al., 2005) and the 
polymerisation of laminin monomers into a network is considered to be the first step in 
basement membrane formation (McKee et al., 2007), differences in laminin deposition may 
ultimately contribute to the structural properties of the mature basement membrane, in 
part specialising the basement membrane for different functions in different tissues of the 
body. 
 
The most mature plaque structures were identified on the extracellular surface of terminally 
differentiated H2K 2B4 myotubes following immunolabelling with an antibody against 
laminin γ1, suggesting this chain is present in the first laminin trimers that deposit at the 
basement membrane.  This is not unexpected since laminin γ1 associates with many 
different laminin α and β chains both in vitro and in vivo (Hallmann et al., 2005) and has 
been identified in basement membranes at all stages of muscle development - as part of the 
trimer laminin 111 in the basement membrane of the somite and in the basement 
membrane surrounding the developing muscle fibre, as part of the laminin trimers 211, 411, 
511 and 521 (Gullberg et al., 1999). 
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Isolated laminin α2 deposits were first identified on H2K 2B4 myotubes after 3 days of 
terminal differentiation, becoming widespread after 5 days of terminal differentiation.  This 
time course of laminin α2 deposition in H2K 2B4 myotubes is consistent with C2C12 cells, 
where punctate deposits and occasional larger clusters were observed after 4 days terminal 
differentiation (Montanaro et al., 1999) and mirrored in human primary muscle cultures, 
where a similar increase in laminin α2 localisation across the extracellular surface is 
observed as terminal differentiation proceeds until day 18, when widespread laminin α2 
immunolabelling was observed across the surface of the myotube (Chen and Burgunder, 
2005).   
 
Laminin α1 deposits were also identified on the extracellular surface of terminally 
differentiated H2K 2B4 cells, but they were more sparsely distributed and less mature in 
structure, relative to deposits identified with the laminin α2 and γ1 antibodies.  However, as 
myotubes terminally differentiate, it has been shown laminin α1 (mRNA) expression 
decreases, while the levels of laminin α2 increase (Vachon et al., 1996, Wewer et al., 1997, 
Gullberg et al., 1999), similarly to in vivo, where laminin α1 expression becomes restricted 
to the myotendinous junction as muscles develop (Gullberg et al., 1999).  Therefore, a 
reason for the immaturity of these laminin α1 deposits in H2K 2B4 could be a 
downregulation in its synthesis and/or a restriction of its expression pattern. 
 
3.4.4 A REDUCTION IN FKRP EXPRESSION DIRECTLY PERTURBS BASEMENT MEMBRANE 
DEPOSITION IN VITRO 
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A reduction in Fkrp expression and the resulting defect in the ability of α-dystroglycan to 
bind to laminin and other LG domain containing extracellular matrix ligands might be 
expected to cause basement membrane defects in two different ways, either by directly 
affecting basement membrane deposition or alternatively, whilst basement membrane 
deposition could be normal, the reduction in Fkrp expression could result in an unstable 
basement membrane, affecting its structural integrity.  To explore the hypothesis a 
reduction in Fkrp expression would directly affect basement membrane deposition; a 
conditionally immortalised cell line was generated from the H2KFKRPKD mouse. The 
H2KFKRPKD 1.C10 is a myogenic cell line, expressing desmin and forming myotubes upon 
terminal differentiation.  Additionally, as a consequence of the reduction in Fkrp expression, 
this cell line has decreased IIH6 immunolabelling at the sarcolemma, indicating reduced α-
dystroglycan glycosylation. 
 
Analysis of basement membrane deposition in terminally differentiated H2KFKRPKD 1.C10 
cells using the assay system devised here showed that the amount of laminin deposited on 
the surface of these myotubes appeared reduced and additionally the maturity of the 
laminin cluster structures are reduced relative to terminally differentiated H2K 2B4 
myotubes.  This suggests a reduction in Fkrp and α-dystroglycan glycosylation impairs the 
very early stages of basement membrane deposition.  A number of studies have shown that 
either directly (Cohen et al., 1997) or indirectly (Henry and Campbell, 1998, Montanaro et 
al., 1999, Henry et al., 2001, Weir et al., 2006) preventing dystroglycan from binding to 
laminin perturbs laminin clustering on the extracellular surface.   
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Laminin monomers are secreted from the cell as intact heterotrimers and then polymerise 
extracellularly into their characteristic network (McKee et al., 2007).  As outlined in Section 
1.9, the polymerisation of laminin into the basement membrane network requires a critical 
concentration of laminin monomers in the extracellular space (Yurchenco et al., 1985), and 
that is decreased by the binding of laminin to cell surface receptors such as dystroglycan 
(Maniotis et al., 1997).  Thus laminin secreted from H2KFKRPKD 1.C10 cells is unable to bind 
to α-dystroglycan (due to the altered, reduced glycosylation), making it more difficult to 
achieve the critical concentration required to initiate polymerisation, thereby delaying 
visible localisation on the extracellular surface.  This hypothesis could be explored further by 
evaluating laminin deposition on H2KFKRPKD 1.C10 cells that had been terminally 
differentiating for longer (7-10 days), or alternatively adding exogenous laminin to the 
culture media. 
 
3.4.5 CONCLUDING REMARKS 
The composition of the pial basement membrane, the extraocular muscle fibre basement 
membrane and the tongue varied, which suggested these differences are important for 
tissue function.  A reduction in Fkrp expression was associated with a reduction in IIH6 
immunolabelling at these basement membranes suggestive of altered α-dystroglycan 
glycosylation.  This altered the composition of these three basement membranes and 
additionally caused marked disruptions in the pial basement membrane.  These 
disturbances perturbed cortical development, causing defects in cortical lamination. 
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4 ROLE OF FKRP IN RETINAL DEVELOPMENT 
 
4.1 INTRODUCTION 
A number of bilateral or unilateral eye and retinal defects have been identified in patients 
with WWS and MEB, including changes in eye size, gross abnormalities and structural retina 
defects (as shown in Figure 4-1), (Cormand et al., 2001, Beltran-Valero de Bernabe et al., 
2004, Muntoni and Voit, 2004, Vajsar and Schachter, 2006), with the underlying causes for 
this vast spectrum still unclear.  Whilst it must be appreciated that there are anatomical 
differences between mouse and human eyes, for example, unlike human eyes, the mouse 
retina does not have a macula or fovea; instead the density of rods, cones and retinal 
ganglion cells peaks in the central retina (area centralis) and decreases towards the 
periphery (Drager and Olsen, 1980, Drager and Olsen, 1981, Chalupa and Williams, 2008), 
there are also a vast number of similarities in eye anatomy between the different 
mammalian species, including general eye structure, retinal thickness and functional retinal 
organisation, both in the cell types present and the neurotransmitters expressed (Arendt, 
2003, Chalupa and Williams, 2008).  Thus, it is proposed that studies of dystroglycanopathy 
mouse models, such as the FKRPKD mouse, will help to elucidate the causative mechanisms 
for at least some aspects of the patient eye phenotype. 
 
A brief characterisation of FKRPKD mouse eye phenotype has already been published 
showing defects of the ILM (Ackroyd et al., 2009).  This work has been expanded on here, to 
test the hypothesis that a reduction in Fkrp expression impacts upon the development of 
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the retina, which will have downstream consequences for function in the adult.  As 
introduced in Section 1.8.7, the ILM and Bruch’s membrane are the two basement 
membranes of the eye.  The ILM, located between the vitreous body and the retina, is 
necessary for normal retina development and maintaining the adherence of the retina to 
the vitreous body (Halfter, 1998, Halfter et al., 2005b), whilst Bruch’s membrane, a 5 
layered structure localised underneath the retina, is involved in filtering substances and 
anchoring/stabilising the retinal pigmented epithelium (RPE) (Aisenbrey et al., 2006).   
 
Firstly, as a number of dystroglycanopathy patients have altered eye size, and/or significant 
structural abnormalities (Cormand et al., 2001, Beltran-Valero de Bernabe, 2004, Muntoni 
and Voit, 2004, Vajsar and Schachter, 2006), the gross morphology and size of the FKRPKD 
eye and retina will be assessed.   econdly, α-dystroglycan glycosylation and the distribution 
of basement membrane proteins at both Bruch’s membrane and the ILM will be evaluated 
together with an assessment of retinal lamination at P0.  Finally, the deposition of laminin 
and other extracellular matrix proteins will be evaluated at the ILM and Bruch’s membrane 
in the developing FKRPKD mouse eye (E12.5 and E15.5).  
 
4.2 HYPOTHESES 
The aim of this chapter is to investigate the consequences a reduction in Fkrp expression will 
have for the eye.  It is hypothesised that these will be defects in eye structure and 
development, associated with aberrant deposition of the ocular basement membranes and 
altered glycosylation of α-dystroglycan. 
  




FIGURE 4-1 EYE PHENOTYPE OF DYSTROGLYCANOPATHY PATIENTS 
The schematic of the eye shown in Figure 1-7 has been annotated to show the range of eye 
defects reported for dystroglycanopathy patients (red) in (Cormand et al., 2001, Beltran-
Valero de Bernabe et al., 2004, Muntoni and Voit, 2004, Vajsar and Schachter, 2006, Martin, 
2006).  Defects which are not limited to a specific part of the eye are listed in a black box to 
the right of the diagram.  This schematic was made and annotated using PowerPoint 
(Microsoft Office 2010)  
 
  




4.3.1 FKRPKD MICE DID NOT DISPLAY ANY OVERT ABNORMALITIES IN GROSS EYE 
ANATOMY 
The mouse eye at birth is relatively immature, but nonetheless multiple components were 
identified including the cornea, the anterior chamber, the ciliary body, the lens, the vitreous 
body, the retinal pigmented epithelium, the retina (subdivided into the inner and outer 
retina) and finally the choroid, (evident underneath the retinal pigmented epithelium) 
(Figure 4-2).  All components were identified in the FKRPKD mouse eye, suggesting the 
FKRPKD mouse did not display any obvious gross developmental eye defects (Figure 4-2), 
although this highlighted potential structural retinal defects, discussed in more detail later. 
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FIGURE 4-2 A COMPARISON OF WILDTYPE AND FKRPKD EYES AT P0 
Images show the FKRPKD and wildtype mouse eye at P0 were comparable in appearance, 
suggesting there were no abnormalities in the gross anatomy of the FKRPKD mouse eye.  
However, these images highlight potential structural retinal defects in the FKRPKD mouse, as 
discussed in more detail later.  The following structures have been indicated - AC = Anterior 
Chamber, C = Cornea, CB = Ciliary body, Ch = Choroid, L =lens, OR = outer retina, RPE = 
retinal pigmented epithelium, RB = retinal body, VB = Vitreous Body.   
 
6µm Bouin’s-fixed paraffin embedded sections of P0 wildtype (n=3) (A, D) and FKRPKD (n=3) 
(B, E) eyes stained with haematoxylin and eosin were kindly provided by Mrs Helen Booler 
(Royal Veterinary College).  At least 5 sections from each individual mouse were viewed, 
with the gross appearance of the mouse eye evaluated using a  DM4000B upright 
microscope (Leica Microsystems).  Representative images were digitally captured with a 
DC500 colour camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  The scale bar denotes 
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4.3.2 A REDUCTION IN EYE SIZE WAS NOT OBSERVED IN FKRPKD MICE 
In some patients with MEB disease or WWS, changes in eye size (microphthalmos or 
buphthalmos) have been identified (Cormand et al., 2001, Beltran-Valero de Bernabe et al., 
2004, Muntoni and Voit, 2004, Vajsar and Schachter, 2006).  Whilst the mean cross-
sectional area of FKRPKD eyes was statistically significantly smaller than wildtype (Figure 4-3) 
FKRPKD neonates are approximately one third smaller than their littermates (Ackroyd et al., 
2009). Consequently when the reduced size of FKRPKD head was taken into account by 
expressing eye size as a proportion of head size, no statistically significant difference in 
FKRPKD eye size relative to wild type was identified (Figure 4-3) 
 
4.3.3 OCCASIONAL STRUCTURAL ABNORMALITIES WERE OBSERVED IN THE FKRPKD RETINA 
Structural retinal defects are seen in the human patients including chorioretinal atrophy, 
retinal detachment, retinal dysplasia and/or retinal hypoplasia (Cormand et al., 2001, 
Beltran-Valero de Bernabe et al., 2004, Muntoni and Voit, 2004, Martin, 2006, Vajsar and 
Schachter, 2006).  Consequently, the eyes of 5 wildtype and 10 FKRPKD mice were analysed 
for retinal abnormalities.  In FKRPKD mouse eyes, ectopic nuclei were frequently observed to 
have invaded into the vitreous body suggesting breaches of the inner limiting basement 
membrane (Figure 4-3).  No evidence of retinal folding or fibrotic tissue was identified in any 
of the FKRPKD retina (Figure 4-3), whilst a single rosette structure was identified in the retina 
of one FKRPKD mouse, and thus was considered a rare occurrence.  No retinal abnormalities 
were seen in eyes from wildtype mice (Figure 4-3). 
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FIGURE 4-3 EYE SIZE AND RETINAL ABNORMALITIES IN THE FKRPKD MOUSE 
The three graphs (A) show, from left to right, the mean cross-sectional areas of heads, eyes 
and proportional eye size with wildtype in green and FKPRKD mice in blue.  A Mann-Whitney 
statistical test was performed using GraphPad Prism version 5.0 for windows and 
significance is shown as follows:   * 0.01≤p<0.05, **0.001≤p<0.01.  The mean 
cross-sectional area of FKRPKD heads and eyes were significantly smaller than wildtype, but 
once the reduced size was accounted for, no significant difference in eye size was observed  
Additionally, an examination of mouse eyes from wildtype (n=5) and FKRPKD (n=10) mice 
showed ectopic nuclei in the vitreous body (B) and the presence of a rosette structure in 
one FKRPKD retina.   
 
For the measurements of head and eye size, digital colour images of 6µm paraffin-
embedded sections stained with haematoxylin and eosin kindly provided by Mrs Helen 
Booler were captured under light microscopy, using a DM4000B upright microscope (Leica 
Microsystems) and a DC500 colour camera (Leica Microsystems).  The cross-sectional area 
of wildtype (n=3) and FKRPKD (n=4) heads and eyes was measured in between 6-8 sections 
for each individual mouse, using ImageJ., compiled using Microsoft Excel and analysed using 
GraphPad Prism version 5.0 for Windows.   
 
To assess the structural retinal abnormalities, transverse 10µm cryosections of wildtype 
(n=5) (B and D) and FKRPKD (C and E) mouse eyes stained with haematoxylin and eosin were 
viewed under light microscopy.  At least 3 sections, separated by a distance of 
approximately 120µm from each individual mouse were evaluated for the presence of the 
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retinal anbnormalities – ectopic nuclei, rosette structures and retinal folding.  The images 
shown have been selected to show the ectopic nuclei observed in all FKRPKD mice evaluated 
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4.3.4 THE INNER RETINA WAS DISORGANISED IN FKRPKD MICE 
FKRPKD eyes appeared to have a disorganised inner retina layer when compared to wildtype 
mice (Figures 4-2 and 4-3); to evaluate this quantitatively measurements were taken of the 
total retinal width and the inner retinal width at both the central and peripheral retina.  
Although no difference in the total retinal thickness between wildtype and FKRPKD mice was 
observed (Figure 4-4) a significant increase in the thickness of the FKRPKD central retina, 
relative to wildtype was identified (Figure 4-4).  Additionally, the inner retina occupied a 
significantly larger percentage of total retinal width, both centrally and peripherally in the 
FKRPKD mouse, relative to wildtype (Figure 4-4). 
 
This suggests the cells in the inner retina are less compact in the FKRPKD mouse.  
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FIGURE 4-4 RETINAL DEPTHS OF FKRPKD MICE 
These images show the disorganisation of the inner, but not the outer retina in the FKRPKD 
mouse (B), when compared to wildtype (A).  To further evaluate this, measurements were 
taken of the inner retina (IR) and outer retina (OR) as indicated in A and B in wildtype and 
FKRPKD mice at both the central and peripheral retina.  C shows the mean total retinal width 
at the central and peripheral retina, D shows the inner retinal width for the central and 
peripheral retina and E shows the inner retinal proportion, expressed as a percentage of 
total retinal width.  A One-Way ANOVA with a post-hoc Tukey’s test was performed on each 
data set to test the null hypothesis that genotype did not affect these retinal measurements 
at the central or peripheral retina, with the results shown as follows: * 0.01≤p<0.05, 
**0.001≤p<0.01, *** 0.001≤p<0.001.  FKRPKD mice have an increased inner retinal width at 
the central retina, not the peripheral, although in both regions the inner retina takes up a 
larger proportion of the total retinal width. 
 
Transverse 10µm cryosections of P0 wildtype (A) and FKRPKD (B) eyes stained with 
haematoxylin and eosin were viewed under light microscopy using a DM4000B upright 
microscope (Leica Microsystems).  Images were digitally captured with a DC500 colour 
camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled in Photoshop CS4 or CS5.  Scale bar denotes 100µm.  The 
annotations were added using Adobe Photoshop CS5In wildtype and FKRPKD mice, the width 
of the central (wildtype and FKRPKD n=7) and peripheral (wildtype n=5 and FKRPKD n=5) 
retina was measured using ImageJ, compiled using Microsoft Excel and analysed graphically 
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using GraphPad Prism version 5.0 for Windows.  At least 3 images were measured for each 
animal and a mean value was calculated  
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4.3.5 ALTERED GLYCOSYLATION OF α -DYSTROGLYCAN IN THE FKRPKD EYE AT P0 
The initial evaluation of the wildtype and FKRPKD retina performed here showed an absence 
of IIH6 immunolabelling at the ILM at P0 (Figure 4-5), which was consistent with previous 
data collected by Dr Mark Ackroyd and reported in the literature (Ackroyd et al., 2009).  
However, further evaluation of α-dystroglycan glycosylation at the wildtype ILM showed 
punctate IIH6 immunolabelling at both the central and peripheral retina (Figure 4-5), at a 
much lower intensity than the sarcolemma of the extraocular muscle fibres.  This punctate 
immunolabelling was absent from the ILM of the FKRPKD retina, both centrally and 
peripherally (Figure 4-5).  Additionally, IIH6 immunolabelling (glycosylated α-dystroglycan) 
was observed at Bruch’s membrane in the wildtype mouse at P0 and again this 
immunolabelling was reduced in the FKRPKD mouse (Figure 4-5).  This suggests a reduction in 
Fkrp expression resulted in altered, reduced glycosylation of α-dystroglycan at both the ILM 
and Bruch’s membrane (Figure 4-5). 
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FIGURE 4-5 GLYCOSYLATION OF Α-DYSTROGLYCAN IN THE FKRPKD EYE AT P0 
Initially an absence of IIH6 immunolabelling (green) was reported at the ILM of both 
wildtype and FKRPKD mouse retina (A-B).  Further evaluation of the retina showed isolated 
areas of IIH6 immunolabelling (red and indicated by white arrows) at the wildtype ILM, both 
centrally and peripherally, which is absent in the FKRPKD.  In C-D a small area of the ILM has 
been enlarged to show IIH6 immunolabelling in monochrome.  The experimental data 
shown in images A and B has already been reported by Dr Mark Ackroyd in Ackroyd et al., 
2009.  The staining has been repeated and included here to highlight the low intensity of 
IIH6 immunolabelling.  All images show IIH6 immunolabelling at wildtype Bruch’s 
membrane, which is reduced in the FKRPKD.  In C-F, a small area of Bruch’s membrane has 
been enlarged to show the IIH6 immunolabelling in monochrome. 
 
Transverse 10µm cryosections from P0 wildtype (n= at least 3) (A, C, E) and FKRPKD (n=at lest 
3) (B, D, F) eye were immunolabelled with the IIH6 antibody against glycosylated α-
dystroglycan (green in A-B, red in C-F) and Hoechst 33342 to visualise the nuclei (blue).  
Additionally, cryosections in A and B were also immunolabelled with the pan-laminin 
antibody (red).  .  At least 2 sections from each individual mouse (separated by a distance of 
approximately 120µm) were viewed under epifluorescence using a DM4000B upright 
microscope (Leica Microsystems), with the pattern of IIH6 immunolabelling described above 
observed in each section..  Representative images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  Where direct comparisons of 
immunolabelling intensity are made, images were captured at the same exposure.  Scale bar 
represents 50µm.  
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4.3.6 PERTURBED BASEMENT MEMBRANE DEPOSITION IN THE FKRPKD MOUSE EYE  
The composition of the two basement membranes of the eye, namely the ILM and Bruch’s 
membrane was evaluated immunohistochemically to identify any differences between the 
FKRPKD and wildtype mouse.  As outlined in the Introduction 1.8.7, the ILM and Bruch’s 
membrane have distinct structures and functions within the eye and therefore the two 
basement membranes might differ in both their composition and the response to a 
reduction in Fkrp expression.  The distribution of basement membrane proteins at first the 
ILM and then Bruch’s membrane will now be presented and discussed, with a summary 
collated in   




4.3.6.1 DEPOSITION OF THE ILM WAS PERTURBED IN THE FKRPKD MOUSE 
The ILM of both wildtype and FKRPKD mice was visualised with the pan-laminin antibody and 
no difference in immunolabelling intensity was identified between the two genotypes 
(Figure 4-6).  In wildtype, the ILM was identified at the outside of the retina, as near 
continuous immunolabelling, forming a border between the retina and the vitreous body 
(Figure 4-6).  In the FKRPKD mouse, the ILM no longer appeared to effectively separate the 
cells of the inner retina and vitreous body, with frequent breaks and areas of fragmentation 
observed (Figure 4-6).   
 
As discussed previously in Chapter 3, whilst the pan-laminin antibody is adequate for 
basement membrane visualisation, it recognises multiple laminin trimers (Domogatskaya et 
al., 2012), so cryosections of P0 mouse eye were evaluated by immunolabelling with 
antibodies raised against individual chains (Figure 4-6). 
Laminin α1 ( 
 
FIGURE 4-7) AND LAMININ Β2 (FIGURE 4-6) WERE PRESENT AT THE ILM OF BOTH 
WILDTYPE AND FKRPKD MICE, WITH NO REDUCTION IN LAMININ Β2 
IMMUNOLABELLING INTENSITY (FIGURE 4-6), BUT A REDUCTION IN LAMININ Α1 
IMMUNOLABELLING WAS IDENTIFIED IN THE FKRPKD ( 
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Figure 4-7).  Immunolabelling with antibodies against each of these laminin chains revealed 
the same fragmentation identified with the pan-laminin antibody (Figures 4-6 and 4-7).  As 
already introduced, the laminin chain most commonly reported as affected in the 
dystroglycanopathy patients is laminin α2 (Jimenez-Mallebrera et al., 2009), but laminin α2 
was not identified at the ILM of either wildtype or FKRPKD mice (Figure 4-6).   
 
Immunolabelling for perlecan, another LG domain containing protein that binds to α-
dystroglycan (Peng et al., 1998) was consistent between wildtype and FKRPKD mice at the 
ILM ( 
 
Figure 4-7), with fragmentation again evident in the FKRPKD.  Interestingly, perlecan 
deposition was more severely affected at the central retina, relative to the periphery, with 




Collagen IV immunolabelling was also performed, to evaluate the deposition of a basement 
membrane protein that does not bind to α-dystroglycan (Aumailley et al., 1989, Paulsson, 
1992, Eble et al., 1993, Hopf et al., 1999, Carmignac and Durbeej, 2012).  Consistent with the 
results for the other basement membrane proteins, the intensity of collagen IV 
immunolabelling was consistent between wildtype and FKRPKD mice, whilst again 
fragmentation was observed ( 
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Figure 4-7).    
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FIGURE 4-6  BASEMENT MEMBRANE COMPOSITION OF THE FKRPKD MOUSE EYE (1) 
Pan-laminin (A) and laminin β2 (E) were identified at the wildtype and FKRPKD ILM, with no 
change in immunolabelling intensity, although the ILM was more diffuse and fragmented in 
the FKRPKD mouse.  Laminin α2 (C) was not identified at the wildtype or FKRPKD ILM.  Pan-
laminin (A, B), laminin α2 (C, D) and laminin β2 (E, F) were identified at Bruch’s membrane in 
wildtype (A, C, E) and FKRPKD (B, D, F) mice.  Pan-laminin immunolabelling was at a 
consistent intensity between wildtype and FKRPKD, whilst immunolabelling for laminin α2 
and laminin β2 was reduced in the FKRPKD.  For both pan-laminin and laminin β2, 
immunolabelling at Bruch’s membrane was a lower intensity in comparison to the ILM in 
both wildtype and FKRPKD mice.  In all the images shown above, Bruch’s membrane (BM), 
vitreal blood vessels (BV) and the inner limiting membrane (ILM) are indicated.  
 
Transverse 10µm cryosections of wildtype (n=3) (A, C, E) and FKRPKD (n= at least 3) (B, D, F) 
mouse eyes at P0 were immunolabelled with antibodies against pan-laminin (A-B) (red), 
laminin α2 (C-D) (green) and laminin β2 (E-F) (red) and Hoechst 33342 to visualise the nuclei 
(blue).  At least 2 sections from each mouse (separated by a distance of approximately 
120µm) were viewed under epifluorescence using a DM4000B upright microscope (Leica 
Microsystems).  The pattern of immunolabelling described above was apparent in all 
sections, although, whilst the disruption to the ILM was always present, it varied with 
respect to severity across the retina.  Representative images of the central retina were 
captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision software 
(Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  Where 
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direct comparisons of immunolabelling intensity are made, the images were captured at the 
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FIGURE 4-7 BASEMENT MEMBRANE COMPOSITION OF THE FKRPKD MOUSE EYE (2) 
Perlecan (E-H) and collagen type IV (C-D) immunolabelling was identified at the wildtype (C, 
E, G) and FKRPKD (D, F, H) ILM, with no change in intensity.  Laminin α1 (A-B) was also 
identified at the wildtype (A) and FKRPKD (B) ILM, with reduced intensity in FKRPKD.  Similarly 
to immunolabelling for other basement membrane proteins, the ILM appeared more diffuse 
and fragmented in the FKRPKD, relative to wildtype.  Additionally, the FKRPKD ILM appeared 
more severely affected in the central retina (A-F), relative to the peripheral retina (G-H), 
with fragmentation only identified centrally.  Laminin α1 (A-B) was evident at Bruch’s 
membrane in wildtype (A) and FKRPKD (B) mice, with immunolabelling intensity reduced in 
the FKRPKD.  Collagen type IV (C-D) and perlecan (E-H) were identified at Bruch’s membrane 
in the wildtype (C, E, G) and FKRPKD (D, F, H) mouse, with no difference in immunolabelling 
intensity.  Additionally, the appearance of Bruch’s membrane is consistent between the 
central (E-F) and peripheral (G-H) retina. 
 
Transverse 10µm cryosections of wildtype (n=3) (A, C, E, G) and FKRPKD (n= at least 3) (B, D, 
F, H) mouse eyes at P0 were immunolabelled with laminin α1 (A-B) and collagen type IV (C-
D) antibodies, which are shown as monochrome images.  E-H shows the peripheral (E-F) and 
central (G-H) retina immunolabelled with a perlecan antibody (green) and Hoechst 33342 
(blue) to identify the nuclei.   At least 2 sections from each mouse (separated by a distance 
of approximately 120µm) were viewed under epifluorescence using a DM4000B upright 
microscope (Leica Microsystems).  The pattern of immunolabelling described above was 
apparent in all sections, although, whilst the disruption to the ILM was always present, it 
varied with respect to severity across the retina.  Representative images of the central (A-E) 
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or peripgeral (G-H) retina were captured with an mRM monochrome camera (Zeiss, U.K.) 
using the Axiovision software (Zeiss) provided and compiled into figures using Photoshop 
CS4 or CS5 (Adobe).  Where direct comparisons of immunolabelling intensity are made, the 
images were captured at the same exposure.  Scale bar represents 50µm.   
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4.3.6.2 EXPRESSION OF BASEMENT MEMBRANE PROTEINS AT BRUCH’  MEMBRANE 
AT P0 
Laminin, visualised with the pan-laminin antibody was evident at Bruch’s membrane in both 
wildtype and FKRPKD mice, with no change in localisation or immunolabelling intensity 
between the two genotypes (Figure 4-6).  Further evaluation of laminin deposition showed 
that laminin α2 ( 
 
Figure 4-7), α1 ( 
 
Figure 4-7) and β2 (Figure 4-6) were localised to Bruch’s membrane in wildtype mice, and 
immunolabelling for these proteins was reduced in intensity in the FKRPKD mouse (Figures 4-
6 and 4-7).  Additionally, immunolabelling for pan-laminin, laminin α1 and laminin β2 is 
reduced at Bruch’s membrane, when compared to the ILM, for both wildtype and FKRPKD 
mice (Figures 4-6 and 4-7). 
 
Other basement membrane proteins, including collagen type IV and perlecan were also 
identified at Bruch’s membrane in the wildtype and FKRPKD mouse, with no difference in 
immunolabelling intensity between wildtype and FKRPKD retina, or Bruch’s membrane and 
the ILM was observed ( 
 
Figure 4-7).  Additionally, immunolabelling with perlecan suggested there was no difference 
in the appearance of Bruch’s membrane between the central and peripheral retina in either 
wildtype or FKRPKD mice. 
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TABLE 4-1 LOCALISATION AND EXPRESSION OF BASEMENT MEMBRANE 
PROTEINS IN THE WILDTYPE AND FKRPKD MOUSE EYE 
This table summarises the basement membrane distribution data presented above, for 
wildtype and FKRPKD mice at both the ILM and Bruch’s membrane.  First, it identifies 
whether pan-laminin, laminin β2, collagen type IV, perlecan, collagen VIII and laminin α1 
were present or absent at the ILM or Bruch’s membrane  Secondly, immunolabelling 
intensity in the FKRPKD mouse was assessed, by a comparison to wildtype mice, which is 
reprtoed here as either “at wildtype levels” or “reduced”.  Additionally, this table provides 
an assessment of whether the basement membrane deposition was affected.  Finally, this 
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4.3.7 RETINAL LAMINATION WAS ALTERED IN THE FKRPKD MOUSE 
 Ectopic nuclei were identified in the vitreous body of the FKRPKD mouse eye (Figure 4-3) and 
the fragmented ILM in these mice suggests these nuclei could be retinal neurons, migrating 
through the ILM.  Retinal ganglion cells are a good candidate for these neurons as they are 
the first retinal cells to differentiate during neurogenesis and are localised to the inner 
retina in the mature mouse eye (Chalupa and Williams, 2008).  Brn3.2, also known as Brn3b 
or Pouf41 is a mammalian class IV POU domain protein (Ryan and Rosenfeld, 1997), first 
expressed in the mouse retina at E13.5 (Erkman et al., 1996), which is commonly used as a 
marker of postmitotic retinal ganglion cells (Edqvist and Hallbook, 2004, Leahy et al., 2004).  
Thus, Brn3 immunolabelling was performed to evaluate the distribution of retinal ganglion 
cells in the FKRPKD and wildtype retina. 
 
Brn3 positive cells were identified in the wildtype and FKRPKD mouse retina, with varying 
intensities of immunolabelling identified across the retina of both genotypes.  In wildtype 
mice, Brn3 positive cells were localised to the inner retina, underneath the ILM (Figure 4-8).  
In the FKRPKD retina, Brn3 positive cells were also localised to the inner retina, but they were 
found both underneath and outside of the ILM, in both the central and peripheral retina 
(Figure 4-8).  The identification of Brn3 positive cells in the vitreous body at multiple 
locations was observed for each individual FKRPKD mouse evaluated.  Finally, isolated Brn3 
positive cells were localised to the wildtype and FKRPKD outer retina (Figure 4-8).  
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FIGURE 4-8 BRN3 IMMUNOLABELLING OF P0 RETINA 
In wildtype mice (A, C, E and G) Brn3 positive retinal ganglion cells are localised to the inner 
retina, underneath the ILM.  In FKRPKD mice (B, D, F and H), Brn3 positive retinal ganglion 
cells are also localised to the inner retina, but not all cells are localised underneath the ILM, 
a number are identified outside the ILM, in the vitreous body.  This was consistently seen in 
the central (A-B, C-D, E-F) and peripheral (G-H) retina.  Bruch’s membrane (BM), vitreal 
blood vessels (BV) and the inner limiting membrane (ILM) are indicated. 
 
Transverse 10µm cryosections of wildtype (n=4) (A, C, E and G) and FKRPKD (n=4) (B, D, F and 
H) mouse eyes at P0 were immunolabelled with antibodies against perlecan (green), Brn3 
(red) and Hoechst 33342 to visualise the nuclei (blue).  At least 2 sections from each 
individual mouse (separated by a distance of approximately 120µm) were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems).  Brn3 positive 
cells were always identified in the vitreous body of the FKRPKD mouse only.  Representative 
images were captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision 
software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  
Where direct comparisons of immunolabelling intensity are made, images were captured at 
the same exposure.  Scale bar represents 50µm in A-B, E-H and 25µm in C-D.   
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4.3.8 PERTURBED BASEMENT MEMBRANE DEPOSITION IN THE DEVELOPING RETINA 
In the FKRPKD mouse retina at P0, basement membrane deposition at the ILM and Bruch’s 
membrane was altered and the localisation of retinal ganglion cells was perturbed.  
Therefore the next step was to assess at what developmental age basement membrane 
defects were first evident in the FKRPKD mouse. 
 
Pan-laminin immunolabelling was observed at the ILM of mice at E12.5 and E15.5, with no 
reduction in immunolabelling intensity between the two genotypes (Figure 4-9).  No 
significant disruptions in the FKRPKD ILM were identified at E12.5, or E15.5, suggesting these 
manifest later in development between E15.5 and P0 (Figure 4-9).  As was the case at P0, 
laminin α2 immunolabelling was not identified at the ILM of wildtype mice at either E12.5 or 
E15.5 (Figure 4-10). 
 
Interestingly, laminin α2 immunolabelling was not identified at Bruch’s membrane at E12.5 
or E15.5, suggesting that laminin α2 is incorporated into Bruch’s membrane in mice 
between E15.5 and P0 (Figure 4-10). 
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FIGURE 4-9 PAN-LAMININ IMMUNOLABELLING OF THE DEVELOPING MOUSE 
RETINA 
These images show pan-laminin immunolabelling at a similar intensity is identified at the 
ILM of wildtype and FKRPKD mice at E12.5 and E15.5.  No significant disruptions in the ILM 
were identified at E12.5 or E15.5.  Additionally, pan-laminin immunolabelling of a similar 
intensity was identified at Bruch’s membrane of both wildtype and FKRPKD mice at E12.5 and 
E15.5. 
 
Transverse 10µm cryosections of wildtype (n=3) (A, C) and FKRPKD (n=3) (B, D) mouse eyes at 
E12.5 (A-B) and E15.5 (C-D) were immunolabelled with the pan-laminin antibody (green in 
A-B, white in C-D) and Hoechst 33342 to visualise the nuclei (blue in A-B).  At least 2 sections 
from each individual mouse (separated by a distance of approximately 120µm) were viewed 
under epifluorescence using a Nikon E1000M Microscope and the pattern of 
immunolabelling described above was apparent in all sections evaluated.  Representative 
images were digitally captured with CoolSnap HQ (Photometrics) CCD monochrome camera 
using an Image Pro Plus Imaging system. All images were compiled and manipulated using 
Photoshop CS4 or CS5 (Adobe).  Where direct comparisons of immunolabelling intensity are 
made, the images were captured at the same exposure and have had equal scaling and 
manipulations applied.  Scale bar represents 50µm in A-B and 100µm in C-D.  Bruch’s 
membrane (BM) and the inner limiting membrane (ILM) are indicated.   
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FIGURE 4-10 LAMININ Α2 EXPRESSION IN THE DEVELOPING MOUSE EYE 
These images show that laminin α2 immunolabelling is not identified at either the ILM or 
Bruch’s membrane of wildtype mice at E12.5 (A) or E15.5 (B). 
 
Transverse 10µm cryosections of wildtype mouse eyes at E12.5 (n=2) (A-B) and E15.5 (n=2) 
(C-D) were immunolabelled with antibodies against laminin α2, pan-laminin and Hoechst 
33342 to visualise the nuclei.  A and C show monochrome images of laminin α2 
immunolabelling alone, while B and D show colour composites with laminin α2 (red), pan-
laminin (green) and Hoechst 33342 (blue).  At least 2 sections from each mouse were 
visualised under epifluorescence using a DM4000B upright microscope (Leica 
Microsystems), with the pattern of immunolabelling described above consistent across all 
sections.  Images were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  Where direct comparisons of immunolabelling intensity are made, the images 
were captured at the same exposure.  Scale bar represents 50µm in A-B, E-H and 25µm in C-
D.  Bruch’s membrane (BM), vitreal blood vessels (BV) and the inner limiting membrane 
(ILM) are indicated. 
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4.3.9 PERTURBED ARRANGEMENT OF THE GLIAL SCAFFOLD IN FKRPKD MOUSE RETINA 
The presence of ectopic retinal ganglion cells in the vitreous body suggests that retinal 
lamination might be disturbed in the FKRPKD mouse.  As presented in Chapter 3, cortical 
lamination is disturbed in the FKRPKD mouse and this is associated with defects in the 
neuroepithelial and radial glial scaffolds.  A similar scaffold is also present in the developing 
eye, which is thought to be intimately linked with retinal lamination, so RC2 
immunolabelling was performed to visualise the glial scaffold in the developing mouse eye.   
 
At E12.5, very little RC2 expression was identified in the neuroepithelial scaffold of the 
wildtype or FKRPKD mouse eye (Figure 4-11),  in comparison to E15.5 when strong RC2 
expression was observed in the neuroepithelial scaffold of the wildtype and FKRPKD retina, 
with the scaffold more disorganised in the FKRPKD, relative to wildtype (Figure 4-11).  
Interestingly at P0 RC2 immunolabelling was again reduced in the Müller glial scaffold of the 
wildtype type and FKRPKD mouse eyes, in comparison to E15.5 (Figure 4-11).  This suggests 
that around developmental age E15.5, RC2 is required for a phase of eye development, and 
the requirement for it has passed by P0, so its expression has been downregulated. 
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FIGURE 4-11 RC2 IMMUNOLABELLING IN THE DEVELOPING MOUSE EYE 
Images A, C, E, G, I and K show RC2 immunolabelling alone in monochrome while images B, 
D, F, H J and L are colour composited with RC2 immunolabelling in red, perlecan in green 
and the nuclei labelled with Hoescht 33342 in blue.  RC2 immunolabelling was identified in 
the wildtype (A-B, E-F, I-J) and FKRPKD eye (C-D, G-H, K-L) at E12.5 (A-D), E15.5 (E-H) and P0 
(I-L), with no difference in immunolabelling intensity between the two genotypes, although  
immunolabelling intensity was markedly enhanced at E15.5 in both wildtype and FKRPKD 
mice, in comparison to E12.5 and P0.  The glial scaffold in the FKRPKD mouse appears more 
disorganised relative to wildtype mice.  Thse images have been labelled to show the ILM and 
Bruch’s membrane (BM). 
 
Transverse 10µm cryosections of wildtype (n=2 at E12.5 and n=3 at E15.5 and P0) (A-B, E-F, 
I-J) and FKRPKD (n=2 at E12.5 and n=3 at E15.5 and P0) (C-D, G-H, K-L) mouse eyes at E12.5 
(A-D), E15.5 (E-H) and P0 (I-L) were immunolabelled with the perlecan and RC2 antibodies 
and Hoechst 33342, which visualised the nuclei.  A, C, E, G, I and J show monochrome 
images of RC2 immunolabelling alone, whilst B, D, F, H J and L, are colour composite images 
with perlecan (green), RC2 immunolabelling (red) and Hoechst 33342 (blue).  At least 2 
sections per individual mouse were evaluated under epifluorescence using a DM4000B 
upright microscope (Leica Microsystems), with the pattern of immunolabelling described 
above consistent across all sections.  Representative images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  Where direct comparisons of 
immunolabelling intensity are made, the images were captured at the same exposure and 
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had equal scalings and/or manipulations applied.  Scale bar represents 25µm in A-H and 
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4.3.10 GLYCOSYLATION OF α-DYSTROGLYCAN IN THE DEVELOPING MOUSE RETINA  
Given the developmental regulation of α-dystroglycan glycosylation identified in the mouse 
cortex in the previous chapter, it was decided to investigate this in the developing mouse 
retina with IIH6 immunolabelling. 
 
Strong IIH6 immunolabelling was identified at the wildtype ILM at E12.5, which was 
comparatively much reduced at later developmental stages (E15.5 and P0), appearing to be 
absent (Figure 4-12).  Additionally, strong IIH6 immunolabelling was observed at Bruch’s 
membrane at E12.5 in the retina, which was much reduced, although still detectable at later 
developmental stages (E15.5 and P0) (Figure 4-12).  Finally, at E12.5, IIH6 immunolabelling 
was also observed in the retina, in a pattern that suggested it was localised to the glial 
scaffold (Figure 4-12). 
 
This suggests that there is a requirement for glycosylated α-dystroglycan at the ILM at 
E12.5, but at later developmental stages, this requirement diminishes, so the levels of 
dystroglycan are reduced, or the glycosylation pattern is altered, both of which would 
manifest as a reduction in IIH6 immunolabelling. 
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FIGURE 4-12 IIH6 IMMUNOLABELLING OF THE DEVELOPING MOUSE RETINA 
Transverse 10µm cryosections of wildtype mouse retina at E12.5 (A-C), E15.5 (D-F) and P0 
(G-I) were immunolabelled with the pan-laminin (green) and the IIH6 (red) antibodies and 
Hoechst 33342 to visualise the nuclei (blue).  Sections were visualised under epifluorescence 
using a DM4000B upright microscope (Leica Microsystems).  Images were captured with an 
mRM monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  All images were captured at the 
same exposure.  Scale bar represents 50µm.  Bruch’s membrane (BM) and the inner limiting 
membrane (ILM) are indicated. 
 
Strong IIH6 immunolabelling was identified at the wildtype mouse ILM at E12.5 (A-C), which 
became markedly reduced in comparison as the eye developed, appearing absent at E15.5 
(D-F) and P0 (G-I).  Strong IIH6 immunolabelling was also seen at Bruch’s membrane in the 
E12.5 mouse retina (A-C), which again became markedly reduced in comparison as the eye 
developed, although some immunoreactivity was observed at E15.5 (D-F) and P0 (G-I).  
Additionally, at E12.5, some IIH6 immunolabelling was observed in the retina, which 
appeared to be localised to the glial scaffold. 
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4.4 DISCUSSION 
In this Chapter it was identified that FKRPKD mice did not have changes in eye size or gross 
anatomical abnormalities.  FKRPKD mice did have an increased inner retinal depth, 
suggesting the retinal ganglion cell layer was less compact, due to defects in the ILM and 
ectopias of retinal ganglion cells.  Additionally, a reduced deposition of laminin at Bruch’s 
membrane was identified in the FKRPKD mouse, highlighting for the first time the role of α-
dystroglycan and laminin α2 in the deposition of this basement membrane.  It was also 
identified here that the glycosylation pattern of α-dystroglycan is developmentally regulated 
at both Bruch’s membrane and the ILM at E12.5, suggesting it plays a crucial role in eye 
development. 
 
4.4.1 FUNCTIONAL IMPLICATIONS OF FKRP DEFICIENCY ON GROSS EYE STRUCTURE 
A reduction in Fkrp is not associated with alterations in eye size, gross eye anatomy or 
widespread structural retinal abnormalities, in contrast to other models with i) inactivation 
of dystroglycan expression (Nestin-Cre/DG null mice  and Xenopus) which have 
microphthalmia, structural retinal defects and in the case of the Nestin-Cre/DG null mice, 
buphthalmos (Lunardi et al., 2006, Satz et al., 2009), ii) altered glycosylation of α-
dystroglycan (Fukutin chimeric mouse, Largemyd, Large
vls
 and POMGnT1 deficient mice), 
where multiple structural abnormalities were identified in the eye including corneal 
thickening, inflammation, adhesion defects and opacification, vitreal fibroplasia and lens 
anomalies and adhesion defects and the retina, such as folding, rosette structures and the 
presence of fibrotic tissue (Takeda et al., 2003, Lee et al., 2005, Rurak et al., 2007, Takahashi 
et al., 2011) and iii) altered basement membrane deposition (laminin α1 knockout and 
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laminin β2--/-γ3-/-  mice) where vitreal fibroplasia and structural retinal defects were 
observed (Edwards et al., 2010, Pinzon-Duarte et al., 2010).   
 
As will be described in more detail later, the abnormalities described above have been 
identified in models with defects in the deposition of the ILM and/or Bruch’s membrane, 
suggesting the integrity of these basement membranes is intimately linked with eye 
development and function.  However, these ocular and retinal abnormalities were identified 
in mice aged 3 weeks or older, so although similar basement membrane defects have been 
identified in the FKRPKD mouse, suggesting eye development and function would be 
perturbed in a similar manner, it is not possible to fully evaluate this due to the perinatal 
lethality of the FKRPKD mouse. 
 
4.4.2 HOW IS ILM DEPOSITION AFFECTED BY A REDUCTION IN FKRP EXPRESSION? 
A reduction in Fkrp expression is associated with defects in the deposition of the ILM - it is 
markedly fragmented, with a reduced deposition of laminin α1.  Similar disruptions to the 
ILM are also seen in mice with perturbed expression of extracellular matrix proteins laminin 
γIII4-deficient and laminin β2-/-γ3-/- mice (Pinzon-Duarte et al., 2010), suggesting these 
defects in deposition arise due to a failed interaction between the basement membrane 
ligands and the end-feet of the apical progenitor cells, i.e. the neuroepithelial cells or the 
Müller glia.  In the case of the FKRPKD mouse, this failure is caused by a loss of glycosyl 
groups on α-dystroglycan and as similar disruptions in the ILM are seen in other models with 
perturbed dystroglycan expression (the Largevls mouse (Lee et al., 2005) and Xenopus 
(Lunardi et al., 2006)), it is likely that dystroglycan is involved in the deposition of the ILM. 
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Glycosylated α-dystroglycan and β-dystroglycan have been identified at the end-feet of the 
Müller glial scaffold in the adult  (Montanaro et al., 1995, Blank et al., 1997, Schmitz and 
Drenckhahn, 1997, Claudepierre et al., 2000, Moukhles et al., 2000) and developing retina 
(Blank et al., 1997, Blank et al., 2002, Anderson et al., 2007).  Thus, it is likely that the small 
amounts of punctate IIH6 immunolabelling identified here at the ILM reflect the end-feet of 
the Müller glia. 
 
Interestingly, in wildtype mice, glycosylated α-dystroglycan was clearly identified by IIH6 
immunolabelling at the wildtype ILM early in eye development (at E12.5), and as the eye 
matured, this immunolabelling intensity drastically reduced, to the small amounts of 
punctate labelling describe above.  This suggests, similarly to the cortex, glycosylation of α-
dystroglycan is strongly developmentally regulated in the mouse eye.   
 
During chick retinal development, between E3 and E7, there is a large expansion of the eye, 
where the surface area of the retina and the ILM undergo a ten-fold expansion, so the basal 
lamina needs to be assembled at a maximum rate during this time (Dong et al., 2002).  
Histological evaluation of the eyes presented in this chapter suggests a similar period of 
rapid expansion in the mouse between E12.5 and E15.5.  As described previously in Section 
1.8.7.3, the basement membrane proteins for the ILM are synthesised by different parts of 
the eye and secreted into the vitreous body, where the ILM is then assembled on the end 
feet of the scaffolding cells in the eye (Dong et al., 2002, Halfter et al., 2000, Halfter et al., 
2008) and here it is has been shown dystroglycan glycosylation is enhanced just prior to a 
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period of rapid basement membrane deposition.  As already mentioned in Section 1.9, 
polymerisation of laminin into a network is the first step in basement membrane deposition 
(McKee et al., 2007), which requires binding to cellular receptors such as dystroglycan 
(Maniotis et al., 1997), so the dystroglycan at the end-feet of the glial scaffold is crucial for 
ILM deposition during this phase (Halfter et al., 2000, Dong et al., 2002). 
 
IIH6 immunolabelling was not identified at the ILM of the FKRPKD at P0, and given the 
reduced, altered glycosylation of α-dystroglycan seen in different tissues of the FKRPKD 
mouse, documented both here and in previous publications (Ackroyd et al., 2009), it is likely 
that α-dystroglycan glycosylation will be reduced in the developing FKRPKD retina at E12.5 
and E15.5 (although not specifically demonstrated here).  Thus, through this altered 
glycosylation in α-dystroglycan, a reduction in Fkrp will perturb deposition of the ILM and 
these defects will affect the development and function of the eye. 
 
4.4.3 IS RETINAL LAMINATION AFFECTED BY DEFECTS IN ILM DEPOSITION? 
There are similarities between retinal development and cortical development - retinal 
progenitor cells (neuroepithelial cells) which span the retina, divide at the basal retina (near 
Bruch’s membrane) to generate retinal neurons, which then migrate to their final position.  
The integrity of the ILM is extremely important functionally for retinal lamination since 1) it 
provides an anchorage site for the retinal progenitor cells and 2) acts as a physical barrier, 
helping to restrict neuronal migration.   
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The increase in retinal width, combined with the protrusion of the retinal ganglion cell layer 
into the vitreous body evident at P0 in the FKRPKD mouse are indicative of retinal lamination 
defects.  This form of retinal ectopia is seen in other animal models including those with 
altered glycosylation of α-dystroglycan (Largevls and POMGnT1 deficient mice) (Lee et al., 
2005, Takahashi et al., 2011) and those carrying mutations or inactivations in basement 
membrane proteins, such as the laminin γIII4-deficient, laminin β2-/-γ3-/- (Pinzon-Duarte et 
al., 2010) and laminin α1 knockout mice (Edwards et al., 2010) and the lamab1 and lamc1 
mutant zebrafish (Lee and Gross, 2007). 
 
This suggests that in these mouse models, including the FKRPKD, the migration of retinal 
neurons is not restricted as in the wildtype, leading to the migration of cells through the ILM 
into the vitreous body.  Interestingly, very few significant disruptions in the FKRPKD ILM were 
identified here at E15.5, in comparison to P0 and at this age ectopias of Brn3 positive retinal 
ganglion cells were not evident either (Prior, Whitmore and Brown, unpublished data).  The 
structure of a basement membrane is similar to a mesh network and perhaps a reduction in 
Fkrp expression results in small initial structural defects, which are not evident early in 
development (E12.5 and E15.5).  However, these defects are then amplified by the 
migration of Brn3 positive retinal ganglion cell through the ILM, resulting in the significant 
fragmentation documented here in the FKRPKD mice.  Retinal differentiation proceeds in a 
wave, from the central retina to the peripheral retina (Chalupa and Williams, 2008) and this 
could also explain why at P0 in the FKRPKD mouse, ILM defects were worse in the central 
retina. 
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As already mentioned, at E12.5 in wildtype mice, α-dystroglycan is heavily glycosylated at 
the ILM, where it is probably involved in anchoring the end-feet of the neuroepithelial cells 
to the ILM.  With neuronal differentiation in the retina thought to begin at approximately 
E12.5 (Bassett and Wallace, 2012), perhaps glycosylated α-dystroglycan is anchoring the 
end-feet of the neuroepithelial cells during the expansion phase which is observed pre-
differentiation (Agathocleous and Harris, 2009).  Then once differentiation has commenced, 
there is no longer a requirement for glycosylated α-dystroglycan as the end-feet are 
anchored, so either glycosylation pattern of α-dystroglycan is altered, or the level of 
dystroglycan at the end-feet is down regulated, both of which would result in a decrease in 
IIH6 immunolabelling. 
 
RC2 is a commonly used marker of neuronal progenitors (Park et al., 2009) and the data 
here suggests that its expression is developmentally regulated in the mouse eye, with strong 
expression evident at E15.5, but not around E12.5 and P0.  Retinal differentiation is in the 
eye is thought to commence around E12.5 (Bassett and Wallace, 2012), suggesting that RC2 
immunolabelling is upregulated during retinal differentiation.  However, it is estimated that 
after the appearance of the first postmitotic neuron in the central retina, it takes 
approximately 2 weeks for complete neuronal differentiation to occur (Turner et al., 1990, 
Bassett and Wallace, 2012).  Therefore, at P0, retinal differentiation will still be on-going, 
but here a downregulation in RC2 expression in the retina has been identified.  Additionally, 
a previous publication did not identify RC2 immunolabelling in the developing mouse eye at 
E16 (Chanas-Sacre et al., 2000), suggesting that the protein recognised by the RC2 antibody 
is highly developmentally regulated.  This protein is thought to be a product of Nestin, 
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although the immunolocalisation of RC2 and Nestin is not identical (Park et al., 2009) and 
Nestin has been documented the mouse retina at E17.5 and P1 (Yang et al., 2000) 
suggesting the potential protein isoforms recognised by these two antibodies are fulfilling 
different roles during retinal development. 
 
4.4.4 HOW I  BRUCH’  MEMBRANE AFFECTED BY A REDUCTION IN FKRP EXPRESSION? 
In wildtype mice, pan-laminin, laminin α2, laminin β2, laminin α1, perlecan and collagen 
type IV are localised to Bruch’s membrane.  It has previously been shown that laminin is 
localised to Bruch’s membrane in Xenopus retina (Lunardi et al., 2006) and more specifically, 
that laminin 111, 511, 521 and 323 are identified at Bruch’s membrane in rat, human and 
cow (Aisenbrey et al., 2006, Bystrom et al., 2006), with laminin α4 identified at Bruch’s 
membrane of developing human foetuses (Bystrom et al., 2006).  So here, an additional 
localisation of laminin α2, at Bruch’s membrane, between the developmental stages E15.5 
and P0 has been identified in the mouse.  This is particularly interesting because laminin α2 
chain was reported as not detected at Bruch’s membrane in the developing human eye up 
to 20 weeks gestation (Bystrom et al., 2006), but given that laminin α2 expression at Bruch’s 
membrane was identified during late mouse embryonic development here, perhaps laminin 
α2 is not expressed in humans until later in gestation. 
 
A reduction in Fkrp expression results in reduced laminin deposition at Bruch’s membrane 
and the reduction in IIH6 immunolabelling observed suggests this is associated with altered, 
reduced glycosylation of α-dystroglycan.  Previously, it has been shown that integrin 
receptors are important for the deposition and function of Bruch’s membrane (Aisenbrey et 
Page 303 of 551 
 
al., 2006), so this data demonstrates a previously unidentified role for glycosylated α-
dystroglycan in the deposition of Bruch’s membrane in the mouse. 
 
Bruch’s membrane is a pentalaminar structure and in mice, the first component of this 
structure to deposit is the basement membrane of the RPE, which can be clearly delineated 
at P0 with electron microscopy (Hirabayashi et al., 2003).  Given the localisation of the 
immunolabelling identified in this project just underneath the retina, it is likely this specific 
component of Bruch’s membrane has been visualised.  Thus, it has probably been shown 
here that the deposition of laminin at the basement membrane of the RPE is perturbed 
when Fkrp expression is reduced, although disruptions or fragmentations in this basement 
membrane were not identified in the FKRPKD mouse.  However, given the reduction in 
laminin deposition and the role of Fkrp in dynamic basement membrane deposition 
highlighted in the previous Chapter, it likely there are ultrastructural defects in Bruch’s 
membrane in the FKRPKD mouse which cannot be detected with immunolabelling of 
cryosections, similarly to the laminin β2-/-γ3-/- knockout mice (Pinzon-Duarte et al., 2010).  
Given the role of Bruch’s membrane in (i) regulating the diffusion of molecules between the 
retina and the choroid, (ii) providing physical support for cell adhesion and (iii) providing a 
barrier for cellular division and migration, were the FKRPKD mouse to live, it would have 
significant defects in retinal function. 
 
4.4.5 CONCLUDING REMARKS 
Here, a reduction in Fkrp expression was not linked to changes in eye size or gross 
anatomical abnormalities, although disorganised retinal patterning and ectopias of retinal 
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ganglion cells were identified.  These defects were associated with perturbed deposition of 
the ILM and Bruch’s membrane, suggesting these basement membranes play a crucial role 
in eye development.  It was also identified here that the glycosylation pattern of α-
dystroglycan developmentally regulated in the eye and additionally varies between the ILM 
and Bruch’s membrane, suggesting this too is crucial for eye development.  
 
  
Page 305 of 551 
 
5 GENERATION OF A MOUSE MODEL FOR LGMD2I  
 
5.1 INTRODUCTION 
The FKRPKD mouse with its global reduction of Fkrp expression, whilst a good model for the 
severe end of the dystroglycanopathy spectrum (and assessing the implications of Fkrp 
deficiency in brain and eye development as described in Chapters 3 and 4), is not a good 
model for assessing the functional implications of Fkrp deficiency in muscle, or testing 
potential therapeutic strategies as it dies in the early postnatal period. 
 
Although the reasons behind the perinatal lethality of the FKRPKD mouse model have not 
been demonstrated, it was hypothesised the severe central nervous system defects 
observed in this mouse (Ackroyd et al., 2009, Ackroyd et al., 2011, Booler et al., 2012) 
perturbed the functioning of the respiratory centres.  As shown in Figure 3-1, the Neomycin 
selection cassette, (which causes the reduction in Fkrp expression) is floxed and can be 
removed with Cre recombinase, to restore Fkrp expression (Ackroyd et al., 2009).  In an 
attempt to correct these central nervous system defects, the FKRPKD mouse line  was 
crossed with a mouse expressing Cre recombinase under the control of the Sox1 promoter 
(Sox1Cre mouse) (Takashima et al., 2007).  Sox1 (Sex determining region Y-box 1) is a 
member of the Sox1B1 transcription factor family and is expressed in early neural 
progenitors at or after the neural induction and is involved in fate determination (Pevny et 
al., 1998).  This strategy would therefore restore Fkrp expression in all neuronal and glial 
cells of the developing and mature nervous system including but not limited to neuronal 
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progenitors and neurons, neuroepithelial cells, radial glial cells, astrocytes and 
oligodendrocytes.  It was hypothesised that this strategy would restore expression of Fkrp in 
the brain of FKRPKD mice, correcting the central nervous system defects and thus allowing 
these mice to survive beyond birth, whilst maintaining the 80% knockdown in Fkrp 
expression in the muscles.  This chapter will describe the generation and characterisation of 
this new mouse line, henceforth referred to as FKRP Muscular Dystrophy, shortened to 
FKRPMD.    
 
Firstly, the breeding strategies used to generate the FKRPMD mutant mouse and maintain 
the animal colony will be described, before attention turns to the FKRPMD mouse and 
demonstrating this genetic approach to restore Fkrp expression in the central nervous 
system has been successful.  Following this, the mutant mouse was evaluated 
physiologically, and four muscles were evaluated histologically and immunohistochemically 
for evidence of dystrophic pathology.  These muscles were chosen to cover the following 
points – 1) a comparison between the proximal and distal muscles as the FKRPMD mouse is 
intended to be a model for LGMD2I, a disease where the limb girdles are the most severely 
muscles, 2) an evaluation of how function, or mechanical use affects dystrophic pathology, 
for example in the mdx mouse the worst histopathology is seen in the diaphragm (Stedman 
et al., 1991), and 3) the effect of fibre type composition, by comparing the soleus, a postural 
muscle composed of predominantly type I and IIA fibres, and the gastrocnemius which is 
predominantly type IIB and IIDB (Augusto et al., 2004).  
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LGMD2I is at the mild end of the dystroglycanopathy spectrum and is associated with 
mutations in Fkrp.  Patients with LGMD2I have a high variability in clinical course and a 
spectrum of clinical phenotypes (Vainzof and Bushby, 2010).  In the most severe cases, 
LGMD2I patients present early with delayed motor milestones and/or hypotonia, 
progressing to a loss of ambulation at the end of their first decade or beginning of their 
second (Vainzof and Bushby, 2010).  Additionally, there is a second, more common 
phenotype, where patients present with a typical characteristic pattern of muscle weakness, 
with the most affected muscles being the axial muscles, the neck flexors and the proximal 
limb muscles of the shoulder and pelvic girdle (Poppe et al., 2003, Vainzof and Bushby, 
2010).  This would allow us to a) establish the FKRPMD mouse as a good pre-clinical model for 
therapeutic testing and b) test the hypothesis that Fkrp deficiency results in basement 




The aim of this section was to generate a new preclinical mouse model with a reduction in 
Fkrp expression which could be used for preclinical testing and further investigating the 
function of Fkrp.  It was hypothesised that the restoration of Fkrp in the central nervous 
system would overcome the perinatal lethality seen in the FKRPKD mouse generating a 
mouse that lives beyond birth.  The reduction in Fkrp expression which would persist in the 
muscle would result in defects in the basement membrane surrounding individual fibres, 
which would result in the development of a dystrophic pathology. 
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5.3 RESULTS 
5.3.1 BREEDING STRATEGY FOR THE GENERATION OF THE FKRPMD MOUSE 
In the original FKRPKD mouse colony, consistent with inheritance of a single recessive trait, 
there were three different genotypes of mice – wildtype (FKRP-NeoTyr307Asn-/-), FKRPKD 
heterozygote (FKRP-NeoTyr307Asn+/-) and FKRPKD (FKRP-NeoTyr307Asn+/+).  As the FKRPKD 
mutant dies perinatally (Ackroyd et al., 2009), it cannot be used for breeding.  Thus, FKRPKD 
heterozygote mice were used to generate the new mouse model, FKRPMD, across two 
successive breeding crosses (shown as a schematic in Figure 5-1), generating animals of 6 
different genotypes, which are summarised in Table 5-1.  The first breeding cross in this 
scheme (A), between a FKRP-NeoTyr307Asn-/-Sox1Cre+/- (Sox1Cre) mouse and a FKRPKD 
heterozygote mouse, was designed to introduce Cre recombinase into the background of 
the FKRPKD mouse colony and generated F1 animals of 4 different genotypes – wildtype 
(FKRP-NeoTyr307Asn-/-Sox1Cre-/-), Sox1Cre (FKRP-NeoTyr307Asn-/--Sox1Cre+/-), FKRPKD heterozygote 
and FKRP-NeoTyr307Asn+/-Sox1Cre+/-  (FKRPMD heterozygote) (Figure 5-1). 
 
In the second breeding cross, a FKRPMD heterozygote mouse was crossed with a FKRP
KD 
heterozygote mouse which generated animals of 6 different genotypes, including the 4 
genotypes generated in the F1 breeding cross (Figure 5-1).  The two additional genotypes 
generated in the second breeding cross (B) were the FKRP-NeoTyr307Asn+/+ (FKRPKD) mouse, 
and finally the FKRP-NeoTyr307Asn+/+Sox1Cre+/- mouse – the FKRPMD mouse (Figure 5-1) 
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Abbreviation FKRP Cre 
recombinase 
Genotype 
Wildtype Wildtype No FKRP-NeoTyr307Asn-/-Sox1Cre-/- 
Sox1Cre  Wildtype Yes FKRP-NeoTyr307Asn-/-Sox1Cre+/- 
FKRPKD heterozygote Heterozygote No FKRP-NeoTyr307Asn+/-Sox1Cre-/- 
FKRPMD heterozygote Heterozygote Yes FKRP-Neo
Tyr307Asn+/-Sox1Cre+/- 
FKRPKD Mutant No FKRP-NeoTyr307Asn+/+Sox1Cre-/- 
FKRPMD Mutant Yes FKRP-Neo
Tyr307Asn+/+Sox1Cre+/- 
 
TABLE 5-1 FKRPKD AND FKRPMD MOUSE LINES 
This table lists the 6 different genotypes produced by the breeding crosses used in the 
generation and maintenance of the FKRPMD mouse colonies, with reference to their 
inheritance of Cre recombinase and the Neomycin cassette.  It also lists the shorthand 
abbreviated terms, will now be used throughout the text when referring to the mice of 
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FIGURE 5-1 FKRPMD MOUSE COLONY BREEDING SCHEMATIC 
Schematic  showing the breeding programs performed to generate FKRPMD mice.  The 
mouse chromosomes are represented by the black lines, while the genes are denoted by 
square boxes, coloured as shown in the key, with wildtype in green, mutant Fkrp in blue and 
the Cre recombinase in purple.  (A) shows the F1 breeding cross between FKRPKD 
heterozygote (FKRP-NeoTyr307Asn+/-) and Sox1Cre heterozygote (FKRP-NeoTyr307Asn-/-Sox1Cre-/-) 
mice.  This produces animals of 4 different genotypes, from left to right, wildtype, Sox1Cre, 
FKRPKD heterozygote and FKRPMD heterozygotes.  (B) shows the second breeding cross 
between a FKRP-NeoTyr307Asn+/-Sox1Cre+/- and an FKRP heterozygote mouse.  This produces 
animals of 6 genotypes, from left to right, wildtype, Sox1Cre, FKRPKD heterozygote, FKRPMD 
heterozygote, FKRPKD and FKRPMD mice.  
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This breeding cross generated FKRPMD mice at a frequency of 28%, which suggests there was 
no prenatal loss of this mutant phenotype.  However to generate a greater incidence of 
FKRPMD littermates for experimental cohorts, two alternative breeding strategies (FKRP
KD 
heterozygote x FKRPMD, and FKRPMD x FKRPMD) were trialled, to reduce the number of 
animals generated during this research.  As expected the cross between an FKRPKD 
heterozygote and an FKRPMD (either male of female) increased the frequency of FKRPMD 
mice, without significantly affecting mean litter size (Figure 5-2).  Thus, as both male and 
female FKRPMD are fertile, a breeding program was set up using 2 FKRPMD mutants and 
although this was associated with a significant trend towards smaller litters (Figure 5-2), all 
offspring generated from this breeding cross were FKRPMD. 
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FIGURE 5-2 MEAN LITTER SIZE IN THE FKRPMD COLONY  
Breeding data shown on the y axis is the mean number of births per litter, for each of the 
different breeding schemes used in the generation and maintenance of the FKRPMD mouse 
colony – (A) Sox1Cre heterozygote x FKRPKD heterozygote (n=16 litters, blue), (B) FKRPMD 
heterozygote x FKRPKD heterozygote (n=52 litters, orange), (C) FKRPMD x FKRPMD (n=41 
litters, purple) and (D) FKRPMD x FKRP
KD heterozygote (n=12 litters, red).  Error bars show 
±SEM. 
 
All data sets passed a D'Agostino & Pearson omnibus normality test.  A One-Way ANOVA 
with a post-hoc Tukey’s multiple comparisons test was performed and the null hypothesis 
that mean litter size was not affected by the genotype of the parents in the breeding 
program was rejected.  The results from the statistical tests are shown on the graph as 
follows - * 0.05>p≥0.01, ** 0.01>p≥0.001, *** 0.001>p≥0.0001.  The data was compiled 
using Microsoft Excel 2010 and analysed using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California U.S.A. 
 
This showed that breeding from 2 FKRPMD mutant mice resulted in a significant reduction in 
the number of births per litter. 
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5.3.2 RESTORATION OF FKRP IN THE NEUROECTODERM RESTORED CORTICAL 
LAMINATION. 
Quantitative real-time PCR analysis performed on 10-12 week FKRPMD and wildtype mice 
showed the knockdown in Fkrp expression was maintained in the muscle of FKRPMD mice, 
while its expression was restored to wildtype levels in the FKRPMD cortex (Figure 5-3).  
Additionally, the severe structural cortical abnormalities seen in the FKRPKD mouse, such as 
fusion of the interhemispheric fissure, hydrocephalus and cortical lamination defects 
(Ackroyd et al., 2009, Ackroyd et al., 2011, Booler et al., 2012) were prevented by a 
restoration of Fkrp expression, as the cortex of the FKRPMD showed no obvious 
abnormalities (Figure 5-4).   
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FIGURE 5-3 FKRP EXPRESSION IN FKRPMD MICE 
Real time PCR (RT-PCR) analysis was performed on brain and skeletal muscle (quadriceps) 
from 11-13 week old wildtype (n=4, green) and FKRPMD (n=4, blue) to evaluate relative 
expression of Fkrp.  Taq man RT-PCR probes were used to measure relative Fkrp mRNA 
expression in these tissues.  Expression levels were normalised relative to the endogenous 
housekeeper gene Gapdh.  Error bars represent ±SEM.  All samples were analysed as 
triplicate data sets.  This RT-PCR was performed and analysed by Dr Mark Ackroyd, Royal 
Veterinary College on tissue from mice bred and harvested by myself.   
 
The data was compiled and analysed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California U.S.A).  The n numbers were too small to perform 
a D'Agostino & Pearson omnibus normality test, so a non-parametric Mann-Whitney 
statistical test was performed to test the null hypothesis that the level of Fkrp expression in 
the quadriceps or the cortex did not differ between wildtype and FKRPMD mice, with the 
results shown - * 0.05>p≥0.01.  The null hypothesis was accepted for the cortex, showing 
Fkrp expression had been restored in the brains of the FKRPMD mice.  The null hypothesis 
was rejected for the muscle - the level of Fkrp expression in FKRPMD muscle was significantly 
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FIGURE 5-4 HISTOLOGICAL EVALUATION OF FKRPKD AND FKRPMD CORTEX  
These images were captured at the level of the corpus callosum and show in the FKRPKD (C, 
F) mouse at P0, the reduction in Fkrp results in a loss of cortical lamination, failure to form 
the interhemispheric fissure and in some cases hydrocephalus.  In FKRPMD mice (B, E), at P0 
restoration of Fkrp expression in the early neuroectoderm reinstates the interhemispheric 
fissure and cortical lamination, resulting in a brain that appears equivalent to wildtype (A, D) 
mice.   
 
6µm paraffin embedded coronal sections of P0 wildtype (n=3) (A, D), FKRPMD (n=2) (B, E) and 
FKRPKD (n=3) (C, F) heads fixed in Bouin’s solution at P0 and stained with haematoxylin and 
eosin were viewed under light microscopy using a DM4000B upright microscope (Leica 
Microsystems).  Sections from FKRPMD mice were evaluated for the cortical 
histopathological features (a loss of cortical lamination, failure to form the interhemispheric 
fissure and hydrocephalus) previously descrbed in the FKRPKD mouse in these publications 
(Ackroyd et al., 2009, Ackroyd et al., 2011, Booler et al., 2012).  Representative images were 
digitally captured with a DC500 colour camera (Leica Microsystems) using the Leica 
Application Suite software (Leica Microsystems) and compiled using Photoshop CS4 or CS5 
(Adobe).  Scale bar in images A-C is 500µm, while scale bar in images D-F represents 200µm.  
Images of these sections were captured from slides kindly provided by Ms Helen Booler 
(Royal Veterinary College).  
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5.3.3 FEMALE FKRPMD MICE HAD SELECTIVE MUSCLE LOSS AND A REDUCTION IN BODY 
WEIGHT 
Gross observation of FKRPMD
 mice found that during and up until weaning they were often, 
but not invariably smaller than their littermate controls, although after this period they 
rapidly put on weight (particularly if given a mash diet).  Physically, FKRPMD mice appeared 
indistinguishable from wildtype, with the exception of an altered resting stance, which was 
occasionally observed.  Additionally, a post-mortem evaluation of 6 FKRPMD female mice at 
20 weeks of age showed these mice had kyphosis, although the severity varied between 
different individual mice. 
 
Analysis of body weight at 6, 12 and 20 weeks of age with a linear mixed effect model 
showed that genotype was not a significant factor affecting body weight of male mice 
(Figure 5-5).  Interestingly, however, this model showed genotype was a significant factor 
affecting body weight in female mice, at 6 weeks of age and 20 weeks of age (Figure 5-5).  
Additionally, necropsies of 6 female FKRPMD mice at 20 weeks of age suggested these mice 
had a loss of muscle mass around the limb girdles, in comparison to wildtype mice (n=5) 
(Figure 5-5),  although the degree of muscle loss varied between different individuals.  
Additionally, this analysis showed that age was a significant factor affecting body weight for 
both male and female mice. 
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FIGURE 5-5 PHYSICAL CHARACTERISTICS OF FKRPMD MICE 
A and B show male wildtype and FKRPMD mice at 25 weeks of age, highlighting the similarity 
in size between wildtype and FKRPMD mice and demonstrating the altered resting stance of 
FKRPMD mice, compared to wildtype mice.  C and D show skinned wildtype (n=5) (C) and 
FKRPMD (n=6) (D) female mice at 20 weeks of age.  A loss of weight in the limb girdles (white 
arrows) and kyphosis (*) in the FKRPMD mice is indicated.   A-D show digital photographs of 
wildtype (A, C) and FKRPMD (B, D) mice captured using an Olympus FE-3000 camera and 
compiled using Photoshop CS5 (Adobe).  Images C-D were captured following the eccentric 
exercise electrophysiology protocol performed by Dr Kim Wells (Royal Veterinary College).   
 
E and F show the mean body weights ± SEM of male (E) and female (F) wildtype (green) and 
FKRPMD (blue) at 6 (male WT n=8, male FKRPMD n=9; female WT n=14, female FKRPMD n=12), 
12 (male WT n=10, male FKRPMD n=17; female WT n=14, female FKRPMD n=24) and 20 weeks 
of age (male WT n=7, male FKRPMD n=13; female WT n=6, female FKRPMD n=12).  Data was 
compiled using Microsoft Excel and graphs were prepared using GraphPad Prism version 5.0 
for Window.  Data was analysed with a Linear Mixed Effects Model performed using SPSS 
Statistics (IBM Corporation, U.S.A).  This model showed that age was a significant factor 
affecting mouse body weight in both male and female mice, but genotype was not a 
significant factor affecting male body weight (p=0.245).  This model showed that genotype 
was a significant factor affecting female body weight, with significance is shown as follows: 
*0.01 ≤p<0.05, ** 0.001≤p<0.01. 
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5.3.4 FKRPMD MICE DID NOT HAVE HINDLIMB MUSCLE WEAKNESS 
Mice normally splay their hindlimbs when picked up by the tail, and a collapse of this 
response could indicate motor deficits in these mice.  To evaluate this, the hindlimb 
extensor reflex of wildtype and FKRPMD mice was evaluated at 12 weeks of age and classified 
into either normal (hindlimbs fully stretched away from the body) or abnormal (either 
partial or full collapse of the reflex, with clasping of the hindlimbs in some cases).  An 
abnormal hindlimb extensor reflex was identified in a small number of FKRPMD mice, whilst 
no abnormalities were identified in wildtype mice (Table 5-2).  
 
5.3.5 FKRPMD MICE DID NOT HAVE A REDUCTION IN FORELIMB GRIP STRENGTH 
To complement the analysis of hindlimb extensor reflex, the forelimb grip strength of 
FKRPMD mice was evaluated.  The forelimb grip strength of mice can be evaluated in 3 ways 
by measuring the ability of the mouse to 1) cling to an inverted or tilted surface, 2) hang 
onto a wire, or the one used in this project, 3) generate force pulling off a narrow bar 
(Brooks and Dunnett, 2009).  Forelimb grip strength was evaluated in wildtype and FKRPMD 
mice aged between 11 and 13 weeks using a protocol based on the standard operating 
procedure for mdx mice downloaded from the Treat NMD website (De Luca, 2008).  This 
analysis showed that both male and female FKRPMD have a trend towards weaker mean 
forelimb grip strength, relative to wildtype mice, although statistical analysis showed this 
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 Male Female 
Wildtype FKRPMD Wildtype FKRPMD 
HL Reflex Normal 6 14 11 14 
Abnormal 0 2 0 2 
 
TABLE 5-2 HINDLIMB EXTENSOR REFLEX OF FKRPMD MICE 
The hindlimb extensor reflex of FKRPMD and wildtype (WT) mice was evaluated at 12 weeks 
of age and classified as either normal (hindlimbs fully splayed away from the body) or 
abnormal (either partial or full collapse of the reflex).  The tables show the number of mice 
at each age with normal and abnormal hindlimb extensor reflexes, with data for the males 
and females presented separately   For females, wildtype n=11, FKRPMD n=16 and for males  
wildtypen=6, FKRPMD n=16. 
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FIGURE 5-6 FORELIMB GRIP STRENGTH MEASUREMENTS 
Mean Forelimb grip strength measurements (g/g mouse) of male (A) and female (B) 
wildtype (green) and FKRPMD (blue) mice.  An unpaired two-tailed t-test was performed 
using GraphPad Prism version 5.0 for Windows to test the null hypothesis that FKRPMD mice 
did not have a significant reduction in forelimb grip strength relative to wildtype mice.  The 
statistical test returned a p value of 0.087 for males and 0.075 for females, so the null 
hypothesis was accepted – both male and female FKRPMD mice do not have a significant 
reduction in forelimb grip strength, relative to age-matched wildtype mice. 
 
Forelimb grip strength measurements were taken from mice aged 11-13 weeks of age using 
a forelimb grip strength meter.  Grip strength was measured in a maximum of 4 different 
trials and a mean value was taken of the force generated.  Values were discarded if the trial 
was not performed correctly.  Mice were given at least a 10 minute rest between trials but 
each mouse included in the analysis successfully performed at least 3 trials.  After the trials 
mice were then weighed so the mean forelimb grip strength per g of mouse could be 
calculated.  The n numbers for male mice are wildtype n=5 and FKRPMD n=14 and for female 
mice – wildtype n=6 and FKRPMD n=14.  The data was compiled using Microsoft Excel and 
the graphs show mean grip strength ± SEM prepared using GraphPad Prism version 5.0 for 
Windows.   
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5.3.6 FKRPMD MICE DID NOT HAVE ELEVATED SERUM CK 
Creatinine kinase (CK) is a cytoplasmic and mitochondrial enzyme, which catalyses the 
phosphorylation of ADP to ATP.  Leakage of CK occurs across damaged membranes, which 
leads to increased levels in the serum.  Therefore, the level of serum CK activity is used as a 
specific marker of muscle injury or damage, particularly given that elevated serum CK levels 
are observed in human patients with muscular dystrophy (Godfrey et al., 2007). 
 
An analysis of serum CK levels were evaluated in male FKRPMD mice at 11-13 weeks of age 
and found to be 36.11 U/L.  No statistical analysis was run on this data, as the value for 
FKRPMD mice was consistent with the wildtype value of 38.17 U/L   (Figure 5-7).  A serum 
sample from a 6 week old mdx mouse was used as a positive control, and this mouse has a 
markedly elevated CK value, relative to wildtype and FKRPMD mice (Figure 5-7).  This 
suggests that FKRPMD mice at this age do not have elevated serum CK. 
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FIGURE 5-7 FKRPMD MICE DO NOT HAVE ELEVATED SERUM CK 
Serum CK levels of 11-13 week old male wildtype (n=3) and FKRPMD (n=3) mice were 
evaluated.  Serum from a 6 week old mdx mouse was used as a positive control.  Each 
sample was run in triplicate, with the exception of the mdx sample which was run in 
duplicate.  Values were normalised to a blank reagent only control.   
 
Data was compiled using Microsoft Excel (Office 2010) and graphs were prepared using 
GraphPad Prism version 5.0 for Windows.  The error bars show ±SEM.  No statistical analysis 
was performed on this data due to similarity of the mean values for wildtype (38.17 U/L) 
and FKRPMD (36.11 U/L) mice.  The similarity of these values suggests FKRPMD mice do not 
have elevated serum CK.  
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5.3.7 FKRPMD MICE DEVELOPED A DYSTROPHIC PATHOLOGY BY 6 WEEKS OF AGE 
Dystrophic pathology in the FKRPMD mouse muscle was evident at 6 weeks of age, 
characterised by the appearance of a few, small isolated patches of necrotic and 
degenerating muscle fibres, clustering regenerating muscle fibres and occasional 
inflammatory infiltrates (Figure 5-8).  At this age, muscles from three invididual FKRPMD mice 
were evaluated.  Although each pathological feature was identified in each mouse, the 
degree and distribution across the muscle was highly variable between each individual, 
implying that 6 weeks of age was the approximate age of pathological onset.  Additionally, 
as described in the next section, the pathology varied between the 4 different muscles 
evaluated (triceps, gastrocnemius, soleus and diaphragm). 
 
By 12 weeks of age, FKRPMD muscles showed widespread focal patches of degeneration, 
necrosis and regeneration, characterised by sarcoplasmic hyalinisation and loss of cross-
striations with occasional sarcoplasmic fragmentation (necrosis) and muscle fibres with 
centralised nuclei (evidence of previous regeneration) (Figure 5-9).  Inflammatory infiltration 
was still present at 12 weeks, but more widespread relative to 6 weeks (Figures 5-8 and 5-9).  
Additionally, small groups of regenerative muscle fibres with large centralised nuclei and a 
granular basophilic cytoplasm were seen (Figure 5-9).  Here, muscles from 4 indiviudal 
FKPRMD mice were evaluated, with degenerating and regenerating muscle fibres, and 
inflammatory infiltrates identified in muscles from all individual mice.  However, there was 
some variation between individual mice, both with respect to the degree of pathology 
present and the distribution of the pathological features across the muscles.  Additionally, 
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there was some variation between the individual muscles evaluated (diaphragm, triceps, 
gastrocnemius and soleus), as discussed in more detail shortly. 
 
In older mice (30 weeks of age), there was very little histological evidence of degeneration 
or necrosis, although the majority of muscle fibres had centralised nuclei, indicative of 
previous regeneration cycles (Figure 5-10).  Three FKRPMD mice were evaluated at this age, 
and this observation was consistent between all three mice.  Additionally in the three 30 
week FKRPMD mice evaluated, there were very few inflammatory infiltrates present (Figure 
5-10).  Interestingly, no evidence of fibrosis, or replacement of muscle fibres by adipose 
tissue was seen in any of the FKRPMD mice at any age (Figures 5-8, 5-9 and 5-10).   
 
At all ages, muscles evaluated from wildtype and heterozygous animals were histologically 
unremarkable and indistinguishable from each other. 
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FIGURE 5-8 FKRPMD MUSCLE AT 6 WEEKS 
Inflammatory infiltrates (In) can be seen in the 6week FKRPMD gastrocnemius (L) along with 
degenerating (*) and regenerative fibre clusters (**) in the gastrocnemius (K-L) and triceps 
(C-D).  Additionally, muscle fibres with centralised nuclei (#), indicating degeneration and 
regeneration can be identified in the triceps (C-D).  No overt histological evidence of 
dystrophic pathology was identified in the soleus (E) or the diaphragm (H) at this age. 
 
Transverse 10µm cryosections from 6 week wildtype (n=2 for all muscles) (A-B, E, G, I-J) and 
FKRPMD (n=3 for all muscles) (C-D, F, H, K-L) triceps (A-D), soleus (E-F), diaphragm (G-H) and 
gastrocnemius (I-L) werestained with haematoxylin and eosin  At least 3 sections from each 
individual mouse were viewed under light microscopy using a DM4000B upright microscope 
(Leica Microsystems) and evaluated for histological evidence of dystrophic muscle 
pathology, such as necrotic, degenerating or regenerating muscle fibres, inflammatory 
infiltrates, fat infiltration, fibrosis, muscle fibres with centralised nculei and a variation in 
muscle fibre size.  Representative images were digitally captured with a DC500 colour 
camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled using Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in A, C, I, K and 100µm in all other images.   
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FIGURE 5-9 FKRPMD PATHOLOGY AT 12 WEEKS 
Centrally nucleated muscle fibres (#) and a variation in muscle fibre size (**) were observed 
in the 12 week FKRPMD triceps (C-D), gastrocnemius (K-L) and diaphragm (H).  Additionally, 
degenerating (*) and regenerating (R) muscle fibres can be identified in the triceps (C-D), 
gastrocnemius (K-L) and diaphragm (H).  Necrotic muscle fibres (N) and inflammatory 
infiltrates (black arrow) were observed in the FKRPMD triceps.  Interestingly the only 
histological hallmark of dystrophic histopathology identified in the FKRPMD soleus at this age 
was a small number of centrally nucleated muscle fibres.  No evidence of dystrophic 
pathology was observed in wildtype muscle, aside from a small number of centrally 
nucleated muscle fibres. 
 
Transverse 10µm cryosections from 12 week wildtype (n=3 for all muscles) (A-B, E, G, I-J) 
and FKRPMD (n=3 for all muscles) (C-D, F, H, K-L) triceps (A-D), soleus (E-F), diaphragm (G-H) 
and gastrocnemius (I-L) were stained with haematoxylin and eosin.  At least 3 sections from 
each individual mouse were viewed under light microscopy using a DM4000B upright 
microscope (Leica Microsystems) and evaluated for histological evidence of dystrophic 
muscle pathology, such as necrotic, degenerating or regenerating muscle fibres, 
inflammatory infiltrates, fat infiltration, fibrosis, muscle fibres with centralised nculei and a 
variation in muscle fibre size.  Representative images were digitally captured with a DC500 
colour camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled using Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in A, C, I, K and 100µm in all other images.   
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FIGURE 5-10 FKRPMD PATHOLOGY AT 30 WEEKS 
Centrally nucleated muscle fibres (#) and a variation in muscle fibre size (**) were observed 
in the 30 week FKRPMD triceps (A-D), gastrocnemius (I-L), soleus (E-F) and diaphragm (G-H).  
Additionally, inflammatory infiltrates (identified by an arrow), degenerating (*) and 
regenerating (R) muscle fibres can be identified in the triceps (A-D).  No evidence of 
dystrophic pathology was observed in wildtype muscle, aside from the occasional centrally 
nucleated muscle fibres. 
 
Transverse 10µm cryosections of 30 week wildtype (n=3 for all muscles) (A-B, E, G, I-J) and 
FKRPMD (n=3 for all muscles) (C-D, F, H, K-L) triceps (A-D), soleus (E-F), diaphragm (G-H) and 
gastrocnemius (I-L) stained with haematoxylin and eosin were viewed under light 
microscopy using a DM4000B upright microscope (Leica Microsystems).  At least 3 sections 
from each individual mouse were viewed under light microscopy using a DM4000B upright 
microscope (Leica Microsystems) and evaluated for histological evidence of dystrophic 
muscle pathology, such as necrotic, degenerating or regenerating muscle fibres, 
inflammatory infiltrates, fat infiltration, fibrosis, muscle fibres with centralised nculei and a 
variation in muscle fibre size.  Representative images were digitally captured with a DC500 
colour camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled using Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in A, C, I, K and 100µm in all other images.   
 
.  
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5.3.8 FKRPMD MICE DISPLAYED EVIDENCE OF DIFFERENTIAL MUSCLE INVOLVEMENT 
4 different muscles from FKRPMD mice (diaphragm, gastrocnemius, soleus and triceps) were 
evaluated to see if at the ages studied here (6, 12, 20 and 30 weeks), the characteristics of 
the dystrophic pathology varied between these muscles. 
 
Three FKRPMD mice were evaluated at 6 weeks of age, and in all three individual mice, 
histological evidence of dystrophic pathology was identified only in the gastrocnemius and 
the triceps; the FKRPMD soleus and the diaphragm were comparable to wildtype mice at this 
age (Figure 5-8).  Additionally, histological differences between the gastrocnemius and the 
triceps were identified in FKRPMD mice at this age (Figure 5-8).  For example, whilst patches 
of actively degenerating and regenerating muscle fibres were found in both muscles in all 
three individual mice, scattered muscle fibres with centralised nuclei were only evident in 
the triceps of the three mice (Figure 5-8).  This suggests that initial onset of degeneration is 
earlier in the triceps (Figure 5-8). 
 
By 12 weeks of age, histological hallmarks of dystrophic pathology were consistently seen 
across the different muscles of the four FKRPMD mice evaluated, with degeneration, 
necrosis, regeneration and inflammatory infiltrates identified in the gastrocnemius, 
diaphragm and triceps of all the FKRPMD muscles evaluated, although there was a small 
amount of variation between individual mice (Figure 5-9).  Interestingly, no evidence of 
dystrophic pathology was observed in the soleus of any of the four FKRPMD mice evaluated 
at this age; aside from a small number of muscle fibres with centralised nuclei (Figure 5-9). 
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In the three older FKRPMD mice (30 weeks of age) evaluated clusters of actively degenerating 
basophilic muscle fibres and inflammatory infiltrates were rare, suggesting very little active 
on-going degeneration (Figure 5-10).  In the triceps, regenerating fibres were identified, 
suggesting recent degeneration, with occasional inflammatory infiltrates and adipocytes, 
although no fibrosis was identified (Figure 5-10).  Consistent with the previous ages, in these 
three FKRPMD mice, the soleus remained relatively spared; with a smaller number of 
centrally nucleated muscle fibres (in comparison to other FKRPMD muscles) and occasional 
variations in fibre size the only pathological hallmarks of dystrophic pathology apparent in 
the muscle (Figure 5-10). 
 
Thus, to summarise, FKRPMD mice have a characteristic pattern of differential muscle 
involvement; with the triceps, a proximal muscle is more severely affected (based on the 
identification of regenerating fibres at 30 weeks of age) than both the diaphragm and the 
gastrocnemius, a distal muscle.  Additionally, the soleus, a postural muscle is the most 
mildly affected. 
 
5.3.9 THE PERCENTAGE OF CENTRALLY NUCLEATED MUSCLE FIBRES REFLECTED THE 
PATTERN OF DIFFERENTIAL MUSCLE INVOLVEMENT 
A commonly used marker of degenerative and regenerative processes in mouse models of 
muscular dystrophy is the proportion of centralised nuclei; especially as typically less than 
3% of muscle fibres in wildtype have a centralised nucleus (Dubach-Powell, 2008, Rüegg and 
Meinen, 2011). Initially, this parameter was evaluated by counting the number of centrally 
nucleated muscle fibres in digital images captured from randomly chosen fields of view 
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across the individual muscles, which is the method commonly used in many publications 
(Gawlik and Durbeej, 2010, Beedle et al., 2012, Rooney et al., 2012).   
 
This Random Areas method showed at 12 weeks, in FKRPMD mice, the gastrocnemius 
(35.2%) had the highest percentage of centrally nucleated muscle fibres relative to the 
diaphragm (17.3%) and the soleus, which had the lowest with approximately 7% of muscle 
fibres having centralised nuclei (Table 5-3).  The percentages of centrally nucleated muscle 
fibres in each muscle evaluated was increased in older mice (30 weeks), and the same 
pattern of muscle involvement was preserved – the gastrocnemius had a higher percentage 
of centrally nucleated muscle fibres (48%) relative to the diaphragm (40%) and the soleus 
(12%) (Table 5-3). 
 
However, since an aspect of the histopathology seen in FKRPMD mice was focal degenerative 
patches across the muscle, counting with the Random Areas method gave rise to large 
variations in the percentage of centrally nucleated muscle fibres between different animals, 
depending on which area of the muscle was captured, as indicated by the high SD values in 
Table 5-3 and high SEM values in Figure 5-11.  The gastrocnemius was particularly affected, 
with a value for SD of 21.97 at 12 weeks and 20.81 at 30 weeks (Table 5-3). 
 
To correct this, and obtain a more accurate representation of the number of centrally 
nucleated muscle fibres, it was decided to count the fibres across the entire muscle section, 
as recommended by the SOP on the Treat NMD website (www.treat-nmd.eu)  for evaluating 
pathology in the mdx and Dy/Dy2J mouse models (Dubach-Powell, 2008, Rüegg and Meinen, 
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2011).  This method has also been used in publications to evaluate the percentage of 
centrally nucleated muscle fibres in mouse models of muscular dystrophy (Carmignac et al., 
2011), and was a more appropriate method for the FKRPMD mouse, as all the focal patches 
of degenerating and regenerating fibres were included in the assessment.   
 
Counting using this Entire Muscle Section method showed the same pattern of muscle 
involvement and age involvement as the Random Areas method, with the gastrocnemius 
having the highest percentage of centrally nucleated muscle fibres, above the diaphragm 
and the soleus, which still had the lowest and all three muscle having an increased 
percentage of centrally nucleated muscle fibres at 30 weeks, relative to 12 weeks (Table 5-
3).  However, counting using this Entire Muscle Section gave different values to the Random 
Areas method, with an increased percentage of centrally nucleated muscle fibres in the 
gastrocnemius (32.41%) and diaphragm (48.94%) at 12 weeks of age, but a slightly 
decreased value in the soleus (5.59%).  Additionally, the Entire Muscle Section method 
reduced the standard deviation values, particularly in the gastrocnemius where the SD 
values for centrally nucleated muscle fibres at 12 and 30 weeks were reduced to 3.63 and 
1.381 (Table 5-3). 
 
This suggests the method of counting centrally nucleated muscle fibres across the entire 
muscle section is more appropriate for the FKRPMD mouse, as it incorporated all patches of 
focal degeneration so a provided a more accurate value for the percentage of centrally 
nucleated muscle fibres and reduced the variation in values between different mice (SD).   
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To assess whether age, muscle and genotype were factors affecting the percentage of 
centralised nuclei, a Generalised Estimating Equations model was used.  This result indicated 
in these mice age, genotype and muscle were significant factors affecting the percentage of 
centralised nuclei (Figure 5-11). 
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Muscle Random Areas - Proportion CN 
fibre (% ± SD) 
Entire Muscle Section - Proportion CN 
muscle fibres (% ± SD) 
 12 weeks 30 weeks 12 weeks 30 weeks 
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TABLE 5-3 FKRPMD CENTRAL NUCLEATION 
Transverse 10µm cryosections of 12 and 30 week wildtype and FKRPMD diaphragm, 
gastrocnemius and soleus stained with haematoxylin and eosin were viewed under light 
microscopy using a DM4000B upright microscope (Leica Microsystems) and images were 
digitally captured with a DC500 colour camera (Leica Microsystems) using the Leica 
Application Suite software (Leica Microsystems).  For the Random Areas counts, images 
were taken of random field of view across sections of that muscle.  For the Entire Muscle 
Section counts, images were captured of the most representative section at the mid-belly 
region of the muscle and stitched together into a composite image using Photoshop CS4 or 
CS5 (Adobe). 
 
The muscle fibres with central and peripheral nuclei were counted using Photoshop CS4 or 
CS5 (Adobe).  For the Random Areas counts, at least 500 muscle fibres for the soleus and 
1000 for the diaphragm and gastrocnemius were counted per individual.  The counts on the 
Entire Muscle Section numbering approximately 500 muscle fibres for the soleus, 1500 for 
the diaphragm and 2000 for the gastrocnemius. Data was compiled and the percentage of 
centrally nucleated muscle fibres was calculated using Excel (Microsoft Office, 2010). 
 
The values shown in the table are mean values, ± standard deviation, calculated using 
GraphPad Prism version 5.0 for Windows.  N=3 for all muscles in both genotypes at both 
ages.  
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FIGURE 5-11 CENTRAL NUCLEATION COUNTS OF FKRPMD MUSCLES 
The graphs shown in A-D have been included to visualise the cental nucleation data from 
FKRPMD and wildtype muscles presented in Table 5-3.  The results from the Random Areas 
counts are shown in A-B and the results from the Entire Muscle Section counts are shown in 
C-D, with data presented separately for the two mouse ages, 12 weeks (A, C) and 30 weeks 
(B, D). E shows the results of the Generalised Estimating Equations Statistical test performed 
on the wildtype and FKRPMD central nucleation counts as a multiple line graph.  This model 
shows age, muscle and genotype are significant interacting factors on the percentage of 
centrally nucleated muscle fibres. 
 
Transverse 10µm cryosections of 12 and 30 week wildtype (n=3 for all muscles at both ages) 
and FKRPMD (n=3 for all muscles at both ages)  diaphragm, gastrocnemius and soleus stained 
with haematoxylin and eosin were viewed under light microscopy using a DM4000B upright 
microscope (Leica Microsystems).  Images were digitally captured with a DC500 colour 
camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems).  For the Random Areas counts, images were taken of random field of view 
across sections of that muscle and at least 500 muscle fibres for the soleus and 1000 for the 
diaphragm and gastrocnemius were counted per individual mouse.  For Entire Muscle 
Section counts, images were captured of the most representative section at the mid-belly 
region of the muscle and stitched together into a composite using Photoshop CS4 or CS5 
(Adobe), numbering approximately 500 muscle fibres for the soleus, 1500 for the diaphragm 
and 2000 for the gastrocnemius.  Muscle fibres with central and peripheral nuclei were then 
counted using Photoshop CS4 or CS5 (Adobe).  Data was compiled and the percentage of 
Page 346 of 551 
 
centrally nucleated muscle fibres calculated using Excel (Microsoft Office, 2010).  Graphs 
were prepared using GraphPad Prism version 5.0 for Windows and show the mean 
percentage of centrally nucleated muscle fibres ± SEM for Random Areas (A-B) and Entire 
Muscle Sections (C-D). 
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5.3.10 CALCIUM DEPOSITS WERE PRESENT IN FKRPMD MICE 
Elevated intracellular calcium levels have been reported in patients with muscular dystrophy 
(DMD) and are thought to reflect an abnormality in calcium homeostasis (Bodensteiner and 
Engel, 1978, Jackson et al., 1985, Culligan and Ohlendieck, 2002).  This abnormal calcium 
homeostasis is thought to render cells more susceptible to necrosis and although there are 
conflicting results on calcium handling, it is thought that intracellular calcium concentration 
is increased in dystrophic muscle (Culligan and Ohlendieck, 2002).  Intracellular deposits 
have been visualised using immunohistochemical stains in the mdx mouse model and also 
patients with DMD (Bodensteiner and Engel, 1978, Cornelio and Dones, 1984, Glesby et al., 
1988).   
 
To evaluate whether abnormal calcium handling is a feature of the pathological process in 
the FKRPMD mouse, the incidence of intracellular muscle fibre calcium deposits in the 
FKRPMD mouse was evaluated by staining cryosections of the diaphragm, gastroncmeius and 
soleus at 12 and 30 weeks of age with Alizarin Red, a compound which binds to calcium 
deposits, forming a red precipitate (Figure 5-12).  These three muscles were chosen to 
facilitate a comparison between the diaphragm, a muscle heavily used in the laboratory 
mouse, the gastrocnemius, a hindlimb muscle and the soleus, a muscle which (aside from an 
increased incidence of centrally nucleated muscle fibres) did not display marked dystrophyic 
histopathology.  The triceps was not included here as it was felt evaluation of these three 
muscles was sufficient to suggest whether extracellular calcium deposits accumulate in 
FKRPMD mouse muscles. 
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The diaphragm, gastrocnemius and soleus from three individual wildtype and three 
individual FKRPMD mice at both 12 and 30 weeks of age were stained with Alizarin Red, with 
at least 3 sections per individual mouse muscle at each age evaluated.  This stain showed 
that calcium deposits were present in the FKRPMD diaphragm and gastrocnemius at both 12 
and 30 weeks of age (Figure 5-12).  Additionally, this evaluation of these sections (at least 3 
sections per individual muscle, with a total of three mice from each genotype at both ages) 
suggested that deposits were larger at 30 weeks, relative to 12 weeks as shown in Figure 5-
12, panels B and D (12 and 30 week gastrocnemius respectively) and F to H (12 and 30 week 
diaphragm respectively).  Finally, evaluation of these sections suggested that calcium 
deposits were not more numerous at 30 weeks, relative to 12 weeks, although the number 
of deposits should be quantified in the future to conclusively demonstrate this (Figure 5-12). 
 
This identification of intracellular calcium deposits in the FKRPMD diaphragm and 
gastrocnemius suggests that abrnomal calcium handling is a feature of the pathological 
process.  In the FKRPMD mouse, like LGMD2I patients, the proximal muscles of the limb 
girdle, such as the triceps are more severely affected than distal muscles of the lower limb.  
Therefore, in the future, calcium deposits should be investigated in the triceps, to see if an 
increase in the number or size of calcium deposits is associated with this increased severity. 
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FIGURE 5-12 CALCIUM DEPOSITS IN FKRPMD MUSCLE 
At both 12 (A-B, E-F, I-J) and 30 (C-D, G-H, K-L) weeks of age, calcium deposits (indicated by 
an arrow) were present in the FKRPMD gastrocnemius (B, D) and diaphragm (F, H).  
Evaluation of these sections (at least 3 sections per individual muscle, with a total of three 
mice from each genotype at both ages) suggested that calcium deposits were larger in size 
at 30 weeks of age (D and H), relative to 12 weeks of age (B and F), although they did not 
appear to be more numerous.  No deposits were identified in muscles from wildtype mice 
(A, C, E, G, I) or the FKRPMD soleus (J, K). 
 
Transverse 10µm cryosections of 12 week (A-B, E-F, I-J) and 30 week (C-D, G-H, K-L) wildtype 
(A, C, E, G, I and K) and FKRPMD (B, D, F, H, J and L) mouse gastrocnemius(n=3 for both 
genotypes at both ages) (A-D), diaphragm (n=3 for both genotypes at both ages) (E-H) and 
soleus (n=3 for both genotypes at both ages) (I-L) were stained with Alizarin Red.  At least 3 
sections from each individual mouse muscle were studied under light microscopy using a 
DM4000B upright microscope (Leica Microsystems) for the presence of red precipitates of 
Alizarin Red, which would indicate calcium deposits, as denoted by the arrows.  Alizarin Red 
deposits were observed in each FKRPMD gastrocnemius and diaphragm muscle as described 
above, although the deposits were not identified in every section of each muscle.  
Representative images of the sections containing Alizarin Red deposits were digitally 
captured with a DC500 colour camera (Leica Microsystems) using the Leica Application Suite 
software (Leica Microsystems) and compiled using Photoshop CS4 or CS5 (Adobe).  Scale bar 
denotes 100µm in A-H and K-L and 200 µm in I-J.   
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5.3.11 INTEGRIN Β1 LOCALISATION IN FKRPMD MICE 
Every nucleated cell type in the body possess an integrin signature (Barczyk et al., 2010).  In 
mouse, the migrating muscle precursor cells express the following integrin subunits -  α4, 
α5, α6, α , αV and β1A expressed, but during the late embryonic and early postnatal period 
there is a change in the integrin β1 subunit expressed, with the β1A isoform, which is 
otherwise ubiquitously expressed, replaced w/ith β1D in skeletal and cardiac muscle (Belkin 
et al., 1997, de Melker and Sonnenberg, 1999, Mayer, 2003).  This is thought to be because 
the β1D isoform, whilst not required for myoblast proliferation and migration, is required for 
the fusion of myoblasts into myotubes (Quach et al., 2009) and additionally provides a 
stronger connection between the extracellular matrix and the cytoskeleton than integrin 
β1A (Belkin et al., 1997).  Thus, the major integrin receptor normally expressed at the 
extrajunctional muscle fibre sarcolemma is α β1D integrin (Mayer, 2003). 
 
In a second model of Fkrp deficiency, the FKRP-Neo-P448L mouse, expression of integrin β1 
was reported at the sarcolemma of muscle fibres, which was not identified in wildtype mice 
(Chan et al., 2010).  As localisation was not reported at the sarcolemma of adult wildtype 
muscle fibres, it was thought that expression of integrin β1A was being detected at the 
sarcolemma of these mutant muscle fibres.  Expression of integrin β1A was identified at the 
basement membrane of blood vessels in cryosections from both wildtype and FKRPMD mice 
(Figure 5-13).   In wildtype mice, immunolabelling with this antibody was not localised to the 
sarcolemma (Figure 5-13), confirming the antibody does not identify integrin β1D (Figure 5-
13).  Additionally, immunolabelling with this antibody was identified at the sarcolemma of 
some muscle fibres in the FKRPMD mouse (Figure 5-13).  
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FIGURE 5-13 IMMUNOLABELLING OF β1 INTEGRIN AND β-DYSTROGLYCAN IN 
WILDTYPE AND FKRPMD MICE 
A and C show greyscale images of integrin β1 immunolabelling alone, while B and D shows a 
colour composite with integrin β1 immunolabelling in red and the nuclei labelled with 
Hoechst 3342 in blue.  The arrows in A-D indicate integrin β1 immunolabelling at the 
sarcolemma of FKRPMD mice only, whilst BV denotes blood vessels labelled with integrin β1. 
 
E, G, I and K show greyscale images of β-dystroglycan immunolabelling alone while F, H, J 
and L show colour composites with β-dystroglycan in red and the nuclei labelled with 
Hoechst 33342 in blue.  This shows β-dystroglycan is localised to the sarcolemma of muscle 
fibres in both wildtype and FKRPMD mice. 
 
Transverse 10µm cryosections of gastrocnemius from 30 week old wild type (n=3) (A-B, E-F 
and I-J) and FKRPMD mice (n=3) (C-D, G-H and K-L) gastrocnemius, (A-H) and soleus (I-L) were 
immunolabelled with antibodies against integrin β1 (A-D) and β-dystroglycan (E-L).  At least 
two sections for each individual mouse muscle were viewed under epifluorescence using a 
DM4000B upright microscope (Leica Microsystems).  Integrin β1 immunolabelling was 
identified at the muscle fibre sarcolemma in each FKRPMD section evaluated, although the 
degree of immunolabelling varied between individual sections and mice.  Additionally, β-
dystroglycan was identified at the muscle fibre sarcolemma of all muscle fibres in all 
sections evaluated in mice of both genotype.  Representative images of the 
immunolabelling were captured with an mRM monochrome camera (Zeiss, U.K.) using the 
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Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  Scale bar represents 50µm. 
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5.3.12 α-DYSTROGLYCAN GLYCOSYLATION WAS ALTERED IN FKRPMD MICE 
β-dystroglycan was identified at the muscle fibre sarcolemma of FKRPMD mice, at an 
intensity similar to control mice, suggesting expression of dystroglycan was similar between 
FKRPMD and wildtype mice (Figure 5-13).  IIH6 is an antibody that binds to a glycosylated 
epitope of α-dystroglycan, the same epitope to which laminin binds (Ervasti and Campbell, 
1991, Ervasti and Campbell, 1993)   
 
Immunolabelling of several muscles (gastrocnemius, diaphragm and soleus) from the 
FKRPMD mice at 12 and 30 weeks of age shows a reduction in IIH6 immunoreactivity, relative 
to wildtype mice (Figure 5-14).  However, based on previous data presented for FKRPKD 
muscles in Chapter 3, an absence of IIH6 immunolabelling, rather than a reduction was 
expected.  However, the group that originally generated the IIH6 antibody suggested that 
IIH6 overestimates the level of glycosylated α-dystroglycan, in part associated with the 
antibody being a mouse monoclonal (personal communication with Dr Kevin Campbell, 
University of Iowa, U.S.A.).  The stain shown in Figure 5-14 was performed without a 
blocking agent, suggesting the immunolabelling observed in FKRPMD muscle in Figure 5-14 is 
background staining and in fact IIH6 immunolabelling is absent in FKRPMD muscle, suggesting 
altered, reduced glycosylation of α-dystroglycan in these muscles. 
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FIGURE 5-14 IIH6 IMMUNOLABELLING OF FKRPMD MUSCLE 
IIH6 immunolabelling intensity is reduced in FKRPMD mice, relative to wildtype at both 12 
(M-T) and 30 weeks (A-L) of age and in different muscles, the diaphragm (A-D), 
gastrocnemius (E-H and M-T) and soleus (I-L).  This suggests that α-dystroglycan 
glycosylation is altered, reduced in FKRPMD mouse muscle. 
 
Immunolabelling of transverse 10µm cryosections from 12 week (M-T) and 30 week (A-L) 
diaphragm (A-D), gastrocnemius (E-H and M-T) and soleus (I-L) from FKRPMD (C-D, G-H, K-L, 
O-P and S-T) and age-matched wildtype mice (A-B, E-F, I-J, M-N and Q-R) with the IIH6 
antibody.  A, C, E, G, I, K, M, O, Q and S show immunolabelling with IIH6 alone while B, D, F, 
H, J, L, N, P, R and T show the colour composite with IIH6 (red) and Hoechst 33342 to 
visualise the nuclei (blue).  At least 2 sections from each individual mouse muscle 
immunolabelled with the IIH6 antibody were viewed under epifluorescence using a 
DM4000B upright microscope (Leica Microsystems).  The reduction in IIH6 immunolabelling 
described here was observed in all FKRPMD muscle sections evaluated.  Representative 
images were digitally captured with an mRM monochrome camera (Zeiss, U.K.) using the 
Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 
(Adobe).  .Where comparisons of immunolabelling intensity are made, images have been 
captured at the same exposure and have had equal scalings and manipulations applied.  
Scale bar = 100µm in M-P and 50 µm in A-L and Q-T.   
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5.3.13 BASEMENT MEMBRANE DEPOSITION IN FKRPMD MICE 
One of the main roles of DAPC in muscle is to anchor the basement membrane of the 
extracellular matrix to the intracellular actin cytoskeleton to prevent damage during muscle 
contraction.  Additionally, it is thought dystroglycan is involved in the organisation of 
basement membrane ligands into the mesh-like network characteristics of the mature 
basement membrane.  Given the altered glycosylation of α-dystroglycan in FKRPMD mice 
(Figure 5-14), basement membrane deposition was evaluated in these mutant mice by 
immunolabelling. 
 
Initially, laminin deposition was evaluated by immunolabelling of FKRPMD mouse muscle 
with the generic pan-laminin antibody.  This showed laminin localisation was unchanged in 
FKPRMD muscle, with immunoreactivity observed at the sarcolemma of all muscle fibres and 
the basement membrane of small blood capillaries (  
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Figure 5-15).  However, a reduction in immunolabelling intensity was seen in older mice (30 
weeks of age) but not younger mice (12 weeks of age), where the intensity of pan-laminin 
immunolabelling was comparable to wildtype mice (  
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FIGURE 5-15 PAN-LAMININ IMMUNOLABELLING OF FKRPMD MUSCLE 
Pan-laminin immunolabelling was identified at the basement membrane surrounding 
muscle fibres in wildtype (A-B, E-F and I-J) and FKRPMD (C-D, G-H, K-L) gastrocnemius (A-H) 
and diaphragm (I-L) at both ages evaluated here, 12 weeks (A-D) and 30 weeks (E-L).  A 
reduction in immunolabelling intensity was seen in FKRPMD mice at 30 weeks of age, in 
comparison to wildtype mice, but this was not seen in mice at 12 weeks of age where 
immunolabelling intensity was comparable to wildtype mice. 
 
Transverse 10µm cryosections of gastrocnemius (A-H) and diaphragm (I-L) from 12 (A-D) and 
30 week (E-H, I-L) wildtype (n=3 for all muscles at both ages) (A-B, E-F, I-J) and FKRPMD mice 
(n=3 for all muscles at both ages) (C-D, G-H) were immunolabelled with an antibody that 
recognised any laminin trimer containing the laminin β1 or γ1 chain.  A, C, E, G, I and K show 
monochrome images of the pan-laminin immunolabelling alone, while B, D, F, H, I and K 
show colour composites, with the laminin in red and the nuclei, visualised by Hoechst in 
blue.  At least 2 sections of each individual mouse muscle were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems), with pan-
laminin immunolabelling was observed at the basement membrane of each muscle fibre in 
all wildtype and FKPRMD muscle sections evaluated.  The reduction in pan-laminin 
immunolabelling in FKRPMD mice at 30 weeks of age was consistent across all mouse muscle 
sections evaluated.  Representative images were captured with a mRM monochrome 
camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures 
using Photoshop CS4 or CS5 (Adobe). Where comparisons are made regarding 
immunolabelling intensity, images were captured at the same exposure and have had equal 
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scalings and manipulations applied..    The scale bar represents 50µm in A-D and I-L and 100 
µm in E-H. 
 
  
Page 364 of 551 
 
The localisation of laminin 211, the main laminin trimer found in the extrasynaptic 
basement membrane is reduced in dystroglycanopathy patients, including those with 
LGMD2I,  although this is a feature which can be variable between individual patients 
(Poppe et al., 2003).  In wildtype mice, laminin α2 was identified with 
immunohistochemistry at the basement membranes surrounding muscle fibres; this 
localisation was consistent across all muscles evaluated (gastrocnemius, diaphragm and 
soleus) (Figure 5-16).  In FKRPMD mice, laminin α2 was much reduced in intensity, indicating 
that laminin α2 deposition is perturbed in these mutant mice (Figure 5-16).  This decreased 
immunolabelling was consistent across all the muscles evaluated (gastrocnemius, 
diaphragm and soleus) (Figure 5-16). 
 
In muscle sections from wildtype mice, laminin α4 is restricted to the neuromuscular 
junctions, the capillary basement membrane and the endoneurium of intramuscular nerves 
(Figure 5-17).  However, at both 12 and 30 weeks in the FKRPMD diaphragm and rectus 
femoris, laminin α4 was additionally localised to the extrasynaptic basal lamina of some 
muscle fibres (Figure 5-17).  The rectus femoris was evaluated here because, like the triceps, 
the rectus femoris is a limb girdle muscle, just of the lower limb rather than the upper limb, 
and so would provide a contrast between a heavily used muscle in the laboratory mouse 
(the diaphragm) and a muscle severely affected in LGMD2I patients.   
 
Addtionally, this evaluation of at least 2 individual sections from three FKRPMD diaphragms 
at 12 weeks of age demonstrated that fibres with laminin α4 immunolabelling at the 
basement membrane were mainly identified clustered together in groups across the 
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diaphragm (Figure 5-17).  These fibres also appeared to be smalled in diameter then 
neighbouring fibres without laminin α4 immunolabelling, suggesting that laminin α4 
immunolabelling was identified at the basement membrane of small diameter regerentating 
muscle fibres at this age (Figure 5-17).  Contrastingly, in older mice (30 weeks of age), 
evaluation of at least 2 sections from three individual mce suggested laminin α4 
immunolabelling was identified at the basement membrane of muscle fibres with varying 
diameters (Figure 5-17).  Finally, this evaluation of all the sections suggested there were ore 
muscle fibres with laminin α4 immunolabelling at the basement membrane in muscles from 
30 week FKRPMD when compared to 12 weeks (Figure 5-17).  However, quantification of the 
number of fibres with laminin α4 localisation to their basement membrane and their fibre 
diameters would be required to confirm this (Figure 5-17).   
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FIGURE 5-16 LAMININ α2 IMMUNOLABELLING OF FKRPMD
 MUSCLE 
Laminin α2 (red) immunolabelling was identified at the basement membrane of muscle 
fibres in the wildtype diaphragm (A), gastrocnemius (C) and soleus (E).  The intensity of 
immunolabelling is much reduced in the FKRPMD diaphragm (B), gastrocnemius (D) and 
soleus (F) relative to wildtype, suggesting reduced deposition of laminin α2 at the basement 
membrane of muscle fibres. 
 
Transverse 10µm cryosections from 30 week FKRPMD (n=3 for each muscle) (B, D, F) and age-
matched controls (n=3 for all three muscle) (A, C, E) with the 4H8 antibody against laminin 
α2 (red) and Hoechst 33342 to visualise the nuclei (blue)   At least 3 sections from each 
invidual muscle were viewed under epifluorescence using a DM4000B upright microscope 
(Leica Microsystems).  Laminin α2 immunolabelling was observed at the basement 
membrane of all muscle fibres in wildtype and FKRPMD muscle, although the 
immunolabelling intensity was much reduced (relative to wildtype) in all FKRPMD muscles 
evaluated.  Representative images were captured with a mRM monochrome camera (Zeiss, 
U.K.) using the Axiovision software (Zeiss) provided and compiled into figures using 
Photoshop CS4 or CS5 (Adobe).  Where comparisons of immunolabelling intensity have been 
made, images from each muscle were captured at the same exposure and have had equal 
scalings and/or manipulations applied..  Scale bar = 50µm . 
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FIGURE 5-17 LAMININ α4 LOCALISATION IN FKRPMD MICE 
In wildtype diaphragm (A-B, E-F) and rectus femoris (I-J) laminin α4 was localised to the 
basement membrane of blood vessels (BV) and the nerve endometrium (*) in the muscle 
sections.  Additionally, in FKRPMD muscles (C-D, G-H, and K-L) laminin α4 immunolabelling 
was identified at the muscle fibre basement membrane.  It appeared at 12 weeks of age (C-
D), that laminin α4 was localised to the basement membrane of small diameter muscle 
fibres which were clustered together in groups, while in older mice (30 weeks of age) in 
both the diaphragm (G-H) and rectus femoris (K-L) laminin α4 was identified at the 
sarcolemma of muscle fibres with varying diameters.   
 
Transverse 10µm cryosections of diaphragm (A-H) and rectus femoris (I-L) from 12 (A-D) and 
30 (E-H, I-L) week old wildtype (n=3 for both muscles at both ages) (A-B, E-F, I-J) and FKRPMD 
(n=3 for both muscles at both ages) (C-D, G-H, K-L) mice were immunolabelled with an 
antibody that recognised any laminin trimer containing laminin α4.  A, C, E and G show 
monochrome images of the laminin α4 immunolabelling alone, while B, D, F and H show 
colour composites, with the laminin in red and the nuclei, visualised by, Hoechst in blue.  At 
least 3 sections per individual mouse muscle were viewed under epifluorescence using a 
DM4000B upright microscope (Leica Microsystems).  At 12 weeks of age, laminin α4 positive 
fibres were identified in each section of diaphragm evaluated and evaluation of these fibres 
in each section suggested they were smaller than surrounding muscle fibres.  At 30 weeks of 
age, laminin α4 immunolabelling was identified at the basement membrane of muscle fibres 
with varying diameters across both the diaphragm and the gastrocnemius.  Additionally,a 
qualitiative evaluation of the diaphragm in these sections at 12 (combined total of at least 9 
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sections) and 30 weeks (combined total of at least 9 sections) suggested that more fibres 
with laminin α4 immunolabelling were present at 30 weeks of age.  Representative images 
of areas with laminin α4 immunolabelling were captured with a mRM monochrome camera 
(Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures using 
Photoshop CS4 or CS5 (Adobe).  The scale bar represents 50µm.  Images A-D, E-F and I-L 
were all captured at the same exposure and have had equal scalings and/or manipulations 
applied. 
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5.4 DISCUSSION 
The aim of this section was to generate a mouse model for LGMD2I by crossing the FKRPKD 
mouse colony with the Sox1Cre mouse, which expresses Cre recombinase under the Sox1 
promoter.  This restoration of Fkrp expression in the developing neural tube prevented the 
cortical abnormalities seen in the FKRPKD mouse and generated a mouse which develops a 
progressive dystrophic pathology, due to the knockdown of Fkrp expression persisting in the 
muscle.  The intention is for this mouse to be a pre-clinical model for LGMD2I, so the first 
part of this discussion will focus on aspects of the FKRPMD mouse phenotype, as to be a good 
pre-clinical model, there needs to be a) some commonalities with the documented patient 
phenotype and b) outcome measures that are easily assessed, so the effectiveness of 
potential therapeutics can be easily evaluated.  In the second part of the discussion, this 
model will briefly be compared with other models for the dystroglycanopathies, to place 
FKRPMD mice in the context of the field.  Finally, the functional implications of Fkrp 
deficiency for postnatal muscle development will be discussed, using the FKRPMD mouse in 
conjunction with an evaluation of the published data on the other mouse model of Fkrp 
deficiency, the FKRP-Neo-P448L mouse. 
 
5.4.1 THE FKRPMD MOUSE IS A GOOD PRE-CLINICAL MODEL FOR LGMD2I  
The most important commonality between FKRPMD mice and the human LGMD2I patients 
(Muntoni et al., 2004) is the disease pathogenesis, with the condition in both FKRPMD mice 
and humans associated with a reduction in IIH6 immunolabelling, suggesting altered α-
dystroglycan glycosylation.  This results in perturbed basement membrane deposition, with 
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laminin α2 particularly affected, although unlike in the FKRPMD mouse, in patients this 
reduced deposition is not always detectable with immunolabelling (Brown et al., 2004). 
 
FKRPMD mice have a characteristic pattern of muscle involvement, with the triceps (a 
proximal muscle of the limb girdle) more severely affect than the soleus, a postural muscle.  
This is reflected in the both pattern of muscle fibre loss and dystrophic histopathology.  This 
phenotype was associated with a reduction in IIH6 immunolabelling and changes in the 
composition of the basement membrane, including a reduction in laminin α2 and an 
increase in laminin α4.  This suggests the FKRPMD mouse is similar to the second human 
patient phenotype outlined at the beginning of this chapter (Poppe et al., 2003, Vainzof and 
Bushby, 2010).   
 
However, there are components of patient phenotype which are not replicated in the 
FKRPMD mouse, including pseudohypertrophy of the calves and distal leg muscles (de Paula 
et al., 2003, Mercuri et al., 2003, Poppe et al., 2003, Poppe et al., 2004, Walter et al., 2004, 
Schwartz et al., 2005, Sveen et al., 2006, Vainzof and Bushby, 2010) and muscle weakness 
(Sveen et al., 2006).  Additionally patients with LGMD2I have respiratory involvements, such 
as a significant drop in forced vital capacity (Mercuri et al., 2003, Poppe et al., 2004), 
suggesting the diaphragm is severely affected in these patients.  Again, this was not 
matched in the FKRPMD mice, where the histopathology in the diaphragm is not as severe as 
in other muscles such as the triceps, or the gastrocnemius.   
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In human patients with LGMD2I, the disease is caused by point mutations and to date, 
approximately 150 disease causing mutations have been identified in FKRP (Brown and 
Winder, 2012).  However, even though a number of disease causing mutations have been 
identified, some mutations are more common than others and the most prevalent disease 
causing mutation in Northern Europe is the Leu276Ile mutation (Sveen et al., 2006, 
Stensland et al., 2011).  Patients can be either homozygotes (both alleles of Fkrp carry the 
Leu276Ile mutation), or compound heterozygotes (one allele of Fkrp carries the Leu276Ile 
mutation and the other allele carries a different mutation in Fkrp) (Stensland et al., 2011).  
Interestingly, there seems to be a genotype-phenotype correlation, with compound 
heterozygotes having an earlier age of onset and a more severe phenotype than Leu276Ile 
homozygotes (Poppe et al., 2003, Sveen et al., 2006, Stensland et al., 2011). 
 
In FKRPMD mice, the phenotype is caused by a different mechanism – a reduction in Fkrp 
expression of approximately 80% that causes the muscular dystrophy phenotype.  However, 
there is still some variation between individual mice – why is this the case if all the FKRPMD 
mice have the same genetic modification?  The transgenic design of the FKRPMD mouse has 
combined the genetic background of 3 different inbred laboratory mouse strains, C57Bl6, 
129 and CBA/Ca (Yagi et al., 1993, Takashima et al., 2007, Ackroyd et al., 2009), resulting in a 
mixed background, making this the most probable cause of the variation between individual 
mice. 
 
To summarise, although there are some differences between the mouse and the 
documented phenotype of LGMD2I, there are important aspects that model the human 
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condition including reduced IIH6 immunolabelling, dystrophic muscle pathology, the pattern 
of differential muscle involvement and basement membrane defects.   
 
5.4.2 HOW DOES FKRPMD COMPARE TO OTHER DYSTROGLYCANOPATHY MODELS? 
All dystroglycanopathies are thought to share the common pathogenic mechanism of 
basement membrane defects associated with altered, reduced α-dystroglycan glycosylation.  
Multiple transgenic mouse models for this spectrum of disorders have been generated, with 
perturbed expression of one of the genes identified in dystroglycanopathy patients.  Thus, it 
is important to compare the phenotype of the FKRPMD mouse with the other mouse models 
for this group of conditions.  However, as a number of the genes have only been recently 
associated with the dystroglycanopathies, here only mouse models with perturbed 
expression of Pomt1, Pomt2, Pomgnt1, Fukutin, Fkrp, Large or Dystroglycan will be 
evaluated. 
 
The table included in Chapter 9 lists a number of characteristics of the FKRPMD mouse 
phenotype, in comparison to the reported phenotype with the dystroglycanopathy mouse 
models – POMGnT1 mutant, POMGnT1-/-, Pomgnt1-KO, Large
myd, Largeenr, Large
vls, Fukutin 
chimera, Fukutin Hp-, postnatal Fukutin null, Myf5-Cre Fktn-KO, MCK-Cre Fktn-KO and 
Dystroglycan KO; some of which will now be discussed in more detail.  However, although 
there are some commonalities between the models, it must be recognised that whilst 
POMT1, POMT2, POMGnT1 and LARGE have been associated with the glycosylation of α-
dystroglycan, the involvement of Fkrp and Fukutin in the glycosylation process is still 
unknown.  There is some variability between the models, which is interesting and suggests 
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each of these genes may have slightly different roles, both spatially and temporally, in the 
glycosylation of α-dystroglycan. 
 
Some of the dystroglycanopathy mouse models have been reported to have a Mendelian 
inheritance, (POMGnT1 mutant, Largemyd, Large
vls) (Lane et al., 1976, Lee et al., 2005, 
Miyagoe-Suzuki et al., 2009), while other models (Largeenr, Myf5-Cre Fktn-KO, MCK-Cre Fktn-
KO) (Kelly et al., 1994, Levedakou et al., 2005, Beedle et al., 2012) have been described as 
having a have sub-Mendelian inheritance, which they attribute to early loss of the mutant 
phenotype.  Additionally, mice models with complete knockout or inactivation of Fukutin 
(Takeda et al., 2003, Kurahashi et al., 2005), Pomt1 (Willer et al., 2004), Pomt2 (Hu et al., 
2011a) and Fkrp (Chan et al., 2010) are embryonic lethal, displaying 100% lethality.  As the 
observed incidence of FKRPMD at 3 weeks was similar to the expected incidence, it is thought 
there is very little prenatal or early loss of FKRPMD phenotype, although further work would 
be required to confirm this as it has not itself been evaluated here.  This variability between 
the models further emphasises the spectrum of phenotypes associated with altered 
glycosylation of α-dystroglycan and that the FKRPMD mouse at the mild end of the spectrum. 
 
A number of dystroglycanopathy mutants have been reported as smaller in size – POMGnT1 
mutant, POMGnT1-/-, Largemyd, Largeenr, Fukutin chimera and Myf5-Cre Fktn-KO, (Lane et al., 
1976, Kelly et al., 1994, Takeda et al., 2003, Liu et al., 2006, Miyagoe-Suzuki et al., 2009, 
Beedle et al., 2012), in a similar way to some of the FKRPMD mice which were observed as 
smaller at the time of weaning.  Additionally, the FKRPKD mice have been reported as being 
approximately a third smaller than littermates (Ackroyd et al., 2009), suggesting this could 
Page 376 of 551 
 
be attributable to actions of α-dystroglycan.   Interestingly, these phenotypes are in marked 
contrast to the muscle specific dystroglycan knockout, which is visibly hypertrophic (Cohn et 
al., 2002). However, this model is slightly different – dystroglycan was inactivated under the 
muscle CK promoter, so dystroglycan expression would be maintained in the satellite cells 
(Cohn et al., 2002)   
 
The earliest reported pathological age of onset is 2 weeks in the Largemyd mice (Grewal et 
al., 2001, Lane et al., 1976), although very early signs of disease onset can be identified in 
the model prior to this age (personal communication from Jane Hewitt (University of 
Nottingham, U.K)).  Pathological onset was found to be slightly late Myf-Cre Fktn-KO (Beedle 
et al., 2012) at 4weeks, the muscle specific dystroglycan knockout (Cohn et al., 2002) at 4-6 
weeks, the FKRPMD mouse, Large
vls (Lee et al., 2005), Largeenr (Kelly et al., 1994) (6 weeks) 
and finally the POMGnT1 mutant (Liu et al., 2006) and MCK-Cre Fktn-KO (Beedle et al., 
2012) at 8 weeks of age.  However, there are several interpretations to “age of onset”, and 
it is not always made clear in these publications what they are classifying as the age of 
onset, for example as the FKRPMD mouse does not have an overt physical phenotype, the 
onset of dystrophic histopathology was used here.   
 
Although an abnormal hindlimb extensor reflex was not observed in the FKRPMD mouse, it 
has been reported in some of the other models including POMGnT1 mutant, Largemyd, 
Largeenr and Fukutin chimera (Lane et al., 1976, Kelly et al., 1994, Takeda et al., 2003, Liu et 
al., 2006), suggesting the FKRPMD mouse phenotype is not as a severe.  However, this is a 
crude measure of neuromuscular function and this reflex can be perturbed by both motor 
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and neurological impairment, so a more accurate way of evaluating neuromuscular function 
is by measuring forelimb grip strength (Brooks and Dunnett, 2009).  The Fukutin chimera, 
Largevls, Large
enr, postnatal Fukutin null, Myf5-Cre Fktn-KO (Kelly et al., 1994, Takeda et al., 
2003, Lee et al., 2005, Levedakou et al., 2005, Beedle et al., 2012) have reduced forelimb 
grip strength.  FKRPMD mice do not have a significant reduction in forelimb grip strength, 
further emphasising the mild nature of the FKRPMD phenotype in comparison to the other 
models.  No other gait abnormalities have been observed in the FKRPMD mouse, although 
they have been observed in other models including Largemyd, Largeenr and Fukutin chimera, 
(Lane et al., 1976, Kelly et al., 1994, Holzfeind et al., 2002, Takeda et al., 2003, Levedakou et 
al., 2005).  An intact hindlimb extension reflex, in combination with the preservation of 
forelimb grip strength and an absence of gait abnormalities suggest overt muscle weakness 
is not part of the FKRPMD phenotype.  This is similar to the conditional Fktn null mouse, 
where inactivation of Fukutin at 6 weeks of age also led to no obvious physical phenotype, 
although they had elevated serum CK from 14 weeks of age and displayed histopathological 
evidence of muscular dystrophy at 20 weeks of age (Beedle et al., 2012). 
 
All dystroglycanopathy models with the exception of the Fukutin Hp- and POMGnT1-/- mouse 
have centralised nuclei and a variation in muscle fibre size (Lane et al., 1976, Kelly et al., 
1994, Grewal et al., 2001, Cohn et al., 2002, Holzfeind et al., 2002, Takeda et al., 2003, 
Browning et al., 2005, Lee et al., 2005, Levedakou et al., 2005, Levedakou and Popko, 2006, 
Liu et al., 2006, Herbst et al., 2009, Kanagawa et al., 2009, Miyagoe-Suzuki et al., 2009, 
Kabaeva et al., 2011, Beedle et al., 2012, MMRRC, 2012), indicating muscle fibre 
degeneration and regeneration.  Histological evidence of necrosis and inflammation, two 
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aspects of dystrophic pathology seen in the FKRPMD mouse has been reported in some 
dystroglycanopathy models.  However, fat infiltration and fibrosis were not observed in the 
FKRPMD mouse, but they have been seen in some of the other dystroglycanopathy models; 
both have been reported in the Largemyd, Largeenr Large
vls and Myf5-Cre Fktn KO mutants 
(Lane et al., 1976, Kelly et al., 1994, Holzfeind et al., 2002, Lee et al., 2005, Levedakou et al., 
2005, Liu et al., 2006, Beedle et al., 2012), while fat infiltration alone was observed in the 
POMGnT1 mutant (Liu et al., 2006) and fibrosis alone has been reported in the Fukutin 
chimera and the postnatal Fukutin null (Takeda et al., 2003).  FKRPMD mice have a distinctive 
pattern of muscle involvement and a similar pattern was seen in the Largemyd mouse, the 
only other model where it was commented on, although the Largemyd, the diaphragm was 
also severely affected (Lane et al., 1976, Holzfeind et al., 2002) unlike the FKRPMD.  
 
Associated with this milder histological phenotype in the FKRPMD mice is a near normal life 
expectancy, unlike the other dystroglycanopathy models where life expectancy is reported, 
which all either have a reduced life expectancy (Largemyd, Largeenr, Myf5-Cre Fktn-KO) or an 
early loss of mutants (POMGnT1 mutant, POMGnT1-/-, Fukutin chimera) (Lane et al., 1976, 
Levedakou et al., 2005, Levedakou and Popko, 2006, Takeda et al., 2003, Liu et al., 2006, 
Miyagoe-Suzuki et al., 2009, Beedle et al., 2012).  A contributory factor to this could be the 
absence of central nervous system involvement in the FKRPMD mouse, unlike the Large
myd, 
Largeenr, POMGnT1 mutant, POMGNT1-/- and Fukutin chimera, although the Myf5-Cre Fktn-
KO mouse, which also does not have  central nervous system involvement, has a reduction 
in life expectancy (Beedle et al., 2012). 
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In summary, all the dystroglycanopathy models show reduced IIH6 immunolabelling 
(suggesting reduced in α-dystroglycan glycosylation), perturbed laminin α2 
localisation/binding and histological evidence of dystrophic pathology.  Interestingly, the 
FKRPMD mice seem to have a milder phenotype than the other models, with no overt gait 
abnormality, a near normal life expectancy and histologically no evidence of muscle fibre 
replacement, with fibrosis or adipose tissue.  This suggests that animal models for the 
dystroglycanopathies can be assembled into a spectrum of phenotypes, with the FKRPMD at 
the mild end of the spectrum, supporting the notion that each of the genes has slightly 
different spatial and temporal roles in the glycosylation of α-dystroglycan. 
 
5.4.3 FKRP DEFICIENCT MOUSE MODELS 
A second mouse model of Fkrp deficiency, a “homozygous knock-in mouse carrying the 
missense P448L mutation” develops severe central nervous system defects, a progressive 
muscular dystrophy and a severe eye phenotype, which the authors attribute to the 
presence of the P448L point mutation (Chan et al., 2010).  However, the P448L mutation 
used in the Chan et al., 2010 publication is not associated with a cortical phenotype in the 
human patients (Brockington et al., 2001a, Mercuri et al., 2003).  Interestingly, the authors 
of this work decided to “retain the NeoR [Neomycin resistance cassette] in the targeted Fkrp 
alleles,” based on the work described here earlier with Fkrp (Ackroyd et al., 2009) and 
additionally sarcoglycan mouse models (Kobuke et al., 2008, Bartoli et al., 2008), where 
removal of the Neomycin cassette led to a failure of the mouse models to develop a 
phenotype (Chan et al., 2010).   
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Thus, an alternative interpretation of the FKRP-Neo-P448L mouse model could be that the 
presence of the Neomycin cassette in the second intron of the Fkrp gene induces a global 
knockdown of approximately 45%, causing the documented pathological changes.  
Therefore, the pathogenetic mechanisms in the FKRPMD and the FKRP-Neo-P448L (Chan et 
al., 2010) are very similar, with the discrepancy in the degree of knockdown in Fkrp 
expression perhaps attributed to a slight difference in the location of the Neomycin 
resistance cassette within the intron.  The general characteristics of the FKRPMD and the 
FKRP-Neo-P448L mutant mice are summarised in Table 5-4 and despite the difference in 
degree of Fkrp knockdown, there are a number of similarities between the mutant mice, 
such as reduced size, similar age of histopathological onset, lack of cardiomyopathy and 
altered distribution of cellular adhesion receptors at the sarcolemma (Chan et al., 2010).  
However, one of the main differences between the two models is the nature of the 
reduction in Fkrp expression with the FKRP-Neo-P448L mutant having a global reduction in 
Fkrp expression, while the FKRPMD mouse has a muscle specific knockdown in Fkrp 
expression (Chan et al., 2010).  Consequently, cortical abnormalities which are not seen in 
the FKRPMD mouse are seen in the FKRP-Neo-P448L mutant and additionally, unlike FKRPMD 
mutants, FKRP-Neo-P448L mice have a variable life expectancy with one third dying at birth 
and the remainder surviving to adulthood (Chan et al., 2010).   
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Characteristic FKRPMD mouse FKRP-Neo-P448L mouse 
Causative Mutation 80% knockdown of Fkrp in all 
cells with no Sox1 expression  
Global 45% knockdown of 
Fkrp expression 
Life Expectancy Near Normal 33% die in early postnatal 
period with the remainder 
surviving over 6 months 
Inheritance Autosomal Recessive Autosomal recessive 
Fertility Both male and female mice 
are fertile 
Not evaluated 
Serum CK Not elevated Elevated 
Physical Appearance Smaller with a wider legged 
stance 
Visibly smaller than control 
mice 
 Age Onset 6 weeks 5 weeks 
Gait and Behavioural 
Abnormalities 
 
"Bunny hop" gait 
abnormalities and no 
behavioural abnormalities 
Abnormal HL retraction at 2 
weeks, muscle weakness 
 
Muscle Pathology Focal areas of - centrally 
nucleated muscle fibres, a 
variation in fibre, necrosis 
and inflammatory infiltrates. 
Focal areas of - centrally 
nucleated muscle fibres, a 
variation in fibre size, fibrosis 
and inflammatory infiltrates 
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 No fibrosis or fat infiltration.  
Histological evidence of 
regeneration. 
No necrosis or fat infiltration.  
Expanded interstitium and 
evidence of regeneration. 
Cardiomyopathy Not evident at 40 weeks Not evident at 10 months 
Differential Muscle 
Involvement 
Proximal muscles the worse 
affected with the soleus 
relatively spared 
Pathology most pronounced 
in the diaphragm and 
quadriceps 
Dystroglycan Glycosylation IIH6 reduced with 
immunohistochemistry 
IIH6 and VIA4-1 absent in 








reduction in laminin α2 
deposition 
Integrin Immunohistochemistry 
shows integrin β1 at the 
sarcolemma 
Immunohistochemical 
analysis shows integrin β1 
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TABLE 5-4 COMPARISON OF FKRP DEFICIENT MOUSE MODELS 
This table summarises selected characteristics of two mouse models of Fkrp deficiency, the 
FKRPMD mouse and the FKRP-Neo-P448L null mouse.  The abbreviations in this table are as 
follows – CK (creatine kinase), HL (hind limb).  The entry not evaluated was entered where 
no mention of this characteristic was mentioned in the publications.  The information on the 
FKRP-Neo-P448L mouse was taken from (Chan et al., 2010). 
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5.4.4 FUNCTIONAL IMPLICATIONS OF FKRP DEFICIENCY IN MUSCLE 
So, what does the FKRPMD mouse, in combination with this second model of Fkrp deficiency 
suggest about the functional implications of Fkrp deficiency in post-natal skeletal muscle?    
 
The reduction of Fkrp expression in FKRPMD mice results in reduced IIH6 immunolabelling 
(suggestive of altered α-dystroglycan glycosylation), which is associated with altered 
basement membrane deposition, specifically reduced deposition of laminin α2, but 
additionally increased deposition of laminin α4 outside of the neuromuscular junction.  This 
is not surprising, given the role dystroglycan is thought to have in basement membrane 
deposition (Henry and Campbell, 1998, Henry et al., 2001).  The altered localisation of 
laminin α4 seen here is not restricted to models of Fkrp deficiency; it has been identified in 
other models where interaction between the DAPC and the basement membrane is 
impaired, such as the zebrafish Candyfloss mutant which has a loss of function mutation in 
laminin α2 (Sztal et al., 2012), the Dy mouse and patients with congenital muscular 
dystrophy (Patton et al., 1997, Patton et al., 1999).  Indeed, it has been shown the 
appearance of laminin α4 at the basement membrane outside the neuromuscular junction is 
a specific response to the loss of laminin α2, with localisation only seen in regions where 
laminin α2 is not deposited correctly, leading to the suggestion there is an inverse, but not 
absolute correlation between laminin α2 reduction and α4 expression at the basement 
membrane (Patton et al., 1999).  Thus, deposition of laminin α4 at the basement membrane 
of FKRPMD could be said to be a compensatory mechanism to the loss of laminin α2 
interaction with the DAPC, which is a downstream consequence of altered α-dystroglycan 
glycosylation here. 
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However, laminin α4 has a truncated N-terminal domain (short arm) lacking domains IV, V 
and VI (Iivanainen et al., 1995, Frieser et al., 1997) suggesting that laminin trimer containing 
α4 will have a compromised ability to be incorporated into basement membrane networks 
due to this truncation (Tunggal et al., 2000, Hallmann et al., 2005).  Therefore, although an 
increase in laminin α4 deposition at the basement membrane of FKRPMD could be a 
compensatory mechanism, if this laminin chain does not polymerise into the basement 
membrane network, then it will offer limited benefit with regards to mechanical stability.  
However, secretion of laminin α4 has been shown to be a survival factor in laminin α2 
deficient zebrafish muscle, acting through integrin receptor complexes to promote fibre 
survival and remodelling (Sztal et al., 2012).  This suggests laminin α4 upregulation could be 
a consequence of reduced signalling through the DAPC in these muscular dystrophies, 
rather than mechanical instability. 
 
Differential muscle involvement is a component of the FKRPMD mouse phenotype and it 
resembles the human patient LGMD2I phenotype, suggesting it is associated with a 
reduction in Fkrp expression, but what could be the reasons for this?  The soleus appears to 
be spared relative to the other muscles studied here (diaphragm, triceps and 
gastrocnemius), witha small percentage of centrally nucleated muscle fibres identified at 30 
weeks of age the only histopathological evidence of dystrophic pathology.  This could be 
related to its functional role as a postural muscle, although in comparison the diaphragm, 
arguably the most used muscle in laboratory mice was not the worst affected muscle.  The 
underlying reasons for this differential muscle involvement in LGMD2I patients are unclear, 
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but it seems to be feature of all muscular dystrophies although the pattern varies depending 
on the disorder. 
 
Dystroglycan and basement membrane ligands have been shown to have a role in mediating 
the stretch response in airway epithelial cells (Budinger et al., 2008, Takawira et al., 2011) 
and similarly in muscle fibres, the anchoring of the basement membrane to the DAPC is 
thought to provides mechanical strength and stability, acting as a “shock absorber” by 
distributing the lateral forces that build up during contraction  and additionally “sensing” 
mechanical forces of contraction intro intracellular signals, modulating gene expression and 
inhibiting apoptosis (Minetti et al., 1992, Williams and Bloch, 1999, Chockalingam et al., 
2002, Lapidos et al., 2004).  It is hypothesised that the loss of function of the DAPC increases 
the frequency of contraction induced sarcolemmal microdisruptions (Alderton and 
Steinhardt, 2000).  In support of this, Alizarin Red staining shows that muscle fibre 
intracellular calcium deposits are increased in the FKRPMD mice, and an elevated muscle 
fibre calcium concentration is observed in dystrophic muscle fibres in vitro, other mouse 
models of muscular dystrophy (mdx) and human patients with DMD (Bertorini et al., 1982, 
Turner et al., 1988, Fong et al., 1990, Alderton and Steinhardt, 2000, Mallouk et al., 2000).   
 
The cause of this increased intracellular calcium is hypothesised to be a combination of 
basement membrane defects allowing calcium ions from the extracellular space into the 
muscle fibre and calcium leak channels having a higher probability of being open in 
dystrophic muscle fibres (Bertorini et al., 1982, Turner et al., 1988, Fong et al., 1990, 
Hamilton et al., 1991).  An elevated intracellular calcium concentration induces proteolysis 
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and degradation of the muscle fibre processes, contributing to degeneration in the muscular 
dystrophies (Bertorini et al., 1982, Turner et al., 1988, Fong et al., 1990, Alderton and 
Steinhardt, 2000). 
 
However, the DAPC does not just provide a mechanical stabilisation role in muscle, it acts as 
a signalling centre and the binding of basement membrane ligands, particularly laminin 
results in activation of various intracellular signalling cascades and mediators altering 
various cellular processes including but not limited to: (i) Rac1-PAK1-JNK1-phosphorylation 
c-Jun inducing muscle cell proliferation (Oak et al., 2003), (ii) PtdIns-3-OH-kinase (PI3K)-Akt-
mTOR resulting in protein synthesis and hypertrophy (Rommel et al., 2001, Lai et al., 2004, 
Peter and Crosbie, 2006) and (iii) Rac1-PI3K-Akt preventing apoptosis of muscle cells in vitro 
(Langenbach and Rando, 2002, Zhou et al., 2006).  In the FKRPMD mouse, signalling through 
these pathways may be altered, which would also contribute to the phenotype. 
 
In both mouse models of Fkrp deficiency (FKRPMD and FKRP-Neo-P448L) integrin β1 is 
localised to the sarcolemma of some muscle fibres (Chan et al., 2010).  Interestingly, 
increased levels of integrin α β1D are seen in the muscle of patients with DMD and BMD 
(Becker muscular dystrophy), (Hodges et al., 1997), suggesting that alterations in integrin 
expression/localisation is associated with the functional loss of the DAPC in these mice.  
However, it appeared to be integrin β1A, not β1D which was localised to the sarcolemma in 
these mice.  As discussed in Section 5.3.11, initially during development integrin β1A is 
expressed at the muscle fibre sarcolemma, later replaced by the β1D isoform (Belkin et al., 
1996, de Melker and Sonnenberg, 1999).  An upregulation in Integrin β1A expression has 
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been documented in regenerating muscle fibres (Kaariainen et al., 2002) and therefore the 
localisation of integrin β1A to the muscle fibre sarcolemma reported in the FKRP-Neo-P448L 
mice (Chan et al., 2010), Dy/Dy mouse model (Hodges et al., 1997) and observed here in the 
FKRPMD could be associated with muscle fibre regeneration.  However, increased integrin β1 
expression is not reported in POMGnT1 null myoblasts (Miyagoe-Suzuki et al., 2009), leading 
Chan et al., 2010 to suggest activation of integrin might be related to a secondary pathway 
activated by Fkrp.  Therefore, further work using other dystroglycanopathy mouse models is 
required to elucidate this. 
 
In integrin α  knockout mice, expression of dystroglycan at the DAPC is upregulated (Mayer 
et al., 1997) and additionally modulating dystroglycan function alters the behaviour of cells 
grown on ligands that bind to integrins (adhesion complexes are altered) (Thompson et al., 
2010), suggesting there is cross-talk, or bi-directional signalling between the two receptor 
complexes (Yoshida et al., 1998).  However, it is unlikely they interact directly, but more 
likely that downstream mediators interact via cross-talking of their downstream mediators 
(Moore and Winder, 2012), for example it has been demonstrated the integrin and DAPC 
receptor complexes have antagonistic roles in ERK signalling (Ferletta et al., 2003). 
 
5.4.5 CONCLUDING REMARKS 
A reduction of Fkrp expression in muscle is associated with a reduction in IIH6 
immunolabelling, which alters the composition of the basement membrane, and is 
associated with the development of dystrophic muscle pathology.  The muscle phenotype of 
FKRPMD mice is consistent with that of other models of the dystroglycanopathies.  
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Additionally, as these mutant mice have easy to evaluate outcome measures, they are a 
good pre-clinical model for testing therapeutic strategies in the dystroglycanopathies. 
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6 THERAPEUTIC STRATEGIES FOR THE DYSTROGLYCANOPATHIES 
 
6.1 INTRODUCTION 
Muscular dystrophies are genetic conditions, so the most ideal therapeutic strategy would 
be one that replaces the defective gene or protein with a functional one, in this case Fkrp.  
However, this would mean that each form of dystroglycanopathy would need to be treated 
with a therapy targeted at that specific protein.  Furthermore, it requires a genetically 
confirmed diagnosis, which can be challenging - a study of patients presented to the 
Dubowitz neuromuscular centre between 2001 and 2008 showed 50% did not have a 
genetic diagnosis 4 years later (Clement et al., 2012) and it was recently estimated that a 
third of dystroglycanopathy patients have an unknown genetic aetiology (Wells, 2013).  
However, one unifying therapy would be one which restored α-dystroglycan glycosylation.   
 
LARGE is a bifunctional, type II Golgi resident glycosyltransferase which is ubiquitously 
expressed, although the organs with the highest levels of LARGE expression are heart, brain 
and skeletal muscle (Peyrard et al., 1999, Brockington et al., 2005, Grewal et al., 2005).  
LARGE binds to the N-terminal domain of α-dystroglycan, where it is thought to act with 
both xylosyltransferase and glucuronyltransferase activity to add a repeating unit of [-
3xylose-α1,3-glucoronic aid-β1-] (Kanagawa et al., 2004, Inamori et al., 2012). 
 
Overexpression of LARGE in vitro increases IIH6 immunolabelling above that of wildtype 
levels  indicating that α-dystroglycan in these cells is hyperglycosylated (Kanagawa et al., 
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2004, Fujimura et al., 2005).   Similarly, overexpression of LARGE in vitro, using cells isolated 
from either dystroglycanopathy patients (with various gene mutations) or animal models of 
the dystroglycanopathies (Largemyd and FCMD) resulted in hyperglycosylated α-dystroglycan 
(increased IIH6 immunolabelling), restoring the ability of dystroglycan in these cells to bind 
to basement membrane ligands, including laminin (Barresi et al., 2004, Kanagawa et al., 
2009, Hu et al., 2011b).  Additionally it was reported that basement membrane deposition 
was improved and histopathological abnormalities were reduced in vivo (Barresi et al., 2004, 
Kanagawa et al., 2009).  This suggests that LARGE upregulation is a potential therapeutic 
strategy for the dystroglycanopathies, although this has not been tested in cell lines derived 
from patients with mutations in FKRP or animal models with deficiencies in Fkrp expression. 
 
In 2010, a mouse generated by this laboratory was published showing that long-term 
transgenic overexpression of LARGE in wildtype mice (referred to as LV5) did not induce any 
adverse histopathological abnormalities, aside from a subclinical defect in the resistance of 
muscle fibres to eccentric exercise in older mice (8 months of age) (Brockington et al., 2010).  
Thus to test the potential of LARGE as a therapeutic strategy for patients with mutations in 
Fkrp, including LGMD2I, a breeding cross was set up between the LV5 mouse line 
(Brockington et al., 2010) and the FKRPMD mouse generated and characterised in this project 
as described in Chapter 5.  This will test the hypothesis that upregulation of LARGE will 
improve the physical and histopathological defects seen in the FKRPMD mouse. 
 
Firstly, the breeding strategies used to generate the FKRPMDLARGE mutant mouse will be 
described.  Since this breeding cross will have slightly altered the initial genetic background 
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of the LV5 mouse, it was then confirmed that upregulation of LARGE was maintained and 
these LV5 mice did not display histopathological evidence of muscular dystrophy by 
evaluating muscle cryosections stained with haematoxylin and eosin and immunolabelled 
with IIH6 and laminin α2 antibodies.  Once this had been shown, the FKRPMDLARGE mouse 
was evaluated physiologically and compared to the FKRPMD mouse; to evaluate the effect of 
LARGE overexpression on mouse body weight, forelimb grip strength, hindlimb extensor 
reflex, resistance to eccentric exercise and serum CK.  Additionally, four different muscles 
(diaphragm, gastrocnemius, soleus and triceps) were evaluated histologically and 
immunohistochemically for evidence of any amelioration of the dystrophic pathology.  
Again, as stated in Chapter 5, these four muscles were chosen to compare the effect of 
mechanical use, fibre type profile and muscle location (proximal or distal) on the pathology.   
 
6.2 HYPOTHESIS 
The aim of this section was to use thepreclinical model developed in the previous chapter, 
the FKRPMD mouse to test LARGE upregulation as a therapeutic strategy for 
dystroglycanopathies associated with Fkrp.  The hypothesis was that transgenic 
upregulation of LARGE would improve the physical and histopathological defects seen in the 
FKRPMD mouse. 
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6.3 RESULTS 
6.3.1 GENERATION OF THE FKRPMDLARGE MOUSE 
Upregulation of LARGE in the FKRPMD mice was achieved through a breeding cross set up 
between the FKRPMD and LV5 mouse colonies.  The LV5 mouse is a published transgenic 
mouse line, with expression of human LARGE under a β-actin promoter, with a human 
cytomegalovirus enhancer (Brockington et al., 2010).  The breeding crosses used to 
generate and maintain this colony, mice gave rise to 9 different genotypes, with different 
combinations of transgenes, as summarised in Table 6-1. 
 
The breeding schematic used to generate the FKRPMDLARGE mouse is shown in Figure 6-1 
and involved two breeding crosses, the first of which was between a FKRP-NeoTyr307Asn-/-
Sox1Cre-/-LV5-/- (LV5 mouse) and a FKRPMD heterozygote mouse (FKRP-Neo
Tyr307Asn+/-
Sox1Cre+/-LV5-/-), to introduce the LARGE transgene into the background of the FKRPMD 
mouse colony.  This initial breeding cross (A) generated F1 animals of 8 different genotypes 
– (i) wildtype, (ii) Sox1Cre, (iii) LV5, (iv)  Sox1CreLV5, (v) FKRPKD heterozygote, (vi) FKRPMD 
heterozygotes, (vii) FKRPKDLARGE heterozygotes and (viii) FKRPMDLARGE heterozygote mice 
(Figure 6-1 and Table 6-1). 
 
 In the second breeding cross (B), one FKRPMDLARGE heterozygote mouse was crossed with 
a FKRPKD heterozygote mouse to generate animals of 12 different genotypes, including the 4 
genotypes generated in the F1 breeding cross (Figure 6-1).  The 4 additional genotypes 
generated in the second breeding cross (B) were (i) FKRPKD, (ii) FKRPKDLARGE, (iii) FKRPMD 
and finally (iv) FKRPMDLARGE mice (Figure 6-1).   
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Abbreviation FKRP Cre 
recombinase 
LV5 Genotype 
WT WT No No FKRP-NeoTyr307Asn-/-Sox1Cre-/-LARGE-/- 
Sox1 Cre WT Yes No FKRP-NeoTyr307Asn-/-Sox1Cre+/-LARGE-
/- 
LV5 WT No Yes FKRP-NeoTyr307Asn-/-Sox1Cre-/-
LARGE+/- 
















Heterozygote Yes Yes FKRP-NeoTyr307Asn+/-Sox1Cre+/-
LARGE+/- 
FKRPKD Mutant No No FKRP-NeoTyr307Asn+/+Sox1Cre-/- 
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FKRPKDLARGE Mutant No Yes FKRP-NeoTyr307Asn+/+Sox1Cre-/-
LARGE+/- 
FKRPMD Mutant Yes No FKRP-Neo
Tyr307Asn+/+Sox1Cre+/-
LARGE/- 





TABLE 6-1 MOUSE GENOTYPES WITHIN THE FKRPMDLARGE MOUSE COLONY 
This table lists the 9 different genotypes produced by the breeding crosses used in the 
generation and maintenance of the FKRPMDLARGE mouse colony, with reference to their 
inheritance of the Neomycin selection cassette in Fkrp and whether they carry one of the 
transgenes (Cre recombinase and/or LV5).  It also lists the shorthand abbreviated terms, 
which will now be used throughout the text when referring to the mice of these different 
genotypes. 
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FIGURE 6-1 SCHEMATIC OF THE BREEDING CROSSES USED TO GENERATE 
FKRPMDLARGE MICE 
Schematic diagram showing the breeding programs performed to generate FKRPMDLARGE 
mice.  The mouse chromosomes are represented by the black lines, while the genes are 
denoted by square boxes, coloured as shown in the key with wildtype Fkrp (green), mutant 
Fkrp (blue), Cre recombinase (purple) and LARGE (red).  (A) shows the F1 breeding cross 
between FKRPMD heterozygote (FKRP-NeoTyr307Asn+/-Sox1Cre+/-LARGE-/-) and LV5 mice (FKRP-
NeoTyr307Asn-/-Sox1Cre-/-LARGE+/-) mice.  This produces animals of 8 different genotypes, as 
shown - wildtype, Sox1Cre, LV5, Sox1CreLV5, FKRPKD heterozygote, FKRPMD heterozygote, 
FKRPKDLARGE heterozygotes and FKRPMDLARGE heterozygote  
 
(B) shows the second breeding cross between an FKRPMDLARGE heterozygote (FKRP-
NeoTyr307Asn+/-Sox1Cre+/-LARGE+/-) mouse and an FKRPKD heterozygote (FKRP-NeoTyr307Asn+/-
Sox1Cre-/-LARGE-/-) mouse.  This produces animals of 12 genotypes, including the 8 
genotypes produced in breeding cross and 4 additional genotypes - FKRPKD, FKRPKDLARGE, 
FKRPMD and FKRPMDLARGE.  
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6.3.2 LV5 MICE ON THE NEW GENETIC BACKGROUND STILL HAD INCREASED IIH6 
IMMUNOLABELLING 
Although the genetic background of the LV5 mouse is mixed (C57Bl10 and CBA/Ca) 
(Brockington et al., 2010), setting up a breeding cross with the FKRPMD mouse, made on a 
different genetic mixed background (C57Bl6, 129 and CBA/Ca) (Yagi et al., 1993, Takashima 
et al., 2007, Ackroyd et al., 2009) will have introduced new genes from these different 
mouse strains.  Recent research into inbred laboratory strains indicates there is much 
greater genetic variation between different strains than previously thought (Yang et al., 
2007) and although it is unlikely the LARGE transgene has been affected by this altered 
background, muscles from LV5 mice on this new background were evaluated 
immunohistochemically with the IIH6 antibody, which showed increased immunolabelling, 
suggesting these mice have altered, hyperglycosylated α-dystroglycan (Figure 6-2).  
Cryosections from muscles of these mice showed no evidence of dystrophic pathology and 
additionally immunolabelling with an antibody against laminin α2 showed the basement 
membrane of these LV5 mice was equivalent to wildtype mice (Figure 6-2).  This data 
demonstrates the alteration in genetic background has not significantly changed the 
expression of the transgene (Figure 6-2). 
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FIGURE 6-2 COMPARISON OF LV5 AND WILDTYPE MICE 
No histologial evidence of dystrophic muscle pathology was observed in either the soleus (B) 
or the triceps (D) from the three LV5 mice evaluated (B, D) on the new genetic background – 
these muscles appeared consistent with wildtype mice (A, C).  .  E and F show that 
immunolabelling with the IIH6 antibody was increased in the LV5 (F) on the new genetic 
background relative to wildtype (E); demonstrating hyperglycosylation of α-dystroglycan is 
maintained.  G and H show comparable immunolabelling of laminin α2 at the muscle fibre 
basement membrane between wildtype (G) and LV5 (H) mice on the new genetic 
background 
 
Transverse 10µm cryosections from 12 week old wildtype (n=3) (A, C) and LV5 mice (n=3) (B 
and D) soleus (A-B) and triceps were stained with haematoxylin and eosin.  At least 2 
sections from each individual mouse muscle were viewed under light microscopy using a 
DM4000B upright microscope (Leica Microsystems), with no histological indicators of 
dystrophic pathology (inflammatory infiltration, muscle degeneration, regeneration or 
necrosis, repleacement of muscle fibres with fat or adipose tissue and marked numbers of 
centrally nucleated muscle fibres) observed in the muscles from LV5 mice, aside from the 
occasional centrally nucleated muscle fibre.  Representative images were digitally captured 
with a DC500 colour camera (Leica Microsystems) using the Leica Application Suite software 
(Leica Microsystems).  Scale bar denotes 100µm.   
  
Transverse 10µm cryosections of the gastrocnemius from 12 week old wildtype (n=3) (E, G) 
and LV5 (n=3) (F and H) mice immunolabelled with antibodies against glycosylated α-
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dystroglycan (IIH6) (E-F) and laminin α2 (G-H) both shown in red, with the the nuclei labelled 
with Hoechst 3342 shown in blue.  At least 3 sections from each individual mouse were 
viewed under epifluorescence using a DM4000B upright microscope (Leica Microsystems), 
with increased IIH6 immunolabelling consistently observed at the sarcolemma of all muscle 
fibres across the gastrocnemius of all muscle sections evaluated.  Additionally, laminin α2 
immunolabelling was observed at a level consistent with wildtype mice across all LV5 
muscle sections evaluated.  Representative images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss).  Scale bar denotes 
50µm 
 
This figure was compiled from these images using Adobe Photoshop CS4 and CS5. 
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6.3.3 PHYSICAL APPEARANCE OF FKRPMDLARGE MICE 
A post-mortem evaluation of 5 female FKRPMDLARGE mice at 20-22 weeks of age suggested 
these mice appeared physically similar to FKRPMD mice, with a reduction in the muscle mass 
around the limb girdles evident in both these genotypes (Figure 6-3).  Additionally, kyphosis 
was observed in both FKRPMD and FKRPMDLARGE mice (Figure 6-3). 
 
Further observations of FKRPMDLARGE found that, similarly to FKRPMD mice, FKRPMDLARGE 
mice were often smaller up until weaning, after which time they rapidly put on weight, 
again often on a mash diet.  Evaluation of mouse body weight in males at 6 and 12 weeks of 
age with a linear mixed effect model showed genotype was not a significant factor affecting 
body weight of male mice (Figure 6-4).  Interestingly, however, this model showed genotype 
was a significant factor affecting body weight in female mice, at 6 weeks of age and 20 
weeks of age (Figure 6-4).  At 6 weeks of age, FKRPMD mice are significantly smaller than 
wildtype mice, but FKRPMDLARGE mice are not, despite weighing less than FKRPMD mice 
(Figure 6-4).  This is most likely a result of the smaller number of female FKRPMDLARGE mice 
weighed (n=4 FKRPMDLARGE mice and n=9 FKRPMD).  By 20 weeks of age, both female 
FKRPMD and FKRPMDLARGE mice weigh significantly less than wildtype mice. 
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FIGURE 6-3  PHYSICAL CHARACTERISTICS OF FKRPMDLARGE MICE 
A-C shows digital photographs of skinned 20 week old female mice that were culled by a 
schedule one method.  A=wildtype (n=5), B=FKRPMD (n=5) and C=FKRPMDLARGE (n=5).  These 
images show the kyphosis in both FKRPMD and FKRPMDLARGE mice (*) and the selective loss 
of muscle mass around both the upper and lower limb girdles in the FKRPMD and 
FKRPMDLARGE mice (**). 
 
D and E show digital photographs of 8 week old male FKRPMD (D) and FKRPMDLARGE (E) mice 
demonstrating the similarity in size of the FKRPMD and FKRPMDLARGE mice.  Additionally, 
these photographs show the altered resting stance of both FKRPMD and FKRPMDLARGE mice 
(#).  All photographs were captured using a digital FE-3000 camera (Olympus) and compiled 
into a figure using Photoshop CS4 or CS5 (Adobe).  
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FIGURE 6-4 FKRPMD AND FKRPMDLARGE BODY WEIGHTS 
The Linear Mixed Effects statistical model showed that age was a significant factor affecting 
mouse body weight in both male and female mice and that genotype was not a significant 
factor affecting male body weight (p=0.245).  This model showed that genotype was a 
significant factor affecting female body weight and significance is shown as follows: 
 *0.01 ≤p<0.05, ** 0.001≤p<0.01.   
 
Mean body weights ± SEM of male (A) and female (B) wildtype (green), FKRPMD (blue) and 
FKRPMDLARGE (red) mice at 6 weeks (male wildtype n=8, male FKRPMD n=9, FKRPMDLARGE 
n=4; female wildtype n=14, female FKRPMD n=12, FKRPMDLARGE n=3), 12 (male wildtype 
n=10, male FKRPMD n=17, FKRPMDLARGE n=8; female wildtype n=14, female FKRPMD n=24, 
female FKRPMDLARGE n=5) and 20 weeks of age (female wildtype n=7, female FKRPMD n=14, 
female FKRPMDLARGE n=4).  Data was compiled using Microsoft Excel and graphs were 
prepared using GraphPad Prism version 5.0 for Window.  The data was analysed with a 
Linear Mixed Effects Model performed using SPSS Statistics (IBM, U.S.A).  This is a second 
A B 
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analysis of the FKRPMD presented in Chapter 5 to evaluate the effect of LARGE 
overexpression on mouse body weight.  
Page 406 of 551 
 
6.3.4 THE HINDLIMB STRETCH REFLEX WAS ALTERED IN FKRPMDLARGE MICE 
Mice normally splay their hindlimbs when picked up by the tail, and a collapse of this 
extensor reflex could indicate motor deficits in these mice.  The hindlimb stretch reflex of 
FKRPMDLARGE mice was classified into either normal or abnormal (as described in Chapters 2 
and 5) and is presented in Table 6-2, with the data from the wildtype and FKRPMD mice for 
comparison.  An abnormal hindlimb extensor reflex was observed in the vast majority of 
FKRPMDLARGE male and female mice at 12 weeks of age, unlike FKRPMD, where an abnormal 
reflex was only observed in a small number of mice (Table 6-2).  This suggests upregulation 
of LARGE has perturbed the hindlimb extensor reflex.  No abnormality of the hindlimb 
extensor reflex was observed in wildtype mice (Table 6-2). 
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 Females Males 
Wild- 
type 
FKRPPMD FKRPMDLARGE Wild- 
type 
FKRPMD FKRPMDLARGE 
Normal 11 14 1 6 14 0 
Abnormal 0 2 4 0 2 7 
Total 11 16 5 6 16 7 
% 
Abnormal 
0 20 100 0 12.5 100 
 
TABLE 6-2 HINDLIMB EXTENSOR REFLEX OF FKRPMDLARGE AND FKRPMD MICE 
FKRPMDLARGE mice have an abnormal hindlimb extension reflex at 12 weeks of age, while 
the vast majority of FKRPMD mice have a normal hindlimb extensor reflex at this age.  All 
wildtype mice had a normal hindlimb extensor reflex.   
 
The hindlimb extensor reflex of female and male wildtype (male n=6 and female n=7), 
FKRPMD (male and female n=16) and FKRPMDLARGE (male n=7 and female n=5) mice was 
evaluated at 12 weeks of age and classified into a normal or abnormal reflex.  This wildtype 
and FKRPMD data is the same data presented in Chapter 5, but has been included here to 
facilitate the comparison to FKRPMDLARGE mice.  A normal hindlimb reflex was scored when 
the mouse hindlimbs were fully stretched away from the body, and an abnormal reflex was 
noted when either a partial or full collapse of the extension reflex was seen.  This table also 
lists the percentage of mice with abnormal hindlimb stretch reflexes at each age.  The data 
was compiled using Microsoft Excel and IBM SPSS Statistics.    
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6.3.5 MALE FKRPMDLARGE MICE HAVE REDUCED FORELIMB GRIP STRENGTH 
Male FKRPMD mice have a trend towards reduced forelimb grip strength (p=0.087), whilst 
male FKRPMDLARGE mice have a significant reduction in forelimb grip strength relative to 
wildtype controls (Figure 6-5), suggesting a worsening of the phenotype in FKRPMDLARGE 
mice.  However, in female mice there was no significant difference in forelimb grip strength 
between the three genotypes (wildtype, FKRPMD and FKRPMDLARGE) mice (p=0.1) (Figure 
6-5).  This raises a potential gender difference, suggesting upregulation of LARGE affects the 
phenotype of male and female FKRPMD mice differently. 
 
6.3.6 FKRPMDLARGE MICE SHOWED A PHYSIOLOGICAL DEFICIT RELATIVE TO FKRPMD  
To compare the functional properties associated with a knock-down of Fkrp and how this 
was altered by the transgenic expression of LARGE anaesthetised mice were subjected to a 
protocol of 10 eccentric (lengthening) contractions in situ. The protocol induced a 15% 
stretch during each of 10 maximal isometric contractions stimulated 2 minutes apart. 
Isometric tetanic forced was measured prior to each stretch and expressed as a percentage 
of baseline isometric force.  FKRPMD mice showed no significant difference with respect to 
their resistance to eccentric contraction-induced injury relative to littermate controls (Figure 
6-6). However, FKRPMDLARGE showed a significant reduction in their resistance relative to 
control littermates, further suggesting that LARGE upregulation has worsened the 
phenotype of the FKRPMD (Figure 6-6) 
  




FIGURE 6-5 FORELIMB GRIP STRENGTH OF FKRPMD AND FKRPMDLARGE MICE 
In female mice there was no statistically significant difference in forelimb grip strength 
between wildtype (green), FKRPMD (blue) and FKRPMDLARGE (red) mice.  Male FKRPMDLARGE 
mice (red) had significantly reduced forelimb grip strength relative to wildtype (green), but 
FKRPMD mice (blue) did not. 
 
Mean forelimb grip strength measurements (g/g mouse) were taken from 11-13 week old 
male (A), wildtype n=5, FKRPMD n=14 and FKRPMDLARGE n=3 and female (B), wildtype n=6, 
FKRPMD n=14 and FKRPMDLARGE mice n=3, using a mechanical grip strength meter following 
a methodology based upon the standard operating protocols from the Treat NMD website 
(www.treat-nmd.eu) (de Luca, 2010).  Data was compiled using Microsoft Excel and graphs 
were prepared using GraphPad Prism version 5.0 for Windows.  Data was analysed 
statistically using a Kruskal-Wallis test with a post-hoc Dunn’s multiple comparison test 
using GraphPad Prism version 5.0 for Windows.  Significance is shown as follows * 
0.01≤p<00.05.  For the female data, the Kruskal-Wallis test gave a p value of 0.10 as a mean 
difference between the 3 genotypes.  This is a second analysis of the FKRPMD data presented 
A B 
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in Chapter 5 to evaluate the effect of LARGE overexpression on mouse forelimb grip 
strength.  
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FIGURE 6-6 ELECTROPHYSICAL ANALYSIS OF FKRPMD AND FKRPMDLARGE MICE 
A Two-way Repeated Measures ANOVA with a post-hoc Tukey’s test showed FKRPMDLARGE 
mice showed a significant reduction in their resistance to eccentric contraction-induced 
injury when compared to wildtype, whereas FKRPMD mice did not, suggesting LARGE 
upregulation worsened the phenotype of the FKRPMD. 
 
Electrophysiological analysis of TA function in 20-22 week old female FKRPMD (n=8), 
FKRPMDLARGE (n=5) and wild type mice (n=7).  Isometric force measurements were made 
from the TA, and the maximum isometric tetanic force (Po) was determined.  After the final 
isometric contraction, the muscle was allowed to rest for 5 min.  A tetanic contraction was 
induced using a stimulus of 120 Hz for 700 ms.  During the last 200 ms the muscle was 
stretched by 15% of Lo at a velocity of 0.5 Los
-1 and relaxed at 0.5 Los
-1.  The isometric tension 
recorded prior to the first stretch was used as a baseline. The muscle was then subjected to 
10 eccentric contractions separated by a 2 min rest period. The isometric tension prior to 
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each stretch was recorded and expressed as a percentage of the baseline tension.   This 
analysis was performed by Dr Kim Wells and Dr Rebecca Terry (Royal Veterinary College) 
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6.3.7 SERUM CK LEVELS WERE NOT ELEVATED IN FKRPMDLARGE MICE 
Elevated serum CK levels are observed in human patients with muscular dystrophy (Godfrey 
et al., 2007), so it is a commonly used method of assessing muscle damage in mouse 
models.  As was shown in the previous chapter, FKRPMD mice did not have an elevated 
serum CK level, and this was evaluated in FKRPMDLARGE, to assess the effect of LARGE 
upregulation on the serum CK levels of FKRPMD mice.  FKRPMDLARGE mice, similar to FKRPMD 
mice do not have elevated serum CK (Figure 6-7). 
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FIGURE 6-7 UPREGULATION OF LARGE DID NOT INCREASE SERUM CK LEVELS 
This figure shows that FKRPMDLARGE, similar to FKRPMD do not have elevated serum CK. 
 
Serum CK levels of 11-13 week old male wildtype (n=3), FKRPMD (n=3) and FKRPMDLARGE 
(n=3) were evaluated.  Serum from a 6 week old mdx mouse was used as a positive control.  
Samples from each individual mouse were run in triplicate, with the exception of the mdx 
sample which was run in duplicate.  Values were normalised to a blank sample only control.  
Data was compiled using Microsoft Excel 2010 and analysed using GraphPad Prism version 
5.0 for Windows.  A Kruskal-Wallis statistical test was run on the data using Graph Pad Prism 
to test the null hypothesis that there was no difference in serum CK values between 
wildtype, FKRPMD and FKRPMDLARGE mice.  This returned a p value of 0.7804, suggesting 
there was no significant difference in the CK value between wildtype, FKRPMD and 
FKRPMDLARGE mice, suggesting the null hypothesis should be accepted.  This is a second 
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analysis of the FKRPMD data presented in Chapter 5 to evaluate the effect of LARGE 
overexpression on serum CK levels. 
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6.3.8 UPREGULATION OF LARGE EXACERBATED DYSTROPHIC PATHOLOGY IN FKPRMD  
As described in Chapter 5, the onset of dystrophic pathology in the FKRPMD mouse muscle 
was at approximately 6 weeks of age, characterised by the appearance of a few, small 
isolated patches of necrotic and degenerating muscle fibres and occasional inflammatory 
infiltrates, with a small number of centrally nucleated muscle fibres in the triceps. (Figures 
6-8 and 6-9).  Muscles from two FKRPMDLARGE mice at 6 weeks of age were evaluated and 
here multiple muscle fibres with centralised nuclei, a wide variation in fibre size and patches 
of inflammatory infiltrates were identified (Figures 6-8 and 6-9). 
  
At 12 weeks of age, FKRPMD mice were in their crisis phase of dystrophic pathology, 
characterised by the presence of muscle fibre degeneration, regeneration and necrosis, 
inflammatory infiltration and a variation in muscle fibre size (Figures 6-10 and 6-11).  Four 
FKRPMDLARGE mice were evaluated here at 12 weeks of age, and in these mice, all the 
histological features described in FKRPMD mice were identified in FKRPMDLARGE muscles 
(Figures 6-10 and 6-11), although there was some variation between individual mice with 
respect to the distribution and localisation of individual pathological features across the 
muscle.  Additionally, in FKRPMDLARGE mice there was evidence of fat infiltration and 
fibrosis, two features that were not observed in FKRPMD muscles.  These two features were 
observed in all four individual FKRPMDLARGE mice, although there was again some variation 
between individuals with respect to both the distribution and degree.  Additionally, in all 
four FKRPMDLARGE mice evaluated, there was a greater variation in muscle fibre size, with 
hypertrophy more apparent histologically in comparison to the FKRPMD mouse (Figure 6-10 
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and Figure 6-11).  Finally, the incidence of fibre splitting was significantly increased in 
FKRPMDLARGE mice, when compared to FKRPMD (Figure 6-12). 
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Figure 6-8 FKRPMD and FKRPMDLARGE Pathology At 6 weeksInflammatory infiltrates (*) 
were seen in the 6 week FKRPMD (B, E, H) and FKRPMDLARGE (C, F, I) gastrocnemius (A-F), but 
not the diaphragm (G-I).  Both the FKRPMD and FKRPMDLARGE gastrocnemius and diaphragm 
displayed a variation in muscle fibre size (**), although it appeared more pronounced in the 
muscles from the 2 FKRPMDLARGE mice in comparison to the FKRPMD.  Hyperchromatic fibres 
are muscle fibres stained more intensely with eosin (denoted by an arrow) and these are 
thought to be fibres about to degenerate.  There appeared to be a greater incidence of 
these fibres in the 2 FKRPMDLARGE muscles when compared to FKRPMD.  Additionally 
degenerating (D) and regenerating fibres (R) were identified in both the FKRPMD and 
FKRPMDLARGE gastrocnemius, although they were more pronounced in the FKRPMDLARGE 
muscle.  Regenerating fibres were also identified in the FKRPMDLARGE diaphragm, but not 
the FKRPMD diaphragm.  Centrally nucleated muscle fibres (#) were identified in the FKRPMD 
and FKRPMDLARGE triceps and diaphragm, although again they appeared to be more 
numerous in the muscles from the two FKRPMDLARGE mice.   
 
Transverse 10µm cryosections from 6 week wildtype (n=3 for both muscles) (A, D, G), 
FKRPMD (n=3 for both muscles) (B, E, H) and FKRPMDLARGE (n=2 for both muscles) (C, F, I) 
diaphragm (A-C) and gastrocnemius (D-I) were stained with haematoxylin and eosin.  At 
least 3 sections from each mouse muscle were viewed under light microscopy using a 
DM4000B upright microscope (Leica Microsystems).  Although there were some differences 
between individual mice of the same genotype with respect to the degree of pathology 
observed, the general pattern of histological observations described above was consistently 
observed between the three genotypes.  Representative images were digitally captured with 
Page 420 of 551 
 
a DC500 colour camera (Leica Microsystems) using the Leica Application Suite software 
(Leica Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in D-F and 100µm in A-C, G-I.   
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FIGURE 6-9 PATHOLOGY IN FKRPMD AND FKRPMDLARGE MUSCLE AT 6 WEEKS (2) 
Inflammatory infiltrates (*) were seen in the 6 week FKRPMD (B, E, H) and FKRPMDLARGE (C, 
F, I) triceps (A-F), but not the soleus (G-I).  Both the FKRPMD and FKRPMDLARGE triceps, and 
additionally the FKRPMDLARGE soleus displayed a variation in muscle fibre size (**), although 
it appeared more pronounced in the muscles from the 2 FKRPMDLARGE mice evaluated.  
Degenerating (D) and regenerating fibres (R) were identified in both the FKRPMD and 
FKRPMDLARGE gastrocnemius, although they were more pronounced in the FKRPMDLARGE 
muscle.  Regenerating fibres were identified in the FKRPMDLARGE soleus, but not the 
FKRPMD.   Centrally nucleated muscle fibres (#) were identified in the FKRPMD and 
FKRPMDLARGE triceps and the FKRPMDLARGE soleus, although again they appeared to be 
more numerous in the muscles from the two FKRPMDLARGE mice evaluated.  Finally, 
hyperchromatic fibres, denoted by an arrow, were also identified in FKRPMD and 
FKRPMDLARGE muscle. 
 
Transverse 10µm cryosections from 6 week wildtype (n=3 for both muscles) (A, D, G), 
FKRPMD (n=3 for both muscles) (B, E, H) and FKRPMDLARGE (n=2 for both muscles) (C, F, I) 
diaphragm (A-C) and gastrocnemius (D-I) were stained with haematoxylin and eosin.  At 
least 3 sections from each mouse muscle were viewed under light microscopy using a 
DM4000B upright microscope (Leica Microsystems).  Although there were some differences 
between individual mice of the same genotype with respect to the degree of pathology 
observed, the general pattern of histological observations described above was consistently 
observed between the three genotypes.  Representative images were digitally captured with 
a DC500 colour camera (Leica Microsystems) using the Leica Application Suite software 
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(Leica Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in D-F and 100µm in A-C, G-I.   
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FIGURE 6-10 FKRPMDLARGE PATHOLOGY AT 12 WEEKS 
Degenerating (*) and regenerating (+) muscle fibres were easily identified in the FKRPMD and 
FKRPMDLARGE triceps , while isolated degenerating fibres were identified in the FKRPMD and 
FKRPMDLARGE soleus.  Isolated necrotic muscle fibres (N) were identified in both the FKRPMD 
and FKRPMD triceps, but not the soleus.  Additionally, isolated hyperchromatic fibres (H) 
were identified in the FKRPMDLARGE triceps.  Fibre splitting (++) was identified in the 
FKRPMDLARGE triceps only – it was not seen in the FKRPMD triceps or the soleus from either 
FKRPMD or FKRPMDLARGE mice.  A variation in fibre size (**) was identified in the both the 
soleus and the triceps of FKRPMD and FKRPMDLARGE mice.  Additionally, centrally nucleated 
muscle fibres (#) were widespread in the FKRPMD and FKRPMDLARGE triceps, but were also 
observed in the FKRPMD and FKRPMDLARGE soleus.  Additionally, some inflammatory 
infiltrates (##) were also observed in the FKRPMD and FKRPMDLARGE triceps. 
 
Transverse 10µm cryosections from 12 week wildtype (n=3 for both muscles) (A, D, G), 
FKRPMD (n=3 for both muscles) (B, E, H) and FKRPMDLARGE (n=4 for both muscles) (C, F, I) 
triceps (A-F) and soleus (G-I) were stained with haematoxylin and eosin.  At least 3 sections 
from each mouse muscle were viewed under light microscopy using a DM4000B upright 
microscope (Leica Microsystems).  Although there were some differences between 
individual mice of the same genotype with respect to the degree of pathology observed, the 
general pattern of histological observations described above was consistently observed 
between the three genotypes.  Representative images were digitally captured with a DC500 
colour camera (Leica Microsystems) using the Leica Application Suite software (Leica 
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Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 200µm in 
A-C and 100µm in D-F, G-I.   
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FIGURE 6-11 FKRPMDLARGE PATHOLOGY AT 12 WEEKS OF AGE (2) 
Regenerating fibres (+) were identified in the FKRPMD (B, E, H) and FKRPMDLARGE (C, F, I) 
gastrocnemius (A-C) and diaphragm (G-I).  Isolated hyperchromatic (H), degenerating (*) and 
necrotic (N) fibres were identified in the muscle sections.  Fibrosis (F), fat infiltration (FI) and 
fibre splitting (++) were identified in the FKRPMDLARGE gastrocnemius and diaphragm 
respectively, but these were not observed in any of the muscles from the FKRPMD mouse.  
Centrally nucleated muscle fibres (#) and a variation in muscle fibre size (**) were 
widespread throughout the muscles of the FKRPMD and FKRPMDLARGE diaphragm and 
gastrocnemius.  Additionally, isolated inflammatory infiltrates were identified in the FKRPMD 
and FKRPMDLARGE muscles.  No evidence of dystrophic pathology was identified in the 
muscles from wildtype mice. 
 
Transverse 10µm cryosections from 12 week old wildtype (n=3 for both muscles) (A, D, G), 
FKRPMD (n=3 for both muscles) (B, E, H) and FKRPMDLARGE (n=4 for both muscles) (C, F, I) 
diaphragm (A-C) and gastrocnemius (D-I) were stained with haematoxylin and eosin.  At 
least 3 sections from each mouse muscle were viewed under light microscopy using a 
DM4000B upright microscope (Leica Microsystems).  Although there were some differences 
between individual mice of the same genotype with respect to the degree of pathology 
observed, the general pattern of histological observations described above was consistently 
observed between the three genotypes.  Representative images were digitally captured with 
a DC500 colour camera (Leica Microsystems) using the Leica Application Suite software 
(Leica Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 
200µm in D-F and 100µm in A-C, G-I.    
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FIGURE 6-12  FKRPMD AND FKRPMDLARGE SPLIT FIBRE INCIDENCE 
The number of split fibres in 12 week old wildtype, FKRPMD and FKRPMDLARGE 
gastrocnemius is shown in A.  A one-tailed Mann-Whitney test was performed to test the 
hypothesis that the split fibre incidence was increased in FKRPMDLARGE mice, with 
significance shown as follows 0.01≤p<0.05.  An example of split muscle fibres in the 
FKRPMDLARGE gastrocnemius is shown in B. 
 
Transverse 10µm cryosections of the gastrocnemius from 12 week old wildtype (n=3), 
FKRPMD (n=3) and FKRPMDLARGE (n=3) stained with haematoxylin and eosin were viewed 
under light microscopy using a DM4000B upright microscope (Leica Microsystems).  Images 
of the most representative section at the mid-belly region of the muscle were digitally 
captured with a DC500 colour camera (Leica Microsystems) using the Leica Application Suite 
software (Leica Microsystems).  Images were arranged into a composite image and split 
muscle fibres were counted across the muscle using Photoshop CS4 or CS5 (Adobe), 
numbering approximately 2000 for the gastrocnemius.  The data was compiled using 
Microsoft Excel and analysed using GraphPad Prism version 5.0 for Windows. 
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Finally, although there were muscle specific differences, generally in older FKRPMD mice (30 
weeks of age) the only histopathological features of muscular dystrophy evident were 
muscle fibres with centralised nuclei and a variation in fibre size (Figures 6-13 and 6-14).  
However, here muscles from four 30 week FKRPMDLARGE were evaluated and in each 
individual mouse, along with these two features (centralised nuclei and a variation in fibre 
size), actively degenerating and regenerating fibres, inflammatory infiltrates, fat infiltration 
and fibrosis were also observed (Figures 6-13 and 6-14).  All these pathological features 
were identified in each individual FKRPMD mouse, although there was some variation 
between individual mice, both with respect to the degree of histopathological features and 
the distribution of the pathological features across the muscle. 
 
This suggested the crisis period of the FKRPMD mice has been extended by the upregulation 
of LARGE (Figures 6-13 and 6-14) and upregulation of LARGE in the FKRPMD mice has 
worsened the dystrophic pathology histologically.   
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FIGURE 6-13 30 WEEK PATHOLOGY IN FKRPMD AND FKRPMDLARGE MICE 
Centrally nucleated muscle fibres (#), regenerating muscle fibres (+), inflammatory infiltrates 
(**) and a variation in fibre size (**) were identified in the muscles from the FKRPMD (B, E, 
H)and FKRPMDLARGE (C, F, I) mice.  These signs were exacerbated in the FKRPMDLARGE 
mouse, relative to FKRPMD mice.  Additionally, degenerating fibres (*), necrotic fibres (N), 
fibre splitting and occasional hypercontracted fibres (H) were only identified in the 
FKRPMDLARGE muscles.  No evidence of dystrophic pathology was identified in muscles from 
wildtype mice. 
 
Transverse 10µm cryosections from 30 week old wildtype (n=3 for both muscles) (A, D, G), 
FKRPMD (n=3 for both muscles) (B, E, H) and FKRPMDLARGE (n=3 for both muscles) (C, F, I) 
gastrocnemius (A-C, G-I) and diaphragm were stained with haematoxylin and eosin.  At least 
3 sections from each mouse muscle were viewed under light microscopy using a DM4000B 
upright microscope (Leica Microsystems).  Although there were some differences between 
individual mice of the same genotype with respect to the degree of pathology observed, the 
general pattern of histological observations described above was consistently observed 
between the three genotypes.  Representative images were digitally captured with a DC500 
colour camera (Leica Microsystems) using the Leica Application Suite software (Leica 
Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 200µm in 
D-F and 100µm in A-C, G-I.   
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FIGURE 6-14 30 WEEK FKRPMD AND FKRPMDLARGE PATHOLOGY (2) 
Centrally nucleated muscle fibres (#) and a variation in fibre size (**) were identified in both 
the FKRPMD (B, E, H) and FKRPMDLARGE (C, F, I) triceps (A-F) and soleus (G-I), although these 
were exacerbated in the FRPMDLARGE muscle, relative to the FKRPMD.  Additionally, 
occasional necrotic fibres (N) were identified in the muscle.  In FKRPMDLARGE muscle, 
fibrosis (F), fat infiltration (FI), degenerating muscle fibres (*) and the occasional 
hyperchromatic fibre were identified.  These were not seen in FKRPMD muscle.  No evidence 
of dystrophic muscle pathology was seen in the wildtype mice. 
 
Transverse 10µm cryosections from 30 week old WT (A, D, G), FKRPMD (B, E, H) and 
FKRPMDLARGE (C, F, I) triceps (A-F) and soleus (G-I) were stained with haematoxylin and 
eosin.  At least 3 sections from each mouse muscle were viewed under light microscopy 
using a DM4000B upright microscope (Leica Microsystems).  Although there were some 
differences between individual mice of the same genotype with respect to the degree of 
pathology observed, the general pattern of histological observations described above was 
consistently observed between the three genotypes.  Representative images were digitally 
captured with a DC500 colour camera (Leica Microsystems) using the Leica Application Suite 
software (Leica Microsystems) and compiled in Photoshop CS4 or CS5 (Adobe).  Scale bar 
denotes 200µm in D-F and 100µm in A-C, G-I.   
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6.3.9 DIFFERENTIAL MUSCLE INVOLVEMENT WAS MAINTAINED IN FKRPMDLARGE MICE 
As discussed in Chapter 5, a specific pattern of differential muscle involvement was 
observed in FKRPMD mice – of the 4 different muscles evaluated (triceps, diaphragm, 
gastrocnemius and soleus), the triceps a proximal limb girdle muscle displayed the most 
severe pathology, while the soleus, a slow postural muscle displayed the least histological 
evidence of muscle fibre degeneration with only a small number of centrally nucleated 
muscle fibres.  This pattern of involvement was still evident in the FKRPMDLARGE, but the 
degree of pathology evident in each muscle section was exacerbated relative to the FKRPMD.  
For example, very little dystrophic pathology (aside from an increased number of central 
nucleated fibres in 30 week old mice) was observed in the FKRPMD soleus, while a variation 
in fibre size and centrally nucleated muscle fibres were evident in the FKRPMDLARGE soleus 
muscles evaluated here at 6, 12 and 30 weeks of age.  Additionally, pathology in the 
diaphragm and gastrocnemius was worsened in all FKRPMDLARGE, with fat infiltration and 
fibrosis (not seen in the FKRPMD) evident in these muscles at 12 and 30 weeks of age 
respectively.   
 
Again, the worst dystrophic pathology was seen in the triceps of both the FKRPMD and 
FKRPMDLARGE mice.  In 30 week old FKRPMD mice, although regeneration is still on-going in 
the triceps, there is no evidence of fibrosis or fat infiltration (Figure 6-13 and Figure 6-14).  
Contrastingly in the FKRPMDLARGE triceps at 30 weeks there is significant histological 
evidence of muscle fibre loss and replacement with fibrosis and adipocytes (Figure 6-13 and 
Figure 6-14). 
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The descriptions given here are based on an evaluation of at least two sections from each 
individual muscle from two FKRPMDLARGE mice at 6 weeks of age, four at 12 weeks of age 
and four at 30 weeks of age.  
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6.3.10 CENTRAL NUCLEATION WAS INCREASED IN FKRPMDLARGE MICE 
The number of centrally nucleated muscle fibres in the gastrocnemius, diaphragm and 
soleus was evaluated and as shown in the bar graph below, FKRPMDLARGE have a greater 
percentage of centrally nucleated muscle fibres in these three muscles at both 12 and 30 
weeks of age than FKRPMD and wildtype mice (Figure 6-15).  To assess whether age, muscle 
and genotype were factors affecting the percentage of centralised nuclei, a Generalised 
Estimating Equations model was used.  This result indicated in these mice age, genotype and 
muscle were significant factors affecting the percentage of centralised nuclei (Figure 6-15). 
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FIGURE 6-15 CENTRAL NUCLEATION COUNTS OF FKRPMDLARGE MUSCLE 
A and B show bar graphs of the mean percentage of centrally nucleated muscle fibres ± SEM 
for 12 week (A) and 30 week (B) wildtype (green), FKRPMD (blue) and FKRPMDLARGE (red) 
mice.  The black line on the graph denotes 5%, which is considered the maximal percentage 
centralised nuclei for non-dystrophic mouse muscle.  Graphs were prepared using GraphPad 
Prism version 5.0 for Windows.   
 
C shows the results of the Generalised Estimating Equations Statistical test as a multiple line 
graph.  This model shows age, muscle and genotype are significant interacting factors on the 
percentage of centrally nucleated muscle fibres. 
 
Transverse 10µm cryosections of 12 and 30 week wildtype, FKRPMD and FKRPMDLARGE 
diaphragm (n=3 for all genotypes at both ages), gastrocnemius (n=3 for all genotypes at 
both ages), and soleus (n=3 for all genotypes at both ages) stained with haematoxylin and 
eosin were viewed under light microscopy using a DM4000B upright microscope (Leica 
Microsystems).  Images of the most representative section at the mid-belly region of the 
muscle were digitally captured with a DC500 colour camera (Leica Microsystems) using the 
Leica Application Suite software (Leica Microsystems).  Images were arranged into a 
composite image and muscle fibres with centralised or peripheral nuclei were counted 
across the section, using Photoshop CS4 or CS5 (Adobe) numbering approximately 500 
muscle fibres for the soleus, 1500 for the diaphragm and 2000 for the gastrocnemius.  The 
data was compiled and the percentage of centrally nucleated muscle fibres was calculated 
using Microsoft Excel.  This is a second analysis of the FKRPMD presented in Chapter 5 to 
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evaluate the effect of LARGE overexpression on the percentage of centrally nucleated 
muscle fibres  
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6.3.11 CALCIUM DEPOSITS WERE INCREASED IN FKRPMDLARGE MICE 
Intracellular calcium deposits have been identified with immunohistochemical stains 
performed on muscle cryosections from both patients and mouse muscle of muscular 
dystrophy (Bodensteiner and Engel, 1978, Cornelio and Dones, 1984, Glesby et al., 1988).  
As presented in the previous chapter, intracellular calcium deposits were visualised with 
Alizarin Red Staining in cryosections of gastrocnemius and diaphragm from the FKRPMD 
mouse at 12 and 30 weeks of age, although the deposits at 12 weeks of age are smaller than 
those identified in the older mice (Figure 5-12 and Figure 6-16).  In three individual 
FKRPMDLARGE mice at both 12 and 30 weeks of age, calcium deposits were visualised 
histologically with Alizarin Red in the gastrocnemius and diaphragm.  Examination of at least 
2 sections from each individual mouse muscle suggested the number of deposits was 
increased between the FKRPMD and FKRPMDLARGE mouse (Figure 6-16).  Additionally, the 
Alizarin Red deposits identified in the FKRPMDLARGE mice were larger, suggesting more 
calcium is incorporated in these deposits (Figure 6-16).  Indeed in some cases these deposits 
were apparent with the naked eye when the FKRPMDLARGE mouse was dissected (Figure 
6-17).  However, further quantification would be requied to confirm  
  




Page 443 of 551 
 
FIGURE 6-16 CALCIUM DEPOSITS IN THE FKRPMDLARGE MOUSE 
Calcium deposits (red precipitate) were evident in both the FKRPMD (B, E, H and K) and 
FKRPMDLARGE (C, F, I and L) muscle.  Calcium deposits in the muscles from the 3 
FKRPMDLARGE mice were larger and appeared increased in number when compared to 
muscles from the 3 FKRPMD mice, although quantification would be required to confirm this.  
No calcium deposits were observed in the wildtype muscle (A, D,G and J). 
 
Transverse 10µm cryosections of 12 week (n=3 for all individual muscles at both ages 
evaluated) (A-I) and 30 week (n=3 for all individual muscles at both ages evaluated) (J-L) old 
wildtype (A, D, G, J), FKRPMD (B, E, H, K) and FKRPMDLARGE (C, F, I, L) diaphragm (A-F, J-L) and 
gastrocnemius (G-I) were stained with Alizarin Red.  At least 3 sections from each individual 
mouse muscle were evaluated under light microscopy using a DM4000B upright microscope 
(Leica Microsystems) for the presence of red precipitates of Alizarin Red, which would 
indicate calcium deposits, as denoted by the arrows.  Alizarin Red deposits were observed in 
each FKRPMD and FKRPMDLARGE gastrocnemius and diaphragm muscle as described above, 
although deposits were not identified in every section of each muscle.  As shown in the 
images above, evaluation of all these sections suggested the deposits were generally more 
numerous and larger in FKRPMDLARGE muscle, when compared to FKRPMD, although 
quantification would be required to confirm these observations.  Representative images of 
the Alizarin Red deposits were digitally captured with a DC500 colour camera (Leica 
Microsystems) using the Leica Application Suite software (Leica Microsystems) and compiled 
using Photoshop CS4 or CS5 (Adobe).  Scale bar denotes 100µm in A-H and K-L and 200 µm 
in I-J.    
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FIGURE 6-17 FKRPMDLARGE DIAPHRAGM IN SITU 
Digital photographs of 12 week old control (n=3) (A, C) and FKRPMDLARGE (n=3) (B, D) 
dissected to show the both diaphragm in situ (A and B) and after it had been isolated from 
the mouse (C, D).  The white arrows show lines in the FKRPMDLARGE diaphragm that be seen 
with the naked eye.  Subsequent analysis revealed these lines to be calcium deposits.  These 
lines or deposits were not seen in the wildtype mouse after dissection.  Additionally, these 
deposits or lines were not observed in any FKRPMD mice (at least 4 mice) evaluated during 
the couse of this project.Images were captured using an Olympus FE-3000 camera and 
compiled using Photoshop CS5 (Adobe).  Images A and B were captured on the lab bench, 
while C and D were captured using an inverted dissection microscope. 
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6.3.12 GLYCOSYLATION OF α-DYSTROGLYCAN WAS INCREASED IN FKRPMDLARGE MICE 
At 12 weeks of age, there was increased IIH6 immunolabelling in the FKRPMDLARGE 
gastrocnemius relative to wildtype mice and FKRPMD mice (Figure 6-18).  This increased 
immunolabelling was consistent with the LV5 mice – wildtype mice overexpressing LARGE 
(Figure 6-18).  Immunolabelling for β-dystroglycan at the muscle fibre of FKPRPMDLARGE 
mice was unchanged, relative to either FKRPMD or wildtype mice (Figure 6-19).  This 
suggested upregulation of LARGE did not alter the overall level of dystroglycan at the 
basement membrane, but it did result in altered, increased α-dystroglycan, as identified by 
increased IIH6 immunolabelling at the muscle fibre sarcolemma (Figure 6-19)  
 
  
Page 446 of 551 
 
  
Page 447 of 551 
 
FIGURE 6-18 IIH6 IMMUNOLABELLING OF FKRPMDLARGE MUSCLE 
As documented previously in Chapter 5, IIH6 immunolabelling was reduced in FKRPMD 
muscle (B, F) relative to wildtype (A, E) mice.  IIH6 immunolabelling was increased in 
FKRPMDLARGE (D, H) mice, indicating altered, increased glycosylation of α-dystroglycan.  This 
increased glycosylation seen in FKRPMDLARGE was equivalent to that seen in LV5 
overexpressing mice (C, G). 
 
Transverse 10µm cryosections of muscle from 12 week old wildtype (n=3) (A, E), FKRPMD 
(n=3) (B, F), LV5 (n=3) (C, G) and FKRPMDLARGE (n=3) (D, I) gastrocnemius were 
immunolabelled with the IIH6 antibody against glycosylated α-dystroglycan (red) and 
Hoechst 33342 to visualise the nuclei (blue).  At least 2 sections from each invidivual mouse 
were viewed under epiflouresence using a DM400B upright microscope (Leica 
Microsystems).  In each FKRPMD section evaluated, IIH6 immunolabelling at the sarcolemma 
was reduced in comparison to wildtype, as described in Chapter 5.  In each FKRPMDLARGE 
section evaluated, increased IIH6 immunoalabelling was observed in comparison to both 
wildtype and FKRPMD.  This increased immunolabelling was consistent with wildtype mice.  
Representative images were captured with an mRM monochrome camera (Zeiss, U.K.) using 
the Axiovision software (Zeiss) provided and compiled into figures using Photoshop CS4 or 
CS5 (Adobe).  Where direct comparisons of immunolabelling intensity are made, the images 
(A-D) and (E-I) were captured at the same exposure.  Scale bar represents 100µm in A-D and 
50µm in E-I. 
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FIGURE 6-19 Β-DYSTROGLYCAN AND INTEGRIN Β1 IMMUNOLABELLING 
Immunolabelling for β-dystroglycan was identified at the gastrocnemius (A-C) and soleus (D-
F) sarcolemma in wildtype (A, D), FKRPMD (B, E) and FKRPMDLARGE (C, F) mice.  No difference 
in immunolabelling intensity was identified, suggesting β-dystroglycan expression was not 
changed by upregulation of LARGE.  Integrin β1 immunolabelling (G-I) was identified at the 
capillary basement membrane in wildtype (G), FKRPMD (H) and FKRPMDLARGE (I) 
gastrocnemius (*).  Additionally, integrin β1 immunolabelling was identified at the muscle 
fibre sarcolemma of some FKRPMD and FKRPMDLARGE muscle fibres (denoted by the arrow).  
The number of fibres with integrin β1 localisation appears consistent between FKRPMD and 
FKRPMDLARGE, suggesting this is not affected by LARGE upregulation.  
 
Transverse 10µm cryosections of 30 week old wildtyp (A, D, G), FKRPMD (B, E, H), and 
FKRPMDLARGE (C, F, I) gastrocnemius (n=3 for both immunostains performed on the three 
genotypes) (A-C, G-I) and soleus (n=3 for both immunostains performed on the three 
genotypes) (D-F) were immunolabelled with antibodies against β-dystroglycan (A-F) and 
integrin β1 (G-I) (red) and Hoechst 33342 to visualise the nuclei (blue).  At least 2 sections 
from each individual mouse (separated by a distance of approximately 120µm) were viewed 
under epifluorescence using a DM4000B upright microscope (Leica Microsystems).  
Immunolabelling for β-dystroglycan was identified at the sarcolemma of all muscle fibres in 
wildtype, FKRPMD and FKRPMDLARGE muscles, at comparable immunolabelling intensities.  
Immunolabelling for integrin β1 was identified at the sarcolemma of some fibres in the 
FKRPMD and FKRPMDLARGE gastrocnemius.  Evaluation of these sections suggested a similar 
number of fibres were immunolabelled in each section, although no quantification was 
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performed to confirm this.  Representative images were captured with an mRM 
monochrome camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and 
compiled into figures using Photoshop CS4 or CS5 (Adobe).  Scale bar represents 50µm.  
Images of A-C, D-F and G-I were captured at the same exposure. 
 
  
Page 451 of 551 
 
6.3.13 BASEMENT MEMBRANE DEPOSITION WAS ALTERED IN FKRPMDLARGE MICE 
It was hypothesised the increased glycosylation, seen as a result of LARGE upregulation, 
would restore laminin binding and localisation of laminin α2 at the basement membrane of 
FKRPMD mice.  Evaluation of laminin deposition at the basement membrane of FKRPMDLARGE 
mice with a pan laminin antibody did not show an increase in immunolabelling at the 
basement membrane, relative to wildtype and FKRPMD mice (Figure 6-20).  
 
However, immunolabelling with an antibody directed specifically against laminin α2 showed 
increased deposition at the basement membrane of FKRPMDLARGE muscle fibres (relative to 
wildtype and FKRPMD mice) (Figure 6-20).  Additionally, immunolabelling for laminin α4 in 
the FKPRMDLARGE mice showed localisation at the basement membrane of some fibres, 
similarly to the FKRPMD mice (Figure 6-20).  It seemed there was an increased incidence of 
fibres with laminin α4 expression at the basement membrane in FKRPMDLARGE mice, 
relative to FKRPMD (Figure 6-20). 
 
Basement membrane deposition was evaluated further, by immunohistochemistry for 
collagen type IV, which was identified at the basement membrane of muscle fibres in the 
FKRPMDLARGE, FKRPMD and wildtype mouse gastrocnemius, with no difference in 
immunolabelling intensity identified between the three genotypes (Figure 6-21).  
Additionally, the localisation of perlecan was evaluated immunohistochemically, as it binds 
to α-dystroglycan.  Perlecan localised to the basement membrane of muscle fibres in the 
FKRPMDLARGE mouse, and there was no difference in immunolabelling intensity between 
FKRPMD, FKRPMDLARGE and wildtype mice (Figure 6-21).  
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FIGURE 6-20 LAMININ IMMUNOLABELLING OF FKRPMDLARGE MUSCLE 
Pan-laminin (green) immunolabelling (A-C) was identified at the basement membrane of 
muscle fibres in wildtype (A), FKRPMD (B) and FKRPMDLARGE (C), with no difference in 
immunolabelling intensity between the three genotypes.  Laminin α2 (red) deposition (D-F) 
was reduced at the basement membrane of muscle fibres of FKRPMD
 mice (E) in comparison 
to wildtype (D).  Laminin α2 immunolabelling was increased in FKRPMDLARGE mice (F), over 
and above that of wildtype mice (E).  Laminin α4 (red) (G-I) was identified at the basement 
membrane of muscle fibres in FKRPMD (H) and FKRPMDLARGE (I) diaphragm, but not wildtype 
mice (G).  Additionally, it appeared that more muscle fibres labelled with the laminin α4 
antibody in the muscles from the 3 FKRPMDLARGE mice, when compared to the three 
FKRPMD mice.   
 
Transverse 10µm cryosections of muscle from 12 week old wildtype (A, D, G), FKRPMD (B, E, 
H) and FKRPMDLARGE (C, F, I) mouse gastrocnemius (A-F) and diaphragm (G-I) were 
immunolabelled with antibodies (shown in red or green) against pan-laminin (n=3 for all 
gentoypes) (A-C), laminin α2 (n=3 for all genotyes) (D-F) and laminin α4 (n=3 for all 
genotypes) (G-I) and Hoescht 33342 to label the nuclei.  At least 2 sections (separated by a 
distance of approximately 120µm) from each individual mouse were viewed under 
epifluorescence using a DM4000B upright microscope (Leica Microsystems).  The increase in 
pan-laminin and laminin α2 immunolabelling was seen at the basement membrane of all 
FKRPMD LARGE sections evaluated.  In the sections immunolabelled with the laminin α4 
antibody, musclefibres were identified in both the FKRPMD and FKRPMDLARGE diaphragm 
with laminin α4 localised to the basement membrane.  An evaluation of these sections here 
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suggested that more fibres with laminin α4 immunolabelling at the basement membrane 
were identified in the FKRPMDLARGE diaphragm, although quantification would be required 
to further confirm this.  Represenative images were captured with an mRM monochrome 
camera (Zeiss, U.K.) using the Axiovision software (Zeiss) provided and compiled into figures 
using Photoshop CS4 or CS5 (Adobe).  Scale bar represents 50µm.   
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FIGURE 6-21 BASEMENT MEMBRANE DEPOSITION IN FKRPMDLARGE MUSCLE 
Collagen type IV (A-C) was localised to the muscle fibre basement membrane of wildtype 
(A), FKRPMD (B) and FKRPMDLARGE (C) gastrocnemius, with no difference in immunolabelling 
intensity.  Perlecan (D-I) was localised to the muscle fibre basement membrane of 12 week 
old wildtype (D, G), FKRPMD (E, H) and FKRPMDLARGE (F, I) gastrocnemius (D-F) and soleus (G-
I), with no difference in immunolabelling intensity. 
 
Transverse 10µm cryosections of mouse muscle from 12 week old wildtype (A, D and G), 
FKRPMD (B, E and H) and FKRPMDLARGE (C, F and I) gastrocnemius (A-F) and soleus (G-I) were 
immunolabelled with antibodies (shown in red or green) against collagen type IV (A-C) (n=3 
for both genotypes) and perlecan (n=3 for both muscles and both genotypes) (D-I) and 
Hoescht 33342 to visualise the nuclei.  At least 2 sections (separated by a distance of 
approximately 120µm) from each individual mouse were viewed under epifluorescence 
using a DM4000B upright microscope (Leica Microsystems).  Collagen type IV and perlecan 
were localised to the basement membrane of all muscle fibres in the FKRPMDLARGE muscles, 
at comparable immunolabelling intensity to wildtype and FKPRMD muscles.  Representative 
images were captured with an mRM monochrome camera (Zeiss, U.K.) using the Axiovision 
software (Zeiss) provided and compiled into figures using Photoshop CS4 or CS5 (Adobe).  
Scale bar represents 50µm.   
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6.4 DISCUSSION 
Upregulation of LARGE in the FKRPMD mouse successfully increased IIH6 immunolabelling at 
the muscle fibre sarcolemma (suggestive of altered, increased α-dystroglycan glycosylation), 
which restored laminin α2 localisation to the basement membrane of muscle fibres.  
However, unexpectedly this did not improve the phenotype of the FKRPMD mouse, instead 
worsening the phenotype of the mice, both physically and histologically. 
 
6.4.1 THE LV5 TRANSGENE HAS EXACERBATED THE FKRPMD MOUSE PHENOTYPE 
Based on previous work in the Largemyd (Barresi et al., 2004), Fukutin Hp- and POMGnT1-/- 
mice (Kanagawa et al., 2009) it was hypothesised that upregulation of LARGE in the FKRPMD 
mice would improve the dystrophic phenotype.   
 
In female FKRPMD mice, a visible loss of muscle mass was identified, particularly from the 
lower limb girdles and this was maintained in the FKRPMDLARGE mice, with female FKRPMD 
and FKRPMDLARGE mice at 20 weeks of age weighing significantly less than wildtype mice.  
Male FKRPMDLARGE mice have a significant reduction in forelimb grip strength when 
compared to wildtype mice, but FKRPMD do not, suggesting upregulation of LARGE induced 
forelimb muscle weakness in FKRPMD mice.  The hindlimb extensor reflex, which is only 
affected in a small number of FKRPMD mouse, is perturbed in all but one of the 
FKRPMDLARGE mice evaluated at the same age.  Finally, female FKRPMDLARGE also have a 
significant reduction in the resistance to eccentric exercise contraction induced injury when 
compared to wildtype, unlike FKRPMD.  In combination, this suggests that upregulation of 
LARGE has worsened the phenotype of the FKRPMD mice.  
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Upregulation of LARGE has also worsened the histopathology of FKRPMD mice, with larger 
calcium deposits, an increased fraction of centrally nucleated muscle fibres and 
histopathological features that were not present in FKRPMD mice – fibrosis and replacement 
of muscle by adipocytes.  FKRPMD mice have a characteristic pattern of muscle involvement 
with proximal muscles, such as the triceps, more severely affected than the distal muscles 
such as the gastrocnemius and the soleus.  This pattern has been preserved in the 
FKRPMDLARGE mouse, but the dystrophic pathology in each muscle is worsened, relative to 
the FKRPMD.  The age of onset in the FKRPMD mouse is approximately 6 weeks, but there 
multiple regenerating fibres and widespread inflammatory infiltrates in the FKRPMDLARGE 
mouse at this age, possibly suggesting an earlier age of onset, although further work would 
be required to confirm this. 
 
The crisis period of muscular dystrophy is the “active” phase of muscular dystrophy, when 
muscle fibres are undergoing necrosis, degeneration and regeneration and it is also 
associated with the presence of inflammatory infiltrates.  The crisis period occurs in the 
FKRPMD mouse between approximately 6 and 12 weeks of age, so that at 30 weeks of age 
there is no overt on-going necrosis or degeneration in most FKRPMD muscles, although the 
number of fibres that are centrally nucleated is increased, due to the earlier crisis phase.  It 
would appear that upregulation of LARGE has worsened the crisis period of FKRPMD mice 
and additionally extended it, with degenerating fibres identified in older FKRPMDLARGE mice, 
but not FKRPMD mice. 
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6.4.2 A COMPARISON WITH OTHER STUDIES EVALUATING LARGE OVEREXPRESSION  
The initial work conducted on LARGE overexpression in vitro was performed on cell lines 
from dystroglycanopathy patients (either fibroblasts or myoblast) with MEB, FCMD and 
WWS carrying mutations in POMGNT1, FUKUTIN and POMT1 respectively (Barresi et al., 
2004).  Since then other in vitro work has been published showing upregulation of LARGE 
increases IIH6 immunolabelling and ligand binding in neural cell lines from POMGnT1-KO 
and POMT2-floxed mice (Hu et al., 2011b).  Whilst these are good proof-of-concept studies 
demonstrating LARGE overexpression increases IIH6 immunolabelling and restoring ligand 
binding, these in vitro studies cannot demonstrate whether long term expression will 
prevent or reduce muscle fibre degeneration in vivo.  There are two other published in vivo 
studies, advocating the upregulation of LARGE as a successful therapeutic strategy (Barresi 
et al., 2004, Kanagawa et al., 2009).  However, there are several key differences between 
the studies – 1) the gene mutation involved, 2) the timing and duration of therapeutic 
intervention and 3) the mechanism by which LARGE overexpression was achieved. 
 
The first in vivo work, performed in Largemyd mice reported that LARGE overexpression 
increased IIH6 immunolabelling over and above that of wildtype mice, suggesting 
hyperglycosylation of α-dystroglycan, which restored the ability of α-dystroglycan to bind to 
laminin and improved the histopathology of the mice (Barresi et al., 2004).  However, this 
study was similar in design to a gene replacement study, as the authors replaced the faulty 
mouse Large gene with a human LARGE gene (Barresi et al., 2004), so the conclusions from 
this work are not necessarily translatable to dystroglycanopathies with mutations in other 
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genes.  Additionally, this was a short-term study, with the effect of LARGE overexpression 
evaluated after 4 weeks (Barresi et al., 2004).  Finally, LARGE overexpression was achieved 
through intramuscular injection of AAV (Barresi et al., 2004), which was limited because 
firstly analysis was restricted to the injected muscle and secondly the number of LARGE 
overexpressing fibres was dependent on transfection efficiency, estimated to be 40-80% in 
this study (Barresi et al., 2004).  Thus, not all the muscle fibres would have been 
overexpressing IIH6 and additionally the level of LARGE overexpression would have been 
variable between the different muscle fibres.   
 
The second in vivo study, published in 2009, evaluated LARGE overexpression in the Fukutin 
Hp- and POMGnT1-/- mouse models and reported increased IIH6 immunolabelling, 
suggesting hyperglycosylated α-dystroglycan and restored laminin binding (Kanagawa et al., 
2009).  However, the Fukutin Hp- mouse did not display histopathological evidence of 
muscular dystrophy (Kanagawa et al., 2009) and consequently this did not provide 
assessment on whether this could prevent development of dystrophic pathology.  The 
second mouse model used, the POMGnT1-/- mouse, has been reported to develop 
dystrophic pathology (Miyagoe-Suzuki et al., 2009), but the histopathological phenotype of 
POMGnT1-/- mice overexpressing LARGE was not reported in the publication (Kanagawa et 
al., 2009).  This study was also a short-term study, with LARGE overexpression achieved 
through intramuscular injection of an AAV, so the analysis again will be restricted to the 
injected muscle and limited by transfection efficiency. 
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In comparison, the study presented was a long-term study with pathology evaluated in the 
FKRPMDLARGE mice at 12 and 30 weeks of age.  Additionally, as LARGE upregulation was 
achieved by a transgenic approach, all muscle fibres would have a consistent level of LARGE 
overexpression, in all muscles, allowing the comparison of multiple muscle groups  This 
makes the data presented here on LARGE upregulation unique as it is the first to document 
a detailed physical and histopathological evaluation of long-term LARGE overexpression in a 
mouse model for the dystroglycanopathies. 
 
6.4.3 WHAT DOES THIS WORSENED PATHOLOGY SUGGEST ABOUT THE FUNCTIONAL 
IMPLICATIONS OF FKRP DEFICIENCY? 
LV5 transgenic mice (wildtype mice with the LARGE transgene) do not show any 
histopathological evidence of muscular dystrophy, aside from a subclinical defect in the 
resistance of muscle fibres to eccentric exercise (Brockington et al., 2010), whilst expressing 
LARGE on a disease background (FKRPMDLARGE) results in a worsening of the  dystrophic 
phenotype.   
 
As already mentioned this strategy was adopted because it was hypothesised that altered, 
increased glycosylation of α-dystroglycan would restore the binding between dystroglycan 
and the muscle fibre basement membrane.  Interestingly, in the FKRPMDLARGE mouse, 
laminin deposition (recognised with antibodies against both generic laminin and laminin α2) 
at the basement membrane was increased, over and above the level seen in wildtype, 
FKRPMD or LV5 mice.  This phenomenon was restricted to laminin, as the deposition of other 
basement membrane proteins was consistent between wildtype, FKRPMD and FRPMDLARGE 
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mice.  This included ligands that bind directly to α-dystroglycan (perlecan) (Peng et al., 1998) 
and those ligands (collagen type IV), which bind to integrins and other basement membrane 
proteins (laminin, nidogen and heparin sulphate proteoglycans), not dystroglycan 
(Aumailley et al., 1989, Paulsson, 1992, Eble et al., 1993, Hopf et al., 1999, Tiger et al., 2001, 
Tulla et al., 2001, Leitinger and Hohenester, 2007, Carmignac and Durbeej, 2012).  Increased 
laminin deposition at the basement membrane was not reported following LARGE 
upregulation in Largemyd,
 FCMD Hp- or POMGNT1-/- mice (Barresi et al., 2004, Kanagawa et 
al., 2009), suggesting this increased laminin deposition is specific to the reduction in Fkrp 
expression seen in the FKRPMDLARGE mouse.  The FKRPMDLARGE mouse was the only model 
with significant evidence of dystrophic histopathology, so these changes could be associated 
with the muscle fibre regeneration seen in this model. 
 
In FKRPMDLARGE mice, the increased ability of α-dystroglycan to bind laminin coupled with 
the increased levels of laminin at the basement membrane suggest the connection between 
the muscle fibre and the basement membrane has been strengthened.  As already 
mentioned, dystroglycan and the basement membrane are part of the costameric lattice, 
which acts as a force distributer and shock absorber during contraction (Karpati, 2010).  In 
the FKRPMD mouse, the binding between α-dystroglycan and the basement membrane is 
perturbed and “breaks” under mechanical stress (during contraction), inducing muscle fibre 
damage.  However, in FKRPMDLARGE mice, the binding between α-dystroglycan and laminin 
is increased, perhaps making this connection too strong and the basement membrane too 
rigid, so that during contraction, the mechanical and physical stresses do not dissipate 
properly, so damage occurs elsewhere, for example at the muscle fibre sarcolemma.  
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Indeed, the data generated in this project seems to suggest that making the adhesion 
between the basement membrane and the muscle fibre too rigid is worse than not being 
strong enough. 
  
As already mentioned, LARGE is thought to be a bifunctional glycosyltransferase that binds 
to the N-terminal domain of dystroglycan, where it acts with both xylosyltransferase and 
glucuronyltransferase activity to add a repeating unit of [-3xylose-α1,3-glucoronic aid-β1-] 
to α-dystroglycan (Kanagawa et al., 2004, Inamori et al., 2012).  However, recently it was 
identified in vitro that LARGE overexpression in dystroglycan deficient cells increased IIH6 
immunolabelling (Zhang et al., 2011).  While this finding has limitations because it was 
identified in an in vitro overexpression study, it suggests that LARGE could have a role in 
glycosylating and additionally conferring laminin binding to other proteins that are not 
dystroglycan (Zhang et al., 2011).   
 
6.4.4 CONCLUDING REMARKS 
The work presented here suggests binding between the basement membrane and the 
extracellular matrix needs to be tightly controlled for muscle function.  This has important 
therapeutic implications for the dystroglycanopathy spectrum, emphasising the value of 
determining the effect of LARGE overexpression on a disease background and suggesting 
that any therapeutic approach involving LARGE upregulation requires careful management. 
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7 DISCUSSION 
The function of Fkrp has not been fully elucidated, but it is thought to be involved in 
glycosylation, given its association with altered, reduced glycosylation of α-dystroglycan.  
Therefore, in this thesis it was decided to adopt a different approach and investigate the 
function of Fkrp through evaluation of the downstream consequences of Fkrp deficiency.  
Defects in the muscle, brain and eye have been identified in dystroglycanopathy patients 
carrying mutations in Fkrp and therefore it was first decided to evaluate these tissues using 
a mouse with a global reduction in Fkrp expression of approximately 80% (the FKRPKD 
mouse). 
 
In the first experimental chapter (Chapter 3), it was demonstrated that a reduction in Fkrp 
expression altered the distribution of basement membrane ligands at the pial basement 
membrane of the cortex.  The disorganisation at this basement membrane was associated 
with aberrant positioning of cortical neurons in the FKRPKD mouse, suggesting these defects 
are associated with defective cortical lamination.  Interestingly, an investigation of wildtype 
mouse cortex showed, for the first time, that early in development (E12.5), there was 
enhanced glycosylation of α-dystroglycan at the pial basement membrane compared to 
newborn.  This glycosylation was lost in the FKRPKD mouse which suggests that defects in 
basement membrane integrity due to abnormal α-dystroglycan glycosylation may be 
intitiated around this time although studies of earlier embryos would be needed to confirm 
this. . 
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Additionally, it was demonstrated that a reduction in Fkrp expression altered the 
distribution of basement membrane ligands in the tongue, but not the extraocular muscles.  
The tongue muscle, like other skeletal limb muscles  is affected in the dystroglycanopathies, 
with hypertrophy reported in some patients, including those carrying mutations in FKRP 
(Quijano-Roy et al., 2002, Mercuri et al., 2003, Louhichi et al., 2004).  Contrastingly, 
although the involvement of the extraocular muscles in the dystroglycanopathies has not 
been reported, this muscle group is reported to be unaffected in other muscular dystrophies 
including DMD (Kaminski et al., 1992, Khurana et al., 1995,  traube and B ttner, 200 ) 
laminin α2 deficient muscular dystrophy (Porter and Karathanasis, 1998), sarcoglycan 
deficiency (Porter et al., 2001) and CMD (Mendell et al., 1995).  It is currently thought that 
intrinsic differences between the extraocular muscles and other skeletal muscles ncluding 
their developmental origins (Karpati, 2010), fibre types (Porter, 2002,  traube and B ttner, 
2007) innervation patterns ( traube and B ttner, 2007) and calcium handling (Zeiger et al., 
2010) are crucial for this phenomenon.  Data presented in this thesis now now suggests that 
differences in basement membrane composition and the glycosylation pattern of α-
dystroglycan may contribute to an individual muscles susceptibility to the disease process.  
In muscular dystrophies, it is thought that defects in the linkage between the actin 
cytoskeleton and the extracellular matrix result in the muscle fibres being subjected to 
cycles of degeneration and regeneration (Karpati, 2010), so these intrinsic differences could 
be protective, contributing to the the sparing of extraocular muscles.  
 
Despite these changes in basement membrane composition and glycosylation of α-
dystroglycan in the FKRPKD tongue, and the involvement of the tongue in the 
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dystroglycanopathy patient phenotype (Quijano-Roy et al., 2002, Mercuri et al., 2003, 
Louhichi et al., 2004), no histological evidence of dystrophic pathology was observed in the 
FKRPKD tongue.  However, since in other models with defects in the functioning of the DAPC 
(the mdx mouse) muscle pathology is first documented histologically at approximately three 
weeks of age , (Bulfield et al., 1984), the absence of dystrophic pathology in the newborn 
FKRPKD tongue may not reflect the situation in adult mice.   
 
In the second experimental chapter of this thesis, it was shown using the FKRPKD mouse that 
a reduction in Fkrp expression was associated with defective basement membrane 
deposition at the two basement membranes of the eye – the ILM and Bruch’s membrane.  
Interestingly, the ligand composition of these two basement membranes varied in wildtype 
mice, with laminin α2 expression identified at Bruch’s membrane, but not the ILM.  Previous 
studies had not reported laminin α2 deposition at Bruch’s membrane (Aisenbrey et al., 
2006, Bystrom et al., 2006, Lunardi et al., 2006), so not only was this thesis the first piece of 
work to identify that laminin α2 deposition was perturbed at Bruch’s membrane in the 
dystroglycanopathies, it was the first study to identify laminin α2 deposition at Bruch’s 
membrane in wildtype mice.  Additionally, there were further differences between these 
two basement membranes since whilst the deposition of ligands was reduced at both 
basement membranes, fragmentation was only observed at the ILM in the FKRPKD mouse.  
 
Glycosylated α-dystroglycan was identified at both the ILM and Bruch’s membrane in 
wildtype mice, with this glycoyslation altered, reduced at both basement membranes in the 
FKRPKD mouse.  Previously, it had only been shown that integrin receptors were important 
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for the deposition and function of Bruch’s membrane (Aisenbrey et al., 2006), so this piece 
of work identified a novel role for dystroglycan in the deposition of Bruch’s membrane.  
Interestingly, similarly to the pial basement membrane of the cortex, it was shown in the 
wildtype mouse eye that glycosylation of α-dystroglycan was enhanced at both the ILM and 
Bruch’s membrane early during development relative to the situation at birth.  This was the 
first time that temporal changes in the pattern of dystroglycan glycosylation during eye 
development have been identified.  In the FKRPKD mouse eye, this glycosylation of α-
dystroglycan was lost, which was associated with defects in retinal structure including an 
increased retinal depth and the protrusion of retinal ganglion cells into the vitreous body.  
This suggests the glycosylation pattern of α-dystroglycan and its temporal regulation are 
crucial for eye development. 
 
Retinal development proceeds across the eye in a wave, beginning at the centre and then 
spreading to the periphery (Harman and Beazley, 1989, Anezary et al., 2001, Fischer and 
Reh, 2003, Fischer et al., 2004, Ghai et al., 2008, Bassett and Wallace, 2012).  Interestingly, a 
similar pattern was observed with respect to the defects associated with a reduction in Fkrp 
expression.  For example, at P0, although the inner retina took up a larger proportion of eye 
depth in the FKRPKD (when compared to wildtype) at both central and peripheral regions, an 
increase in the absolute inner retinal depth was only seen in the central retina.  Additionally, 
whilst protrusion of retinal ganglion cells through the ILM was observed in the FKRPKD 
mouse in both the central and peripheral regions, significant fragmentation was only 
observed in the central retina.  This suggests that, similarly to retinal differencetiation and 
eye development, the defects induced by a reduction in Fkrp expression might begin in the 
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central retina and expand to the peripheral retina as the eye develops.  This further 
highlights the importance of Fkrp and the glycosylation of α-dystroglycan for retinal 
development.   
 
Mouse eyes are relatively immature at birth, since a lot of their development occurs 
postnatally (Pang and Clark, 2010) and therefore the decision was made to focus on retinal 
development in this thesis, as the perinatal death limits the analysis of the FKRPKD eye.  
However, the defects in basement membrane deposition, retinal organisation and retinal 
lamination seen in the FKRPKD eye at P0, suggest that a reduction in Fkrp expression would 
have severe consequences for eye function.  One of the layers of Bruch’s membrane is the 
RPE, which is an important support tissue for the retina, particularly for signal transduction 
– the conversion of light impulses into neuronal signals.  Additionally, the increased retinal 
width and the protrusion of retinal ganglion cells into the vitreous body suggest that the 
neurons in the retina would not pattern in the absence of Fkrp.  In combination, these 
would have significant consequences for signal transduction through the retina, markedly 
affecting vision. 
 
So, it has been shown here that a reduction in Fkrp expression is associated with basement 
membrane defects in the muscle, the brain and the eye.  These basement membrane 
defects observed in vivo could arise through either a direct mechanism, where the 
basement membrane fails to deposit correctly, or alternatively an indirect mechanism, 
where the basement membrane initially deposits correctly, but its structure is not stabilised, 
so it degenerates.  In the first experimental chapter of this thesis, it was demonstrated that 
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a reduction in Fkrp expression directly affects the deposition of basement membrane 
ligands, using the first conditionally immortalised clonal myogenic cell line with a reduction 
in Fkrp expression (H2K-FKRPKD 1.C10).  As α-dystroglycan has been shown to have a crucial 
role in basement membrane deposition (Williamson et al., 1997, Henry et al., 2001), it is 
likely that the altered reduced glycosylation of α-dystroglycan seen in H2K-FKRPKD 1.C10  
contributes to this defective basement membrane deposition  
 
The initial work presented in the first two chapters of this thesis was conducted in the 
FKRPKD mouse, which has a global reduction in Fkrp expression of approximately 80% and 
dies in the early perinatal period.  Whilst this mouse is a good model for both the severe 
end of the dystroglycanopathy patient spectrum and evaluating tissue development on a 
background of reduced Fkrp expression, its perinatal lethality makes it unsuitable for 
evaluating tissue function, the long-term effects of reduced Fkrp expression, testing 
therapeutic strategies for the dystroglycanopathies or modelling the limb girdle muscular 
dystrophies at the milder end of the dystroglycanopathy patient spectrum.  Therefore it was 
necessary to generate a new mouse model for these analyses.   
 
In the FKRPKD mouse model, the reduction in Fkrp expression is caused by the presence of 
the Neomycin cassette in the second intron of the Fkrp gene (Ackroyd et al., 2009).  This 
Neomycin selection cassette is flanked by loxP sites, so removal of the Neomycin selection 
cassette with Cre recombinase will restore Fkrp expression.  LoxP sites and Cre recombinase 
are commonly used to generate transgenic mouse models – by inserting loxP sites within 
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the gene of interest and expressing Cre recombinase under different tissue specific 
promoters, one can investigate the consequences of a loss in gene expression within 
different tissues.  A complete deletion of dystroglycan is embryonic lethal at approximately 
E7.5 in the mouse due to a failure to form Reichert’s membrane (Williamson et al., 1997) 
making it impossible to study the implications of an absence of dystroglycan on subsequent 
tissue development.  However, the development and use of conditional knockouts, with 
tissue or cell specific deletion of dystroglycan, have allowed the role of dystroglycan in the 
muscle (Cohn et al., 2002), the eye (Satz et al., 2009) and brain development (Moore et al., 
2002, Satz et al., 2008) to be studied.  However, the use of Cre recombinase in this thesis is 
different, as Cre recombinase was not used to inactivate Fkrp expression, but instead to 
restore Fkrp expression in the tissue of interest, the central nervous system. 
 
This different approach could be taken because of both the design of the FKRPKD model and 
the problem which had to be addressed.  It was thought that the perinatal lethality seen in 
the FKRPKD mouse was due to the documented severe central nervous system 
defects(Ackroyd et al., 2009, Ackroyd et al., 2011, Booler et al., 2012), so therefore it was 
hypothesised that a restoration of Fkrp expression in the central nervous system would 
ameliorate these defects, allowing the mice to live beyond birth.  However, at the time this 
study was undertaken, whilst the importance of Fkrp expression and dystroglycan 
glycosylation for cortical development was known, it was not clear what the mechanism was 
and therefore cell types were crucial for development of the phenotype.  Nonetheless, once 
Cre recombinase has excised the genetic sequence flanked by the LoxP sites, the sequence is 
removed, so none of the daughter cells derived from that cell will contain the excised 
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sequence.  The implications of this for the new mouse model were that, provided Fkrp 
expression was restored early enough in neural development, it would be almost irrelevant 
that the mechanism behind the cortical phenotype was not known.   
 
Sox1 is a transcription factor which is expressed in the early neuroectoderm and has been 
shown to be involved in early nervous system development, specifically maintaining the 
identity of neuronal progenitors (Pevny et al., 1998).  Therefore, by utilising the Sox1Cre 
mouse, a model developed to study mesenchymal stem cells which expresses Cre 
recombinase under the Sox1 promoter (Takashima et al., 2007) in a breeding cross with the 
FKRPKD mouse, Fkrp expression would be restored in all the cells derived from the 
neuroectoderm, i.e. the majority of cells found in the developing and mature central 
nervous system, including neuroepithelial cells,  radial glial cells, neurons, astrocytes and 
oligodendrocytes, with the exception of the microglia, which differentiate in the bone 
marrow from haematopoietic stem cells.  This strategy was successful generating a mutant 
mouse with wildtype levels of Fkrp expression in the brain but a reduction in Fkrp 
expression of approximately 80% in other tissues, including skeletal muscle.  This mouse, 
referred to as the FKRPMD mouse lived beyond the perinatal period and had a cortical 
histology comparable to wildtype, highlighting the importance of Fkrp expression for cortical 
development. 
 
Due to this restriction in the restoration of Fkrp expression to the central nervous system, 
the FKRPMD mouse had an 80% reduction in Fkrp expression in the skeletal muscle.  This was 
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associated with defects in the muscle fibre basement membrane including reduced 
expression of laminin α2 and increased expression of laminin α4.  These changes were 
associated with altered reduced glycosylation of α-dystroglycan.  The changes in the 
basement membrane ligand distribution and α-dystroglycan glycosylation were associated 
with the development of a dystrophic pathology in the FKRPMD mouse.  Histological onset of 
this pathology was approximately 6 weeks of age, with the crisis period at approximately 12 
weeks of age, when widespread muscle fibredegeneration, regeneration and necrosis was 
observed in the muscles, along inflammatory infilitration and the presence of calcium 
deposits.  By 30 weeks of age, the muscle pathology had stabilised and there was very little 
ongoing degeneration or regeneration at this age, although the majority of the muscle fibres 
were centrally nucleated, indicating previous regeneration cycles in the crisis period.  
Interestingly, like LGMD2I patients there was a muscle specific variation in pathology, with 
the triceps, a limb girdle muscle more severely affected than the soleus, a postural muscle.  
However,  this  histological evidence of dystrophic pathology was identified in the FKRPMD 
mouse, the physical phenotype appeared comparatively mild, with no significant reduction 
in forelimb grip strength or the resistance of the muscles to eccentric exercise. 
 
Dystroglycan functionally acts as a basement membrane anchor, providing a physical 
connection between the basement membrane and the cytoskeleton of the cells (Moore and 
Winder, 2010) and so the loss of this physical connection means that these structures will be 
physically weakened.  As highlighted here, the loss of this physical connection has different 
consequences for different tissues.  At the pial basement membrane and ILM, the 
consequences of this for tissue integrity are evident during development - the weakened 
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basement membrane was no longer able to restrict neuronal migration effectively, resulting 
in the mislocalisation of Tbr1 positive neurons in the cortex and ectopias of Brn3 positive 
retinal ganglion cells in the eye.  Contrastingly in the muscle the implications of this 
weakened basement membrane manifest postnatally, with the development of a dystrophic 
phenotype.  Yet, despite these differences in phenotype the cortex, the muscle and the eye, 
a physical weakness in the basement membrane is still a contributory factor. 
 
Additionally, a reduction in Fkrp expression was associated with altered distribution of 
laminin trimers at the basement membrane.  The arrangement and distribution of laminin 
trimers at the basement membrane is tissue specific (Hallmann et al., 2005), suggesting that 
the alteration of the laminin trimer composition will have important functional 
consequences.  Interestingly and probably related to the tissue specific patterning of 
laminin, the specific alterations in the laminin trimer distribution varied between the 
different basement membranes – laminin α1 localisation to the pial basement membrane 
and the ILM was reduced,   laminin α2 expression was reduced at the muscle fibre basement 
membrane and Bruch’s membrane, whilst increased localisation of laminin α4 was identified 
at the muscle fibre basement membrane only.  Despite the heterogeneity in the laminin 
trimer changes, these changes will alter the structural and functional properties of each 
individual basement membrane, including their interaction with the cellular adhesion 
receptors, as different laminin α chains have different binding affinities for both 
dystroglycan and the integrin receptor complexes (Hallmann et al., 2005).  These changes 
will then of course be compounded by the basement membrane being structurally weaker, 
as described above. 
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As previously mentioned, it was noted in this thesis that a reduction in Fkrp expression 
resulted in an altered reduced pattern of α-dystroglycan glycosylation in the muscle, the 
brain and the eye, visualised as a reduction in IIH6 immunolabelling.  The molecular weight 
of dystroglycan has been shown to vary between different mature tissues (approximately 
156 kDa in muscle, 140kDa in cardiac muscle and 120kDa in brain (Ibraghimov-Beskrovnaya 
et al., 1993)), suggesting its glycosylation pattern varies between different these tissues - 
this could include core glycan structures, extended structures and terminal decorations 
between these different tissues (Gomez Toledo et al., 2012).  The IIH6 antibody recognises 
one epitope of α-dystroglycan and this piece of work has identified for the first time 
differences in IIH6 immunolabelling in the same tissue at different stages of development, 
suggesting that the glycosylation pattern of α-dystroglycan is both developmentally and 
tissue regulated.  It is currently thought that the heterogeneity of glycosylation is in part 
achieved through competition between glycosyltransferases and inefficiencies of the 
enzyme reactions (Moremen et al., 2012).  Interestingly, the expression of Fkrp varies 
between different tissues with the highest levels identified in the brain, lungs, kidney heart, 
placenta and liver (Brockington et al., 2001a, Esapa et al., 2002, Ackroyd et al., 2009) and it 
is developmentally  regulated in human muscle (Torelli et al., 2005), suggesting that either 
different tissues have differing requirements for the glycan modification Fkrp is involved in 
or that there are a number of different proteins in the brain that are targets for FKRP. This 
could also be the case at different stages of development.  Based on the functional 
implications of Fkrp deficiency highlighted here, this modification seems to be important 
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prenatally in the cortex and the retina for neuronal lamination, whereas in muscle it seems 
to be required postnatally for stabilisation of the basement membrane. 
 
IIH6 is a commonly used antibody for the clinical diagnosis of dystroglycanopathies, with 
dystroglycan classified as hypoglycosylated on the basis of a reduction, or absence of 
immunolabelling on a patient muscle biopsy, although, since IIH6 only recognises one 
glycosylation epitope, a reduction or loss of immunolabelling simply indicates a reduction or 
absence of that glycosyl structure.  Nevertheless, a Western Blot analysis of patient samples 
with the same antibody identifies a protein with a reduced molecular weight (Brockington et 
al., 2001a, Michele et al., 2002), which does indicate there is an overall loss of glycosyl 
structures from α-dystroglycan in the dystroglycanopathies.   
 
In the dystroglycanopathies there is a wide spectrum of clinical phenotypes, with mutations 
in a number of genes, although there is no correlation between the severity of the clinical 
phenotype and the gene carrying the mutation.  Instead, there seems to be a correlation 
between the specific mutations in each individual gene and the clinical phenotype, for 
example with respect to FKRP, the Leu276Ile point mutation is associated with an milder 
adult onset LGMD2I phenotye (Brockington et al., 2001b), whilst the Tyr307Asn mutation 
has been associated with a severe MEB phenotype (Beltran-Valero de Bernabe et al., 2004, 
Mercuri et al., 2006).  This suggests that the nature of each point mutation and how it 
perturbs enzymatic function within the glycosylation pathway, which is important, rather 
than the specific enzyme involved.  
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Associated with this, it should also be noted that if the glycosylation pattern of α-
dystroglycan is achieved through competition between different enzymes, then the loss of 
functioning in one enzyme will not simply result in a loss of glycosylation structures from the 
protein, as immunolabelling with IIH6 implies.  Instead, as the balance of 
glycosyltransferases will be altered, it is likely there will also be rearrangement of the 
remaining glycosyl structures on α-dystroglycan.  Therefore, in the dystroglycanopathies, 
the pattern of α-dystroglycan glycosylation should be referred to as altered, reduced and 
not simply reduced.  
 
It has often been proposed that a good therapeutic strategy for this group of disorders 
would be one which restored the glycosylation of α-dystroglycan.  LARGE is a bifunctional 
glycosyltransferase which, when upregulated, has been reported in several short-term 
studies to improve the dystrophic phenotype of other dystroglycanopathy mouse models 
(Barresi et al., 2004, Kanagawa et al., 2009, Hu et al., 2011b).  Contrastingly, here it has been 
shown in a long-term study, contrary to the hypothesis, that transgenic upregulation of 
LARGE exacerbated the histopathological and physical phenotype of FKRPMD mice.  Whilst 
this result should not mean that LARGE upregulation as a therapeutic strategy should be 
abandoned, it does suggest it requires further investigation before proceeding into clinical 
trials with dystroglycanopathy patients, particularly as upregulation of LARGE on a wildtype 
mouse background does not induce histological or physical abnormalities, aside from a small 
subclinical defect in the resistance of the muscle to eccentric exercise contractions 
(Brockington et al., 2010).  As discussed above, wildtype and FKRPMD mice will have a 
different pattern of α-dystroglycan glycosylation before the overexpression of LARGE and 
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overxpression of LARGE in FKRPMD mice will have generated another, different glycosylation 
arrangement.  It is likely that the downstream implications of these different arrangements 




7.1 CONCLUDING REMARKS 
 
A reduction in Fkrp expression was associated with reduced, altered glycosylation of α-
dystroglycan in the brain, the eye and muscle, which contributed to defects in the ligand 
distribution and structure of the basement membrane.  These had significant implications 
for tissue integrity, with defects in cortical and retinal lamination observed.  A new mouse 
model for the dystroglycanopathies (the FKRPMD) was developed, which showed a reduction 
in Fkrp expression in the muscle was associated with the development of a dystrophic 
pathology.  This dystrophic pathology was unexpectedly exacerbated following the 
upregulation of LARGE, suggesting this therapeutic strategy requires further investigation. 
 
7.2 FURTHER WORK  
Here, it has been shown that a reduction in Fkrp expression affects the pattern of laminin 
deposition, both how it deposits and the global expression of laminin trimers, which will 
affect the structure of the basement membrane.  Therefore, the ILM, Bruch’s membrane, 
pial basement membrane and the muscle fibre basement membrane should be examined 
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ultrastructurally, to compare the arrangement of different basement membranes and then 
consequently how these are perturbed by a reduction in Fkrp expression. 
 
The data generated here from the FKRPMD mouse implies that a reduction in Fkrp expression 
perturbs a number of intracellular downstream signalling pathways in muscle, due to the 
impaired interaction between laminin and dystroglycan.  Using the FKRPMD mouse, these 
pathways should be investigated further, either in vitro or in vivo, to confirm these 
conclusions.  Additionally, the alteration in the distribution of Tbr1 positive neurons 
identified in the FKRPKD cortex suggested the cortical spinal tract might be affected by a 
reduction in Fkrp expression.  This will have implications for the function of the peripheral 
nervous system, and even more specifically, muscle innervation.  This should be investigated 
further histologically, by evaluating the spinal cord, peripheral nerves and the 
neuromuscular junction and functionally, by measuring nerve conduction.  Finally, as the 
FKRPMD mouse has a knockdown in Fkrp expression, in all cells and tissues that did not 
express Sox1 (the central nervous system), a full phenotyping study should be conducted to 
further understand the functional implications of Fkrp deficiency, as in this thesis only 
muscle function and pathology was evaluated..   
 
It was hypothesised that part of the mechanism for a worsened disease phenotype in the 
FKRPMDLARGE mice was a more inflexible, or rigid basement membrane and this should be 
evaluated further.  For example laminin or agrin overlays could be used to assess the 
interaction between dystroglycan and these basement membrane ligands.  Additionally, the 
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rigidity of the basement membrane could be assessed with atomic force microscopy, in 
comparison to the FKRPMD and wildtype mice.   
 
Here, the generation of a FKRP deficient conditionally immortalised novel clonal myogenic 
cell line has been described.  As it is a clonal cell line, all daughter cells are identical and 
should behave in a similar manner when exposed to different conditions.  This cell line 
displays reduced IIH6 immunolabelling, suggestive of altered, reduced glycosylation of α-
dystroglycan, and perturbed laminin deposition on the extracellular surface, which can be 
used as outcome measures for an initial screening of drugs as potential therapeutic agents.  
These  could include therapies that have been shown promise in other mouse muscular 
dystrophy models where interactions between the muscle fibre and the basement 
membrane was impaired, including doxycycline (Girgenrath et al., 2009), insulin growth 
factor 1 (Kumar et al., 2011), mini-agrin (Bentzinger et al., 2005) and laminin 111 protein 
therapy (Rooney et al., 2012).  Any strategies successful in culture could be followed up in 
vivo using the FKRPMD mouse. 
 
Here, developmental and tissue regulation of α-dystroglycan and the importance of this for 
tissue morphogenesis and function has been highlighted.  However, as Fkrp expression 
cannot currently be reliably detected, it is unknown if expression of Fkrp parallels this.  
Therefore, a way to reliably detect Fkrp should be generated, for example a reporter mouse, 
so that localisation and expression of Fkrp can be analysed and compared to the 
glycosylation pattern of α-dystroglycan.  
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Gene Defect Life 
Expectancy 
Inheritance Fertility 
FKRPMD Muscle specific 80% 
reduction in Fkrp 
Near Normal Autosomal 
recessive 
Both ♂  and ♀ 





POMGnT1 with a 
retoroviral vector 
Variable, from 
adolescence to 20 




 ♂ mice are not 
fertile, ♀ are 
fertile 
POMGnT1-/- Global - Pomgnt1 
inactivation -  exon 
18 replaced with  
Neomycin cassette 
Variable – over 
60% die within 3 







Pomgnt1-KO Global inactivation 
– deletion Pomgnt1 
exons 7-16 
Reduced – only 






Largemyd Global - deletion 
Large exons 5-7 
induces premature 
stop codon 
Range is 5-39 
weeks, mean 
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6-8 months of 










Largevls Global - deletion 
Large exons 3-5 
induces premature  
stop codon 











using ES cells.  
Evaluated “high 
chimeric” mice -   
over 70% chimeric 
Some die within a 
month, but 48% 








Fukutin Hp-  3kb SVA 
retrotransposon 
insertion into 









Fukutin allele is 
floxed – knocked 











– mice normal 
until Fukutin 
inactivation 





under myf5 – 
Fukutin completely 
inactive in muscle 
(E8-14) 
Yes - 11% die 
before 20 weeks 
and 78% die 








under MCK – 
Fukutin completely 
inactive in muscle 
(E17-P10) 





























FKRPMD Elevated Smaller with a wider 
legged stance and 
growth retardation 
6 weeks "Bunny hop" gait 
abnormality with 







Visibly smaller than 
controls 
















No comment made No 
comment 
made 
No comment made 




















6 weeks Abnormal HL 
retraction, 
Stiffened/splayed HL, 
60% reduction FL grip 
strength and muscle 
weakness 
Largevls Elevated Visibly smaller than 
controls and can 
develop muscle 
wasting 







Reduced body weight 1 month Muscle weakness, 
positional instability, 
abnormal HL reflex 







No comment made No 
comment 
made 











Reduction in FL grip 
strength 
Myf5-Cre Fktn- Elevated at Reduced body weight 4 weeks of Reduction in FL grip 
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Not reported  12 weeks 
of age 
No reduction in FL 
grip strength but 




Yes Visibly hypertrophic 4-6 weeks No comment made 
  





CN VFS Fibrosis Necrosis Inflammation Fat 
Infiltration 
Other Aspects 











No No After 
muscle 
injury 









NR NR NR NR NR NR No comment 
made 





Largeenr Yes Yes Yes Yes No Yes Phagocytosis, 
Fibre splitting, 
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Regeneration 
Largevls Yes Yes Yes Yes No comment 
made 









No No No No No No No uptake Evans 







































FKRPMD Not evident 



















Not evident  No comment 
made 










Not reported  No comment 
made 
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affected.   
WB - VIA4-1 
absent and 













WB - VIA4-1 
absent and 
reduced on IHC 
No reduction 























IIH6 and VIA4-1 
reduced on IHC 
and WB 
IHC - Laminin 
α2 not 
reduced but 




























No IIH6 reduced on 















































Laminin α2 is 
unchanged 
Integrin 
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TABLE 9-1 DYSTROGLYCANOPATHY MOUSE MODELS 
This table summarises selected characteristics of the FKRPMD model generated in this piece 
of work and other models for the dystroglycanopathies – POMGnT1 knockout, Largemyd, 
Largevls, Largeenr, Fukutin chimera and dystroglycan knockout.  Abbreviations are as follows – 
CK (creatine kinase), DG (dystroglycan), FL (forelimb), HL (hindlimb), IHC 
(immunohistochemistry), NMJ (Neuromuscular Junction), WB (Western Blot).  The text “No 
comment made” was entered where no direct comment was made on this specific aspect of 
the mouse phenotype in the published literature.  All information used in this table was 
taken from these references: Largemyd (Lane et al., 1976, Grewal et al., 2001, Holzfeind et al., 
2002, Browning et al., 2005, Herbst et al., 2009, Kabaeva et al., 2011), Largevls (Lee et al., 
2005), Largeenr (Kelly et al., 1994, Levedakou et al., 2005, Levedakou and Popko, 2006), 
muscle specific dystroglycan knockout (Cohn et al., 2002), Fukutin chimera (Takeda et al., 
2003), POMGnT1-/- mice (Liu et al., 2006), POMGnT1 mutant mice (Miyagoe-Suzuki et al., 
2009), POMGnT1-KO (MMRRC, 2012), Fukutin Hp- mice (Kanagawa et al., 2009), postnatal 
Fukutin null (Beedle et al., 2012), Myf-Cre Fktn null (Beedle et al., 2012), MCK-Cre Fktn null 
(Beedle et al., 2012). 
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10 APPENDIX 2 PUBLISHED MATERIAL 
  
This appendix contains the material which has been published duringthis PhD.  The abstracts 
are listed first, with my name shown in bold.  Some of the work from these abstracts has 
already been described and discussed duing this thesis.  Where data on the same topic has 
been presented at multiple conferences, the abstract from the most recent conference has 
been included, with citations for the other abstracts listed underneath.  The abstracts are 
followed by the Ackroyd et al., 2011 publication, where I am listed as the second author.  
 
 
H. BOOLER, C. WHITMORE, M. FERNANDEZ-FUENTE & S.C. BROWN 2012. G.P.4. A 
comparison of the structural brain defects in dystroglycanopathy mouse models. 
Neuromuscular Disorders 22 (9-10) 813. 
 
Mutations in several genes encoding for either determined or putative glycosyltransferases 
are associated with the hypoglycosylation of a-dystroglycan, which eﬀectively disrupts the 
linkage between the dystrophin-associated glycoprotein complex and the extracellular 
matrix. These mutations are responsible for a clinically heterogenous group of muscular 
dystrophies, which vary in severity from severe congenital muscular dystrophies, with 
substantial brain and eye involvement, to relatively mild adult-onset limb girdle muscular 
dystrophies. The underlying reason for the spectrum of defects, ranging from complete 
lissencephaly in patients with Walker–Warburg syndrome to isolated cerebellar involvement 
is at present unclear. In order to further investigate this aspect we have undertaken a 
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comparative study of structural brain involvement in diﬀerent dystroglycanopathy mouse 
models, with a particular emphasis on the deposition of the pial basement membrane. Our 
data indicate that several processes contribute to the disease process and that there are 
important diﬀerences between models. 
 
H. BOOLER, C. WHITMORE, M. FERNANDEZ FUENTE & S.C. BROWN 2012.  P19 Structural 
brain defects associated with a knock-down in fukutin related protein in the mouse.  
Neuromuscular Disorders 22 (S1) S12 
 
Mutations in fukutin-related protein (FKRP) are associated with the hypoglycosylation of a-
dystroglycan, which effectively disrupts the linkage between the dystrophin-associated 
glycoprotein complex and the extracellular matrix. These mutations are responsible for a 
clinically heterogenous group of muscular dystrophies, which vary in severity from severe 
congenital muscular dystrophies, with substantial brain and eye involvement, to relatively 
mild adult-onset limb girdle muscular dystrophies. To investigate the pathogenesis of these 
diseases, we have developed a mouse model, which has approximately 80% reduction in 
levels of FKRP. The brain of this mouse displays a marked disturbance in the deposition of 
laminin a-chains including a1, a2, a4, and a5 at the pial basement membrane, together with 
a diffuse pattern of laminin deposition below the pial surface [1]. In view of the previously 
reported spectrum of structural defects, ranging from complete lissencephaly in patients 
with Walker–Warburg syndrome to isolated cerebellar involvement [2] we now present a 
detailed characterisation and localisation of the neuropathologic ﬁndings in the newborn 
FKRP knock-down mouse. 




[1] Ackroyd, M.R., Whitmore, C., Prior, S., Kaluarachchi, M., Nikolic, M., Mayer, U., Muntoni, 
F., Brown, S.C. (2011) Fukutin-related protein alters the deposition of laminin in the eye and 
brain. J. Neurosci., 31, 12927– 12935. 
[2] Clement, E., Mercuri, E., Godfrey, C., Smith, J., Robb, S., Kinali, M., Straub, V., Bushby, K., 
Manzur, A., Talim, B., et al. (2008) Brain involvement in muscular dystrophies with defective 
dystroglycan glycosylation. Ann.Neurol., 64, 573–582. 
 
 
C. WHITMORE, H. BOOLER, C. PARR, M. ACKROYD, M. FERNANDEZFUENTE, F. MUNTONI, D. 
WELLS & S.C. BROWN 2012.  G.P.6. Assessing the long term expression of LARGE as a 
potential therapy in a mouse model of LGMD2I.  Neuromuscular Disorders 22 (9-10) 813-
814. 
 
Mutations in at least eight genes, including fukutin related protein (FKRP) are responsible 
for a common group of muscular dystrophies ranging from adult onset limb girdle muscular 
dystrophies to severe congenital forms with associated structural brain involvement 
including Walker–Warburg syndrome. We have now generated a mouse with a knock-down 
in Fkrp expression in the skeletal muscle, but not the central nervous system (FKRPMD). 
Analysis of skeletal muscle from this mouse demonstrates hypoglycosylation of a-
dystroglycan and a clear muscle pathology by 12 weeks of age. Previous work has shown 
that LARGE overexpression induces hyperglycoyslation of a-dystroglycan in wildtype cells 
Page 536 of 551 
 
and additionally cells from dystroglycanopathy patients with various primary gene defects, 
suggesting LARGE could be an important therapeutic approach in these disorders. To test 
this strategy for FKRP associated disorders, we have crossed our FKRPMD mouse line with a 
second line overexpressing LARGE. Here we present our histological and physiological 
evaluation of these mice (FKRPMDLARGE). 
 
C. WHITMORE, H. BOOLER, R. TERRY, A. ASHRAF, C. PARR, M. ACKROYD, M. 
FERNANDEZFUENTE, F. MUNTONI, D.J. WELLS & S.C. BROWN 2012.  Assessing the 
therapeutic potential of LARGE in a mouse model for the limb girdle muscular dystrophies.  
Neuromuscular Disorders 22 (S1) S14. 
 
C. WHITMORE, M.R. ACKROYD, S. MUSES, A. ASHRAF, F. MUNTONI, BROWN, S.C. & WELLS, 
D.J. 2012.  Assessing the therapeutic potential of LARGE in a new mouse model of 
dystroglycanopathy.  Neuromuscular Disorders 21 (9-10) 665. 
 
 
J. KIM, A. UPADHYAYA, M. FUENTE-FERNANDEZ, C. WHITMORE & S.C. BROWN 2012.  G.P.10 
Basement membrane deposition in the skeletal muscle of the FKRP knockdown mouse.  
Neuromuscular Disorders 22 (9-10) 814-815. 
 
Mutations in fukutin-related protein (FKRP) are associated with a clinically heterogenous 
group of muscular dystrophies, which vary in severity from severe congenital muscular 
dystrophies, with structural brain and eye involvement, to relatively mild adult-onset limb 
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girdle muscular dystrophies. Central to the pathogenesis of these disorders is the 
hypoglycosylation of alpha dystroglycan, and defects in basement membrane deposition. 
We previously generated a mouse model, which has an approximately 80% reduction in 
levels of FKRP. The newborn brain of this mouse displays a marked reduction in alpha 
dystroglycan glycosylation and a disturbance in the deposition laminin at the pial basement 
membrane. In skeletal muscle there is a reduction in both alpha dystroglycan and laminin 
alpha 2 immunolabelling by the time of birth in the FKRP knock-down compared to controls. 
There is in addition an associated reduction in muscle mass of the FKRP knockdown, the 
origin of which is unclear. Here we present our ﬁndings with regard to the expression of 
alpha dystroglycan and its associated ligands laminin alpha 2 and perlecan during muscle 
development and at birth in the FKRP knock-down relative to wild type controls. Overall our 
data shows that alpha dystroglycan and its extracellular matrix ligands laminin alpha 2 and 
perlecan immunolabelling clearly delineate the basement membrane at E15.5 in the mouse. 
This is a period when secondary myotubes align along the surface of the primaries 
suggesting that a reduction in the glycosylation of alpha dystroglycan may inﬂuence 
secondary myogenesis. 
 
J. KIM, A. UPADHYAYA, M. FUENTE-FERNANDEZ, C. WHITMORE & S.C. BROWN 2012.  
Basement membrane deposition in the skeletal muscle of the FKRP knockdown mouse.  
Neuromuscular Disorders 22 (S1) S12-S13. 
 
 
Page 538 of 551 
 
C.WHITMORE, M.R. ACKROYD, A. ASHRAF, B. ALYOSHKIN, F. MUNTONI & S.C. BROWN 
(2011) P2.12 Generation of a new mouse model for therapeutic testing in the 
dystroglycanopathies.  Neuromuscular Disorders 21 (9-10) 664. 
 
Mutations in fukutin related protein (FKRP) are responsible for a common group of muscular 
dystrophies ranging from adult onset limb girdle muscular dystrophies to severe congenital 
forms with associated structural brain involvement, including Muscle Eye Brain Disease. We 
have previously generated a mouse with a knock-down in Fkrp expression levels (FKRPKD) 
due to insertion of a ﬂoxed neomycin cassette in intron 2 of the mouse Fkrp gene.  ince this 
mouse dies at birth due to central nervous involvement we have now replaced FKRP activity 
in the developing neural tube by crossing this line with one expressing Cre recombinase 
under the Sox-1 promoter. This has resulted in a viable mouse model in which glycosylated 
adystroglycan and laminin alpha 2 has been restored at the pial basement membrane in the 
brain. These mice display a marked reduction in the glycosylation of skeletal muscle a-
dystroglycan (ADG) throughout postnatal life and develop a clear muscle phenotype (ﬁbre 
degeneration and regeneration) in both the limb muscles and the diaphragm by 12 weeks of 
age. This new model should prove invaluable in the design and testing of future therapeutic 
strategies in the dystroglycanopathies. 
 
C.WHITMORE, M.R. ACKROYD, A. ASHRAF, F. MUNTONI & S.C. BROWN (2011) Generation of 
a new mouse model for therapeutic testing in the dystroglycanopathies.  Neuromuscular 
Disorders 21 (S1) S10. 
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C. WHITMORE, M.R. ACKROYD, A. ASHRAF & S.C. BROWN (2011).  P2.16 Deposition of the 
inner limiting membrane in the eye of a mouse model for Muscle Eye Brain disease.  
Neuromuscular Disorders 21 (S1) S10.   
 
Dystroglycan is composed of two subunits; b-dystroglycan (transmembrane) and a-
dystroglycan (peripheral membrane protein), the latter of which binds to several 
extracellular matrix proteins including laminin, perlecan and agrin. a-Dystroglycan is 
extensively glycosylated and mutations in at least 8 known genes have so far been shown to 
be associated with defective dystroglycan processing and a phenotype now commonly 
referred to as a dystroglycanopathy. Mutations in one of these genes, fukutin related 
protein or FKRP is associated with a wide clinical spectrum, the most severe of which 
includes Walker Warburg Syndrome and Muscle Eye Brain disease both of which are 
associated with eye abnormalities. To further investigate the underlying basis for this we 
used a FKRP knock-down mouse model to examine the pattern of a-dystroglycan 
glycosylation and associated basement membrane proteins at the inner limiting membrane 
(ILM) from E12.5 up until birth (P0). We demonstrate that the glycosylation of a-
dystroglycan is developmentally regulated and that glycosylation defects in the FKRP knock-
down mouse is associated with breaches in the ILM during developments. 
 
 
M.R. ACKROYD, C. WHITMORE, U. MAYER & S.C. BROWN 2011.  A reduction in the 
expression of Fukutin-related protein leads to the altered deposition of multiple laminin 
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alpha chains in a mouse model for Muscle Eye Brain disease.  Neuromuscular Disorders 21 
(S1) S9-S10.   
 
Glycosylated alpha dystroglycan (ADG) is an essential component of the dystrophin-
associated glycoprotein complex (DGC) and functions as a bridge between the cell 
membrane and the extracellular matrix (ECM). Previously reported ECM ligands of ADG 
include laminin alpha 2, perlecan, agrin and neurexin which bind to glycosylated epitopes on 
ADG. Loss of these glycans, speciﬁcally that identiﬁed by IIH6, is associated with a group of 
neuromuscular disorders collectively termed the dystroglycanopathies. Fukutin related 
protein (FKRP) is one of six determined/putative enzymes implicated in the glycosylation of 
ADG. We have previously generated a FKRP knock-down mouse which displays a 
hypoglycosylation of ADG and reduced laminin alpha 2 immunostaining at the muscle 
sarcolemma, the pial basement membrane and the inner limiting membrane (ILM) of the 
eye. Of particular interest is the absence of either IIH6 or laminin alpha 2 at the ILM in 
control or FKRPKD mice indicating that a novel ADG axis is involved at this basement 
membrane. In this paper we present evidence of an altered deposition of several laminin 
alpha chains in the eye and brain and suggest that multiple ligand interactions contribute to 
the pathogenesis of the dystroglycanopathies. Furthermore we have evidence indicating 
that DG interacts with laminin alpha 1 in the eye and the brain and that levels of laminin 
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M.R. ACKROYD, C. WHITMORE, M. NIKOLIC, U. MAYER, F. MUNTONI & S.C. BROWN 2011.  
Novel insight in muscle and brain involvement in dystroglycanopathies.  Neuromuscular 
Disorders 21 (S1) S6. 
 
Mutations in fukutin related protein (FKRP) are responsible for a common group of muscular 
dystrophies ranging from adult onset limb girdle muscular dystrophies to severe congenital 
forms with associated structural brain involvement, including Muscle Eye Brain disease. The 
key deﬁning feature of this group of disorders is the hypoglycosylation of a-dystroglycan and 
its inability to effectively bind various extracellular matrix ligands such as laminin a2. In 
muscle this leads to basement membrane fragility that compromises the ability of the ﬁbre 
to withstand repeated cycles of contraction and relaxation. However, the disease process 
may be more complex given that a-dystroglycan has the potential to interact with a number 
of laminin isoforms many of which are basement membrane/tissue speciﬁc and 
developmentally regulated. In order to investigate this aspect we used our FKRP knock-
down mouse model (FKRPKD) to evaluate laminin a chain expression in the cerebral cortex 
and eye. Our data show that in the cerebral cortex the hypoglycosylation of a-dystroglycan 
is associated with a marked disturbance in the deposition of several laminin a chains 
including a1, a2, a4 and a5, although only laminin a chain mRNA expression showed a 
signiﬁcant upregulation. The entire pial basement membrane appeared disrupted with a 
diffuse pattern of laminin deposition being evident below the pial surface. This pattern of 
deposition correlated with an abrupt termination of many of the radial glial cells which 
along with pial basement membrane defects contributed to the abnormal positioning of 
both early and late born neurons. In summary these observations demonstrate that a 
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reduction in Fkrp inﬂuences the ability of a-dystroglycan to direct the deposition of several 
different laminin isoforms. These ﬁndings should assist in the design of future therapeutic 
strategies for the FKRP related group of diseases. 
 
 
The Ackroyd et al., 2011 publication, on which I am second author, is included on the next 
page.  I was involved in the designing of the research, the gathering of the data (specifically 
the quantification of Tbr1 and Tbr2 neuron distribution and the analysis of α-dystroglycan 
glycosylation at the ILM) and the analysis of the data. 
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